

# **21<sup>st</sup> Residential Course on Clinical Pharmacology of Antiretrovirals**

## **Residential & Web Course**

**Starhotels Majestic,  
corso Vittorio Emanuele II 54, Torino**

**Web Course  
www.fcarvturin.it  
c/o HealthData Consulting srl, via Morghen 27, Torino**

**22-23 January, 2026**

## **COURSE RATIONALE**

Viral infections are a major cause of disease, with enormous costs in morbidity/mortality and economic losses worldwide. Since only a few viral diseases can currently be prevented by vaccination, antiviral therapy is an essential instrument to control virus infections.

Antiviral pharmacology has evolved significantly over the past four decades and around 50 drugs have been approved for human use against viruses such as HIV, HSV, CMV, the influenza virus, HBV and HCV.

Our understanding has significantly progressed in the area of antivirals, particularly as for their mechanisms of action, pharmacokinetics, pharmacodynamics, pharmacogenomics and clinical implications, all of which contribute to optimizing their use.

The course aims to explore and elucidate these intricate pharmacological aspects of antiviral medications. It presents a unique opportunity for interdisciplinary cross-fertilization of ideas and incorporation of personalized medicine approaches in the areas of antivirals.

Combined as in-person and virtual participation to ensure a wide-reaching and inclusive engagement, the course brings together experts to discuss all aspects of the optimal use of current antiviral drugs and to focus on recent advances in the clinical pharmacology of antiviral therapies.

## **FORMAT**

Attendees can choose to attend physically or join virtually via scheduled online sessions, like a webinar, from any location with an internet connection. To offer and promote flexibility in learning, the course sessions will be accredited separately.

## DATES AND SCHEDULE

January 22-23, 2026

Thursday (14:00-18:00); Friday (9:00-16:30)

## LANGUAGE

The official language of the Course is English. There is no simultaneous interpretation.

## TARGET AUDIENCE AND ITALIAN CME

Residential participants 85 –Web Course participants 150

Professione	Discipline
FARMACISTA	FARMACISTA PUBBLICO DEL SSN;
BIOLOGO	BIOLOGO;
TECNICO SANITARIO LABORATORIO BIOMEDICO	TECNICO SANITARIO LABORATORIO BIOMEDICO; ISCRITTO NELL'ELENCO SPECIALE AD ESAURIMENTO;
MEDICO CHIRURGO	CARDIOLOGIA; ENDOCRINOLOGIA; GASTROENTEROLOGIA; MALATTIE DELL'APPARATO RESPIRATORIO; MALATTIE INFETTIVE; MEDICINA E CHIRURGIA DI ACCETTAZIONE E DI URGENZA; MEDICINA INTERNA; NEFROLOGIA; PEDIATRIA; PSICHIATRIA; BIOCHIMICA CLINICA; FARMACOLOGIA E TOSSICOLOGIA CLINICA; MICROBIOLOGIA E VIROLOGIA; PATOLOGIA CLINICA (LABORATORIO DI ANALISI CHIMICO-CLINICHE E MICROBIOLOGIA); IGIENE, EPIDEMIOLOGIA E SANITÀ PUBBLICA; DIREZIONE MEDICA DI PRESIDIO OSPEDALIERO; PSICOTERAPIA;

## COURSE DIRECTOR

**Giovanni Di Perri**, Infectious Diseases Unit, Department of Medical Sciences, University of Torino, Italy.

## SCIENTIFIC SECRETARIAT

**Stefano Bonora**, Infectious Diseases, Department of Medical Sciences, University of Torino, Italy.  
Phone: + 39-011-4393980 / 4393867 - Fax: +39-011-4393882

## ORGANISING SECRETARIAT & CME PROVIDER

HealthData Consulting S.r.l.  
via Morghen, 27 Torino - Italy  
P.IVA 01429280058  
Phone: +39-011-0267950 - Fax: +39-011-0267954

HealthData Consulting S.r.l.

Via Morghen 27, 10143, Torino (TO)  
Tel. 011 0267950 - Fax 011 0267954 - Email: segreteria@hdcons.it  
P.IVA - C.F. 01429280058, C.C.I.A.A. Torino n° REA 1125824  
www.hdcons.it



Certificato N° ER 1397/2008

## COURSE WEBSITE

Updated information will be found on the course website, <http://www.fcavrturin.it/>

## FACULTY

- Stefano Bonora**, Infectious Diseases, Department of Medical Sciences, University of Torino, Italy.
- Andrea Calcagno**, Unit of Infectious Diseases, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
- Antonella Castagna**, Infectious Diseases, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milan, Italy.
- Dario Cattaneo**, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy.
- Silvia Corcione**, Department of Medical Science, University of Turin, AOU Città della Salute e della Scienza di Torino.
- Davide Corti**, Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
- Jessica Cusato**, Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Italy.
- Antonio D'Avolio**, Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Italy.
- Francesco Giuseppe De Rosa**, Department of Medical Science, University of Turin, AOU Città della Salute e della Scienza di Torino.
- Giovanni Di Perri**, Infectious Diseases, Department of Medical Sciences, University of Torino, Italy.
- Susanna Maria Roberta Esposito**, Pietro Barilla Children's Hospital, Department of Medicine and Surgery, University of Parma, Italy.
- Micol Ferrara**, Infectious Diseases, Department of Medical Sciences, University of Torino, Italy.
- Tom Fletcher**, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
- Emanuele Focà**, Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.
- Valeria Ghisetti**, Microbiology and Virology Laboratory, Amedeo di Savoia Hospital, Turin, Italy.
- Andrea Gori**, Infectious Diseases Unit, ASST Fatebenefratelli, Ospedale L. Sacco - University of Milan, Milan, Italy.
- Loreta Kondili**, Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
- Minh Patrick Lê**, APHP, Pharmacology & Toxicology Laboratory and IAME, Inserm UMR 1137, Université Paris, Paris, France.
- Per Ljungman**, Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
- Paolo Maggi**, Infectious Disease Department of Medicine And Surgery, University of Enna Kore, Italy.
- Catia Marzolini**, Service of Clinical Pharmacology, University Hospital Lausanne, Lausanne and Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
- Cristina Mussini**, Institute of Infectious Diseases, University of Modena, Italy.
- Silvia Nozza**, Infectious Diseases, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milan, Italy.

**Giuseppe Nunnari**, Institute of Infectious Diseases, University of Messina, Italy.

**Carlo Federico Perno**, Multimodal Research Area, Microbiology and Diagnostics of Immunology Unit, Bambino Gesù Children Hospital IRCCS, Rome, Italy.

**Francesco Saladini**, Department of Medical Biotechnology, University of Siena, Siena, Italy.

**Mattia Trunfio**, University of California San Diego School of Medicine and Sanford Stem Cell Institute, La Jolla, CA, USA

**Mauro Viganò**, Hepatology Unit, Ospedale San Giuseppe, University of Milan, Milan, Italy.

## **SCIENTIFIC PROGRAM**

*This program may be progressively updated as long as we get confirmation and details from the speakers*

13:00 Course registration

### **DAY 1 – 22 JANUARY 2026– AFTERNOON SESSION - WEBINAR I**

14:00 Welcome and introduction to the Course (**G. Di Perri, S. Bonora, A. Calcagno**)

14:30 Introductory Lecture - Clinical pharmacology of Antiviral drugs: what clinicians should know (**G. Di Perri**)

### **SESSION I - PRECISION MEDICINE IN HAART MANAGEMENT: THE LONG-ACTING ERA (Chair: A. Gori, G. Nunnari)**

15:00 Pipeline of new antiretroviral LA agents (**C. Mussini**)

15:20 Clinical pharmacology of LA: strengths and weaknesses (**G. Di Perri**)

15:40 Advances in selection of PLWH candidates to LA (**A. Castagna**)

16:00 Plenary discussion

16:20 Coffee break

### **SESSION II - OPTIMIZATION OF HEPATITIS TREATMENTS (Chair: V. Ghisetti, C. F. Perno)**

16:40 Personalisation of HBV treatment (**M. Viganò**)

17:00 Pharmacogenetic and Pharmacokinetic Profiling of Bulevirtide in Patients with Hepatitis D (**J. Cusato**)

17:20 Lesson learned from the PITER real life cohort (**L. Kondili**)

- 17:40 Plenary discussion  
18:00 Closing remarks day 1  
20:00 Social dinner

## ***DAY 2 – 23 JANUARY 2026– MORNING SESSION - WEBINAR II***

### **SESSION III - PERSONALIZATION OF HAART: NEW PERSPECTIVES (Chair: D. Cattaneo, A. D'Avolio)**

- 9:00 Use of statins and selection of antiretrovirals with less cardiometabolic impact (**P. Maggi**)  
9:20 Virological characteristics of PLWH with long term suppression: one size does not fit all (**F. Saladini**)  
9:40 Towards personalization of virologic monitoring for oral treatments: the weight of forgiveness (**S. Bonora**)  
10:00 Intracellular drug distribution of ARVs: a new element to consider for treatment personalisation? (**M. Ferrara**)  
10:20 Drug-drug interaction in specific populations (**C. Marzolini**)  
10:40 Personalization of PrEP: to whom and with what? (**S. Nozza**)  
11:00 Plenary discussion  
11:30 Coffee break

### **SESSION IV - PERSPECTIVES IN ANTIVIRAL TREATMENT (Chair: A. Calcagno, S. Corcione)**

- 11:50 Advances in antiviral treatment of viral hemorrhagic fevers (**T. Fletcher**)  
12:10 Advances in monoclonal antibodies for the treatment and prevention of viral infections (**D. Corti**)  
12:30 Status of advanced respiratory syncytial virus antiviral therapeutics (**S. Esposito**)  
12:50 Viral metagenomics: the clinician's perspective (**A. Calcagno**)  
13:10 Plenary discussion  
13:30 Lunch

**SESSION V - PERSPECTIVES IN ANTIVIRAL TREATMENT (Chair: F.G. De Rosa, E. Focà)**

14:30 Virome and HIV infection (**M. Trunfio**)

14:50 Current and Future Treatments of Cytomegalovirus (**P. Ljungmam**)

15:10 Ganciclovir PK/PD in CMV therapy. Who will benefit from Dose Optimization? (**M.P. Lê**)

15:30 Plenary discussion

15:50 Conclusions (**G. Di Perri**)

16:00 CME questionnaire

**FORMATO EUROPEO  
PER IL CURRICULUM  
VITAE**



**INFORMAZIONI PERSONALI**

Nome	Stefano Bonora
Indirizzo	Via san Francesco d'Assisi 2/1, 10122 Torino
Telefono	<b>3493193281</b>
Fax	
E-mail	<b>stefano.bonora@unito.it</b>
Nazionalità	italiana
Data di nascita	8 luglio 1967

**ESPERIENZA LAVORATIVA**

Il 5 marzo 2001 ha assunto il ruolo di **Ricercatore** presso la **Clinica delle Malattie Infettive dell'Università di Torino**, dopo essere risultato vincitore della procedura di valutazione comparativa 116\_R indetta dalla facoltà di Medicina e Chirurgia di Torino (G.U. n.29 del 11/04/2000)

Nel marzo 2005 è stato nominato **Professore Associato di Malattie Infettive** presso l'Università di Torino.

**ISTRUZIONE E FORMAZIONE**

Si è laureato in **Medicina e Chirurgia** con 110/110 e lode presso l'Università di Verona il 5/11/1992

Successivamente il dott. Bonora ha frequentato la **Scuola di Specializzazione in Malattie Infettive** dell'Università di Verona, dove si è diplomato il 23/10/1997 con 50/50 e lode .

Nel periodo compreso tra il gennaio e agosto 1993 il dott. Bonora ha frequentato l'Istituto di **Patologia Generale** dell'Università di Verona, nel quadro di una collaborazione con la Cattedra di Malattie Infettive. Ha proseguito anche successivamente tale collaborazione scientifica in qualità di partecipante al progetto di ricerca "Produzione di citochine da parte di granulociti polimorfonucleati umani nella Sindrome da Immunodeficienza Acquisita e meccanismi di regolazione" coordinato dal Prof. Cassatella nell'ambito dell'VIII Progetto di Ricerca sull'AIDS 1995 dell'Istituto Superiore di Sanità

Nel periodo 24 marzo-30 maggio 1997 ha frequentato il corso di **Mycobactériologie Médicale** (Micobatteriologia Medica) presso l'Istituto Pasteur di Parigi, risultando primo negli esami di fine corso.

Dal 2/3 al 10/7/1998 ha effettuato uno stage di perfezionamento concernente "**Il typing molecolare dei bacilli della tubercolosi**" presso il Centro Nazionale di Riferimento per i Micobatteri dell'Istituto Pasteur di Parigi,

Il dott. Bonora ha fruito dall'1/8/1998 al 31/1/1999 di una borsa di studio concessa dall'Università degli Studi di Verona riguardante un progetto di ricerca dal titolo: "**Epidemiologia molecolare della tubercolosi**" (responsabile scientifico Prof. Ercole Concia, Cattedra di Malattie Infettive dell'Università di Verona).

Nel periodo compreso tra il 1/2/1999 ed il 31/12/1999 il dott. Bonora ha usufruito di una borsa di studio concessa dall'ANLAIDS-Sezione Veneto per il progetto di ricerca "**Monitoraggio degli effetti collaterali dei farmaci inibitori della proteasi in corso di infezione da HIV**" (responsabile scientifico Prof. Ercole Concia, Cattedra di Malattie Infettive dell'Università di Verona).

Nel 2000 il dott. Stefano Bonora è risultato vincitore di una borsa di studio finalizzata alla lotta all'AIDS dell'Istituto Superiore di Sanità (D.D. 8/05/2000) per un progetto dal titolo "**L'impatto dell'infezione da HIV sulla dinamica diffusiva della malattia tubercolare nell'area veronese**". L'attività di ricerca inerente a tale borsa è stata effettuata in qualità di medico frequentatore presso la Clinica delle Malattie Infettive dell'Università di Torino diretta dal Prof. Giovanni Di Perri.

Nel settembre 2003 è risultato vincitore del premio di ricerca HIV Virology Awards di 40.000 euro dell'azienda Bristol-Myers Squibb per un progetto di ricerca da titolo: "**Studio del valore predittivo delle concentrazioni di efavirenz sulla durata della risposta virologica in rapporto all'utilizzo di una nuova metodica ultrasensibile di determinazione della viremia plasmatica**"

Nel marzo 2004 ha partecipato al corso "**HIV Management: Three-day Preceptorship for Italian Specialists**" tenutosi presso il Johns Hopkins Hospital di Baltimora (USA), responsabile prof John G. Bartlett.

## CAPACITÀ E COMPETENZE

### PERSONALI

*Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.*

PRIMA LINGUA           **italiano**

ALTRE LINGUE

### **Inglese, francese**

- Capacità di lettura           buona
- Capacità di scrittura       buona
- Capacità di espressione orale   buona

<b>CAPACITÀ E COMPETENZE RELAZIONALI</b> <i>Vivere e lavorare con altre persone, in ambiente multiculturale, occupando posti in cui la comunicazione è importante e in situazioni in cui è essenziale lavorare in squadra (ad es. cultura e sport), ecc.</i>	ottime
<b>CAPACITÀ E COMPETENZE ORGANIZZATIVE</b> <i>Ad es. coordinamento e amministrazione di persone, progetti, bilanci; sul posto di lavoro, in attività di volontariato (ad es. cultura e sport), a casa, ecc.</i>	ottime
<b>CAPACITÀ E COMPETENZE TECNICHE</b> <i>Con computer, attrezzature specifiche, macchinari, ecc.</i>	buone
<b>CAPACITÀ E COMPETENZE ARTISTICHE</b> <i>Musica, scrittura, disegno ecc.</i>	scadenti
<b>ALTRE CAPACITÀ E COMPETENZE</b> <i>Competenze non precedentemente indicate.</i>	nessuna
<b>PATENTE O PATENTI</b>	B

## ULTERIORI INFORMAZIONI

### ALLEGATI

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 196/03.

Città , data  
Torino, 21 febbraio 2011

NOME E COGNOME (FIRMA)



Regione Piemonte  
ASL 102  
Ospedale Amedeo di Savoia 010013  
MALATTIE INFETTIVE CU 2403  
Dirigente Medico  
Dott. Prof BONORA STEFANO  
089001 BS

# Prof. Andrea Calcagno

---



**Current position** Since October 2020, Associate Professor of Infectious Diseases in the Department of Medical Sciences, University of Turin (Turin, Italy).

**Education** I Graduated with honors at the post-graduate School of Infectious Diseases and Tropical Medicine of the University of Turin (Turin, Italy) with a dissertation on the pharmacogenetics of nevirapine in people with HIV.

I Received the Diploma in Tropical Medicine & Hygiene (DTM&H) at Mahidol University, (Bangkok, Thailand) in 2006.

In 2004, I Graduated with honors in Medicine and Surgery at the University of Turin (Turin, Italy) with a dissertation on antibiotic resistance in Intensive Care Units.

In August 2003, I spent one month as a trainee at the Internal Medicine ward of the University Hospital in Khartoum (Khartoum, Sudan).

In the academic year 2001/2, I attended the fourth year of my Medical training at the University of Cordoba (Cordoba, Spain).

**Working Experience - Clinical** Since 2008, I have been working as Infectious Diseases Consultant at the “Amedeo di Savoia” Hospital (ASL TO2 and then ASL “Città di Torino”, Turin, Italy).

I have been mostly working in the inpatient ward taking care of patients with different infections including immune-compromised hosts (with expertise in patients with HIV/AIDS), patients with COVID-19, and tropical diseases. Since 2020, I have been involved in Infectious Diseases consultation in 8 other hospitals including internal medicine, surgical, intensive care, and onco-hematological wards. I am currently in charge of a multidisciplinary outpatient service for patients with non-tuberculous mycobacteria infections. In the last two years, I opened a referral outpatient consultation for orthopedic infections (once a week).

I spent six months (October 2006 – April 2007) and then one month (February 2009) in a rural hospital in Kiremba (Burundi) as responsible for the Pediatric and Malnourished children ward (50 beds) and of the HIV clinic.

Since 2003, I am registered at the Turin Medical Board of Physicians and Surgeons (License number 20030).

**Teaching and Academic Experience** I have covered the positions of Research Fellow (March 2008 - March 2012) and then temporary Assistant Professor in Infectious Diseases (October 2012 - September 2020) at the Unit of Infectious Diseases, Department of Medical Sciences, University of Turin (Turin, Italy).

Since 2013/2014, I have been responsible for the Infectious Diseases course at the Nursing School (3 courses) and, since the academic year 2017/2018, co-responsible of

the Infectious Disease course at the School of Medicine and Surgery of the University of Turin. The courses for students in Medicine and Surgery have been held at the San Luigi Hospital (in English) and at the Città della Salute e della Scienza (in Italian), in Turin (Italy).

Since 2012, I have been teaching in the post-graduate school in Infectious Diseases and Tropical Medicine at the University of Turin (Turin, Italy).

Since the academic year 2021/2022 I have been teaching in the PhD Programme in Experimental Medicine and Therapy, University of Turin (Turin, Italy).

I have been teaching on HIV/AIDS in Luanda (Angola) in the years 2022, 2023 and 2024 following a collaborative project led by the IRCCS Negrar (Verona, Italy).

**Research  
experience and  
interests**

I have been working in a group with internationally recognized expertise in the pharmacology of antiretrovirals; we gradually expanded our interests and research activities in the field of pharmacokinetics and pharmacogenetics of antibiotic, antifungal and antitubercular drugs.

I developed my personal research focus on the central nervous system complication of HIV and other viral infections by creating an internal group and external collaborations with neurologists, neuropsychologists, and radiologists and by enhancing the capacity of our research lab (in terms of biomarker analysis and development). I am also one of the founders of the GEPPPO multicenter and multidisciplinary cohort that studies ageing in people with and without HIV.

In the last three years, I helped create collaborations with pulmonologists (on tuberculosis and NTM infections), orthopedics (on prosthetic joint infections), microbiologists (on gut microbiome and cerebrospinal fluid virome), and with veterinary doctors (on vector-borne zoonosis): studies in these fields are currently ongoing.

I have been a sub-investigator and principal investigator of phase II, III, and independent trials in the fields of HIV, tuberculosis, NTM, and COVID-19.

**Fund Raising**

I raised a total of approximately 690k euros from public funding (Italian Ministry of Health and University of Turin), Private Companies' international calls and support to investigator-initiated studies.

**PhD Committee**

I was part of PhD Committees for the University of Liverpool (UK), University of Basel (Switzerland) and Univeristyb of Cordoba (Spain).

**Appointments**

I was a Member of the Governing Council of the Italian Society of Infectious Diseases and Tropical Medicine (SIMIT) in the years 2015-2019.

**Editorial and  
Society/Study  
Group Board**

Since 2013, Associate Editor of "BMC Infectious Diseases" Journal. Since 2015, Vice Editor of "Infectious Diseases and Tropical Medicine" and Associate Editor of "Le Infezioni in Medicina". Since 2018, Academic Editor of "PlosOne".

Since 2015, in the Scientific Committee of the ICONA foundation (Italian Cohort Naïve Antiretrovirals). Since 2015 member of the GEPP0 (GEriatric Patients living with HIV/AIDS: a Prospective Multidimensional cOHort) Study Group and, since 2017, in the Scientific Board of the cohort. Since 2017 in the Scientific Committee of "IRENE" (Italian Registry of Pulmonary Non-Tubercular Mycobacteria). Since 2022 member of the Scientific Committee of StopTB Italia.

Since 2017, I have been the Coordinator of the Study group on Mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine (SIMIT).

**Conference Organization**

I have been a Member of the Organizing Committee of the International "Antivirals PK Workshop" 2018-2023 and I am now in the Scientific Committee of the Workshop.

I have been a member of the Scientific Committee of the Italian Conference on AIDS and Antiviral Research in the years 2013 and (2016 to 2025).

Since 2018 I have been in the Scientific Committee of the Residential Course on the Clinical Pharmacology of Antivirals, held every year in January in Turin.

**Guidelines**

I have been a member of the HIV/AIDS expert Panel writing the Italian Guidelines on the use of antiretroviral drugs and on the management of HIV-positive patients (from 2012 until 2017, when the last version was released).

**Committees**

Since 2021, I have been a member of the Regional Committees (Piedmont, Italy) on Antimicrobial Resistance (PP10) and prevention of Infectious Diseases (PL14).

**National and International Collaborations**

Since 2014, I helped building a research collaboration with the Infectious Disease Institute, Makerere University (Kampala, Uganda): the main topics were the capacity building of laboratory facilities and conduction of phase IV studies.

I personally received three Erasmus+ projects (in collaboration with the Department of Social Sciences) for the years 2019-2022, 2020-2023, and 2022-2025 for promoting the exchange between the University of Torino and the Makerere University (Teachers and third-grade students exchange). Since 2020 we have been organizing the ToAfrica Summer School (<https://www.toafrica.it>).

Several collaborations are currently ongoing in Italy and Europe (specifically in centers in the United Kingdom, Spain, and France). A research and tutoring collaboration is ongoing with the University of California at San Diego (UCSD, Prof. Scott Letendre). An ongoing clinical and reaserch collaboration between our Unit, an NGO (Idea onlus), and a rural hospital in North Uganda (Kalongo Hospital) has been created and it is still ongoing.

**Awards**

- Winner of the "ICAR CROI Award" in the years 2012, 2013, 2014, 2015 and 2016.
- Winner of the special jury "ICAR CROI Award 2017" for young Italian researchers for the project entitled "Discordant HIV RNA in Olfactory Mucosa

of HIV-positive Patients" (Calcagno A, et al. 24th Conference on Retroviruses and Opportunistic Infections, February 13-16, 2017, Seattle, WA, USA. P379).

Orcid ID 0000-0003-2534-8815

- Publications**
1. [Calcagno A](#), Pizzi C, Pocongo B, Ronzoni N, Alladio F, Francisco NM, Kalume A, Di Perri G, Gobbi F. Factors Associated with HIV Viral Suppression in People Followed in an Outpatient Clinic in Angola During and After the COVID-19 Pandemic. **AIDS Patient Care STDS**. 2024 Oct 4. doi: 10.1089/apc.2024.0175. Epub ahead of print. PMID: 39364627.
  2. Kincer LP, Dravid A, Trunfio M, [Calcagno A](#), Zhou S, Vercesi R, Spudich S, Gisslen M, Price RW, Cinque P, Joseph SB. Neurosymptomatic HIV-1 CSF escape is associated with replication in CNS T cells and inflammation. **J Clin Invest**. 2024 Oct 1;134(19):e176358. doi: 10.1172/JCI176358. PMID: 39352388; PMCID: PMC11444166.
  3. Stroffolini G, Atzori C, Imperiale D, Trunfio M, Di Perri G, [Calcagno A](#). Central Nervous System Disorders with Auto-Antibodies in People Living with HIV. **Microorganisms**. 2024 Aug 24;12(9):1758. doi: 10.3390/microorganisms12091758. PMID: 39338433; PMCID: PMC11433650.
  4. Riccardi N, Monari C, Antonello RM, Sadari L, Occhineri S, Pontarelli A, Zucchi P, Buonsenso D, Falbo E, Faverio P, Aliberti S, Parrella R, Falcone M, Besozzi G, [Calcagno A](#), Goletti D, Gualano G, Sotgiu G, Tadolini M, Codecasa L. TB outpatient care in a high-income, low-incidence country. **Int J Tuberc Lung Dis**. 2024 Oct 1;28(10):513-515. doi: 10.5588/ijtld.24.0059. PMID: 39334547.
  5. Stroffolini G, Lupia T, Gaviraghi A, Venuti F, Cinnirella G, Gori A, Spotti M, Blasi F, Codecasa L, [Calcagno A](#), Aliberti S; IRENE Study group collaborators. Prescription habits and drugs accessibility for the treatment of non-tuberculous mycobacteria infections in Italy: a multicentric survey from the IRENE study group. **Infection**. 2024 Sep 20. doi: 10.1007/s15010-024-02390-y. Epub ahead of print. PMID: 39302627.
  6. Lazzaro A, Vai D, Barco A, Stroffolini G, Pirriatore V, Guastamacchia G, Nigra M, Ghisetti V, Tettoni MC, Noce G, Giaccone C, Trunfio M, Trentalange A, Bonora S, Di Perri G, [Calcagno A](#). Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical Trial. **J Acquir Immune Defic Syndr**. 2024 Oct 1;97(2):180-191. doi: 10.1097/QAI.0000000000003480. PMID: 39250652.
  7. [Calcagno A](#), Cusato J, Cinque P, Marchetti G, Bernasconi D, Trunfio M, Bruzzesi E, Rusconi S, Gabrieli A, Muscatello A, Antinori A, Ripamonti D, Gulminetti R, Antonucci M, Nozza S. Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized study. **Brain**. 2024 Aug 22:awae271. doi: 10.1093/brain/awae271. Epub ahead of print. PMID: 39171829.
  8. Longo BM, Trunfio M, [Calcagno A](#). Dual  $\beta$ -lactams for the treatment of Mycobacterium abscessus: a review of the evidence and a call to act against an antibiotic nightmare. **J Antimicrob Chemother**. 2024 Aug 16:dkae288. doi: 10.1093/jac/dkae288. Epub ahead of print. PMID: 39150384.
  9. Trunfio M, Vuaran E, Vai D, Quarta C, Di Stefano A, Imperiale D, Cinnirella G, Bonora S, Di Perri G, Letendre SL, [Calcagno A](#). Symptomatic and Asymptomatic Neurocognitive Impairment, ART Adherence and HIV Control: A 4-Year Observational Study. **AIDS Behav**. 2024 Jul 30. doi: 10.1007/s10461-024-04440-w. Epub ahead of print. PMID: 39080201.
  10. Longo BM, Merli M, Achana B, Okao M, Smart Okot G, Ribero S, [Calcagno A](#), Montrucchio G, Orlotti C. A noma case report: A warning message from Northern Uganda. **Trop Med Int Health**. 2024
  11. De Vito A, Colpani A, Moi G, Babudieri S, [Calcagno A](#), Calvino V, Ceccarelli M, Colpani G, d'Ettorre G, Di Biagio A, Farinella M, Falaguasta M, Focà E, Giupponi G, Habed AJ, Isenia WJ, Lo Caputo S, Marchetti G, Modesti L, Mussini C, Nunnari G, Rusconi S, Russo D, Saracino A, Serra PA, Madeddu G. Assessing ChatGPT's Potential in HIV Prevention Communication: A Comprehensive Evaluation of Accuracy, Completeness, and Inclusivity. **AIDS Behav**. 2024
  12. Trunfio M, Bonora S, di Perri G, [Calcagno A](#). Further considerations on the use of cerebrospinal fluid C-X-C motif chemokine ligand 13 in the diagnosis of neurosyphilis among people with HIV. **AIDS**. 2024
  13. Gaviraghi A, de Nicolò A, Venuti F, Stroffolini G, Quaranta M, Cat Genova E, Ponzetta L, Alladio F, Marinaro L, D'Avolio A, [Calcagno A](#). Low azithromycin maximal concentrations in patients concomitantly taking rifampicin: time to move away from rifampicin in the treatment of non-tuberculous mycobacteria? **Antimicrob Agents Chemother**. 2024
  14. De Nicolò A, Palermiti A, Dispinseri S, Marchetti G, Trunfio M, De Vivo E, D'Avolio A, Muscatello A, Gori A, Rusconi S, Bruzzesi E, Gabrieli A, Bernasconi DP, Banderà A, Nozza S, [Calcagno A](#); INACTION (Italian Network of Acute HIV Infection) study group. Plasma, Intracellular and Lymph Node Antiretroviral Concentrations and HIV DNA Change During Primary HIV Infection: Results from the INACTION P25 Study. **Int J Antimicrob Agents**. 2024
  15. Bai F, Bono V, Borghi L, Bonazza F, Falcinella C, Vitaletti V, Miraglia F, Trunfio M, [Calcagno A](#), Cusato J, Vegni E, d'Arminio Monforte A, Marchetti G. Association between tight junction proteins and cognitive performance in untreated persons with HIV. **AIDS**. 2024
  16. [Calcagno A](#), Tutone M, Del Re S, Delmonte S, Agosta D, Ghisetti V, Lucchini A. Doxycycline Post-exposure Prophylaxis and Sexually Transmitted Infections in Italy, 2023. **Clin Infect Dis**. 2024
  17. Cusato J, Manca A, Palermiti A, Mula J, Avataneo V, Antonucci M, Marinaro L, Bonora S, Trunfio M, Di Perri G, D'Avolio A, [Calcagno A](#). Host single nucleotide polymorphisms and biomarkers of neuronal damage and inflammation in people living with HIV. **Int J Antimicrob Agents**. 2024
  18. Colpani A, De Vito A, Zauli B, Menzaghi B, [Calcagno A](#), Celesia BM, Ceccarelli M, Nunnari G, De Socio GV, Di Biagio A, Leoni N, Angioni G, Giambenedetto SD, D'Ettorre G, Babudieri S, Madeddu G. Knowledge of Sexually Transmitted Infections and HIV among People Living with HIV: Should We Be Concerned? **Healthcare (Basel)**. 2024
  19. Ambrosioni J, Díaz NA, Marzolini C, Dragovic G, Imaz A, [Calcagno A](#), Luque S, Curran A, Troya J, Tuset M, Khoo S, Burger D, Cortés CP, Naous N, Molto J. Outcomes of Drug Interactions Between Antiretrovirals and Co-Medications, Including Over-the-Counter Drugs: A Real-World Study. **Infect Dis Ther**. 2024
  20. Aliberti S, Blasi F, Burgel PR, [Calcagno A](#), Fløe A, Grogono D, Papavasileiou A, Polverino E, Prados C, Rohde G, Salzer HJF, Sánchez-Montalvá A, Shteinberg M, Van Braeckel E, van Ingen J, Veziris N, Wagner D, Loebinger MR. Mycobacterium avium complex pulmonary disease patients with limited treatment options. **ERJ Open Res**. 2024.

21. Ranzani A, Castelli F, Di Biagio A, d'Arminio Monforte A, D'Avolio A, Soria A, Bai F, Focà E, Taramasso L, [Calcagno A](#), Bresciani E, Torsello A, Bonfanti P, Lapadula G. Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects. **HIV Med.** **2023**.
22. Tincati C, Bono V, Cannizzo ES, Tosi D, Savi F, Falcinella C, Casabianca A, Orlandi C, Luigiano C, Augello M, Rusconi S, Muscatello A, Bandera A, [Calcagno A](#), Gori A, Nozza S, Marchetti G; on behalf of the Italian Network of ACuTe HIV Infection (INACTIION). Primary HIV infection features colonic damage and neutrophil inflammation yet containment of microbial translocation. **AIDS.** **2023**.
23. Trunfio M, Sacchi A, Vai D, Pittaluga F, Croce M, Cavallo R, Imperiale D, Bonora S, Di Perri G, Letendre SL, [Calcagno A](#). Intrathecal production of anti-EBV Viral Capsid Antigen IgG is associated with Neurocognition and tau pathology in people with HIV. **AIDS.** **2023**.
24. Stroffolini G, Lazzaro A, Barco A, Pirriatore V, Vai D, Giaccone C, Nigra M, Atzori C, Trunfio M, Bonora S, Di Perri G G, [Calcagno A](#). Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment Regimen. **J Neuroimmune Pharmacol.** **2023**.
25. Babiloni C, Del Percio C, Piervincenzi C, Carducci F, Ferri R, Onorati P, Toma G, Ferracuti S, Roma P, Correr V, Di Campi F, Aceti A, Salvatore M, Soricelli A, Teti E, Pennica A, Sarmati L, Vullo V, D'Ettore G, Mastroianni C, Petsas N, Pantano P, Floris R, Stocchi F, Andreoni M, Di Perri G, [Calcagno A](#), Noce G. Parietal resting-state EEG alpha source connectivity is associated with subcortical white matter lesions in HIV-positive people. **Clin Neurophysiol.** **2023**.
26. Global Tuberculosis Network; TB/COVID-19 Global Study Group; TB/COVID-19 Global Study Group; Casco N, Jorge AL, Palmero DJ, Alffenaar JW, Fox GJ, Ezz W, Cho JG, Denholm J, Skrahina A, Solodovnikova V, Arbex MA, Alves T, Rabahi MF, Pereira GR, Sales R, Silva DR, Saffie MM, Salinas NE, Miranda RC, Cisterna C, Concha C, Fernandez I, Villalvazn C, Vera CG, Tapia PG, Cancino V, Carbonell M, Cruz A, Muv±oz E, Muv±oz C, Navarro I, Pizarro R, SVñchez GPC, Riquelme MSV, Vilca E, Soto A, Flores X, Garavagno A, Bahamondes MH, Merino LM, Pradenas AM, Revillot ME, Rodriguez P, Salinas AS, Taiba C, Valdvs JF, Subiabre JN, Ortega C, Palma S, Castillo PP, Pinto M, Bidegain FR, Venegas M, Yucra E, Li Y, Cruz A, Guelvez B, Plaza RV, Hoyos KYT, Van Den Boom M, Andrv@jak C, Blanc FX, Dourmane S, Froissart A, Izadifar A, Riviv®re F, Schlemmer F, Manika K, Diallo BD, Hassane-Harouna S, Artiles N, Mejia LA, Gupta N, Ish P, Mishra G, Patel JM, Singla R, Udwardia ZF, Alladio F, Angeli F, [Calcagno A](#), Centis R, Codecasa LR, De Lauretis A, Esposito SMR, Formenti B, Gaviraghi A, Giacomet V, Goletti D, Gualano G, Matteelli A, Migliori GB, Motta I, Palmieri F, Pontali E, Prestileo T, Riccardi N, Sadari L, Sapor,À. Long-term outcomes of the global TB and COVID-19 coinfection cohort. **Eur Respir J.** **2023**.
27. Longo BM, Venuti F, Gaviraghi A, Lupia T, Ranzani FA, Pepe A, Ponzetta L, Vita D, Alice T, Gregorc V, Frascione PMM, De Rosa FG, [Calcagno A](#), Bonora S. Sequential or Combination Treatments as Rescue Therapies in Immunocompromised Patients with Persistent SARS-CoV-2 Infection in the Omicron Era: A Case Series. **Antibiotics (Basel).** **2023**.
28. Bruzzesi E, Gabrieli A, Bernasconi D, Marchetti G, [Calcagno A](#), Ripamonti D, Antinori A, Squillace N, Cingolani A, Muscatello A, Bandera A, Gori A, Rusconi S, Nozza S; INACTIION Study Group. HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTIION) clinical trial. **J Med Virol.** **2023**.
29. De Benedetto I, Biagini F, Urbano G, Mongini TE, Cassetta I, Scaglione L, Curtoni A, Calleri G, [Calcagno A](#), De Rosa FG, Corcione S. A case of histological diagnosis of Toxoplasma gondii myositis in a person living with HIV. **Infez Med.** **2023**.
30. Venuti F, Gaviraghi A, De Nicolvs, Stroffolini G, Longo BM, Di Vincenzo A, Ranzani FA, Quaranta M, Romano F, Cattellani E, Marchiaro C, Cinnirella G, D'Avolio A, Bonora S, [Calcagno A](#). Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant Pseudomonas aeruginosa Infection in the Outpatient Setting. **Antibiotics (Basel).** **2023**.
31. Venuti F, Trunfio M, Martson AG, Lipani F, Audagnotto S, Di Perri G, [Calcagno A](#). Extended and Continuous Infusion of Novel Protected Beta-Lactam Antibiotics: A Narrative Review. **Drugs.** **2023**.
32. Di Girolamo L, Ferrara M, Trevisan G, Longo BM, Alice T, Burdino E, Alladio F, Fantino S, Di Perri G, [Calcagno A](#), Bonora S. Transient plasma viral rebound after SARS-CoV-2 vaccination in an exceptional HIV-1 elite controller woman. **Virol J.** **2023**.
33. De Vito A, Colpani A, Trunfio M, Fiore V, Moi G, Fois M, Leoni N, Ruiu S, Babudieri S, [Calcagno A](#), Madeddu G. Living with HIV and Getting Vaccinated: A Narrative Review. **Vaccines (Basel).** **2023**.
34. Cusato J, Manca A, Palermiti A, Mula J, Costanzo M, Antonucci M, Trunfio M, Corcione S, Chiara F, De Vivo ED, Ianniello A, Ferrara M, Di Perri G, De Rosa FG, D'Avolio A, [Calcagno A](#). COVID-19: A Possible Contribution of the MAPK Pathway. **Biomedicines.** **2023**
35. Cusato J, Manca A, Palermiti A, Mula J, Costanzo M, Antonucci M, Chiara F, De Vivo ED, Maiese D, Ferrara M, Bonora S, Di Perri G, D'Avolio A, [Calcagno A](#). COVID-19: Focusing on the Link between Inflammation, Vitamin D, MAPK Pathway and Oxidative Stress Genetics. **Antioxidants (Basel).** **2023**
36. Trunfio M, Mighetto L, Napoli L, Atzori C, Nigra M, Guastamacchia G, Bonora S, Di Perri G, [Calcagno A](#). Cerebrospinal Fluid CXCL13 as Candidate Biomarker of Intrathecal Immune Activation, IgG Synthesis and Neurocognitive Impairment in People with HIV. **J Neuroimmune Pharmacol.** **2023**
37. Ecarton F, Boccardi V, [Calcagno A](#), Franceschi C, Fülöp T, Itzhaki RF, Michel JP, Panza F, Rainero I, Solfrizzi V, Ticinesi A, Veronese N, Maggi S. Dementia, infections and vaccines: 30 years of controversy. **Aging Clin Exp Res.** **2023**
38. Trunfio M, Pinnetti C, Arsuffi S, Bai F, Celani L, D'Ettore G, Vera JH, D'Arminio Monforte A, Focà E, Ghisetti V, Bonora S, Antinori A, [Calcagno A](#). The presence of resistance-associated mutations in reverse transcriptase gene is associated with cerebrospinal fluid HIV-1 escape: A multicentric retrospective analysis. **J Med Virol.** **2023**
39. Trunfio M, Pinnetti C, Arsuffi S, Bai F, Celani L, D'Ettore G, Vera JH, Monforte AD, Focà E, Ghisetti V, Bonora S, Antinori A, [Calcagno A](#). The Presence of Resistance-associated Mutations in Reverse Transcriptase Gene is Associated with Cerebrospinal Fluid HIV-1 Escape: a multicentric retrospective analysis. **J Med Virol.** **2023** Mar 26.
40. Stroffolini G, Gaviraghi A, Penna D, Piccioni P, Venuti F, Botto C, Trezzi M, Betti M, Sestini S, Erba PA, Lupia T, Di Perri G, Aliberti S, [Calcagno A](#). 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with non-tuberculous mycobacterial infections: A case series on the use of Nuclear Medicine in NTM-PD. **J Infect.** **2023** Mar 17: S0163-4453(23)00142-1.
41. Cusato J, Avataneo V, Antonucci M, Trunfio M, Marinaro L, Palermiti A, Manca A, Di Perri G, Mula J, Bonora S, D'Avolio A, [Calcagno A](#). Antiretroviral Levels in the Cerebrospinal Fluid: The Effect of Inflammation and Genetic Variants. **Diagnostics (Basel).** **2023**.

42. Cusato J, Borghetti A, Teti E, Milesi M, Tettoni MC, Bonora S, Trunfio M, D'Avolio A, Compagno M, Di Giambenedetto S, Di Perri G, [Calcagno A](#). Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study. **Metabolites**. 2022.
43. Manzini PM, Ciccone G, De Rosa FG, Cavallo R, Ghisetti V, D'Antico S, Galassi C, Saccona F, Castiglione A, Birocco N, Francisci T, Hu H, Pecoraro C, Danielle F, Labanca L, Bordiga AM, Lorenzi M, Camisasca G, Giachino O, Pagliarino M, Ottone P, Scuvera ITD, Guaschino R, Freilone R, Berti P, Pittaluga F, Avolio M, Costa C, Raso S, Nucci A, Milan M, Baffa A, Russo A, Tornello A, Maddalena L, Delios G, Marletto FP, De Micheli AG, Mattei A, Baldassano S, Canta F, Russo ML, Bergamo D, Vitale F, Liccardi MM, Chinaglia A, [Calcagno A](#), Converso M, Aldieri C, Libanore V, Bланgetti I, Benedetti V, Mitola B, Scozzari G; PLACO COVID Study Group. Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial. **BMC Infect Dis**. 2022
44. Sciascia S, Arbrile M, Trunfio M, [Calcagno A](#), Radin M, Roccatello D, Lembo D, Civra A. The role of bacteria and viruses in Behçet syndrome: Should we move towards new paradigms? **Autoimmun Rev**. 2022
45. Trunfio M, Di Girolamo L, Ponzetta L, Russo M, Burdino E, Imperiale D, Atzori C, Di Perri G, [Calcagno A](#). Seropositivity and reactivations of HSV-1, but not of HSV-2 nor VZV, associate with altered blood-brain barrier, beta amyloid, and tau proteins in people living with HIV. **J Neurovirol**. 2022
46. Riccardi N, Antonello RM, Giacomelli A, Saderi L, Canetti D, Pallotto C, Mazzaferri F, Degli Antoni AM, Cardellino C, Motta I, [Calcagno A](#), Falcone M, Trezzi M, Comelli A, Pascale R, Merli M, Binda F, Angheben A, Sotgiu G, Gobbi F, Nozza S. The challenge of infectious diseases consultations in the emergency department: an Italian nationwide survey. **New Microbiol**. 2022.
47. De Nicolò A, [Calcagno A](#), Motta I, De Vivo E, D'Avolio A, Di Perri G, Wiesner L, Ebrahim IE, Maartens G, Orrell C, McIlleron H. The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study. **Antimicrob Agents Chemother**. 2022 Jun 21;66(6):e0013622.
48. Cusato J, Palermiti A, Manca A, Mula J, Antonucci M, De Nicolò A, Allegra S, De Francia S, Chiara F, Di Perri G, Rosa FG, [Calcagno A](#), D'Avolio A. Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants. **Pharmaceuticals (Basel)**. 2022 May 20;15(5):630.
49. Ochoa-Azze R, Chang-Monteagudo A, Climent-Ruiz Y, Macías-Abraham C, Valenzuela-Silva C, de Los Angeles García-García M, Jerez-Barceló Y, Triana- Marrero Y, Ruiz-Villegas L, Dairon Rodríguez-Prieto L, Guerra-Chaviano PP, Sánchez-Ramírez B, Hernández-García T, Orosa-Vázquez I, Díaz-Hernández M, Chiodo F, [Calcagno A](#), Ghisetti V, Rodríguez-Acosta M, Noa-Romero E, Enríquez-Puertas J, Ortega-León D, Valdivia-Álvarez I, Delahanty-Fernández A, Palenzuela-Díaz A, Rodríguez-Noda L, González-Mugica R, Valdés-Balbín Y, García-Rivera D, Verez-Bencomo V. Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial. **Lancet Respir Med**. 2022 Aug;10(8):785-795.
50. De Benedetto I, Barco A, Rossi M, Lapadula G, Lupia T, Bonfanti P, Bonora S, Di Perri G, [Calcagno A](#). BCGitis after Bacille Calmette-Guerin intravesical administration from two referral centers: clinical characteristics and risk factors. **Infez Med**. 2022 Jun 1;30(2):242-246.
51. Trunfio M, Scabini S, Rugge W, Bonora S, Di Perri G, [Calcagno A](#). Concurrent and Subsequent Co-Infections of *Clostridioides difficile* Colitis in the Era of Gut Microbiota and Expanding Treatment Options. **Microorganisms**. 2022 Jun 23;10(7):1275.
52. Mastorino L, Dapavo P, Trunfio M, Avallone G, Rubatto M, [Calcagno A](#), Ribero S, Quagliano P. Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Tuberclogenic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy. **Acta Derm Venereol**. 2022 Sep 6. doi: 10.2340/actadv.v102.1982.
53. Trunfio M, Portesani F, Vicinanza S, Nespoli P, Traverso F, Cortese G, Bonora S, [Calcagno A](#), Di Perri G. Real-life Evidence of Lower Lung Virulence in COVID-19 Inpatients Infected with SARS-CoV-2 Omicron Variant Compared to Wild-type and Delta SARS-CoV-2 Pneumonia. **Lung**. 2022 Oct;200(5):573-577.
54. Ferrara M, Cusato J, Salvador E, Trentalange A, Alcantarini C, Trunfio M, Cannizzo ES, Bono V, Nozza S, De Nicolò A, Ianniello A, De Vivo E, D'Avolio A, Di Perri G, Bonora S, Marchetti G, [Calcagno A](#). Inflammation and Intracellular Exposure of Dolutegravir, Darunavir, Tenofovir and Emtricitabine in People living with HIV. **Br J Clin Pharmacol**. 2022 Sep 17.
55. Trunfio M, Atzori C, Pasquero M, Di Stefano A, Vai D, Nigra M, Imperiale D, Bonora S, Di Perri G, [Calcagno A](#). Patterns of Cerebrospinal Fluid Alzheimer's Dementia Biomarkers in People Living with HIV: Cross-Sectional Study on Associated Factors According to Viral Control, Neurological Confounders and Neurocognition. **Viruses**. 2022 Apr 4;14(4):753.
56. Trunfio M, Richiardi L, Alladio F, Staffilano E, Longo B, Venuti F, Ghisetti V, Burdino E, Bonora S, Vineis P, Di Perri G, [Calcagno A](#). Determinants of SARS-CoV-2 Contagiousness in Household Contacts of Symptomatic Adult Index Cases. **Front Microbiol**. 2022 Apr 1;13:829393.
57. Stroffolini G, Rossi L, Lupia T, Faraoni S, Paltrinieri G, Lipani F, [Calcagno A](#), Bonora S, Di Perri G, Calleri G. Trichinella britovi outbreak in Piedmont, North-West Italy, 2019-2020: Clinical and epidemiological insights in the one health perspective. **Travel Med Infect Dis**. 2022.
58. Avataneo V, Palermiti A, De Nicolò A, Cusato J, Giussani G, [Calcagno A](#), D'Avolio A. Monthly Increase in Vitamin D Levels upon Supplementation with 2000 IU/Day in Healthy Volunteers: Result from "Integriamoci", a Pilot Pharmacokinetic Study. **Molecules**. 2022. Feb 3;27(3):1042. Impact Factor 4.412.
59. Babiloni C, Del Percio C, Lizio R, Lopez S, Pennica A, Roma P, Correr V, Cucciolla F, Toma G, Soricelli A, Di Campi F, Aceti A, Teti E, Sarmati L, Crocetti G, Ferri R, Lorenzo I, Galli M, Negri C, Angarano G, Saracino A, Lepore L, Di Pietro M, Fusco FM, Vullo V, D'Ettorre G, Pagliano P, Di Flumeri G, Celesia BM, Gentilini Cacciola E, Di Perri G, [Calcagno A](#), Stocchi F, Ferracuti S, Onorati P, Andreoni M, Noce G. Parietal intrahemispheric source connectivity of resting-state electroencephalographic alpha rhythms is abnormal in Naïve HIV patients. **Brain Res Bull**. 2022. Apr;181:129-143. Impact factor 4.079.
60. Barco A, Orlando S, Stroffolini G, Pirriatore V, Lazzaro A, Vai D, Guastamacchia G, Noce G, Atzori C, Trunfio M, Bonora S, Di Perri G, [Calcagno A](#). Correlations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disorders. **J Neurovirol**. 2022. Impact Factor 2.643.
61. Trunfio M, De Francesco D, Vai D, Medina C, Milesi M, Domini S, Alcantarini C, Imperiale D, Bonora S, Di Perri G, [Calcagno A](#). Screening Accuracy of Mini Addenbrooke's Cognitive Examination Test for HIV-Associated Neurocognitive Disorders in People Ageing with HIV. **AIDS Behav**. 2022. Impact Factor 3.895.

62. Trunfio M, Verga F, Ghisetti V, Burdino E, Emanuele T, Bonora S, Di Perri G, [Calcagno A](#). Clinical Phenotype and Contagiousness of Early Breakthrough SARS-CoV-2 Infections after BNT162b2 COVID-19 mRNA Vaccine: A Parallel Cohort Study in Healthcare Workers. **Vaccines (Basel)**. 2021. Impact factor 4.422.
63. Stroffolini G, Segala FV, Lupia T, Faraoni S, Rossi L, Tomassone L, Zanet S, De Rosa FG, Di Perri G, [Calcagno A](#). Serology for *Borrelia* spp. in Northwest Italy: A Climate-Matched 10-Year Trend. **Life (Basel)**. 2021. Impact Factor 3.817.
64. [Calcagno A](#), Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, Arena V, d'Ettorre G, Guaraldi G, Gisslen M, Di Perri G. Alzheimer Dementia in People Living With HIV. **Neurol Clin Pract**. 2021. Impact Factor 1.241.
65. Stroffolini G, Guastamacchia G, Audagnotto S, Atzori C, Trunfio M, Nigra M, Di Stefano A, Di Perri G, [Calcagno A](#). Low cerebrospinal fluid Amyloid-Beta 1-42 in patients with tuberculous meningitis. **BMC Neurol**. 2021. Impact Factor 2.293.
66. TB/COVID-19 Global Study Group. Tuberculosis and COVID-19 co-infection: description of the global cohort. **Eur Respir J**. 2021 [Epub ahead of print] Impact factor 16.670.
67. Ulfhammer G, Edén A, Antinori A, Brew BJ, [Calcagno A](#), Cinque P, De Zan V, Hagberg L, Lin A, Nilsson S, Oprea C, Pinnetti C, Spudich S, Trunfio M, Winston A, Price RW, Gisslén M. Cerebrospinal Fluid viral load across the spectrum of untreated HIV-1 infection: a cross-sectional multi-center study. **Clin Infect Dis**. 2021 [Epub ahead of print] Impact factor 8.313.
68. Airoldi C, [Calcagno A](#), Di Perri G, Valinotto R, Gallo L, Locana E, Trunfio M, Patrucco F, Vineis P, Faggiano F. Seroprevalence of SARS-CoV-2 Among Workers in Northern Italy. **Ann Work Expo Health**. 2021. Impact factor 1.81
69. Trunfio M, Scabini S, Mornese Pinna S, Ruggie W, Alcantarini C, Pirriatore V, Di Perri G, Bonora S, Castelnovo B, [Calcagno A](#). The Manifesto of Pharmacoenosis: Merging HIV Pharmacology into Pathocoenosis and Syndemics in Developing Countries. **Microorganisms**. 2021 Jul 31;9(8):1648. Impact factor 4.128.
70. Cusato J, Mula J, Palermi A, Manca A, Antonucci M, Avataneo V, De Vivo ED, Ianniello A, [Calcagno A](#), Di Perri G, De Nicolò A, D'Avolio A. Seasonal Variation of Antiretroviral Drug Exposure during the Year: The Experience of 10 Years of Therapeutic Drug Monitoring. **Biomedicines**. 2021 Sep 12;9(9):1202.
71. Parietti M, Trunfio M, Delmonte S, Conti L, Trentalange A, Bonora S, [Calcagno A](#), Ribero S. Efflorescence of acquired epidermodysplasia verruciformis due to immune reconstitution inflammatory syndrome-like mechanisms following anti-HPV vaccination in a HIV-positive patient. **Int J STD AIDS**. 2021 Oct 11:9564624211048343.
72. Avallone G, Trunfio M, Mastorino L, Agostini A, Merli M, Rubatto M, Caracciolo D, [Calcagno A](#), Senetta R, Fierro MT, Quaglino P, Ribero S. Case Report: Atypical Cutaneous Presentation of Human T-cell Lymphotropic Virus Type 1-Related Adult T-cell Lymphoma. **Am J Trop Med Hyg**. 2021 Oct 11:tpmd210630.
73. Focà E, [Calcagno A](#), Calza S, Renzetti S, Chiesa A, Siano M, De Socio G, Piconi S, Orofino G, Madeddu G, Cattelan AM, Nozza S, Ferrara M, Milic J, Celesia BM, Castelli F, Guaraldi G. Durability of Integrase STRand Inhibitor (INSTI)-based regimen in geriatric people living with HIV in the GEPP0 cohort. **PLoS One**. 2021 Oct 13;16(10):e0258533.
74. Cusato J, Tempestilli M, [Calcagno A](#), Vergori A, Piselli P, Antonucci M, Avataneo V, Palermi A, Notari S, Antinori A, Di Perri G, Agrati C, D'Avolio A. Vitamin D as Modulator of Drug Concentrations: A Study on Two Italian Cohorts of People Living with HIV Administered with Efavirenz. **Nutrients**. 2021 Oct 12;13(10):3571.
75. Clerico M, Dogliotti I, [Calcagno A](#), Grimaldi D, Leone S, Ragaini S, Boffini M, Caracciolo D, Ferrero S, Barbero C, Zanotto E, Stroffolini G, Cavallo R, Rinaldi M, Bruno B, Cavallo F. COVID-19 in a Post-transplant Heart Recipient Who Developed Aggressive Lymphoma: A Biphasic Course During Rituximab Treatment. **Hemisphere** 2021.
76. Chan TY, De Zan V, Gregg A, Alagaratnam J, Gerevini S, Antinori A, Monforte AD, Saracino A, Trunfio M, Everitt A, Rackstraw S, Marta M, [Calcagno A](#), Cinque P, Winston A. Cerebrospinal fluid HIV RNA escape symptomatology. **AIDS** 2021.
77. De Nicolò A, Manca A, Ianniello A, Palermi A, [Calcagno A](#), Ferrara M, Antonucci M, Cusato J, Avataneo V, De Vivo E, Bonora S, De Rosa FG, Di Perri G, D'Avolio A. Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma. **Pharmaceuticals (Basel)** 2021.
78. De Nicolò A, Avataneo V, Cusato J, Palermi A, Mula J, De Vivo E, Antonucci M, Bonora S, [Calcagno A](#), Di Perri G, De Rosa FG, D'Avolio A. Analytical Validation and Clinical Application of Rapid Serological Tests for SARS-CoV-2 Suitable for Large-Scale Screening. **Diagnostics (Basel)** 2021.
79. Caligaris G, Trunfio M, Ghisetti V, Cusato J, Nigra M, Atzori C, Imperiale D, Bonora S, Di Perri G, [Calcagno A](#). Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated Biomarkers. **Diagnostics (Basel)**. 2021.
80. [Calcagno A](#), Trunfio M, D'Avolio A, Di Perri G, Bonora S. The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV. **Expert Opin Drug Metab Toxicol** 2021.
81. [Calcagno A](#), de Nicolò A, Pizzi C, Trunfio M, Tettoni C, Ferrara M, Alcantarini C, Trentini L, D'Avolio A, Di Perri G, Bonora S. Medication burden and clustering in people living with HIV undergoing therapeutic drug monitoring. **Br J Clin Pharmacol** 2021.
82. Trunfio M, [Calcagno A](#), Bonora S, Di Perri G. Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases. **Lancet Infect Dis** 2021.
83. Trunfio M, Longo BM, Alladio F, Venuti F, Cerutti F, Ghisetti V, Bonora S, Di Perri G, [Calcagno A](#). On the SARS-CoV-2 "Variation Hypothesis": No Association Between Viral Load of Index Cases and COVID-19 Severity of Secondary Cases. **Front Microbiol** 2021.
84. Ancona G, Merlini E, Tincati C, Barassi A, [Calcagno A](#), Augello M, Bono V, Bai F, Cannizzo ES, d'Arminio Monforte A, Marchetti G. Long-Term Suppressive cART Is Not Sufficient to Restore Intestinal Permeability and Gut Microbiota Compositional Changes. **Front Immunol** 2021.
85. Trunfio M, Venuti F, Alladio F, Longo BM, Burdino E, Cerutti F, Ghisetti V, Bertucci R, Picco C, Bonora S, Di Perri G, [Calcagno A](#). Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. **Viruses** 2021.
86. Guaraldi G, Calza S, Milic J, [Calcagno A](#), Focà E, Rota M, Renzetti S, Celotti A, Siano M, Celesia BM, Piconi S, de Socio GV, Cattelan AM, Orofino G, Riva A, Nozza S, di Perri G. Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV. **AIDS** 2021.
87. Lin SP, [Calcagno A](#), Letendre SL, Ma Q. Clinical Treatment Options and Randomized Clinical Trials for Neurocognitive Complications of HIV Infection: Combination Antiretroviral Therapy, Central Nervous System Penetration Effectiveness, and Adjuvants. **Curr Top Behav Neurosci** 2021.

88. Trentalange A, Borgogno E, Motta I, Antonucci M, Pirriatore V, Costa C, Rossi G, Barco A, De Nicolò A, Piccioni P, D'Avolio A, Bonora S, Perri GD, [Calcagno A](#). Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses? **Int J Antimicrob Agents** 2021.
89. The TB/COVID-19 Global Study Group. TB and COVID-19 co-infection: rationale and aims of a global study. **Int J Tuberc Lung Dis** 2021.
90. Trunfio M, Salvador E, Gaviraghi A, Audagnotto S, Marinaro L, Motta I, Casciari R, Ghisetti V, Fava C, Bonora S, Di Perri G, [Calcagno A](#); e-COVID Study Group. Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity. **Antivir Ther** 2021.
91. De Nicolò A, Ianniello A, Ferrara M, Avataneo V, Cusato J, Antonucci M, De Vivo E, Waitt C, [Calcagno A](#), Trentalange A, Muccioli G, Bonora S, Di Perri G, D'Avolio A. Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV. **Pharmaceuticals (Basel)** 2020.
92. [Calcagno A](#), Dal Conte I, Cattaneo D, Testi R, Mistrangelo M, Gervasoni C, de Nicolò A, Bonora S, D'Avolio A, Di Perri G. Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders. **Antimicrob Agents Chemother** 2020.
93. Maggiolo F, Bandera A, Bonora S, Borderi M, [Calcagno A](#), Cattelan A, Cingolani A, Gianotti N, Lichtner M, Lo Caputo S, Madeddu G, Maggi P, Marchetti GC, Maserati R, Nozza S, Rusconi S, Zazzi M, Di Biagio A. Enhancing care for people living with HIV: current and future monitoring approaches. **Expert Rev Anti Infect Ther** 2020.
94. Trunfio M, Salvador E, Cabodi D, Marinaro L, Alcantarini C, Gaviraghi A, Trentalange A, Lipani F, Sciascia S, Roccatello D, Bonora S, Di Perri G, [Calcagno A](#); e-COVID Study group. Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection. **Thromb Res** 2020.
95. [Calcagno A](#), Ghisetti V, Emanuele T, Trunfio M, Faraoni S, Boglione L, Burdino E, Audagnotto S, Lipani F, Nigra M, D'Avolio A, Bonora S, Di Perri G. Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy. **Emerg Infect Dis** 2020.
96. [Calcagno A](#), Ghisetti V, Burdino E, Trunfio M, Allice T, Boglione L, Bonora S, Di Perri G. Coinfection with other respiratory pathogens in COVID-19 patients. **Clin Microbiol Infect** 2020.
97. De Benedetto I, Trunfio M, Guastamacchia G, Bonora S, [Calcagno A](#). A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs. **J Neurovirol** 2020.
98. [Calcagno A](#), Moltò J, Borghetti A, Gervasoni C, Milesi M, Valle M, Avataneo V, Alcantarini C, Pla-Junca F, Trunfio M, D'Avolio A, Di Giambenedetto S, Cattaneo D, Di Perri G, Bonora S. Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. **Clin Pharmacokinet** 2020.
99. Trunfio M, Ruggie W, Mighetto L, Vai D, Atzori C, Nigra M, Domini S, Borgogno E, Guastamacchia G, Bonora S, Di Perri G, [Calcagno A](#). Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV. **AIDS**. 2020.
100. Taramasso L, Fabbiani M, Nozza S, De Benedetto I, Bruzzesi E, Mastrangelo A, Pinnetti C, [Calcagno A](#), Ferrara M, Bozzi G, Focà E, Quiros-Roldan E, Ripamonti D, Campus M, Celesia BM, Torti C, Cosco L, Di Biagio A, Rusconi S, Marchetti G, Mussini C, Gulminetti R, Cingolani A, d'Ettorre G, Madeddu G, Franco A, Orofino G, Squillace N, Muscatello A, Gori A, Antinori A, Tambussi G, Bandera A; INACTION study group. Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort. **HIV Med** 2020.
101. Dravid AN, Gawali R, Betha TP, Sharma AK, Medisetty M, Natrajan K, Kulkarni MM, Saraf CK, Mahajan US, Kore SD, Rathod NM, Mahajan US, Letendre SL, Wadia RS, [Calcagno A](#). Two treatment strategies for management of Neurosymptomatic cerebrospinal fluid HIV escape in Pune, India. **Medicine (Baltimore)** 2020.
102. Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, Bonora S, [Calcagno A](#), Cecchi I, Cinnirella G, Converso M, Cozzi M, Crosasso P, De Iaco F, Di Perri G, Eandi M, Fenoglio R, Giusti M, Imperiale D, Imperiale G, Livigni S, Manno E, Massara C, Milone V, Natale G, Navarra M, Oddone V, Osella S, Piccioni P, Radin M, Roccatello D, Rossi D. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. **Clin Exp Rheumatol** 2020.
103. Muscatello A, Nozza S, Fabbiani M, De Benedetto I, Ripa M, Dell'acqua R, Antinori A, Pinnetti C, [Calcagno A](#), Ferrara M, Focà E, Quiros-Roldan E, Ripamonti D, Campus M, Maurizio Celesia B, Torti C, Cosco L, Di Biagio A, Rusconi S, Marchetti G, Mussini C, Gulminetti R, Cingolani A, D'ettorre G, Madeddu G, Franco A, Orofino G, Squillace N, Gori A, Tambussi G, Bandera A; Inaction Study Group. Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection-Results of Italian Network of ACuTe HIV InfectiON (INACTION) Retrospective Study. **Pathog Immun** 2020.
104. Mornese Pinna S, Trunfio M, Imperiale D, [Calcagno A](#). JC virus DNA in cerebrospinal fluid: insight into clinical significance. **Diagn Microbiol Infect Dis** 2020.
105. Lupia T, Milia MG, Atzori C, Gianella S, Audagnotto S, Imperiale D, Mighetto L, Pirriatore V, Gregori G, Lipani F, Ghisetti V, Bonora S, Di Perri G, [Calcagno A](#). Presence of Epstein-Barr virus DNA in cerebrospinal fluid is associated with greater HIV RNA and inflammation. **AIDS** 2020.
106. Joseph SB, Trunfio M, Kincer LP, [Calcagno A](#), Price RW. What can characterization of cerebrospinal fluid escape populations teach us about viral reservoirs in the central nervous system? **AIDS** 2019.
107. Lwanga I, Nabaggala MS, Kiragga A, [Calcagno A](#), Guaraldi G, Lamorde M, Castelnuovo B. Implementing routine physical function screening among elderly HIV-positive patients in Uganda. **AIDS Care** 2019.
108. Goletti D, Navarra A, Petruccioli E, Cimaglia C, Compagno M, Cuzzi G, De Carli G, Fondaco L, Franzetti F, Giannetti A, Gori A, Lapadula G, Lichtner M, Mastroianni CM, Mazzotta V, Orchi N, Pavone P, Piacentini D, Pirriatore V, Pontali E, Sarmati L, Spolti A, Tacconelli E, Galli M, Antinori A, [Calcagno A](#), Girardi E. Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases. **Int J Infect Dis**. 2020.
109. Lupia T, Scabini S, Stroffolini G, [Calcagno A](#). I have got you under my skin. **Infection** 2020.
110. Montrucchio C, De Nicolò A, D'Ettorre G, D'Ascenzo F, Lazzaro A, Tettoni M, D'Avolio A, Bonora S, Celani L, Di Perri G, [Calcagno A](#). Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the Effect of Probiotic Supplementation. **Int J Antimicrob Agents**. 2020.
111. Costa C, Scabini S, Kaimal A, Kasozi W, Cusato J, Kafufu B, Borderi M, Mwaka E, Di Perri G, Lamorde M, [Calcagno A](#), Castelnuovo B. Calcaneal quantitative ultrasound and urine retinol binding protein in HIV-positive antiretroviral-treated patients in Uganda: a pilot study. **J Infect Dis** 2020.

112. [Calcagno A](#), Cusato J, Ferrara M, De Nicolò A, Lazzaro A, Manca A, D'Avolio A, Di Perri G, Bonora S. Antiretroviral concentrations in the presence and absence of valproic acid. **J Antimicrob Chemother** 2020.
113. Cusato J, [Calcagno A](#), Marinaro L, Avataneo V, D'Avolio A, Di Perri G, Bonora S. Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients. **Pharmacogenomics J** 2019.
114. Focà E, Magro P, Guaraldi G, Riva A, Cattelan AM, De Socio GV, Costa C, Piconi S, Celesia BM, Nozza S, Orofino G, Castagna A, Di Perri G, Castelli F, [Calcagno A](#); GEPP0 (GEriatric Patients living with HIV/AIDS: a Prospective Multidimensional cOhort) Study Group. Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian "GEPP0" Cohort. **PLoS One** 2019.
115. Trunfio M, Manini C, Trentalange A, Boghi A, Audagnotto S, Imperiale D, Taraglio S, Bonora S, Di Perri G, [Calcagno A](#). The "milky way" galaxy of HIV-related central nervous system immune reaction syndromes. **J Neurovirol** 2019.
116. Di Stefano A, Alcantarini C, Atzori C, Lipani F, Imperiale D, Burdino E, Audagnotto S, Mighetto L, Milia MG, Di Perri G, [Calcagno A](#). Cerebrospinal fluid biomarkers in patients with central nervous system infections: a retrospective study. **CNS Spectr** 2019.
117. Armenia D, Di Carlo D, Cozzi-Lepri A, [Calcagno A](#), Borghi V, Gori C, Bertoli A, Gennari W, Bellagamba R, Castagna A, Latini A, Pinnetti C, Cicalini S, Saracino A, Lapadula G, Rusconi S, Castelli F, Di Giambenedetto S, Andreoni M, Di Perri G, Antinori A, Mussini C, Ceccherini-Silberstein F, Monforte AD, Perno CF, Santoro MM; ICONA Foundation Study Group. Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. **Antivir Ther** 2019.
118. Cusato J, [Calcagno A](#), De Nicolò A, Mogyorosi K, D'Avolio A, Di Perri G, Bonora S. Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2. **Diagn Microbiol Infect Dis** 2019.
119. Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, [Calcagno A](#), Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P. Low Antituberculosis Drug Concentrations in HIV-Tuberculosis Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines? **Antimicrob Agents Chemother** 2019.
120. Ssebambulidde K, Segawa I, Laker E, Lamorde M, Castelnuovo B, Nakasujja N, [Calcagno A](#). Symptomatic cerebrospinal fluid HIV-1 escape in two patients on second-line antiretroviral therapy in Uganda. **Oxf Med Case Reports**. 2019. *Not Impacted*.
121. [Calcagno A](#), Cusato J, Sekaggya-Wiltshire C, von Braun A, Motta I, Turyasingura G, Castelnuovo B, Fehr J, Di Perri G, Lamorde M. The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Co-infected Patients in Uganda in the SOUTH Study. **Clin Pharmacol Ther** 2019.
122. Pinzone MR, Ceccarelli M, Venanzi Rullo E, Maresca M, Bruno R, Condorelli F, Di Rosa M, Madeddu G, Focà E, [Calcagno A](#), Celesia BM, Cacopardo B, Nunnari G, Pellicanò GF. Circulating angiopoietin-like protein 2 levels are associated with decreased renal function in HIV+ subjects on cART: A potential marker of kidney disease. **Biomed Rep**. 2019. *Not Impacted*.
123. Peyracchia M, Verardi R, Rubin SR, Abu-Assi E, Montrucchio C, Perl L, Grossomarra W, [Calcagno A](#), Omedè P, Montefusco A, Bonora S, Moretti C, D'Amico M, Mauro R, D'Ascenzo F. In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis. **J Cardiovasc Med (Hagerstown)** 2019.
124. Mondì A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, [Calcagno A](#), De Luca A, Maggiolo F, Marchetti G, Antinori A, d'Arminio Monforte A; Icona Foundation Study Group. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. **J Int AIDS Soc** 2019.
125. Lupia T, Costa C, Forni N, [Calcagno A](#). A "Tinea" immune reconstitution inflammatory syndrome in a HIV-positive patient starting combination antiretroviral treatment. **G Ital Dermatol Venereol** 2019.
126. Bertero L, Joseph SB, Trunfio M, Alice T, Catera S, Imperiale D, Cassoni P, Kincer LP, Pirriatore V, Ghisetti V, Amasio E, Zanusso G, Bonora S, Di Perri G, [Calcagno A](#). HIV-1 detection in the olfactory mucosa of HIV-1 infected participants. **AIDS** 2019.
127. Borghetti A, Calcagno A, Lombardi F, Cusato J, Belmonti S, D'Avolio A, Ciccarelli N, La Monica S, Colafigli M, Delle Donne V, De Marco R, Tamburrini E, Visconti E, Di Perri G, De Luca A, Bonora S, Di Giambenedetto S. SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. **J Antimicrob Chemother** 2018.
128. Trunfio M, Pinnetti C, Focà E, Bai F, Maffongelli G, Celani L, Cinque P, Celotti A, Andreoni M, Monforte AD, D'Ettorre G, Antinori A, [Calcagno A](#). Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities: is it time to assess the definitions? **AIDS** 2018.
129. Di Perri G, [Calcagno A](#), Trentalange A, Bonora S. The clinical pharmacology of integrase inhibitors. **Expert Rev Clin Pharmacol** 2018.
130. [Calcagno A](#), Fiumanò M, Zugna D, Cusato J, Montrucchio C, Marinaro L, Trentini L, Ferrara M, D'Avolio A, Pizzi C, Di Perri G, Bonora S. Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization? **Pharmacogenomics J** 2019.
131. von Braun A, Castelnuovo B, Ledergerber B, Cusato J, Buzibye A, Kambugu A, Fehr J, [Calcagno A](#), Lamorde M, Sekaggya-Wiltshire C. High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. **J Antimicrob Chemother** 2019.
132. Trentalange A, Prochet A, Imperiale D, Cusato J, Tettoni M, Nunnari G, Barco A, Bonora S, Di Perri G, [Calcagno A](#). Cerebral white matter Hyperintensities in HIV-positive patients. **Brain Imaging Behav** 2018.
133. Aliberti S, Codecasa LR, Gori A, Sotgiu G, Spotti M, Di Biagio A, [Calcagno A](#), Nardini S, Assael BM, Tortoli E, Besozzi G, Ferrarese M, Matteelli A, Girardi E, De Lorenzo S, Seia M, Gramegna A, Del Prato B, Terranova L, Oriano M, Sverzellati N, Mirsaeidi M, Chalmers JD, Haworth CS, Loebinger MR, Aksamit T, Winthrop K, Ringshausen FC, Prevedi G, Blasi F; IRENE Network. The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol. **Multidiscip Respir Med** 2018. *Not Impacted*.
134. Merlini E, Iannuzzi F, [Calcagno A](#), Bai F, Trunfio M, d'Arminio Monforte A, Bonora S, Marchetti G. Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART). **J Neurovirol** 2018.
135. Scabini S, Trunfio M, Pirriatore V, Imperiale D, Audagnotto S, Bertucci R, Ghisetti V, Cinnirella G, Cistaro A, Perna M, [Calcagno A](#), Di Perri G. Antiviral activity of maraviroc plus mirtazapine in a low-risk HIV-negative patient with progressive multifocal leukoencephalopathy. **Infez Med** 2018. *Not Impacted*.

136. Allegra S, Cardellino CS, Fatiguso G, Cusato J, De Nicolò A, Avataneo V, Bonora S, D'Avolio A, Di Perri G, [Calcagno A](#). Effect of ABCG2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. **J Clin Pharmacol** 2018.
137. Focà E, Cavaglià G, Rusconi S, Cascavilla A, Cenderello G, Re A, Casari S, van den Bogaart L, Zinzani PL, Caracciolo D, Di Perri G, Bonito A, Lucchini A, Cassola G, Viale P, [Calcagno A](#). Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study. **HIV Med** 2018.
138. Peyracchia M, De Lio G, Montrucchio C, Omedè P, d'Ettore G, [Calcagno A](#), Vullo V, Cerrato E, Pennacchi M, Sardella G, Manga P, GrossoMarra W, Vullo F, Fedele F, Biondi-Zoccai G, Moretti C, Vachiat A, Bonora S, Rinaldi M, Mancone M, D'Ascenzo F. Evaluation of coronary features of HIV patients presenting with ACS: The CUORE, a multicenter study. **Atherosclerosis** 2018.
139. Trunfio M, Vai D, Montrucchio C, Alcantarini C, Livelli A, Tettoni MC, Orofino G, Audagnotto S, Imperiale D, Bonora S, Di Perri G, [Calcagno A](#). Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders. **HIV Med** 2018.
140. Focà E, [Calcagno A](#), Bonito A, Cusato J, Domenighini E, D'Avolio A, Quiros Roldan E, Trentini L, Castelnuovo F, Di Perri G, Castelli F, Bonora S. Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir. **Antimicrob Agents Chemother** 2018.
141. Guaraldi G, Malagoli A, [Calcagno A](#), Mussi C, Celesia BM, Carli F, Piconi S, De Socio GV, Cattelan AM, Orofino G, Riva A, Focà E, Nozza S, Di Perri G. The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 - 74 years and more than 75 years. **BMC Geriatr** 2018.
142. [Calcagno A](#), Pinnetti C, De Nicolò A, Scarvaglieri E, Gisslen M, Tempestilli M, D'Avolio A, Fedele V, Di Perri G, Antinori A, Bonora S. Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration. **Br J Clin Pharmacol**. 2018.
143. Bigliano P, [Calcagno A](#), Lucchini A, Audagnotto S, Montrucchio C, Marinaro L, Alcantarini C, Ghisetti V, Di Perri G, Bonora S. The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment. **Antivir Ther** 2018.
144. [Calcagno A](#), Barco A, Trunfio M, Bonora S. CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose. **Curr HIV/AIDS Rep** 2018.
145. Palazzo A, Trunfio M, Pirriatore V, Milesi M, De Nicolò A, Alcantarini C, D'Avolio A, Bonora S, Di Perri G, [Calcagno A](#). Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid. **J Antimicrob Chemother** 2017.
146. Trunfio M, Joseph SB, Ghisetti V, Romito A, Martini C, Cusato J, Audagnotto S, Pesci Kincer L, Ferrara M, Sala A, Imperiale D, Di Perri G, [Calcagno A](#). Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia. **J Neurovirol**. 2017.
147. Motta I, [Calcagno A](#), Bonora S. Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? **Expert Opin Drug Metab Toxicol** 2018.
148. Cusato J, Allegra S, Nicolò A, [Calcagno A](#), D'Avolio A. Precision medicine for HIV: where are we? **Pharmacogenomics**. 2018.
149. Motta I, Trunfio M, [Calcagno A](#), Pirriatore V, Scabini S, Palazzo A, Audagnotto S, Fatiguso G, Liberini V, Bellò M, D'Avolio A, Di Perri G, Bonora S. Undetectable antimicrobial plasma concentrations in an HIV-positive patient with protein-losing enteropathy and chylothorax during *Mycobacterium genavense* and Leishmania abdominal infections. **J Antimicrob Chemother** 2017.
150. Focà E, [Calcagno A](#), Bonito A, Simiele M, Domenighini E, D'Avolio A, Quiros Roldan E, Trentini L, Casari S, Di Perri G, Castelli F, Bonora S. Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients. **J Antimicrob Chemother** 2017.
151. [Calcagno A](#), Piconi S, Focà E, Nozza S, Carli F, Montrucchio C, Cattelan AM, Orofino G, Celesia BM, Morena V, De Socio GV, Guaraldi G; GEPP0 (Geriatric Patients living with HIV/AIDS: a Prospective Multidimensional cOHort) Study Group. Role of Normalized T-Cell Subsets in Predicting Comorbidities in a Large Cohort of Geriatric HIV-infected Patient. **J Acquir Immune Defic Syndr** 2017.
152. Mornese Pinna S, Scarvaglieri E, Milia MG, Imperiale D, Ghisetti V, Audagnotto S, Prochet A, Lipani F, Bonora S, Di Perri G, [Calcagno A](#). Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy? **J Neurovirol** 2017.
153. Nozza S, Malagoli A, Maia L, [Calcagno A](#), Focà E, De Socio G, Piconi S, Orofino G, Cattelan AM, Celesia BM, Gervasi E, Guaraldi G; GEPP0 Study Group. Antiretroviral therapy in geriatric HIV patients: the GEPP0 cohort study. **J Antimicrob Chemother** 2017.
154. Allegra S, Fatiguso G, [Calcagno A](#), Baietto L, Motta I, Favata F, Cusato J, Bonora S, Di Perri G, D'Avolio A. Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics. **Pharmacogenomics** 2017.
155. [Calcagno A](#), Lucchini A, Caracciolo D, Balbiano R, Bracchi M, Sordella F, Gregori G, Lipani F, Audagnotto S, Chiriotto M, Cavaglià G, Ghisetti V, Di Perri G, Bonora S. High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative Disorders. **Curr HIV Res** 2017.
156. [Calcagno A](#), Pagani N, Ariaudo A, Arduino G, Carcieri C, D'Avolio A, Marinaro L, Tettoni MC, Trentini L, Di Perri G, Bonora S. Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure. **J Antimicrob Chemother** 2017.
157. Biagini R, Montrucchio C, [Calcagno A](#), Trentini L, Tettoni MC, Alcantarini C, Barco A, Trentalange A, Milesi M, Ferrara M, Bertucci R, Di Perri G, Bonora S. Geriatrics in HIV infection: multimorbidity, polypharmacy and primary prevention in patients above 65 years). **Journal of HIV and Ageing**. 2017. *Not Impacted*
158. Motta I, Alice T, Romito A, Ferrara M, Ecclesia S, Imperiale D, Ghisetti V, Di Perri G, Bonora S, [Calcagno A](#). Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia. **Antivir Ther** 2017.
159. Motta I, [Calcagno A](#), Baietto L, Bigliano P, Costa C, Baruffi K, Fatiguso G, D'Avolio A, Di Perri G, Bonora S. Pharmacokinetics of first-line antitubercular drugs in plasma and PBMCs. **Br J Clin Pharmacol** 2017.
160. Montrucchio C, Biagini R, Alcantarini C, [Calcagno A](#), Barco A, Ferrara M, Milesi M, Costa C, Trentalange A, Trunfio M, Tettoni MC, Grosso Marra W, D'Ascenzo F, Ballocca F, Lonni E, Gili S, Vai D, Imperiale D, Gaita F, Bonora S, Di Perri G. Cardiovascular risk and neurocognitive deficits in HIV-positive individuals. **Infectious Diseases & Tropical Medicine** 2017. *Not Impacted*.

161. [Calcagno A](#), Di Perri G, Bonora S. Treating HIV Infection in the Central Nervous System. **Drugs** 2017.
162. Armenia D, Di Carlo D, [Calcagno A](#), Vendemiati G, Forbici F, Bertoli A, Berno G, Carta S, Continenza F, Fedele V, Bellagamba R, Cicalini S, Ammassari A, Libertone R, Zaccarelli M, Ghisetti V, Andreoni M, Ceccherini-Silberstein F, Bonora S, Di Perri G, Antinori A, Perno CF, Santoro MM. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. **J Antimicrob Chemother** 2016.
163. Marinaro L, [Calcagno A](#), Ripamonti D, Cenderello G, Pirriatore V, Trentini L, Salassa B, Bramato C, Orofino G, D'Avolio A, Rizzi M, Di Perri G, Rusconi S, Bonora S. Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. **J Clin Virol** 2016.
164. Guaraldi G, Menozzi M, Zona S, [Calcagno A](#), Silva AR, Santoro A, Malagoli A, Dolci G, Mussi C, Mussini C, Cesari M, Khoo SH. Impact of polypharmacy on antiretroviral prescription in people living with HIV. **J Antimicrob Chemother** 2016.
165. [Calcagno A](#), Romito A, Atzori C, Ghisetti V, Cardellino C, Audagnotto S, Scarvaglieri E, Lipani F, Imperiale D, Di Perri G, Bonora S. Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus Astrocytosis. **J Neuroimmune Pharmacol** 2016.
166. Sanfilippo C, Nunnari G, [Calcagno A](#), Malaguarnera L, Blennow K, Zetterberg H, Di Rosa M. The chitinases expression is related to Simian Immunodeficiency Virus Encephalitis (SIVE) and in HIV encephalitis (HIVE). **Virus Res** 2016.
167. [Calcagno A](#), Cusato J, D'Avolio A, Bonora S. Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs. **Clin Pharmacokinet** 2016.
168. Gili S, Mancone M, Ballocca F, Grosso Marra W, [Calcagno A](#), D'Ettoire G, Cannillo M, D'Ascenzo F, Orofino G, Marruncheddu L, Lonni E, Cinque A, Vullo F, Ceccarelli G, Vilardi I, Sardella G, Vullo V, Moretti C, Fedele F, Bonora S, Gaita F. Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study. **J Cardiovasc Med (Hagerstown)** 2016.
169. Ruggiero T, Burdino E, [Calcagno A](#), Bonora S, Boglione L, Di Perri G, Ghisetti V. HCV NS3 naturally occurring variants in HIV/HCV coinfecting DAA-naïve patients: consideration for HCV genotyping resistance testing. **Infection** 2016.
170. Focà E, Nunnari G, [Calcagno A](#). The good, the bad and the ugly: Determinants of antiretroviral-associated toxicities. *Future Virology* 2016.
171. Patti F, [Calcagno A](#), Simiele M, Bonasso M, Di Perri G, D'Avolio A, Bonora S. Pharmacokinetics of an antiretroviral regimen in a patient unable to swallow solid oral dosage forms. **Am J Health Syst Pharm** 2016.
172. [Calcagno A](#), Di Perri G, Bonora S. What do we know about tailoring treatment with tenofovir? **Pharmacogenomics** 2016.
173. [Calcagno A](#), Simiele M, Motta I, Mornese Pinna S, Bertucci R, D'Avolio A, Di Perri G, Bonora S. Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients. **AIDS Res Hum Retroviruses** 2016.
174. Ballocca F, Gili S, D'Ascenzo F, Marra WG, Cannillo M, [Calcagno A](#), Bonora S, Flammer A, Coppola J, Moretti C, Gaita F. HIV Infection and Primary Prevention of Cardiovascular Disease: Lights and Shadows in the HAART Era. **Prog Cardiovasc Dis** 2016.
175. Trentalange A, [Calcagno A](#), Ghisetti V, Atzori C, Busolli P, Bonora S, Imperiale D. Clearance of cerebrospinal fluid JCV DNA with mirtazapine in a patient with progressive multifocal leukoencephalopathy and sarcoidosis. **Antivir Ther** 2016.
176. Gili S, Grosso Marra W, D'Ascenzo F, Lonni E, [Calcagno A](#), Cannillo M, Ballocca F, Cerrato E, Pianelli M, Barbero U, Mancone M, DiNicolantonio JJ, Lavie CJ, Omedè P, Montefusco A, Bonora S, Gasparini M, Biondi-Zoccai G, Moretti C, Gaita F. Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. **Eur Heart J** 2016.
177. Lucchini A, Lipani F, Costa C, Scarvaglieri M, Balbiano R, Carosella S, [Calcagno A](#), Audagnotto S, Barbui AM, Brossa S, Ghisetti V, Dal Conte I, Caramello P, Di Perri G. Louseborne Relapsing Fever among East African Refugees, Italy, 2015. **Emerg Infect Dis**. 2016.
178. Cusato J, Tomasello C, Simiele M, [Calcagno A](#), Bonora S, Marinaro L, Leggieri A, Allegra S, Di Perri G, D'Avolio A. Efavirenz pharmacogenetics in a cohort of Italian patients. **Int J Antimicrob Agents** 2015.
179. Motta I, [Calcagno A](#), Baietto L, D'Avolio A, De Rosa FG, Bonora S. A probable drug-to-drug interaction between voriconazole and haloperidol in a slow CYP2C9 metabolizer. **Infez Med** 2015. *Not impacted*.
180. Bonora S, [Calcagno A](#), Trentalange A, Perri GD. Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults. **Expert Opin Pharmacother** 2015.
181. Fatiguso G, Allegra S, [Calcagno A](#), Baietto L, Motta I, Favata F, Cusato J, Bonora S, Perri GD, D'Avolio A. Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. **Int J Pharm**. 2015.
182. [Calcagno A](#), Rostagno R, Arnaudo I, Zanusso G, Bonora S, Lucchini A, Maiello A, Dal Conte I, Meoli I, Ferrari S, Monaco S, Rizzuto N, Di Perri G. CSF 14-3-3 protein and its  $\zeta$  isoform are prognostic markers in HIV positive patients with CNS disease. **Infectious Diseases & Tropical Medicine** 2015. *Not Impacted*.
183. [Calcagno A](#), Cusato J, Marinaro L, Simiele M, Lucchiarini M, Alcantarini C, Tettoni MC, Trentini L, Mengozzi G, D'Avolio A, Di Perri G, Bonora S. Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment. **AIDS** 2016.
184. Livelli A, Orofino GC, [Calcagno A](#), Farenga M, Penoncelli D, Guastavigna M, Carosella S, Caramello P, Pia L. Evaluation of a Cognitive Rehabilitation Protocol in HIV Patients with Associated Neurocognitive Disorders: Efficacy and Stability Over Time. **Front Behav Neurosci** 2015.
185. Andreoni M, Marcotullio S, Puro V, De Carli G, Tambussi G, Nozza S, Gori A, Rusconi S, Santoro MM, Clementi M, Perno CF, d'Arminio Monforte A, Maggiolo F, Castagna A, De Luca A, Galli M, Giacomelli A, Borderi M, Guaraldi G, [Calcagno A](#), Di Perri G, Bonora S, Mussini C, Di Biagio A, Puoti M, Bruno R, Zuccaro V, Antinori A, Cinque P, Croce D, Restelli U, Rizzardini G, Lazzarin A. An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXtAim Project. **New Microbiol** 2015.
186. [Calcagno A](#), Cusato J, Marinaro L, Trentini L, Alcantarini C, Mussa M, Simiele M, D'Avolio A, Di Perri G, Bonora S. Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines. **Pharmacogenomics J** 2015.
187. [Calcagno A](#), Montrucchio C, Capetti A, Guaraldi G, Cenderello G, Calza L, Lanzafame M, Marinaro L, Tettoni MC, Trentini L, D'Avolio A, Di Perri G, Bonora S. Raltegravir plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-positive Patients: Safety, Efficacy and Pharmacokinetics. **Curr HIV Res** 2015.
188. [Calcagno A](#), Trentalange A, Simiele M, Marinaro L, Patti F, Tettoni MC, Trentini L, Di Perri G, D'Avolio A, Bonora S. Rilpivirine Pharmacokinetics in 3 HIV-Positive Patients With Liver Cirrhosis Concomitantly Receiving Pantoprazole. **Ther Drug Monit** 2015.

189. [Calcagno A](#), Atzori C, Romito A, Vai D, Audagnotto S, Stella ML, Montrucchio C, Imperiale D, Di Perri G, Bonora S. Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients. **J Neurovirol** 2015.
190. Siccardi M, Olagunju A, Simiele M, D'Avolio A, [Calcagno A](#), Di Perri G, Bonora S, Owen A. Class-specific relative genetic contribution for key antiretroviral drugs. **J Antimicrob Chemother** 2015.
191. Bonora S, Rusconi S, [Calcagno A](#), Bracchi M, Viganò O, Cusato J, Lanzafame M, Trentalange A, Marinaro L, Siccardi M, D'Avolio A, Galli M, Di Perri G. Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). **J Antimicrob Chemother** 2015.
192. [Calcagno A](#), Motta I, Ghisetti V, Lo Re S, Alice T, Marinaro L, Milia MG, Tettoni MC, Trentini L, Orofino G, Salassa B, Di Perri G, Bonora S. HIV-1 Very Low Level Viremia is Associated with Virological Failure in HAART-treated Patients. **AIDS Res Hum Retroviruses** 2015.
193. [Calcagno A](#), D'Avolio A, Bonora S. Pharmacokinetic and pharmacodynamic evaluation of Raltegravir and Experience from Clinical Trials in HIV-positive Patients. **Expert Opinion On Drug Metabolism and Toxicology** 2015.
194. Baietto L, [Calcagno A](#), Motta I, Baruffi K, Poretti V, Di Perri G, Bonora S, D'Avolio A. A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. **J Antimicrob Chemother** 2015.
195. Simiele M, Carcieri C, De Nicolò A, Ariaudo A, Sciandra M, [Calcagno A](#), Bonora S, Di Perri G, D'Avolio A. A LC-MS method to quantify tenofovir urinary concentrations in treated patients. **J Pharm Biomed Anal** 2015.
196. [Calcagno A](#), Nozza S, Muss C, Celesia BM, Carli F, Piconi S, De Socio GV, Cattelan AM, Orofino G, Ripamonti D, Riva A, Di Perri G. Ageing with HIV: a multidisciplinary review. **Infection** 2015.
197. Cerrato E, [Calcagno A](#), D'Ascenzo F, Biondi-Zoccai G, Mancone M, Grosso Marra W, Demarie D, Omedè P, Abbate A, Bonora S, DiNicolantonio JJ, Estrada V, Escaned J, Moretti C, Gaita F. Cardiovascular disease in HIV patients: from bench to bedside and backwards. **Open Heart** 2015. *Not Impacted*.
198. D'Ascenzo F, Cerrato E, [Calcagno A](#), Grossomarra W, Ballocca F, Omedè P, Montefusco A, Veglia S, Barbero U, Gili S, Cannillo M, Pianelli M, Mistretta E, Raviola A, Salera D, Garabello D, Mancone M, Estrada V, Escaned J, De Marie D, Abbate A, Bonora S, Zoccai GB, Moretti C, Gaita F. High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis. **Atherosclerosis** 2015.
199. Ghisetti V, [Calcagno A](#), Burdino E, Orofino G, Bonora S. Acute HIV infection: Improved algorithms for HIV testing. **J Clin Virol** 2015.
200. [Calcagno A](#), Motta I, Milia M, Rostagno R, Simiele M, Libanore V, Fontana S, D'Avolio A, Ghisetti V, Di Perri G, Bonora S. Dried Plasma/Blood Spots for Monitoring Antiretroviral Treatment Efficacy and Pharmacokinetics: a Cross-sectional Study in Rural Burundi. **Br J Clin Pharmacol** 2015.
201. [Calcagno A](#), Simiele M, Alberione MC, Bracchi M, Marinaro L, Ecclesia S, Di Perri G, D'Avolio A and Bonora S. Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control. **Clin Infect Dis** 2015.
202. Baietto L, D'Avolio A, Cusato J, Pace S, [Calcagno A](#), Motta I, Corcione S, Di Perri G, De Rosa FG. Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. **J Antimicrob Chemother** 2014.
203. [Calcagno A](#), Di Perri G, Bonora S. Pharmacokinetics and Pharmacodynamics of Antiretrovirals in the Central Nervous System. **Clinical Pharmacokinetics** 2014.
204. Trentalange A, [Calcagno A](#), Raviolo S, Prochet A, Audagnotto S, Ghisetti V, Di Perri G and Bonora S. Cytomegalovirus Central Nervous System Compartmentalization in a Patient Presenting with AIDS. **Antiviral therapy** 2014.
205. Bonora S, [Calcagno A](#), Viganò O, Bigliano P, Marinaro L, Colella E, Orofino G, Trentini L, Tettoni MC, D'Avolio A, Mercadante S, Galli M, Di Perri G and Rusconi S. Efficacy, Tolerability and Virological Consequences of Long-term Use of Unboosted Atazanavir plus 2 NRTIs in HIV-infected Patients. **Current HIV Research** 2014.
206. [Calcagno A](#), Baietto L, Pagani N, Simiele M, Audagnotto S, D'Avolio A, De Rosa FG, Di Perri G and Bonora S. Voriconazole and Atazanavir: a CYP 2C19-dependant Manageable Drug to Drug Interaction. **Pharmacogenomics** 2014.
207. Cannillo M, D'Ascenzo F, Grosso Marra W, Cerrato E, [Calcagno A](#), Omedè P, Bonora S, Mancone M, Vizza D, DiNicolantonio JJ, Pianelli M, Barbero U, Gili S, Annone U, Raviola A, Salera D, Mistretta E, Vilardi I, Colaci C, Abbate A, Zoccai GB, Moretti C, Gaita F. Heart failure in patients with human immunodeficiency virus: a review of the literature. **J Cardiovasc Med (Hagerstown)** 2014.
208. Lanzafame M, Bonora S, Lattuada E, [Calcagno A](#), Di Perri G, Concia E. Disappearance of renal stones in a HIV-1-infected patient after reduction of atazanavir dose. **AIDS Res Hum Retroviruses** 2014.
209. D'Avolio A, Carcieri C, Cusato J, Simiele M, [Calcagno A](#), Allegra S, Sciandra M, Trentini L, Di Perri G, Bonora S. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. **J Antimicrob Chemother** 2014.
210. D'Ascenzo F, Quadri G, Cerrato E, [Calcagno A](#), Omedè P, Grosso Marra W, Abbate A, Bonora S, Biondi Zoccai G, Moretti C, Gaita F. A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era. **J Cardiovasc Med (Hagerstown)** 2014.
211. [Calcagno A](#), Alberione MC, Romito A, Imperiale D, Ghisetti V, Audagnotto S, Lipani F, Raviolo S, Di Perri G, Bonora S. Prevalence and predictors of blood-brain barrier damage in the HAART era. **J Neurovirol**. 2014.
212. D'Ascenzo F, Cerrato E, Appleton D, Moretti C, [Calcagno A](#), Abouzaki N, Vetrovec G, Lhermusier T, Carrie D, Das Neves B, Escaned J, Cassese S, Kastrati A, Chinaglia A, Belli R, Capodanno D, Tamburino C, Santilli F, Parodi G, Vachiat A, Manga P, Vignali L, Mancone M, Sardella G, Fedele F, DiNicolantonio JJ, Omedè P, Bonora S, Gaita F, Abbate A, Biondi Zoccai G. Prognostic Indicators for Recurrent Thrombotic Events in HIV-infected Patients With Acute Coronary Syndromes: Use of Registry Data From 12 sites in Europe, South Africa and the United States. **Thrombosis Research** 2014.
213. [Calcagno A](#), Marinaro L, Nozza S, Aldieri C, Carbone A, Ghisetti V, Trentalange A, D'Avolio A, Castagna A, Di Perri G and Bonora S. Etravirine Plasma Exposure is Associated with Virological Efficacy in Treatment-experienced HIV-positive Patients. **Antiviral Res** 2014.
214. [Calcagno A](#), Lamorde M, D'Avolio A and Bonora S. Personalizing HIV Therapeutics in Resource-Limited Rural Communities: Lessons Learned From the Use of New Tools in Africa. **Current Pharmacogenomics and Personalized Medicine** 2014. *Not Impacted*
215. De Nicolò A, Simiele M, [Calcagno A](#), Abdi AM, Bonora S, Di Perri G and D'Avolio A. Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitors regimens. **Antimicrob Agents Chemother** 2014.

216. [Calcagno A](#), Nozza S, Simiele M, Milia MG, Chiappetta S, D'Avolio A, Ghisetti V, Lazzarin A, Di Perri G, Bonora S. Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. **J Antimicrob Chemother** 2014.
217. De Nicolò A, Simiele M, [Calcagno A](#), Mohamed Abdi A, Bonora S, Di Perri G, D'Avolio A. Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitors regimens. **Antimicrob Agents Chemother** 2014.
218. Corcione S, Cardellino CS, [Calcagno A](#), Fossati L, Costa C, Cavallo R, Di Perri G, De Rosa FG. Health-care Associated KPC-BSI: The Time Has Come. **Clin Infect Dis** 2014.
219. Salizzoni S, D'Ascenzo F, Moretti C, Bonora S, [Calcagno A](#), Omedè P, Montrucchio C, Cerrato E, Colaci C, Sheiban I, Marra S, Rinaldi M, Gaita F. Transcatheter aortic valve implantation in a 54-year-old patient with aggressive HIV. **World J Clin Cases** 2014. *Not Impacted*
220. Marchetti G, Cozzi-Lepri A, Tincati C, [Calcagno A](#), Ceccherini-Silberstein F, De Luca A, Antinori A, Castagna A, Puoti M, Monforte Ad; Icona Foundation Study Group. Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study. **BMC Infect Dis** 2014.
221. Nozza S, Bigoloni A, [Calcagno A](#), Galli L, Pignataro AR, D'Avolio A, Carbone A, Ripa M, Bonora S, Lazzarin A, Castagna A. Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. **J Antimicrob Chemother** 2014.
222. De Francia S, D'Avolio A, Ariaudo A, Pirro E, Piccione F, Simiele M, Fava C, [Calcagno A](#), Di Perri G, Saglio G. Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia. **Ther Drug Monit** 2014.
223. [Calcagno A](#), D'Avolio A, Di Perri G and Bonora S. Comment on "Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral therapy is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid". **J Acquir Immune Defic Syndr** 2013.
224. [Calcagno A](#), Cusato J, Simiele M, et al. High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. **J Antimicrob Chemother** 2014.
225. Ruggiero T, De Rosa F, Cerutti F, Pagani N, Alice T, Stella ML, Milia MG, [Calcagno A](#), Burdino E, Gregori G, Urbino R, Di Perri G, Ranieri MV, Ghisetti V. A(H1N1)pdm09 hemagglutinin D222G and D222N variants are frequently harbored by patients requiring extracorporeal membrane oxygenation and advanced respiratory assistance for severe A(H1N1)pdm09 infection. **Influenza Other Respi Viruses** 2013.
226. [Calcagno A](#), Baietto L, Pagani N, et al. Pharmacokinetics of caspofungin increased dosage in a patient on rifampin-containing anti-tubercular treatment. **Scand J Infect Dis** 2013.
227. D'Avolio A, Cusato J, [Calcagno A](#) and Di Perri G. Estimating Ribavirin plasma exposure: genetics or therapeutic drug monitoring? **J Hepatol** 2013.
228. [Calcagno A](#), Trentini L, Marinaro L, Montrucchio C, D'Avolio A, Ghisetti V, Di Perri G, Bonora S. Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART in late pregnancy. **J Antimicrob Chemother** 2013.
229. [Calcagno A](#), Nozza S, de Requena DG, Galli A, D'Avolio A, Simiele M, Chiappetta S, Di Perri G, Lazzarin A, Bonora S. Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naïve patients. **J Antimicrob Chemother** 2013.
230. [Calcagno A](#), Boglione L, De Rosa FG, Di Perri G, Bonora S. Elimination Half-Life May Explain the Relative Efficacy of Boceprevir and Telaprevir in the Treatment of Hepatitis C Virus Genotype 1. **Clin Infect Dis** 2013.
231. [Calcagno A](#), Gonzalez de Requena D, Simiele M, D'Avolio A, Tettoni M, Salassa B, Orofino G, Bramato C, Libanore V, Motta I, Bigliano P, Orsucci E, Di Perri G, Bonora S. Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function. **Antimicrob Agents Chemother** 2013.
232. Santoro MM, Armenia D, Alteri C, Flandre P, [Calcagno A](#), Santoro M, Gori C, Fabeni L, Bellagamba R, Borghi V, Forbici F, Latini A, Palamara G, Libertone R, Tozzi V, Boumis E, Tommasi C, Pinnetti C, Ammassari A, Nicastri E, Buonomini A, Svicher V, Andreoni M, Narciso P, Mussini C, Antinori A, Ceccherini-Silberstein F, Di Perri G, Perno CF. Impact of pre-therapy viral load on virological response to modern first-line HAART. **Antivir Ther** 2013.
233. Cerrato E, D'Ascenzo F, Biondi-Zoccai G, [Calcagno A](#), Frea S, Grosso Marra W, Castagno D, Omedè P, Quadri G, Sciuto F, Presutti D, Frati G, Bonora S, Moretti C, Gaita F. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. **Eur Heart J** 2013.
234. [Calcagno A](#), Tettoni MC, Simiele M, Trentini L, Montrucchio C, D'Avolio A, Di Perri G, Bonora S. Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. **J Antimicrob Chemother** 2013.
235. Rekić D, Röshammar D, Bergstrand M, Tarning J, [Calcagno A](#), D'Avolio A, Ormaasen V, Vigan M, Barrail-Tran A, Ashton M, Gisslén M, Abelö A. External Validation of the Bilirubin-Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients. **AAPS J** 2013.
236. D'Avolio A, Simiele M, [Calcagno A](#), Siccardi M, Larovere G, Agati S, Baietto L, Cusato J, Tettoni M, Sciandra M, Trentini L, Di Perri G, Bonora S. Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. **J Antimicrob Chemother** 2012.
237. D'Avolio A, Ciancio A, Siccardi M, Smedile A, Simiele M, Cusato J, Baietto L, Marucco DA, Cariti G, [Calcagno A](#), Gonzalez de Requena D, Sciandra M, Troshina G, Caviglia GP, Bonora S, Rizzetto M, Di Perri G. Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. **Ther Drug Monit** 2012.
238. [Calcagno A](#), Rostagno R, Di Perri G. Anti-CD20 antibody therapy for B-cell lymphomas. **N Engl J Med** 2012.
239. Bibas M, Lorenzini P, Cozzi-Lepri A, [Calcagno A](#), di Giambenedetto S, Costantini A, Castagna A, Manfrin V, Monforte AD, Antinori A; for the ICONA Cohort Study Group. Polyclonal serum free light chains elevation in HIV-infected patients. **AIDS** 2012.
240. [Calcagno A](#), Yilmaz A, Cusato J, Simiele M, Bertucci R, Siccardi M, Marinaro L, D'Avolio A, Di Perri G, Bonora S. Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. **AIDS**. 2012.
241. D'Avolio A, De Nicolò A, Simiele M, Turini S, Agnesod D, Boglione L, Cusato J, Baietto L, Cariti G, [Calcagno A](#), Sciandra M, Di Perri G, Bonora S. Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. **J Pharm Biomed Anal**. 2012.
242. [Calcagno A](#), D'Avolio A, Simiele M, Cusato J, Rostagno R, Libanore V, Baietto L, Siccardi M, Bonora S and Di Perri G. Influence of CYP2B6 and ABCB1 SNPs on Nevirapine Plasma Concentrations in Burundese HIV-positive Patients Using Dried Sample Spots Devices. **British Journal of Clinical Pharmacology** 2012.

243. D'Avolio A, Ciancio A, Siccardi M, Smedile A, Baietto L, Simiele M, Aguilar Marucco D, Cariti G, [Calcagno A](#), Gonzalez de Requena D, Sciandra M, Cusato J, Troshina M, Bonora S, Rizzetto M and Di Perri G. ITPA polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associated anaemia in patients under standard anti-HCV treatment. **Therapeutic Drug Monitoring 2012**.
244. Bonora S, [Calcagno A](#), Cometto C, Fontana S, Aguilar D, D'Avolio A, Gonzalez de Requena D, Maiello A, Dal Conte I, Lucchini A and Di Perri G. Short Term Additional Enfuvirtide Therapy is Associated with a Greater Immunological Recovery in HIV Very Late Presenters: a Controlled Pilot Study. **Infection 2012**.
245. Siccardi M, D'Avolio A, Rodriguez-Novoa S, Simiele M, Baietto L, [Calcagno A](#), Moss D, Back D, Owen A, Bonora S and Di Perri G. Intra and inter patient pharmacokinetic variability of raltegravir in the clinical setting. **Therapeutic Drug Monitoring 2012**.
246. D'Avolio A, Ciancio A, Siccardi M, Baietto L, Simiele M, Cariti G, [Calcagno A](#), Smedile A, Cusato J, Bonora S, Rizzetto M and Di Perri G. Ribavirin Pharmacokinetics and IL28 plus CYP27B1 SNPs as predictors of response to Peg-IFN/RBV treatment in HCV ¼ infected patients. **Hepatology 2011**.
247. [Calcagno A](#), Bonora S, Simiele M, Rostagno R, Tettoni MC, Bonasso M, Romito A, Imperiale D, D'Avolio A and Di Perri G. Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. **AIDS 2011**.
248. [Calcagno A](#), Nozza S, Bonora S, Castagna A, Gonzalez de Requena D, D'Avolio A, Lazzarin A and Di Perri G. Pharmacokinetics of the Raltegravir/Maraviroc/Etravirine Combination. **J Antimicrob Chemother 2011**.
249. Bonora S, Gonzalez de Requena D, D'Avolio A, [Calcagno A](#), Tettoni MC, Siccardi M, Baietto L, Simiele M, Trentini L, Di Perri G. Pharmacokinetics of switching unboosted Atazanavir co-administered with Tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. **Antiviral Therapy 2011**.
250. Gonzalez de Requena D, Bonora S, Viganò O, [Calcagno A](#), Cometto C, D'Avolio A, Baietto L, Ghisetti V, Magnani S, Ferramosca S, Vitiello P, Galli M, Rusconi S, Di Perri G. Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. **J Antimicrob Chemother 2011**.
251. [Calcagno A](#), Baietto L, De Rosa FG, Tettoni MC, Libanore V, Bertucci R, D'Avolio A, Di Perri G. Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis. **J Antimicrob Chemother 2011**.
252. Lanzafame M, Bonora S, Lattuada E, [Calcagno A](#), Vento S. A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients. **Braz J Infect Dis 2011**.
253. Siccardi M, D'Avolio A, Nozza S, Simiele M, Baietto L, Stefani FR, Moss D, Kwan W, Castagna A, Lazzarin A, [Calcagno A](#), Bonora S, Back D, Di Perri G, Owen A. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521C>T polymorphism. **Pharmacogenet Genomics 2010**.
254. [Calcagno A](#), Rostagno R, Audagnotto S, D'Avolio A, Bonora S, Ghisetti V, Di Perri G. Is peritoneal fluid a sanctuary site for HIV? **J Antimicrob Chemother 2010**.
255. [Calcagno A](#), Bonora S, D'Avolio A, Siccardi M, Simiele M, Chiesa M, Gonzalez de Requena D, Di Perri G. Raltegravir penetration in seminal plasma of healthy volunteers. **Antimicrob Agents Chemother 2010**.
256. [Calcagno A](#), Bonora S, Bertucci R, Lucchini A, D'Avolio A, Di Perri G. Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients. **AIDS 2010**.
257. Lanzafame M, Hill A, Lattuada E, [Calcagno A](#), Bonora S. Raltegravir: is a 400 mg once-daily dose enough? **J Antimicrob Chemother 2010**.
258. [Calcagno A](#), Bonora S, Tettoni MC, D'Avolio A, Lanzafame M, Penco G, Di Perri G. Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting. **J Acquir Immune Defic Syndr 2009**.
259. Bonora S, [Calcagno A](#), Di Perri G. HIV infection: treatment of naïve patients. **Infez Med 2009**. *Not Impacted*.
260. Bonora S, Nicastrì E, [Calcagno A](#), Gonzalez de Requena D, D'Etorre G, Sarmati L, Palmisano L, Vullo V, Di Perri G, Andreoni M. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. **J Med Virol 2009**.
261. Bonora S, Mondo A, Trentini L, [Calcagno A](#), Lucchini A, Di Perri G. Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins. **Journal of Infection 2008**.
262. González de Requena D, Bonora S, Castagna A, Hasson H, Marucco Aguilar D, D'Avolio A, Sciandra M, Trentini L, [Calcagno A](#), Lazzarin A, Di Perri G. Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. **J Antimicrob Chemother 2008**.
263. González de Requena DG, Bonora S, [Calcagno A](#), D'Avolio A, Siccardi M, Fontana S, Milia MG, Sciandra M, Garazzino S, Di Garbo A, Baietto L, Trentini L, Di Perri G. Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens. **Antimicrob Agents Chemother 2008**.
264. Bonora S, [Calcagno A](#), Fontana S, D'Avolio A, Siccardi M, Gobbi F, Di Perri G. Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject. **Clin Infect Dis 2007**.
265. Aguilar Marucco D, Veronese L, de Requena DG, Bonora S, [Calcagno A](#), Cavecchia I, Sinicco A, De Rosa FG, Cariti G, Di Perri G. Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus. **J Antimicrob Chemother 2007**.
266. González de Requena D, [Calcagno A](#), Bonora S, Ladetto L, D'Avolio A, Sciandra M, Siccardi M, Bargiacchi O, Sinicco A, Di Perri G. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. **AIDS 2006**.
267. Garazzino S, Tettoni M, [Calcagno A](#), D'Avolio A, Bonora S, Di Perri G. Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases. **J Antimicrob Chemother 2006**.
268. Bonora S, [Calcagno A](#), Gonzalez de Requena D, Bargiacchi O, Di Perri G. Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors. **Infez Med 2006**. *Not Impacted*.

**Indexes** Published articles: 268  
 Citations (Scopus): 4003  
 H-index (Scopus): 30  
 H-index (Google Scholar): 36  
 i10-index (Google Scholar): 160

**Lectures at National and International Conferences**

I have gathered experience in speaking and chairing at national and international conferences since 2008: I have been public speaking in Italian, English, and Spanish. The topics I have been covering are HIV, tuberculosis, NTM, central nervous system and hospital-acquired infections.

**Books**

I Co-wrote the chapter "*Staphylococcus aureus* meticillino-resistente" in the book "Infezioni di difficile trattamento in terapia intensiva – Approccio Clinico", 2024, Minerva Medica. Editors: Luca Brazzi and Gioria Montrucchio. ISBN: 9788855322522.

I Participated in the writing of the Chapter "Clinical Treatment Options and Randomized Clinical Trials for Neurocognitive Complications of HIV Infection: Combination Antiretroviral Therapy, Central Nervous System Penetration Effectiveness, and Adjuvants" in the book "Neurocognitive Complications of HIV-Infection" Springer. Editors: Lucette A. Cysique and Sean B. Rourke ISBN: 978-3-030-80758-0.

I Co-Wrote the chapter "Aging with HIV and Oxidative stress", in the book "HIV/AIDS, Oxidative Stress and Dietary Antioxidants" Elsevier. Editors: Victor Preedy Ronald Watson. ISBN: 9780128098530.

I Wrote the chapter "Antiretroviral Drug Penetration into the CNS Compartment" in the printed and online "Encyclopedia of AIDS" Springer. Editors: Thomas J. Hope, Mario Stevenson, Douglas Richman. ISBN: 978-1-4614-9610-6 (Online)

I am one of the authors of the chapter "Natural History of HIV Infection and Evolution of Antiretroviral Therapy" in the book "Cardiovascular Disease in AIDS", Springer-verlag Italia S.r.l., 2008, Barbaro G, Boccara F and Skolnik PR.

I Participated in the writing of the chapter "Donovanosis" in the book "Infezioni Genitali: Aspetti patogenetici, clinici e diagnostici", Latino MA, Magliano E, AMCLI, Milano, 2009.

**Reviwer activity**

I am acting as a reviewer for several national and international scientific journals and for national and international grant applications.

**Spoken Languages**

Good knowledge of English and Spanish, basic knowledge of French. Italian as mother tongue.

Torino, Italy; October 10<sup>th</sup> 2024  
CALCAGNO ANDREA



*Autorizzo il trattamento dei miei dati personali ai sensi dell'art. 13 d. lgs. 30 giugno 2003 n°196-  
"Codice in materia di protezione dei dati personali" e dell'art. 13 GDPR 679/16 – "Regolamento europeo sulla protezione dei dati personali"*

Torino, Italy; October 10<sup>th</sup> 2024  
CALCAGNO ANDREA



---

## CURRICULUM VITAE

### EUROPEAN FORM



#### PERSONAL INFORMATION

First name / Surname Castagna Antonella  
Address Unità Operativa di Malattie Infettive  
IRCCS Ospedale San Raffaele  
Via Stamira d'Ancona, 20 – 20127 Milano Italia  
Phone +39 02.2643.7934 (segr)  
Fax +39 02.2643.7903  
E-mail castagna.antonella1@hsr.it  
Nationality Italian  
Place and Date of birth Lecco (Italy) - January 24, 1958

#### PROFESSIONAL EXPERIENCE

November 2016 – to date Director of specialization school in Infectious and Tropical Diseases, Vita-Salute San Raffaele University, School of Medicine, Milan, Italy  
Director of PML Center of Studies, Vita-Salute San Raffaele University, Milan, Italy.  
Director of Studies and research project for Physician-Scientist (PhS), Experimental and Clinical Medicine on HIV cures. Vita-Salute San Raffaele University, Milan, Italy.  
April 2015 – to date Associate Professor in Infectious Diseases, Vita-Salute San Raffaele University, Milan, Italy.  
April 2013 – to date Italian National Scientific Qualification (ASN) of Italian Ministry for Education, University and Research (MIUR) for Full Professor role in Infectious Diseases, sector 06/D4  
Italian National Scientific Qualification (ASN) of Italian Ministry for Education, University and Research (MIUR) for Professor role in Infectious Diseases, sector 06/D4  
2002 – to date Head of Unit for “Management of HIV Infection and antiretroviral treatment” at the Department of Infectious Diseases, San Raffaele Hospital, Milan, Italy (Dir. Prof. Adriano Lazzarin).

1992 - 2001  
 Medical Doctor at the Department of Infectious Diseases, San Raffaele Hospital, Milano, Italy ( Dir. Prof Adriano Lazzarin)  
 Consultant in Infectious Diseases at Neurological Institute “C. Besta”, Milan.  
 Consultant in Infectious Diseases at National Cancer Institute, Milan.

1988 - 1992  
 Medical Doctor at Infectious Diseases University Clinic, Ospedale “L. Sacco”, Università degli Studi di Milano (Dir. Prof. Mauro Moroni)  
 Senior registrar at Infectious Diseases University Clinic, Ospedale “L. Sacco”, Università degli Studi di Milano (Dir. Prof. Mauro Moroni)  
 Associate Researcher at the Department of Neurology, Karolinska Institute (Dir. Prof. Hans Link), Huddinge, Sweden  
 Associate Researcher at the National Bacteriological Laboratory (Dir. Prof Britta Wharen) Stoccolma, Sweden  
 Fellow at the Neuroimmunology Lab, Department of Neurology, University of Chicago, Illinois, USA (Dir. Prof Robert Roos)

**EDUCATIONAL AND TRAINING**

1989 Degree of Specialization in Infectious Diseases, post-graduated school of medicine, Università degli studi di Milano, Italy

1985 Degree in Medicine and Surgery, Università degli studi di Milano, Italy

**LANGUAGES**

Italian mother tongue.  
 English: C2 level in understanding, speaking and writing  
 French: B2 level in understanding, speaking and writing

**COMPUTER SKILLS**

Basic knowledge of the Microsoft Office programs (for Windows and Apple)

**DRIVING LICENSE**

Category B, Italy

**ADDITIONAL INFORMATION**

1999 – to date Chief of the CSLHIV Cohort Study (the Infectious Diseases database on HIV-infected patients at the San Raffaele Hospital, Milan), collecting clinical and laboratory data from all people who living with HIV followed at the Department of Infectious Diseases.

2019 – to date Principal Investigators and Italian National Coordinator of STIPnet (European HIV & STI Prevention Study)

2017 – to date	Principal Investigator and Coordinator of National PRESTIGIO Registry (Italian Register of Patients with HIV Infection and resistance to Inverse Transcriptase Inhibitors, Integrase, Viral protease) ( <a href="http://www.registroprestigio.com">www.registroprestigio.com</a> )
2016 – to date	Member of the Steering Committee of RESPOND (International Cohort Consortium of Infectious Diseases)  Member of the Scientific Committee of Fondazione “The Bridge”
2012 – to date	Member of the Scientific Committee of ICONA (Italian Cohort of Antiretroviral Naive Patients)  Member of the EUROSIDA Study group
2019 - date	Chair of Panel on Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons.
2005 – to date	Member of Panel on Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons.  <b><i>Ad hoc reviewer for:</i></b> Lancet Infectious Diseases Lancet HIV AIDS Journal of Antimicrobial Chemotherapy JAIDS Journal of Acquired Immune Deficiency Syndromes PlosOne BMC Infectious Diseases Scientific Report HIV Medicine

**SUMMARY OF SCIENTIFIC PRODUCTION**

Author or coauthor of 394 peer-reviewed scientific publications

<b>ORIGINAL ARTICLES</b>	394
<b>TOTAL N. CITATIONS</b>	9493
<b>AVERAGE N. CITATIONS/PAPER</b>	24
<b>H-INDEX (ISI Web of Knowledge)</b>	47
<b>ORCID N.</b>	0000-0002-8338-9714

**MOST RELEVANT PUBLICATIONS**

Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM, Grinsztejn B, Diaz R, Castagna A, Kumar P, Latiff G, DeJesus E, Gummel M, Gartland M, Pierce A, Ackerman P, Llamoso C, Lataillade M; BRIGHT E Trial Team. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. *N Engl J Med.* 2020 Mar 26;382(13):1232-1243. doi: 10.1056/NEJMoa1902493. PubMed PMID: 32212519.

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastrì E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T. Compassionate Use of Remdesivir for Patients with Severe Covid-19. *N Engl J Med.* 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10. PMID: 32275812

Greenberg L, Ryom L, Wandeler G, Grabmeier-Pfistershammer K, Ållinger A, Neesgaard B, Stephan C, Calmy A, Rauch A, Castagna A, Spagnuolo V, Johnson M, Stingone C, Mussini C, De Wit S, Necsoi C, Campins AA, Pradier C, Stecher M, Wasmuth JC, Monforte AD, Law M, Pühr R, Chkhartishvili N, Tsertsvadze T, Garges H, Thorpe D, Lundgren JD, Peters L, Bansi-Matharu L, Mocroft A; RESPOND Study Group. Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. *J Acquir Immune Defic Syndr.* 2020 Mar 1;83(3):240-250. doi:10.1097/QAI.0000000000002250. PubMed PMID: 31923088.

Castagna A, Muccini C, Galli L, Bigoloni A, Poli A, Spagnuolo V, Nozza S, Racca S, Galli A, Cinque P, Carini E, Lazzarin A. Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study). *J Antimicrob Chemother.* 2019 Jul 1;74(7):2039-2046. doi: 10.1093/jac/dkz138. PubMed PMID: 31225610.

Gianotti N, Castagna A. Switching antiretrovirals in older patients. *Lancet HIV.* 2019 Oct;6(10):e640-e641. doi: 10.1016/S2352-3018(19)30229-2. PubMed PMID:31578950.

Castagna A, Galli L. Stepping up HIV-1 low-level viraemia surveillance in South Africa. *Lancet Infect Dis.* 2018 Feb;18(2):130-131. doi:10.1016/S1473-3099(17)30680-1. Epub 2017 Nov 17. PubMed PMID: 29158100.

leDEA and COHERE Cohort Collaborations. Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. Clin Infect Dis. 2018 Mar 5;66(6):893-903. doi: 10.1093/cid/cix915. PubMed PMID: 29373672; PubMed Central PMCID: PMC5848308.

The undersigned is aware that, pursuant to art. art. 76 of Presidential Decree 445/2000, false declarations, falsehood in the deeds and use of false deeds are punished pursuant to the penal code and special laws.

Furthermore, the undersigned authorizes the processing of personal data in accordance with the provisions of EU Regulation 679/2016.

Milan, July 20, 2020  
Milan, May 12, 2022

A handwritten signature in black ink, appearing to read 'A. Castagna', written in a cursive style.

Professor Antonella Castagna



## Curriculum Vitae Europass

### Informazioni personali

Nome(i) / Cognome(i) **Dario Cattaneo**  
E-mail [dario.cattaneo@asst-fbf-sacco.it](mailto:dario.cattaneo@asst-fbf-sacco.it) ; [dario.cattaneo@unimi.it](mailto:dario.cattaneo@unimi.it)  
Cittadinanza Italiana  
Luogo di nascita **Bergamo**  
Data di nascita **13/05/1970**  
Codice Fiscale **CTTDRA70E13A7940**  
Sesso Maschile

### Settore professionale **Farmacologia Clinica**

### Esperienza professionale

Date	Da Novembre 2008 a oggi
Lavoro o posizione ricoperti	Dirigente Ospedaliero di I° livello (Farmacista)
Principali attività e responsabilità	Farmacologo Clinico
Nome e indirizzo del datore di lavoro	ASST Fatebenefratelli Sacco, via Grassi 74 – 20157 Milano
Tipo di attività o settore	Ospedale pubblico – settore: farmacologia clinica/malattie infettive
Date	Da Settembre 2006 a oggi
Lavoro o posizione ricoperti	Professore a contratto
Principali attività e responsabilità	Corso di Farmacologia Medica – Facoltà di Medicina e Chirurgia
Nome e indirizzo del datore di lavoro	Università degli Studi di Milano
Tipo di attività o settore	Università Pubblica
Date	Da Settembre 2006 a Novembre 2008
Lavoro o posizione ricoperti	Ricercatore di II° livello
Principali attività e responsabilità	Responsabile Unità di Farmacologia e Farmacogenetica
Nome e indirizzo del datore di lavoro	Istituto di Ricerche Farmacologiche Mario Negri, via Camozzi 3 – 24022 Ranica (BG)
Tipo di attività o settore	Ente Morale – settore: farmacologia clinica
Date	Da Settembre 1997 a Settembre 2006
Lavoro o posizione ricoperti	Borsista
Principali attività e responsabilità	Ricercatore presso Laboratorio di Farmacocinetica e Chimica Clinica
Nome e indirizzo del datore di lavoro	Istituto di Ricerche Farmacologiche Mario Negri, via Camozzi 3 – 24022 Ranica (BG)
Tipo di attività o settore	Ente Morale – settore: farmacologia clinica


Date	Da Agosto 1996 a Agosto 1997
Lavoro o posizione ricoperti	Collaboratore dipendente
Principali attività e responsabilità	Farmacista
Nome e indirizzo del datore di lavoro	Farmacia Gustinetti di Torre de Busi (LC)
Tipo di attività o settore	Farmacia privata
Date	Da Febbraio 1995 a Agosto 1996
Lavoro o posizione ricoperti	Borsista
Principali attività e responsabilità	Responsabile della biblioteca Pfiffer
Nome e indirizzo del datore di lavoro	Istituto di Ricerche Farmacologiche Mario Negri, via Gavazzeni,11 – Bergamo
Tipo di attività o settore	Ente Morale – settore: farmacologia clinica

## Istruzione e formazione

Date	Da Ottobre 2001 a Novembre 2005
Titolo della qualifica rilasciata	Titolo di Doctor of Philosophy (Ph.D) in Biomedical Sciences
Principali tematiche	Farmacologia Clinica, farmacocinetica, medicina del trapianto, metodologia della ricerca clinica
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Open University, London, UK
Date	Da Settembre 1999 a Luglio 2001
Titolo della qualifica rilasciata	Diploma di specializzazione post-laurea in Farmacologia Clinica
Principali tematiche	Farmacologia Clinica e Sperimentale
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli Studi di Milano – Facoltà di Farmacia
Date	Da Settembre 1997 a Luglio 2000
Titolo della qualifica rilasciata	Diploma di specializzazione post-laurea in Specialista in Ricerca Farmacologica
Principali tematiche	Farmacologia, farmacocinetica, farmacodinamica, chimica clinica, immunologia, statistica
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Istituto di Ricerche Farmacologiche Mario Negri – Regione Lombardia
Date	Da Gennaio 1990 a Febbraio 1996
Titolo della qualifica rilasciata	Laurea Magistrale in Farmacia
Principali tematiche	Farmacologia, tecnica e legislazione farmaceutica, chimica farmaceutica, tossicologia
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli Studi di Milano – Facoltà di Farmacia
Date	Da Settembre 1984 a Luglio 1989
Titolo della qualifica rilasciata	Diploma di Perito Chimico
Principali tematiche	Tutte le discipline inerenti alla chimica
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Istituto Tecnico Industriale di Stato per la Chimica G. Natta, via Gavazzeni,11 – Bergamo

## Capacità e competenze personali

Madrelingua(e) **Italiano**

Altra(e) lingua(e)	<b>Inglese</b>
• Capacità di lettura	Buona
• Capacità di scrittura	Buona
• Capacità di espressione	Buona
Capacità e competenze organizzative	Buone capacità di coordinamento, sviluppate prevalentemente in ambito lavorativo, dovute dalla necessità di dover gestire le attività di più collaboratori subordinati
Capacità e competenze tecniche	Utilizzo di svariati programmi operativi di Windows (Word, Excel, Power Point, Adobe Acrobat, Access, ecc). Ottima padronanza dell'utilizzo di banche dati mediche e biomediche (PUBMED, EMBASE) utilizzabili per eseguire ricerche bibliografiche. Conoscenza dei principi teorici, delle componenti strumentali e delle applicazioni pratiche della cromatografia liquida ad elevate prestazioni. Buona conoscenza di software statistici e di farmacocinetica
Patente	A, B
<b>Ulteriori informazioni</b>	<ul style="list-style-type: none"> <li>- 2006: conseguimento dell'attestato di abilitazione all'esercizio della professione di Farmacista</li> <li>- dal 2006 membro dell'International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)</li> <li>- dal 2007 membro della Società Italiana di Farmacologia (SIF)</li> <li>- dal 2009 membro del American College of Clinical Pharmacology</li> <li>- dal 2017 membro dell'editorial board della rivista Eur J Drug Metab Pharmacokin</li> <li>- dal 2017 co-chair, anti-infective committee, IATMCT</li> <li>- dal 2019 membro dell'editorial board della rivista Therapeutic Drug Monitoring</li> <li>- dal 2019: abilitazione scientifica nazionale per Professore di II Fascia (Farmacologia)</li> <li>- dal 2024: abilitazione scientifica nazionale per Professore di I Fascia (Farmacologia)</li> <li>- dal 2019 President-elect, IATDMCT</li> <li>- dal 2021 President, IATDMCT</li> <li>- dal 2023 Past-President IATDMCT</li> </ul> <p>Autore di</p> <ul style="list-style-type: none"> <li>- circa 300 articoli scientifici con oltre 9000 citazioni (H-index=46)</li> <li>- circa 70 abstracts presentati a meeting Internazionali</li> <li>- 7 capitoli di libri</li> <li>- circa 400 presentazioni orali a meeting, convegni etc nazionali ed internazionali</li> </ul> <p><i>" Il sottoscritto è a conoscenza che, ai sensi dell'art. art. 76 del DPR 445/2000, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali ai sensi dell'art. 13 GDPR 679/16 – "Regolamento europeo sulla protezione dei dati personali".</i></p>
<b>Firma</b>	
<b>Data</b>	<b>30/10/2024</b>



## Curriculum Vitae Europass

### Informazioni personali

Cognome(i) / Nome(i) **CORCIONE SILVIA**  
Indirizzo(i) BERRUTI 2, 10034 CHIVASSO (Italia)  
Telefono(i) 3384276234  
Cittadinanza Italiana  
Data di nascita 03/09/1984  
Sesso Femminile

### Occupazione desiderata / Settore professionale

**MEDICO CHIRURGO**

### Esperienza professionale

Date	01/10/2011 - 01/07/2012
Lavoro o posizione ricoperti	Medico Chirurgo
Principali attività e responsabilità	Conferimento borsa di studio "Farmacologia clinica del Linezolid in pazienti con infezioni da Mrsa: contributo organizzativo per lo studio epidemiologico
Nome e indirizzo del datore di lavoro	Clinica di malattie infettive Ospedale Amedeo di Savoia, Torino Prof. G. Di Perri Ospedale S. Giovanni Battista Molinette, Torino Dipartimento di Anestesia e Rianimazione , Prof. V.M. Ranieri Torino (Italia)
Date	01/09/2010 - 01/10/2010
Lavoro o posizione ricoperti	Assistente medico
Principali attività e responsabilità	Stage presso il servizio di Malattie Infettive, diretto dal Prof. Enos Bernasconi.
Nome e indirizzo del datore di lavoro	EOC, Ospedale regionale di Lugano (Svizzera) Lugano (Svizzera)
Date	01/09/2009 - 01/10/2009
Lavoro o posizione ricoperti	Medico
Principali attività e responsabilità	Stage presso il servizio di Malattie Infettive, diretto dal Prof. Filippo Fatuzzo
Nome e indirizzo del datore di lavoro	Programma di scambio nazionale SISM, Facoltà di Medicina e Chirurgia. Ospedale Ferrarotto Catania (Italia)
Date	01/09/2008 - 04/07/2009
Lavoro o posizione ricoperti	Assistente medico
Principali attività e responsabilità	Vincitrice Progetto ERASMUS Facoltà di Medicina e Chirurgia di Torino
Nome e indirizzo del datore di lavoro	Universiteè de Nice Sophia Antipolis Nizza (Francia)
Date	01/11/2008 - 01/07/2009
Lavoro o posizione ricoperti	Medico
Principali attività e responsabilità	Stage presso il Service de Maladie Infectieuse, Prof.Pierre Dellamonica

Nome e indirizzo del datore di lavoro	Collaborazione con il dott. Rodolphe Garraffo, Service de Pharmacologie Hopital Pasteur Hopital Pasteur Nizza (Francia)
Date	01/11/2007 - 01/04/2008
Lavoro o posizione ricoperti	Medico
Principali attività e responsabilità	Stage c/o Centro riferimento regionale patologie infettive in gravidanza Dott. ssa C. Tibaldi
Nome e indirizzo del datore di lavoro	Ospedale Universitario S. Anna Torino (Italia)
Date	01/09/2005 - 01/10/2005
Lavoro o posizione ricoperti	Medico
Principali attività e responsabilità	Stage presso il Dipartimento di oncologia molecolare Prof. P.Comoglio
Nome e indirizzo del datore di lavoro	IRCC Candiolo, Torino (Italia)
<b>Istruzione e formazione</b>	
Date	04/07/2012 →
Titolo della qualifica rilasciata	Medico in formazione specialistica
Principali tematiche/competenze professionali acquisite	SCUOLA SPECIALIZZAZIONE MALATTIE INFETTIVE, PROF. G. DI PERRI
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	UNIVERSITÀ DEGLI STUDI DI TORINO, Dipartimento Scienze Mediche, Clinica di Malattie Infettive Ospedale Amedeo di Savoia Torino (Italia)
Date	01/09/2004 - 08/07/2010
Titolo della qualifica rilasciata	Medico Chirurgo
Principali tematiche/competenze professionali acquisite	Laurea magistrale in Medicina e Chirurgia, votazione 110/110 lode e dignità di stampa Titolo tesi: "Farmacologia clinica di regimi complessi di terapia antiretrovirale" Relatori: Prof. Giovanni Di Perri; Dott. Rodolphe Garraffo
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli Studi di Torino, facoltà di Medicina e Chirurgia Torino (Italia)
Date	01/07/2007 → 30/08/2007
Principali tematiche/competenze professionali acquisite	UCSD Extension Certificate 80hours Conversation Plus Programme – Advanced English Final Mark: A plus (with recommendation letter)
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	University of San Diego, CALIFORNIA San Diego, California (Stati Uniti d'America)
Date	13/06/2003
Titolo della qualifica rilasciata	Diploma
Principali tematiche/competenze professionali acquisite	Diploma di maturità classica, votazionw 98/100.
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Liceo classico I. Newton Chivasso, Torino (Italia)

### Capacità e competenze personali

Madrelingua(e) **Italiano**

Altra(e) lingua(e)

Autovalutazione  
Livello europeo (\*)

Francese

Inglese

Comprensione				Parlato				Scritto	
Ascolto		Lettura		Interazione orale		Produzione orale			
C1	Utente avanzato	C1	Utente avanzato	C1	Utente avanzato	C1	Utente avanzato	B2	Utente autonomo
C1	Utente avanzato	C1	Utente avanzato	B2	Utente autonomo	B1	Utente autonomo	B1	Utente autonomo

(\*) [Quadro comune europeo di riferimento per le lingue](#)

## Ulteriori informazioni

### Pubblificazioni

- F G. De Rosa, A D'Avolio, **Corcione S**, L Baietto, , S. Raviolo, P. Centofanti, D. Pasero, M. Rinaldi, G. Di Perri Anidulafungin for C. glabrata Infective Endocarditis Antimicrobial Agents and Chemotherapy, 2012;56(8):4552
- De Rosa FG, **Corcione S**, Pagani N, Stella ML, Urbino R, Di Perri G, Ranieri VM. High rate of respiratory MDR gram-negative bacteria in H1N1-ARDS treated with ECMO. Intensive Care Med. 2013;39(10):1880-1
- De Rosa FG, **Corcione S**, Baietto L, Ariaudo A, Di Perri G, Ranieri VM, D'Avolio A. Pharmacokinetics of linezolid during extracorporeal membrane oxygenation. Int J Antimicrob Agents. 2013 Jun;41(6):590-1.
- De Rosa FG, Treccarichi EM, Montrucchio C, Losito AR, Raviolo S, Posteraro B, **Corcione S**, Di Giambenedetto S, Fossati L, Sanguinetti M, Serra R, Cauda R, Di Perri G, Tumbarello M Mortality in patients with early- or late-onset candidaemia. J Antimicrob Chemother. 2013;68(4):927-35
- Francesco G. De Rosa, **Corcione S**, Lorena Baietto, Daniela Pasero, Giovanni Di Perri, V. Marco Ranieri, Antonio D'Avolio. Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVH. J Chemother, 2013 Apr 19.
- Baietto L, D'Avolio A, Ariaudo A, **Corcione S**, Simiele M, Cusato J, Urbino R, Di Perri G, Ranieri VM, De Rosa FG. Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;936:42-7.
- FG De Rosa, Montrucchio C, Raviolo S, **Corcione S**, N Pagani, Di Perri G. "Candidemia: una patologia in aumento in ambiente internistico". Infez in Med vol. 20 Supp.4, 2012.
- FG De Rosa, **Corcione S**, N Pagani "Rischio infettivo e farmaci Biologici: una review della letteratura 2011". Progetto SHARE, membro dello Young Panel.

### POSTER

- Corcione S**, Calcagno A, Bonora S, D'Avolio A, Ferrando S, Vassallo M, Castagna A, Nozza S, Garraffo R, Della Monica P, Di Perri G. "Clinical pharmacology of complex regimens of antiretroviral therapy including Etravirine, Maraviroc and Raltegravir." -12 International Workshop on Clinical Pharmacology of HIV therapy" Miami, FLORIDA (USA)
- Corcione S**, Motta I, DeMatteis J, Fossati L, Serra R, Ranieri V.M, De Rosa FG. Molecular Epidemiology of Methicillin-Resistant *S.aureus* in ICU Setting" ICAAC 2013, Denver (USA)
- Corcione S**, Pagani N, Aldieri C, Fossati L, Cavallo R, Di Perri G, De Rosa FG. "Monoterapia o terapia di combinazione nelle sepsi da KPC", SIMIT 2013, Milano (28-30 ottobre 2013)

### CONCORSI

- Vincitrice concorso iAcademy 2012 "Infezioni fungine invasive" con l'elaborato "Farmacocinetica di anidulafungina in pazienti critici con shock settico sottoposti a CVVH". Concorso iAcademy 2012, Torino (11 novembre 2012)

In fede

Torino, 21/2/14

A handwritten signature in black ink, appearing to read "Mary Corcione". The signature is written in a cursive style and is positioned above a dark, irregular rectangular area that likely represents a stamp or a shadow.

# Davide Corti

## Biografia

Dopo il lavoro iniziale presso l'IRB di Bellinzona, Davide Corti si è trasferito a Humabs, una piccola azienda biotecnologica dove ha avviato un programma di scoperta di anticorpi di livello mondiale. Negli ultimi 19 anni ha apportato contributi rivoluzionari alla scoperta, alla caratterizzazione e allo sviluppo di anticorpi monoclonali umani contro agenti patogeni virali e batterici. Dalle cellule B della memoria e dalle plasmacellule di donatori immunitari, ha isolato una pleora di anticorpi contro i virus dell'influenza A e B, RSV, HBV, virus Dengue e Zika, virus della rabbia, batteri resistenti agli antibiotici e tossine caratterizzate da affinità di legame, neutralizzazione potenza e per il loro profilo di scappabilità. Ha dimostrato che la specificità dell'epitopo determina non solo l'ampiezza della neutralizzazione, ma anche la capacità degli anticorpi di stimolare la funzione effettrice. In poche parole, il lavoro di Davide Corti ha stabilito i criteri per la selezione di anticorpi terapeutici ad ampio spettro in grado di coinvolgere le difese immunitarie. Nel 2011 ha identificato il primo anticorpo ampiamente neutralizzante che mirava a tutti i virus dell'influenza A umani e animali e due anni dopo un altro anticorpo che neutralizzava quattro paramixovirus. Dal 2017, Davide Corti è responsabile della ricerca sugli anticorpi presso Vir Biotechnology, ora alla guida di un team di oltre 80 scienziati. Il suo lavoro ha portato allo sviluppo di due anticorpi commercializzati per il trattamento dell'Ebola (Ebanga, ansuvimab) e del COVID-19 (Xevudy, sotrovimab), e di altri attualmente testati in studi clinici per prevenire la malattia da virus dell'influenza A (VIR-2482) e per il trattamento dell'epatite cronica B (VIR-3434). Attraverso la definizione strutturale di epitopi protettivi, il suo lavoro apre anche la strada all'implementazione della progettazione di vaccini basati sulla struttura.

# Curriculum Vitae

**JESSICA CUSATO**

Born in Turin (TO), 22/11/1986

## ACADEMIC BACKGROUND

[2008] Degree in Biological Sciences, Faculty of Science, University of Turin (107/110).

[2010] Degree in Health Biology, Faculty of Science, University of Turin (108/110).

[2012] Professional Qualification and registration in the Biologist Board.

[2016] Specialization Degree in Microbiology and Virology, Faculty of Medicine, University of Turin (70/70).

[2019] PhD in Complex Systems for Life Sciences.

[From 09/2011-today] Research fellowship for the Study of Pharmacogenetics in the "Laboratory of Clinical Pharmacology and Pharmacogenetics", University of Turin at the Hospital Amedeo di Savoia (ASL CITTA' di TORINO).

[23-12-2019-today] Researcher (RTD-B) in Pharmacology, University of Turin.

## RESEARCH & CLINICAL ACTIVITY

- The research and clinical activity of Dr. Cusato, in universities and hospitals (ASL CITTA' di TORINO), as manager of the "Laboratory of Clinical Pharmacology and Pharmacogenetics", took place from 2006 to present on the following topics:

- clinical pharmacology of anti-infectives, oncology drugs (including tyrosine kinase inhibitors, mitotane, etc.), antihypertensive drugs, iron chelators drugs, etc.;
- study of pharmacogenetics of anti-infectives, oncology drugs, iron chelators drugs, etc.;
- management and therapy customization in patients; plasma, intracellular and tissue pharmacokinetic evaluation of anti-infective drugs and not, even through the use of pharmacogenetics applied to the clinic in patients receiving chemotherapy (as part of clinical routine and clinical trials). PBMCs isolation with Ficoll and CPT tubes.
- Routinary diagnostic analysis for clinical biological samples arriving at the laboratory for "therapeutic drug monitoring" (drug quantification) and pharmacogenetic tests (evaluation of single nucleotide polymorphisms).

- In recent years the research activity is expanding, as evidenced by the numerous recent publications, especially on other not infectious issues, but always in the context of clinical pharmacology; This activity was possible by analyzing data coming not only from its own laboratory, but also from other numerous research centers (national and international hospitals) with which we are opened for partnerships acting within pharmacology, pharmacogenetics and related diagnostics.

## TEACHING (last three years)

Academic Year 2017/18-2018/19 and 2019/20 Pharmacology; Degree in Nursing and School of Spécialization in Infectious Diseases

## PUBLICATIONS/SPEECHES, CITATIONS AND NORMALIZED H-INDEX (updated 07/11/2022)

Since 2010 she has participated as speaker at more than 80 between congresses, conferences, courses and seminars.

Author and / or co-authored more than 80 posters and congressional action.

Author and/or co-author of more than 134 international scientific publications: n.99 indexed in PubMed ("CUSATO J" in [www.ncbi.nlm.nih.gov/pubmed](http://www.ncbi.nlm.nih.gov/pubmed)) and 130 indexed in ISI - Web of Knowledge (Tomson).

H-INDEX (Scopus): 25

### Google Scholar

<u>Citations Index</u>	All	From 2017
<u>Citations</u>	2696	2077
<u>H-Index</u>	30	20
<u>i10-index</u>	68	59

DATA

07/11/2022

FIRMA





## Curriculum Vitae Europass

### Informazioni personali

Nome(i) / Cognome(i) **Antonio D'Avolio** **C.F. DVLNTN70H06H355X**  
Indirizzo Residenza Via Roma 15, 10093, Collegno (TO), Italia.  
Indirizzo Lavoro Ospedale "Amedeo di Savoia", Padiglione Q, C.so Svizzera 164, 10149, Torino, Italia  
Telefono Ufficio/Lab. +39.011.4393841 Cellulare: +39.338.9937305  
Fax Ufficio/Segr. +39.011.4393979  
E-mail [antonio.davolio@unito.it](mailto:antonio.davolio@unito.it)  
Cittadinanza Italiana  
Data di nascita 06/06/1970  
Sesso Maschile

**Settore professionale** **Docente Universitario**

### Esperienza professionale

Lavoro o posizione ricoperti 3/1996-8/2004, Bioanswers sas; Responsabile di Produzione e Progettazione.  
9/2004-9/2006 Attività di consulenza specialistica in ambito cromatografico-analitico.  
Dal 1994 ad oggi ha partecipato, anche come relatore, a più di 300 tra congressi, convegni, corsi e seminari.  
Autore e/o coautore di circa 300 pubblicazioni scientifiche (alla fine del CV i dati specifici).

Il Prof. D'Avolio si è principalmente occupato di monitoraggio terapeutico dei farmaci antifettivi (Therapeutic Drug Monitoring), creando dal 2002, inizialmente attraverso borse di studio e poi con assegni di ricerca prima di essere strutturato, all'interno del Dipartimento di Scienze Mediche il Laboratorio di Farmacologia Clinica e Farmacogenetica, unico del suo genere ad essere certificato UNI EN ISO 9001, 13485 e AIFA (per Fase 1), di cui è ora il responsabile.

Attualmente è il responsabile dei seguenti corsi universitari dell'Università degli Studi di Torino:

- Farmacologia; Corso di Laurea in Medicina e Chirurgia – Torino (Canale A e B)
- Farmacologia; Corso di Laurea in Biotecnologie Mediche – Torino
- Farmacologia; Corso di Laurea in Infermieristica – Torino (Canale A)
- Farmacologia; Corso di Laurea in Infermieristica Pediatrica – Torino
- Docente nel corso di Dottorato in Medicina e Terapia Sperimentale della Scuola di Dottorato in Scienze della Vita e della Salute dell'Università degli Studi di Torino
- Tutor Corso di Laurea Magistrale in Biotecnologie Mediche - Classe LM-9
- Docente di Farmacologia nelle seguenti scuole di specialità:
  - Malattie Infettive e tropicali
  - Genetica Medica
  - Medicina Interna
  - Anestesia e Rianimazione

2015. Co-fondatore dello Spin-Off Accademico dell'Università di Torino CoQua Lab srl.

2018 Fondatore e Vice-Direttore del CIFACS (Interdepartmental Center for Clinical and Experimental Pharmacology, Università di Torino)

### Istruzione e formazione

Date Dicembre 2017  
Titolo della qualifica rilasciata **Abilitato ASN a Professore Ordinario (Prima Fascia) in Farmacologia**

Principali tematiche/competenze professionali possedute	Farmacologia, Farmacologia Clinica e Farmacognosia
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Ministero dell'Istruzione (Abilitazione Scientifica Nazionale)
Date	Dicembre 2016
Titolo della qualifica rilasciata	<b>Professore Associato (Seconda Fascia) in Farmacologia</b>
Principali tematiche/competenze professionali possedute	Farmacologia, Farmacologia Clinica e Farmacognosia
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli Studi di Torino/ASL Città di Torino
Date	Ottobre 2006
Titolo della qualifica rilasciata	<b>Ricercatore Universitario</b>
Principali tematiche/competenze professionali possedute	Responsabile del Laboratorio di Farmacologia Clinica e Farmacogenetica
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli Studi di Torino/ASL TO2
Date	Luglio 2002 (17/07/2002)
Titolo della qualifica rilasciata	<b>Specializzazione in Microbiologia e Virologia, (70/70).</b>
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Facoltà di Medicina e Chirurgia, Università degli Studi di Torino.
Date	2001
Titolo della qualifica rilasciata	Abilitazione all'insegnamento nelle scuole medie superiori per la classe di concorso A060 (Scienze naturali, Chimica, Geografia e Microbiologia), in seguito a concorso ordinario, vinto, per titoli ed esami.
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	
Date	1994
Titolo della qualifica rilasciata	Laurea in Scienze Biologiche, con Indirizzo Fisiopatologico (104/110).
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Facoltà di MFN, Università degli Studi di Torino.
Date	Luglio 1989
Titolo della qualifica rilasciata	Diploma di Maturità Scientifica
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Liceo Scientifico "Lagrange" Rivoli -TO-

### Capacità e competenze personali

Madrelingua **Italiano**

Altra lingua **Inglese**


Autovalutazione

Livello europeo (\*)

**Lingua Inglese**

Comprensione				Parlato				Scritto	
Ascolto		Lettura		Interazione orale		Produzione orale			
C2	Livello Avanzato	C2	Livello Avanzato	C1	Livello Avanzato	C1	Livello Avanzato	C1	Livello Avanzato

(\*) [Quadro comune europeo di riferimento per le lingue](#)

Capacità e competenze tecniche	<p><b>Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.</b></p> <ul style="list-style-type: none"> <li>➤ Ottima attitudine e capacità di studio, sviluppo e utilizzo delle tecniche e/o metodiche applicate alla cromatografia, in particolare per il dosaggio di farmaci, marker biologici ed altro (proteine, DNA...) in campo diagnostico, chimico, ambientale ed alimentare, mediante H.P.L.C. (High Performance Liquid Chromatography), HPLC-MS e MS/MS, GC, GC-MS, U.P.L.C. e D-H.P.L.C..</li> <li>➤ Conoscenza delle tecniche di base della biologia molecolare (anche con l'uso di materiale radioattivo) [con particolare attenzione ai risvolti clinici della Farmacogenetica/Farmacogenomica], colture cellulari, microbiologiche e virali.</li> <li>➤ Conoscenza delle metodiche applicate in microbiologia clinica per l'individuazione dei possibili patogeni (attraverso lettura a fresco dei prelievi cervico-vaginali in ambulatorio, mediante colorazione Gram e Ziehl-Neelsen, semina su terreni selettivi secondo le metodologie consigliate dall'AMCLI, test biochimici ecc.) e relativo antibiogramma (con strumentazione bioMerieux VITEK, ATB e KB) per i diversi materiali processati in un laboratorio di microbiologia clinica (urine, feci, escreti, sangue, bronco aspirati, liquor, tamponi e materiali vari).</li> <li>➤ Conoscenza delle metodiche applicate in virologia clinica per l'individuazione dei possibili virus patogeni, attraverso tecniche di biologia molecolare e colture cellulari (identificazione degli effetti citopatici su varie linee cellulari), per i diversi materiali processati in un laboratorio di virologia.</li> <li>➤ Conoscenza delle metodiche applicate nei laboratori di mutagenesi ed ecotossicologia per la ricerca di sostanze tossiche e mutagene partendo, anche, da matrici complesse quali aria, suolo ed acqua.</li> <li>➤ Conoscenza dei principi generali della fermentazione in campo alimentare e applicazione degli stessi, con ottimizzazione del prodotto e/o processo fermentativo, a livello industriale per prodotti da forno e non.</li> <li>➤ Conoscenza delle norme sul controllo qualità (GLP, ISO 9001 e 13485), sicurezza (626/94 e 81/2008) nei laboratori e validazione dei Diagnostici In Vitro (IVDR).</li> </ul>												
Capacità e competenze informatiche	Conoscenza di DOS/Windows; Pacchetto Office; SPSS; Gestione Internet e Siti Web; ecc.												
Patente	Munito di patente B ed auto propria.												
<b>Ulteriori informazioni</b>	<p><b>Publicazioni/Interventi, Citazioni Normalizzate e H-index</b> (ultimo aggiornamento <b>30/08/2022</b>)</p> <p>Dal 1994 ad oggi ha partecipato, anche come relatore, a più di <b>200</b> tra congressi, convegni, corsi e seminari.</p> <p>Autore e/o coautore di oltre <b>350</b> tra poster ed interventi congressuali.</p> <p>Autore e/o coautore di oltre <b>350</b> pubblicazioni scientifiche, di cui n. <b>303</b> pubblicazioni scientifiche internazionali indicizzate su PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed">www.ncbi.nlm.nih.gov/pubmed</a>), e di n. <b>347</b> indicizzate su ISI - Web of Knowledge (Tomson).</p> <p>H-index Scopus: <b>36</b></p> <p>Dati aggiornati tratti da Google Scholar</p> <table border="1" data-bbox="478 1500 1133 1646"> <thead> <tr> <th></th> <th>Tutte</th> <th>Dal 2017</th> </tr> </thead> <tbody> <tr> <td>Citazioni</td> <td>6898</td> <td>4007</td> </tr> <tr> <td>Indice H</td> <td>42</td> <td>29</td> </tr> <tr> <td>i10-index</td> <td>172</td> <td>123</td> </tr> </tbody> </table>		Tutte	Dal 2017	Citazioni	6898	4007	Indice H	42	29	i10-index	172	123
	Tutte	Dal 2017											
Citazioni	6898	4007											
Indice H	42	29											
i10-index	172	123											
<b>Allegati</b>	-												
<b>Firma</b>	<p>Autorizzo il trattamento dei dati personali ai sensi dell'art. 13 GDPR (RU 2016/679).</p>  <p style="text-align: right;">Torino, 30/08/2022</p>												



Torino 10 Febbraio 2022

**Curriculum Vitae****Francesco Giuseppe De Rosa****Indirizzo(i)**Dipartimento di Scienze Mediche, Università di Torino  
SCDU Malattie Infettive, AOU Città della Salute e della Scienza (CDSS), Torino  
SCU Malattie Infettive, Ospedale Cardinal Massaia, Asti.**E-mail**

francescogiuseppe.derosa@unito.it

**Cittadinanza**

Italiana

**Data di nascita**

01 aprile 1971

**Sesso**

Maschile

**Occupazione**

Professore Associato in Malattie Infettive (MED/17), Dipartimento di Scienze Mediche, Università di Torino; Direttore, SCDU Malattie Infettive 2, Città della Salute e Scienza (CDSS), Torino &amp; Ospedale Cardinal Massaia –Asti-; Riferimento regionale per le malattie infettive nei trapianti (Regione Piemonte); Componente, Comitato Etico Interaziendale della Città della Salute e Scienza, Torino; Componente del gruppo GLICA (Gruppo di Lavoro Infezioni Correlate all'Assistenza), Regione Piemonte.

**Istruzione****Date**1995: Laurea in Medicina e Chirurgia *cum laude*, Università La Sapienza Roma;  
2000: Specialista in Medicina Interna *cum laude*, Università "La Sapienza", Roma  
2000-novembre 2005: Ricercatore Universitario in Malattie Infettive (MED/17, Università di Torino, Ospedale Amedeo di Savoia); Fellow in Infectious Diseases & Immunology Research, Boston University & Lahey Clinic, Burlington, MA, USA (2001-2003);  
2005-: Professore Associato in Malattie Infettive, Università di Torino; 2011-: Riferimento Regionale per le malattie infettive nei trapianti d'organo e midollo osseo; 2013-2018: Vice-Direttore alla Didattica, Dipartimento di Scienze Mediche, Università di Torino; Novembre 2016: Dirigente Medico I Livello, SCU Medicina 4 (Prof. Veglio), CDSS, Torino; Dicembre 2017-: Direttore, SCDU Malattie Infettive, CDSS Torino. 2021: *Fellow, Infectious Diseases Society of America.***Capacità personali**

Consulenze infettivologiche; Infezioni in ospiti critici. Attitudine alla docenza. Lavoro interdisciplinare.

**Madrelingua(e)****Italiano****Altra(e) lingua(e)****Inglese****Autovalutazione****Livello europeo (\*)****Lingua****Lingua**


Comprensione		Parlato		Scritto	
Ascolto	Lettura	Interazione orale	Produzione orale		
Ottima	Ottima	Ottima	Ottima	Ottimo	
Ottima	Ottima	Ottima	Ottima	Ottimo	

**Pubblicazioni**

Autore di 248 pubblicazioni a stampa (Scopus: h-index 36) e di vari capitoli su libri specialistici.

**Attività didattica**

Università di Torino: Scuola di Specializzazione in Malattie Infettive, Microbiologia, Nefrologia, Geriatria, Ematologia, Medicina d'Urgenza, Anestesiologia, Neurologia; Corso di Laurea Magistrale in Odontoiatria e Protesi Dentaria; Corso di Laurea in Infermieristica (Torino), Corso di Laurea Magistrale in Medicina e Chirurgia, sede Molinette e sede S. Luigi; Dottorato di Ricerca in Fisiopatologia Medica.

**Firma**Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".  


Il sottoscritto, consapevole che le dichiarazioni mendaci, la falsità negli atti e l'esibizione di atto falso o contenente dati non più rispondenti a verità sono puniti dal codice penale e delle leggi speciali in materia, dichiara la veridicità delle informazioni contenute nel presente curriculum. Autorizza, altresì, il trattamento dei dati personali ai sensi del D.lgs 196/03 e della normativa vigente in materia, esclusivamente ai fini degli adempimenti necessari per la corretta registrazione di eventi formativi validi ai fini del programma nazionale di Educazione Continua in Medicina.

In fede





## Curriculum Vitae Europass

### INFORMAZIONI PERSONALI

Nome **GIOVANNI DI PERRI**  
Indirizzo  
Telefono  
Fax  
E-mail  
  
Nazionalità Italiana  
Data di nascita 4 GIUGNO 1958

### ESPERIENZA LAVORATIVA

- Date (da – a) Da 04 novembre 1991 a 31 ottobre 1998
- Nome e indirizzo del datore di lavoro Università degli Studi di Verona
- Tipo di azienda o settore Università / Facoltà di Medicina e Chirurgia
- Tipo di impiego Ricercatore Universitario
- Principali mansioni e responsabilità Ricerca scientifica, istruzione, assistenza medica specialistica
  
- Date (da – a) Da 01 novembre 1998 a 31 ottobre 2000
- Nome e indirizzo del datore di lavoro Università degli Studi di Torino
- Tipo di azienda o settore Università / Facoltà di Medicina e Chirurgia
- Tipo di impiego Professore Associato di Malattie Infettive
- Principali mansioni e responsabilità Docenza, Ricerca scientifica, assistenza medica specialistica
  
- Date (da – a) Da 01 novembre 2000 a 31 ottobre 2003
- Nome e indirizzo del datore di lavoro Università degli Studi di Torino
- Tipo di azienda o settore Università / Facoltà di Medicina e Chirurgia
- Tipo di impiego Professore Straordinario di Malattie Infettive
- Principali mansioni e responsabilità Docenza, Ricerca scientifica, assistenza medica specialistica
  
- Date (da – a) Da 01 novembre 2003 a tutt'oggi
- Nome e indirizzo del datore di lavoro Università degli Studi di Torino
- Tipo di azienda o settore Università / Facoltà di Medicina e Chirurgia
- Tipo di impiego Professore Ordinario di Malattie Infettive
- Principali mansioni e responsabilità Docenza, Ricerca scientifica, assistenza medica specialistica

## ISTRUZIONE E FORMAZIONE

- |  |  |
|--|--|
| <ul style="list-style-type: none"><li>• Nome e tipo di istituto di istruzione o formazione<ul style="list-style-type: none"><li>• Date (da – a)</li><li>• Principali materie / abilità professionali oggetto dello studio</li><li>• Qualifica conseguita</li><li>• Livello nella classificazione nazionale (se pertinente)</li></ul></li></ul> | <p>Da 1972 a 1977<br/>Liceo Scientifico "G. Galilei", Siena</p> <p>Diploma Liceo Scientifico<br/>48/60</p>   |
| <ul style="list-style-type: none"><li>• Nome e tipo di istituto di istruzione o formazione<ul style="list-style-type: none"><li>• Date (da – a)</li><li>• Principali materie / abilità professionali oggetto dello studio</li><li>• Qualifica conseguita</li><li>• Livello nella classificazione nazionale (se pertinente)</li></ul></li></ul> | <p>Da 1977 a 1983<br/>Università degli Studi di Siena – Facoltà di Medicina e Chirurgia</p> <p>Laurea in Medicina e Chirurgia<br/>110/110 e lode</p>                                   |
| <ul style="list-style-type: none"><li>• Nome e tipo di istituto di istruzione o formazione<ul style="list-style-type: none"><li>• Date (da – a)</li><li>• Principali materie / abilità professionali oggetto dello studio</li><li>• Qualifica conseguita</li><li>• Livello nella classificazione nazionale (se pertinente)</li></ul></li></ul> | <p>Da 1984 a 1988<br/>Università degli Studi di Pavia – Scuola di Specialità in Malattie Infettive</p> <p>Diploma di Specialità in Malattie Infettive<br/>110/110 e lode</p>           |
| <ul style="list-style-type: none"><li>• Nome e tipo di istituto di istruzione o formazione<ul style="list-style-type: none"><li>• Date (da – a)</li><li>• Principali materie / abilità professionali oggetto dello studio</li><li>• Qualifica conseguita</li><li>• Livello nella classificazione nazionale (se pertinente)</li></ul></li></ul> | <p>Da 1986 a 1987<br/>London School of Hygiene and Tropical Medicine</p> <p>Ricerca nell'area delle Malattie Tropicali</p> <p>Diplome in Tropical Medicine and Hygiene (DTM&amp;H)</p> |

## CAPACITÀ E COMPETENZE

### PERSONALI

*Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.*

#### MADRELINGUA

Italiano

#### ALTRE LINGUA

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

Inglese  
Buona  
Buona  
Buona

Francese

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

Buona  
Buona  
Buona

#### CAPACITÀ E COMPETENZE RELAZIONALI

*Vivere e lavorare con altre persone, in ambiente multiculturale, occupando posti in cui la comunicazione è importante e in situazioni in cui è essenziale lavorare in squadra (ad es. cultura e sport), ecc.*

Grande rispetto delle gerarchie e forte senso di appartenenza alla struttura di lavoro.  
Buona capacità di lavorare in equipe e buon motivatore dei colleghi e delle persone sottoposte.  
Efficace capacità ideativa ed organizzativa.  
Sport praticati attivamente: sci e ciclismo.

#### CAPACITÀ E COMPETENZE ORGANIZZATIVE

*Ad es. coordinamento e amministrazione di persone, progetti, bilanci; sul posto di lavoro, in attività di volontariato (ad es. cultura e sport), a casa, ecc.*

Capacità di coordinamento di gruppi di lavoro, anche in ambienti difficili come paesi in situazione di guerra.  
Buon autocontrollo anche nelle situazioni difficili.  
Buone capacità di risoluzione dei problemi e situazioni improvvise.

#### CAPACITÀ E COMPETENZE TECNICHE

*Con computer, attrezzature specifiche, macchinari, ecc.*

Discreta capacità di utilizzo del computer e dei software Word, Power Point, Excel, Outlook Express.

#### CAPACITÀ E COMPETENZE ARTISTICHE

*Musica, scrittura, disegno ecc.*

#### ALTRE CAPACITÀ E COMPETENZE

*Competenze non precedentemente indicate.*

#### PATENTE O PATENTI

B

#### ULTERIORI INFORMAZIONI


Ho lavorato per circa due mesi all'anno a partire dal 1992 presso l'Ospedale di Kiremba, in Burundi, per attività di assistenza, ricerca ed istruzione. Dal 1995 sono consulente della WHO per l'associazione HIV/TB e per la terapia della Malaria. Dal 2003 sono compreso fra gli esperti del Consiglio Superiore di Sanità per le Malattie Infettive.

#### Trattamento dei dati

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dal DLgs 196/2003.

Luogo e data : \_\_\_\_\_

Nome e Cognome (FIRMA) \_\_\_\_\_



**FORMATO EUROPEO  
PER IL CURRICULUM  
VITAE**



**INFORMAZIONI PERSONALI**

Nome **SUSANNA ESPOSITO (CF SPSSNN71P45F205V)**  
Indirizzo **VIA LUIGI ANELLI 2, 20122 MILANO**  
Telefono **02 55032498 – 335 6561739**  
Fax **02 50320206**  
E-mail **[susanna.esposito@unimi.it](mailto:susanna.esposito@unimi.it)**

Nazionalità **Italiana**

Data di nascita **05/09/1971**

**ESPERIENZA LAVORATIVA**

- Professore Associato di Pediatria (settore scientifico-disciplinare MED/38 – Pediatria Generale e Specialistica) della Facoltà di Medicina e Chirurgia dell'Università degli Studi di Milano.
- Direttore della UO Pediatria ad Alta Intensità di Cura, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano.

**ISTRUZIONE E FORMAZIONE**

**Istruzione preuniversitaria e universitaria**

- Diploma di maturità classica conseguito nel 1989 (Liceo ginnasio Zaccaria, Milano).
- Istruzione universitaria presso la Facoltà di Medicina e Chirurgia dell'Università degli Studi di Milano.

**Laurea in Medicina e Chirurgia**

Presso l'Università degli Studi di Milano il 27 luglio 1995, con voti 110/110 e lode.

**Specializzazione**

In Pediatria (1999), presso la Scuola di Specializzazione in Pediatria III dell'Università degli Studi di Milano.

In Malattie Infettive (2006), presso la Scuola di Specializzazione

in Malattie Infettive dell'Università degli Studi di Milano.

## CAPACITÀ E COMPETENZE

### PERSONALI

Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

### Sintesi dei lavori pubblicati

L'attività di ricerca si è concretizzata in:

230 articoli su periodici a diffusione internazionale riportati dal *PubMed*, con il nome riportato tra gli autori principali

*Impact Factor* complessivo 1.216,440  
*h index* 41

273 articoli su periodici a diffusione nazionale  
1 volume a diffusione internazionale  
4 volumi a diffusione nazionale  
9 capitoli su volumi a diffusione internazionale  
21 capitoli su volumi a diffusione nazionale  
36 articoli di carattere divulgativo

- 310 relazioni su invito a congressi di Società Scientifiche

- 346 *abstracts* e comunicazioni selezionati in congressi di Società Scientifiche

Ha coordinato il progetto MIUR No. 2005068289\_001 intitolato "La vaccinazione antinfluenzale in età pediatrica: copertura vaccinale nei bambini con malattia cronica e in quelli sani ed efficacia del vaccino nel periodo epidemico". E' risultata, inoltre, vincitrice del Bando Giovani Ricercatori RF 2007, indetto dal Ministero del Lavoro, della Salute e delle Politiche Sociali, con un progetto intitolato "Impatto dell'influenza e immunogenicità ed efficacia della vaccinazione influenzale in età pediatrica: valutazione clinica e socioeconomica in ospedale e sul territorio" e del Bando Giovani Ricercatori RF 2009, indetto dal Ministero del Lavoro, della Salute e delle Politiche Sociali, con un progetto intitolato "Genetic variants and susceptibility to severe and/or recurrent lower respiratory tract infections with wheezing in children ».

E' risultata vincitrice del progetto « Neomero study - Efficacy, pharmacokinetics and safety of meropenem in infants below 90 days of age (inclusive) with clinical or confirmed late-onset sepsis and meningitis » (no. 242146, FP7-HEALTH-2009) e del progetto "ARPEC - Antimicrobial prescribing in children across Europe" (no. A/101039, Second Programme of Community action in the field of Health 2008-2013).

Collabora con la Health Protection Agency e con la St George's Hospital Medical School di Londra (UK), con la University of Oxford a Oxford (UK), con l'Erasmus Medical Center di Rotterdam (The Netherlands) e con il Children's

Hospital di Dallas (TX, USA). Coordina un progetto di assistenza e consulenza pediatrica presso l'Ospedale di Kiremba in Burundi (Africa).

E' membro dell'Editorial Board di The Pediatric Infectious Disease Journal e di BMC Infectious Diseases. Esegue attività continuative di revisore per numerose riviste internazionali tra cui Lancet, Thorax e BMJ.

### **Premi di studio post-laurea**

- Premio "Carlo Imperato", consegnato dal Presidente della Società Italiana di Pediatria in occasione del 58° Congresso Nazionale della Società Italiana di Pediatria (Montecatini, 28 settembre-2 ottobre 2002).
- Young Investigator Award, consegnato dal Chairman del III World Congress of Pediatric Infectious Diseases (Santiago, Chile, November 19-23 2002).
- Titolo di "George McCracken Fellowship", ricevuto al 43<sup>rd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (Chicago, Illinois, September 14-17 2003).
- Young Scientist Grant, consegnato dal Chairman della Options for the Control of Influenza V (Okinawa, Japan, October 7-11 2003).
- Premio Amici di Milano – Medaglie d'Oro insigniti della Targa d'Argento del Presidente della Repubblica Italiana e della Targa d'Argento del Presidente della Regione Lombardia, consegnato dal Sindaco di Milano il 24 marzo 2004, come migliore ricercatrice medica.
- Premio Soci SIP 2008, quale migliore ricercatrice di pediatria generale e specialistica nell'ambito della Società Italiana di Pediatria, attribuito durante la cerimonia inaugurale del 64° Congresso della Società Italiana di Pediatria il 15 ottobre 2008 a Genova.
- Premio Ambasciatore di Milano a livello internazionale consegnato dall'Onorevole Lupi il 23 maggio 2011.

PRIMA LINGUA

ITALIANO

### **CAPACITÀ E COMPETENZE**

#### **RELAZIONALI**

*Vivere e lavorare con altre persone, in ambiente multiculturale, occupando posti in cui la comunicazione è importante e in situazioni in cui è essenziale lavorare in squadra (ad es. cultura e sport), ecc.*

### **Attività in organismi internazionali**

- Rappresentante per la sezione pediatrica nello "Share-The IAS educational program on HIV clinical care" (dal 1999 al 2005). In tale veste, ha tenuto un corso su "Management of pediatric HIV infection" il 22 ottobre 1999 a Kuala Lumpur, Malesia.
- Membro del Consiglio Direttivo della European Society for Paediatric Infectious Diseases (ESPID) (dal 2004 al 2007).
- Membro del Committee for Training della European Society for Paediatric Infectious Diseases (ESPID) (dal 2007).
- Membro del Committee for Research della European Society for Paediatric Infectious Diseases (ESPID) (dal 2010).

### **Attività in organismi nazionali**

- \* Membro del Consiglio Direttivo della Società Italiana di Infettivologia Pediatrica (dal 2002 al 2005).
- \* Membro del Consiglio Direttivo della Società Italiana di Pediatria – Sezione Lombarda (dal 2004 al 2007).
- \* Membro della task force sulle vaccinazioni della Società Italiana di Immunologia e Allergologia Pediatrica (dal 2004).
- \* Tesoriere della Società Italiana di Infettivologia Pediatrica (dal 2005 al 2007).
- \* Membro della Commissione Antibiotici della Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano (dal 2005).
- \* Membro del Comitato di Prevenzione e Controllo delle Infezioni Ospedaliere della Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano (dal 2005).
- \* Commissario della Commissione di valutazione della didattica dell'Università degli Studi di Milano (dal 2005).
- \* Commissario della Commissione didattica di Polo (Polo Centrale) dell'Università di Milano (dal 2005 al 2010).
- \* Segretario della Società Italiana di Pediatria Preventiva e Sociale (dal 2007).
- \* Vice-Presidente della Società Italiana di Infettivologia Pediatrica (dal 2007).
- \* Rappresentante pediatra nel Consiglio Direttivo della Associazione Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili (SIMaST, dal 2011).

### **Attività in società scientifiche**

- \* Membro della Società Italiana di Pediatria (dal 1998).
- \* Membro della Società Italiana di Infettivologia Pediatrica (dal 1998).
- \* Membro dell'International AIDS Society (dal 1999 al 2005).
- \* Membro della European Society for Paediatric Infectious Diseases (dal 2002).
- \* Membro dell'American Society for Microbiology (dal 2003).
- \* Membro della Società Italiana di Pediatria Preventiva e Sociale (dal 2007).
- \* Membro della Associazione Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili (SIMaST, dal 2010).

#### CAPACITÀ E COMPETENZE ORGANIZZATIVE

*Ad es. coordinamento e amministrazione di persone, progetti, bilanci; sul posto di lavoro, in attività di volontariato (ad es. cultura e sport), a casa, ecc.*

#### Sono state **coordinate**:

1. ricerche epidemiologiche sul ruolo di virus e batteri nelle principali infezioni dell'età pediatrica;
2. sperimentazioni cliniche controllate sugli schemi ottimali per la terapia di alcune malattie infettive pediatriche;
3. sperimentazioni cliniche controllate sulle vaccinazioni nei primi anni di vita;

4. lezioni e corsi di antibioticoterapia;
5. lezioni e corsi di infettivologia pediatrica;
6. proposte di linee-guida sull'approccio diagnostico-terapeutico alle principali malattie infettive dell'età pediatrica;
7. proposte di linee-guida sul nuovo calendario vaccinale e sulle vaccinazioni raccomandate per l'infanzia.

Dall'1 settembre 1997 all'11 dicembre 2000 è stata la responsabile del laboratorio di ricerca della Clinica Pediatrica IV dell'Università degli Studi di Milano; dal 12 dicembre 2000 è responsabile del laboratorio di ricerca della Clinica Pediatrica 1 dell'Università degli Studi di Milano. I due laboratori sotto la sua guida nei principali studi multicentrici italiani sono diventati il riferimento per:

1. i dosaggi sierologici e di biologia molecolare per la ricerca di *Mycoplasma pneumoniae*;
2. l'identificazioni di virus respiratori comuni (virus respiratorio sinciziale, virus influenzali, adenovirus, virus parainflenzali, rhinovirus) ed emergenti (coronavirus, metapneumovirus, bocavirus);
3. la valutazione della risposta immunitaria umorale e cellulo-mediata ai principali vaccini dell'età pediatrica.

Ha organizzato numerosi corsi di formazione e congressi nazionali di infettivologia pediatrica e due corsi internazionali ESPID & SITIP Advances in Paediatric Infectious Diseases.

#### CAPACITÀ E COMPETENZE

##### TECNICHE

*Con computer, attrezzature specifiche, macchinari, ecc.*

Ottima conoscenza dell'inglese (scritto e parlato).

Buona conoscenza dello spagnolo (scritto e parlato).

Ottimo utilizzo dei normali programmi informatici Windows.

Buona conoscenza dei programmi statistici SAS e SPSS.

Buona conoscenza delle metodiche di laboratorio ELISA, delle metodiche per lo studio dell'immunità cellulo-mediata e delle principali metodiche di biologia molecolare.

#### ALTRE CAPACITÀ E COMPETENZE

*Competenze non precedentemente indicate.*

#### **Attività didattica**

Nell'ambito dell'insegnamento di Pediatria Generale e Specialistica della Facoltà di Medicina e Chirurgia dell'Università degli Studi di Milano, dall'anno accademico 2000-2001 svolge lezioni e attività tutoriale (esercitazioni, seminari, discussione di casi clinici), facendo parte delle commissioni per gli esami di profitto e guidando gli studenti nell'impostazione e discussione delle tesi di laurea. Dall'anno accademico 2007-2008 è il titolare del corso di insegnamento di Pediatria Generale e Specialistica (settore scientifico-disciplinare MED/38) presso il Polo Centrale – Linea H della Facoltà di Medicina e Chirurgia dell'Università degli Studi di Milano ed è il presidente della commissione giudicatrice dei relativi esami di profitto.

Nell'ambito della Scuola di Specializzazione in Pediatria I della Facoltà di Medicina e Chirurgia dell'Università di Milano, nell'anno accademico 2000-2001 ha svolto attività tutoriale e nell'anno accademico 2001-2002 è stata Professore a contratto. Dal 2003 svolge attività didattica prima come Ricercatore universitario e poi come Professore associato.

Dall'anno accademico 2003-2004 è responsabile dell'insegnamento di Pediatria Generale e Specialistica (settore scientifico-disciplinare MED/38) del Corso integrato di Scienze medico-specialistiche interdisciplinare (durata: 17 ore, pari a CFU 1) nel Corso di Laurea di Ortottista e Assistente di Oftalmologia dell'Università degli Studi di Milano.

Ha tenuto lezioni, inoltre, presso la Scuola di Specializzazione in Malattie Infettive della Facoltà di Medicina e Chirurgia dell'Università degli Studi di Milano, il Corso di Perfezionamento in "Malattie Infettive Pediatriche Emergenti e Riemergenti" dell'Università di Firenze e ai Corsi Teorico-Pratici di Otorinolaringoiatria Pediatrica organizzati dalla Società Italiana di Infettivologia Pediatrica.

Dall'anno accademico 2003-2004 è responsabile del Corso Elettivo "Terapia antibiotica in pediatria" della Facoltà di Medicina e Chirurgia dell'Università degli Studi di Milano (durata: 40 ore, pari a CFU 1,6). Dall'anno accademico 2006-2007 è responsabile del Corso Elettivo "Emergenze in pediatria" della Facoltà di Medicina e Chirurgia dell'Università degli Studi di Milano (durata: 40 ore, pari a CFU 1,6).

### **Attività assistenziale**

Specializzanda presso la Clinica Pediatrica IV dell'Università degli Studi di Milano: dal 1 novembre 1995 al 31 ottobre 1999.

Medico interno universitario presso la Clinica Pediatrica IV dell'Università degli Studi di Milano: dal 1 novembre 1999 al 12 marzo 2000.

Dirigente medico di 1° livello supplente presso la Clinica Pediatrica IV dell'Azienda Ospedaliera L. Sacco di Milano: dal 13 marzo 2000 al 12 novembre 2000.

Dirigente medico di 1° livello incaricato presso la Clinica Pediatrica IV dell'Azienda Ospedaliera L. Sacco di Milano: dal 13 novembre 2000 all'11 dicembre 2000.

Dirigente medico di 1° livello incaricato presso la Clinica Pediatrica I degli Istituti Clinici di Perfezionamento di Milano: dal 12 dicembre 2000 al 31 luglio 2001.

Dirigente medico di 1° livello di ruolo presso la Clinica Pediatrica I degli Istituti Clinici di Perfezionamento di Milano: dal 1 agosto 2001 al 9 dicembre 2002.

Responsabile del servizio ambulatoriale di infettivologia e dell'attività di consulenza in infettivologia presso la Clinica Pediatrica I degli Istituti Clinici di Perfezionamento di Milano: dal

10 dicembre 2002 al 31 gennaio 2005.

Ricercatore Universitario di ruolo convenzionato presso la Clinica Pediatrica I della Fondazione IRCCS "Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena": dal 1 febbraio 2005 al 30 settembre 2005.

Professore associato di ruolo convenzionato presso la UOC Pediatria 1 Clinica della Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico: dal 1 ottobre 2005 e continua tuttora.

Responsabile del servizio ambulatoriale di infettivologia e immunoprofilassi e dell'attività di consulenza in infettivologia presso la UOC Pediatria 1 Clinica della Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico: dal 1 febbraio 2005 e continua tuttora.

Responsabile del Centro Regionale di Riferimento per l'AIDS pediatrico della Regione Lombardia presso la UOC Pediatria 1 Clinica della Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico: dal 1 febbraio 2005 e continua tuttora.

Responsabile del Centro per il bambino viaggiatore presso la UOC Pediatria 1 Clinica della Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico: dal 1 maggio 2005 e continua tuttora.

Vice-direttore della UOC Pediatria 1 Clinica della Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico: dal 1 luglio 2006 al 29 novembre 2010.

Direttore f.f. della UOC Pediatria 1 Clinica della Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico: dal 30 novembre 2011.

Responsabile dell'Unità Operativa Semplice di Infettivologia Pediatrica presso la UOC Pediatria 1 Clinica della Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico: dal 19 dicembre 2007 e continua tuttora.

PATENTE O PATENTI

Patente A (guida di autovetture)

*Il sottoscritto è a conoscenza che, ai sensi dell'art. 76 del D.P.R. 445/2000 le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi nei casi previsti dal presente testo unico è punito ai sensi del codice penale e delle leggi speciali in materia.*

*Il sottoscritto, inoltre, autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 196/03.*



Milano, 15.01.2016

“

**EUROPEAN  
CURRICULUM VITAE  
FORMAT**



**PERSONAL INFORMATION**

Name FERRARA Micol  
Address VIA CHIODO N 151, 19121 LA SPEZIA, ITALY  
Telephone 3291480018  
Fax  
E-mail micol.ferrara29@gmail.com  
Nationality Italian  
Date of birth 29 JANUARY 1986  
FRRMCL86A69E463P

**WORK EXPERIENCE**

- Dates (from – to) Since 2012 to 2013: *Work as doctor on call in Emergency Medical Care; attending physician at Infectious Diseases Ward, La Spezia Hospital; substitute of General Practitioner*  
Since 07/Aug/2018 to today:
- Name and address of employer Amedeo di Savoia Hospital, corso Svizzera 164, Torino
  - Type of business or sector Department of Infectious Diseases
  - Occupation or position held Medical Doctor Scholarship Holder
- Main activities and responsibilities Specialist Care Activity (Outpatient Clinic of University)  
Clinical research in HIV infection and Antiretroviral Pharmacology, clinical management and follow-up of HIV and HCV/HIV coinfecting patients, sub-investigators of several clinical trials.

**EDUCATION AND TRAINING**

- Dates (from – to) From 2006 to 2012:  
Degree in Medicine and Surgery at University of Pisa, final mark: 110/110 *magna cum laude*
- Name and type of organisation providing education and training From 2013 to 2018:  
Infectious Disease Residency, Università degli Studi di Torino
- Principal subjects/occupational skills covered Resident of Infectious Diseases
- Title of qualification awarded Postgraduated in Infectious Diseases on August the 7<sup>nd</sup>, 2018, final mark: 70/70 *cum laude*
- Level in national classification (if appropriate)

**PERSONAL SKILLS  
AND COMPETENCES**

*Acquired in the course of life and career  
but not necessarily covered by formal  
certificates and diplomas.*

2012-2013: Work as doctor on call in Emergency Medical Care; attending physician at Infectious Diseases Ward, La Spezia Hospital; substitute of General Practitioner

During professional training period I participated to clinical and researches activities in infectious diseases items, both in the antibiotic and the antiretroviral field. During internship in Infectious Diseases I acquired specific clinical competences in particular in HIV positive patients care and antiretroviral pharmacology. I participated to international and national clinical trials in the field of HIV research as sub-investigator. The most important study protocols I followed are:

NCT01328041

NCT01449929

NCT01910402

MK-1439-018

Progetto Prestigio, Italian Multicentric Study

The Geppo cohort study

May-December 2017: Visiting Scholar for 6 moth-time Research Project experience at UCSD, San Diego AVRC (Antiretroviral Research Center), participating in research activity and Grant writing

2015-2018: Teaching in CIO "Infections and Colonizations" lessons at CTO Hospital, Turin

After obtaining the Postgraduated Degree I continued clinical trials activities as sub-investigator and I am still involved in clinical practice regarding the management of HIV patients, in active collaboration with other Infection Diseases Units in Italy, participating in multicenter research activity such as DAU Study Group, Prestigio Study Group, Inaction Study Group.

I participated to National and International Congresses as presenters of clinical datas, relator in 14<sup>th</sup> Residential Course on Clinical Pharmacology of Antiretrovirals and ICAR 2016, 2018 and 2019

2018-19 ; 2019-20 ; 2020-21: Teaching Assistant of Infectious Diseases at Nursing Degree, Istituto Rosmini, University of Turin, Italy

2019-2020 : Teaching Assistant of Infectious Diseases at Obstetrics Degree, Ospedale S. Anna, University of Turin, Italy

Selected as Abstract Reviewer for ICAR 2019, Milan and ICAR 2020, Riccione.

June-November 2019: Selected as participant at "The Voice Project" Gilead programme

March 2020 - Present: Fixed-term contract Medical Doctor at Amedeo di Savoia Hospital Infectious Diseases Clinic, Torino

Oct 2021: winner of Best Abstract "Social and Epidemiology Sciences" ICAR 2021 Riccione

**MOTHER TONGUE**

Italian

**OTHER LANGUAGES**

- Reading skills
- Writing skills
- Verbal skills

**ENGLISH**

GOOD

GOOD

FLUENT

**SOCIAL SKILLS**

Good ability in teamwork

AND COMPETENCES  
*Living and working with other people, in multicultural environments, in positions where communication is important and situations where teamwork is essential (for example culture and sports), etc.*

Proficient in establishing longstanding collaborative relationships with multiple physicians and investigators  
Familiar with working in an international environment and interacting with people from different cultural backgrounds

ORGANISATIONAL SKILLS  
AND COMPETENCES  
*Coordination and administration of people, projects and budgets; at work, in voluntary work (for example culture and sports) and at home, etc.*

Global approach  
Good organizer

TECHNICAL SKILLS  
AND COMPETENCES  
*With computers, specific kinds of equipment, machinery, etc.*

MS Word, Excel, PowerPoint, Outlook, MacOS, Internet Explorer, Firefox, Netscape, SPSS and JMP.

OTHER SKILLS  
AND COMPETENCES  
*Competences not mentioned above.*

Competent in critical thinking and data analysis  
Expertise in peer-to-peer discussions of scientific data  
Presentation of research results at national and international conferences.

DRIVING LICENCE(S)

EU driving licence type B

ADDITIONAL INFORMATION  
PUBLICATIONS  
Original articles

- **“Clinical and Epidemiological characteristic of a cohort of HIV positive immigrants late presenters”** M. Ferrara , F. Patti , L. Trentini , M. Tettoni , L. Marinaro , C. Alcantarini , M. L. Stella , A. Calcagno, S. Bonora, G. Di Perri. SIMET 2013, Oral Communication
- **Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia.** *Motta I<sup>1,5</sup>, Alice T<sup>2</sup>, Romito A<sup>3</sup>, Ferrara M<sup>1</sup>, Ecclesia S<sup>1</sup>, Imperiale D<sup>4</sup>, Ghisetti V<sup>2</sup>, Di Perri G<sup>1</sup>, Bonora S<sup>1</sup> and Calcagno A<sup>1</sup> Antivir Ther. 2017 Feb*
  - **Neurosymptomatic HIV-1 Escape without Resistance-associated Mutations** *Trunfio Mattia 1 , MD, Joseph Sarah Beth 2 , BSc, PhD, Ghisetti Valeria 3 , BSc, PhD, Romito Alessandra 4 , MD, Martini Caterina 5 , MD, Cusato Jessica 1 ,BSc, MSc, Audagnotto Sabrina 1 , MD, Kincer Laura Pesci 6 , BSc, Ferrara Micol 1 , MD, Sala Arianna 7 ,BSc, MSc, Imperiale Daniele 8 , MD, Di Perri Giovanni 1 , MD, PhD, Calcagno Andrea 1 , MD*
  - **Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus.** *Antonella Castagna <sup>1,2</sup>, Micol Ferrara<sup>3</sup>, Laura Galli<sup>1</sup> Mauro Zaccarelli<sup>4</sup>, Antonio Di Biagio<sup>5</sup>, Marianna Menozzi<sup>6</sup>, Annachiara Cericola<sup>7</sup>, Eleonora Magistrelli<sup>8</sup>, Antonio Muscatello<sup>9</sup>, Andrea Rocadori<sup>10</sup>, Giuseppe Forastieri<sup>11</sup>, Paolo Rizzini<sup>11</sup> on behalf of the PRESTIGIO National Database, JAC, 2018*
  - **Tenofovir Exposure and the Risk of Discontinuation for Renal Outcomes: is Tenofovir Disoproxil Fumarate Safe in Selected HIV-positive Patients?** *Andrea Calcagno Laura Trentini, Martina Fiumanò, Costanza Pizzi, Daniela Zugna, Jessica Cusato, Letizia Marinaro, Chiara Montrucchio, Antonio D'Avolio, Micol Ferrara, Giovanni Di Perri, Stefano Bonora*
  - **“Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy”** *Antonella Castagna 1 , Stefano Rusconi 12 , Roberto Gulminetti 2 , Stefano Bonora 3 , Giovanni Mazzola 4 ,Maria Eugenia Quiros-Roldan 5 , Giuseppe Vittorio De Socio 6 , Nicoletta Ladisa 7 , Sinibaldo Carosella 8 , Annamaria Cattelan 9 , Simona Di Giambenedetto 10 , Maurizio Mena 11 , Andrea Poli 1 , Laura Galli 1 , Agostino Riva 12 on behalf of DAU Study Group†, AIDS, 2019 IN PRINTING*
  - **“Geriatrics in HIV infection: multimorbidity, polipharmacy and primary prevention in patients above 65 years”** *Biagini R, Montrucchio C, Calcagno A, Trentini L, Tettoni M, Alcantarini C, Barco A, Trentalange A, Milesi M, Ferrara M, Bertucci R, Di Perri G, Bonora S Journal of HIV and Aging pp.19-25*
  - **“Dolutegravir and unboosted atazanavir: a dual NRTI- and booster-free antiretroviral regimen simplification in HIV-1 infected patients with viral suppression”** *Agostino Riva1; Andrea Poli2; Stefano Rusconi3; Stefano Bonora4; Anna Maria Cattelan5; Eugenia Quiros Roldan6; Micol Ferrara4; Vincenzo Spagnuolo2; Layla Pagnucco7; Silvia Cavinato5; Dario Cattaneo8; Roberto Gulminetti7 and Antonella Castagna. HIV Drug Therapy –Glasgow 2016*

- **“Determinants of dolutegravir plasma concentrations in the clinical setting”**  
Chiara Alcantarini; Andrea Calcagno; Letizia Marinaro; Micol Ferrara; Maurizio Milesi; Alice Trentalange; Ambra Barco; Chiara Montrucchio; Amedeo De Nicolò ; Alessandra Ariaudo; Fabio Favata; Antonio D’Avolio; Giovanni Di Perri and Stefano Bonora. HIV Drug Therapy –Glasgow 2016
- **“Cardiovascular risk and neurocognitive deficits in HIV-positive individuals”** Montrucchio C, Biagini R, Alcantarini C, Calcagno A, Barco A, Ferrara M, Milesi M, Costa C, Trentalange A, Trunfio M, Tettoni M, Grosso Marra W, D’Ascenzo F, Ballocca F, Lonni E, Gili S, Vai D, Imperiale D, Gaita F, Bonora S, Di Perri G. *Infect Dis*
- **“RUOLO DEL BOOSTER (RITONAVIR, RTV E COBICISTAT, (COBI) VS UNBOOSTED SULLA FARMACOCINETICA (PK) PLASMATICA E INTRACELLULARE (IC) DI DOLUTEGRAVIR (DTG) NEL SETTING CLINICO DI DUAL THERAPY CON INIBITORI DI PROTEASI (PI).”** M. Ferrara, C. Alcantarini, L. Marinaro, M.C. Tettoni, A. De Nicolò, A. D’Avolio, S. Bonora
- **“NEUTROPENIA E FEBBRE INDOTTE DA PIPERACILLINA-TAZOBACTAM: DESCRIZIONE DI 6 CASI”**  
F. Lipani<sup>1</sup> , C. Alcantarini<sup>1</sup> , A. Lucchini<sup>1</sup> , N. Forni<sup>1</sup> , A. Lazzaro<sup>1</sup> , A. Barco<sup>1</sup> , M. Ferrara<sup>1</sup> , C. Lipani<sup>3</sup> , G. Cinnirella<sup>2</sup> , D. Piccioni<sup>2</sup>, C. Carcieri<sup>2</sup> , G. Di Perri<sup>1</sup>, SIMIT 2018
- **“ANALISI COMPARATIVA DELLA FARMACOCINETICA DI MARAVIROC CO-SOMMINISTRATO CON RITONAVIR O COBICISTAT”** C. Carcieri<sup>1</sup> , A. Calcagno<sup>1</sup> , C. Alcantarini, A. De Nicol.<sup>1</sup> , L. Marinaro<sup>1</sup> , A. Barco<sup>1</sup> , M. Ferrara<sup>1</sup> , A. Palazzo<sup>1</sup> , V. Avataneo<sup>1</sup> , A. D’Avolio<sup>1</sup> , G. Di Perri<sup>1</sup> , S. Bonora<sup>1</sup>. SIMIT 2018
- **“CIRROSI SECONDARIA A EPATITE CRONICA HCV CORRELATA CON SIEROLOGIA NEGATIVA PER HCV, ANA E ASMA POSITIVI IN DONNA CON INFEZIONE DA HIV SOTTOPOSTA A TRAPIANTO EPATICO E TRATTATA CON DAAS.”** C. Alcantarini<sup>1</sup> , F. Lipani<sup>1</sup> , A. Lucchini<sup>1</sup> , M. Tettoni<sup>1</sup> , L. Trentini<sup>1</sup> , C. Montrucchio<sup>1</sup> , M. Ferrara<sup>1</sup> , V. Pirriatore<sup>1</sup> , N. Forni<sup>1</sup> , A. Barco<sup>1</sup> , A. Lazzaro<sup>1</sup> , M. Milesi<sup>1</sup> , M. Vangeli<sup>2</sup> , M. Merli<sup>3</sup> , M. Puoti<sup>3</sup> , S. Bonora<sup>1</sup> , G. Di Perri<sup>1</sup>, SIMIT 2018
- **“UN CASO DI PIELONEFRITE ACUTA DA STAPHYLOCOCCUS SAPROPHYTICUS GENE MEC-A POSITIVO”**  
F. Lipani, A. Lucchini, C. Alcantarini, A. Barco, M. Ferrara, I. De Benedetto, F. Brandolino, A. Lazzaro, C. Lipani<sup>1</sup> , R. Milano<sup>2</sup> , E. Burdino<sup>2</sup> , V. Ghisetti<sup>2</sup>, G. Di Perri, SIMIT 2018
- **“CASO DI IPERSENSIBILITÀ CUTANEA IN SEGUITO A SWITCH DA KIVEXA® AD ABACAVIR/LAMIVUDINA GENERICO”** Lazzaro A, Angilletta R, Forni, N, Pirriatore V, Alcantarini A, **Ferrara M**, Tettoni M, Bonora S, Di Perri G CISAI 2019, Poster
- **“MODELLO DI GESTIONE MULTIDISCIPLINARE DELLE COMORBIDITÀ NON HIV CORRELATE IN UNA POPOLAZIONE DI PAZIENTE CON INFEZIONE DA HIV”** Lazzaro A, Montrucchio C, Angilletta R, Forni, N, Pirriatore V, Alcantarini A, **Ferrara M**, Tettoni M, Grosso Marra W, Bonora S, Calcagno A, Di Perri G “CISAI 2019, Poster

- **“Glecaprevir/pibrentasvir pharmacokinetics in HCV/HIV patients co-administered with antiretroviral drugs.”**  
L. Marinaro, V. Pirriatore, R. Angilletta, A. Palazzo, A. Barco, C. Alcantarini, C. Montrucchio 1, **M. Ferrara**, MC. Tettoni, A. De Nicolò, A. D’Avolio 1, A. Calcagno, G. Di Perri 1 and S. Bonora  
-20th international workshop on clinical pharmacology of hiv, hepatitis & other antiviral drugs 2019.
- **Cobicistat-boosted Protease Inhibitors plasma and intracellular pharmacokinetics in Nicotine Users“**  
**M. Ferrara**<sup>1</sup>, A. Trentalange<sup>1</sup>, C. Alcantarini<sup>1</sup>, L. Marinaro<sup>1</sup>, V. Pirriatore<sup>1</sup>, A. Ianniello<sup>1</sup>, A. De Nicolò<sup>1</sup>, A. D’Avolio<sup>1</sup>, A. Calcagno<sup>1</sup>, G. Di Perri<sup>1</sup>, S. Bonora<sup>1</sup>. “-20th international workshop on clinical pharmacology of hiv, hepatitis & other antiviral drugs 2019.
- **Plasma and intracellular pharmacokinetics of cobicistat in the clinical setting”**  
**M. Ferrara**<sup>1</sup>, A. Trentalange<sup>1</sup>, C. Alcantarini<sup>1</sup>, A. Lazzaro<sup>1</sup>, N. Forni<sup>1</sup>, A. Ianniello<sup>1</sup>, V. Avataneo<sup>1</sup>, A. D’Avolio<sup>1</sup>, A. Calcagno<sup>1</sup>, G. Di Perri<sup>1</sup>, S. Bonora<sup>1</sup> “-20th international workshop on clinical pharmacology of hiv, hepatitis & other antiviral drugs 2019.
- **.”Valproic Acid Co-administration Is Not Associated With Lower Non-Dolutegravir Antiretrovirals’ Exposures”**  
Calcagno A, Cusato J, **Ferrara M**, De Nicolò A, Lazzaro A, Manca A, D’Avolio A, Di Perri G and Bonora S 20th international workshop on clinical pharmacology of hiv, hepatitis & other antiviral drugs 2019
- **“Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study”**  
Livelli A, Vaida F, Ellis RJ, Ma Q, **Ferrara M**, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Morgello S, Sacktor N, Simpson DM, Grant I, Letendre SL; CHARTER Group. Lancet HIV, 2019
- **“Antiretroviral Concentrations in the Presence and Absence of Valproic Acid”** Calcagno, Andrea; Cusato, Jessica; **Ferrara, Micol**; De Nicolò, Amedeo; Lazzaro, Alessandro; Manca, Alessandra; D’Avolio, Antonio; Di Perri, Giovanni; Bonora, Stefano JAC-2019-2156.R1, Feb 2020
- **“96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation”** V. Di Cristo, F. Adorni, R. Maserati, M. Annovazzi Lodi, G. Bruno, P. Maggi, A. Volpe, P. Vitiello, C. Abeli S. Bonora, **M. Ferrara**, MV. Cossu, ML Oreni, E. Colella, S. Rusconi. HIV Clinical Trials, Feb 2020
- **“Antiretroviral Drug Concentrations in Brain Tissue of Adult Decedents”** **Micol Ferrara** 1, Namandjé N. Bumpus 2, Qing Ma 3, Ronald J. Ellis 4, Virawudh Soontornniyomkij 4, Jerel A. Fields 4, Ajay Bharti 4, Cristian L. Achim 4, David J. Moore 4, and Scott L. Letendre 4. AIDS, 2020

- **Simplification to High Genetic Barrier 2-Drug Regimens in People Living With HIV Harboring 4-Class Resistance Enrolled in the PRESTIGIO Registry** Diana Canetti 1, Laura Galli, Nicola Gianotti, Anna Celotti, Leonardo Calza, Roberta Gagliardini, Stefano Rusconi, Sara Modica, Giovanni Cenderello, **Micol Ferrara**, Maria Mercedes Santoro, Maurizio Zazzi, Antonella Castagna, PRESTIGIO Study Group, J Acquir Immune Defic Syndr 2020 Aug
  
- **“Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort L** Taramasso 1 M Fabbiani,2 S Nozza,3 I De Benedetto,4 E Bruzzesi,3 A Mastrangelo,3 C Pinnetti,5 A Calcagno,4 **M Ferrara**,4 G Bozzi,1 E Focà,6 E Quiros-Roldan,6 D Ripamonti,7 M Campus,8 BM Celesia,9 C Torti,10 L Cosco,11 A Di Biagio , 12 S Rusconi,13 G Marchetti,14 C Mussini,15 R Gulminetti,2 A Cingolani,16 G d’Ettorre,17 G Madeddu,18 A Franco,19 G Orofino,20 N Squillace,21,22 A Muscatello,1 A Gori,1,23 A Antinori,5 G Tambussi3 and A Bandera1,23 on behalf of INACTION study group HIV Medicine 2020
  
- **“Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection-Results of Italian Network of ACuTe HIV InfectiON (INACTION) Retrospective Study”** Antonio Muscatello 1 , Silvia Nozza 2 , Massimiliano Fabbiani 3 , Ilaria De Benedetto 4 , Marco Ripa 2 , Raffaele Dell’acqua 2 , Andrea Antinori 5 , Carmela Pinnetti 5 , Andrea Calcagno 4 , **Micol Ferrara** 4 , Emanuele Focà 6 , Eugenia Quiros-Roldan 6 , Diego Ripamonti 7 , Marco Campus 8 , Benedetto Maurizio Celesia 9 , Carlo Torti 10 , Lucio Cosco 11 , Antonio Di Biagio 12 , Stefano Rusconi 13 , Giulia Marchetti 14 , Cristina Mussini 15 , Roberto Gulminetti 4 , Antonella Cingolani 16 , Gabriella D’ettorre 17 , Giordano Madeddu 18 , Antonina Franco 19 , Giancarlo Orofino 20 , Nicola Squillace 21 , Andrea Gori 1 22 , Giuseppe Tambussi 2 , Alessandra Bandera 1 22 , Inaction Study Group. Path. Immun. Feb 2020
  
- **“Validation of a UHPLC-MS/MS method to quantify twelve antiretroviral drugs within peripheral blood mononuclear cells from people living with HIV”** Amedeo De Nicolò 1, \* , Alice Ianniello 1 , **Micol Ferrara** 1 , Valeria Avataneo 1 , Jessica Cusato 1 , Miriam Antonucci 1 , Elisa De Vivo 1 , Catriona Waitt 2 , Andrea Calcagno 1 , Alice Trentalange 1 , Giampiero Muccioli 3 , Stefano Bonora 1 , Giovanni Di Perri 1 and Antonio D’Avolio 1 Journal of Pharmaceutical and Biomedical analysis, 2020
  
- **Medication Burden and Clustering in People Living with HIV Undergoing Therapeutic Drug Monitoring** Andrea Calcagno1 , Amedeo de Nicolò2 , Costanza Pizzi3 , Mattia Trunfio1 , Cristina Tettoni1 , **Micol Ferrara**1 , Chiara Alcantarini1 , Laura Trentini1 ,

Antonio D'Avolio<sup>2</sup>, Giovanni Di Perri<sup>1</sup> and Stefano Bonora<sup>1</sup>, *Br. J. Clin. Pharmacol.*, p. bcp.14869, Apr. 2021

- **Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma**, Amedeo De Nicolò, Alessandra Manca, Alice Ianniello, Alice Palermi, Andrea Calcagno, **Micol Ferrara**, Miriam Antonucci, Jessica Cusato, Valeria Avataneo, Elisa De Vivo, Stefano Bonora, Francesco Giuseppe De Rosa, Giovanni Di Perri and Antonio D'Avolio, *Pharmaceuticals*, 2021
- **Inflammation Affects Antiretrovirals Plasma and Intracellular Exposure** **M. Ferrara**<sup>1\*</sup>, E. Salvador<sup>1</sup>, A. Trentalange<sup>1</sup>, C. Alcantarini<sup>1</sup>, M. Trunfio<sup>1</sup>, E.S. Cannizzo<sup>2</sup>, V. Bono<sup>2</sup>, S. Nozza<sup>3</sup>, A. De Nicolò<sup>4</sup>, A. Ianniello<sup>4</sup>, E. De Vivo<sup>4</sup>, A. D'Avolio<sup>4</sup>, G. Di Perri<sup>1</sup>, S. Bonora<sup>1</sup>, G. Marchetti<sup>2</sup>, A. Calcagno<sup>1</sup> *under review JAC 2021*
- **Durability of Integrase STRand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPO cohort** *Plos one 2021*

#### Abstracts of oral communications/posters

- **M. Ferrara**, F. Patti, L. Trentini, M. Tettoni, L. Marinaro, C. Alcantarini, M. L. Stella, A. Calcagno, S. Bonora, G. Di Perri. "Clinical and Epidemiological characteristic of a cohort of HIV positive immigrants late presenters" SIMET 2013, Oral Communication
- L. Marinaro, A. Calcagno, M. Simiele, L. Trentini, M.C. Tettoni, C. Alcantarini, S. Raviolo, **M. Ferrara**, J. Cusato, A. D'Avolio, G. Di Perri and S. Bonora "Intracellular Pharmacokinetics of Rilpivirine in HIV-positive Patients Treated with Single-tablet Regimen Fixed-dose Combination" ICAR2014
- **M. Ferrara**, L. Marinaro, G. Vendemiati, M. Simiele, M.C. Tettoni, L. Trentini, A. Calcagno, A. D'Avolio, G. Di Perri, S. Bonora. "Tenofovir Pharmacokinetics and Early Tubular Safety in HIV-positive Patients Switching to Tenofovir/emtricitabine/rilpivirine" ICAR 2015 Oral Communication
- I. Motta, A. Calcagno, M.G. Milia, A. Romito, **M. Ferrara**, D. Imperiale, A. Prochet, V. Ghisetti, G. Perri, S. Bonora "Undetectable Cerebrospinal Fluid HIV RNA is Predicted by Plasma HIV RNA and is Associated with Low Neopterin" ICAR 2015 Poster Presentation
- **M. Ferrara**, L. Marinaro, S. Rusconi, A. Crippa, A. Riva, A. Ariaudo, M. Simiele, A. D'Avolio, M.C. Tettoni, A. Castagna, M. Galli, G. Di Perri, and S. Bonora "Intensive pharmacokinetics (PK) of dolutegravir 50 mg associated with atazanavir 400 mg once daily in the clinical setting" ICAR 2016, Poster Presentation
- Agostino Riva\* 1, Andrea Poli 2, Stefano Rusconi 1, Stefano Bonora 3, **Micol Ferrara** 3, Roberto Gulminetti 4, Layla Pagnucco 4, Anna Maria Cattelan 5, Silvia Cavinato 5, Vincenzo Spagnuolo

2, Eugenia Quiros Roldan 6, Antonella Castagna 2. “The BOOSTER-FREE project: a new role of unboosted-atazanavir (ubATV) plus dolutegravir (DTG) in virologically suppressed HIV-positive subjects receiving HAART” ICAR 2016

- A. Muscatello<sup>1</sup>, A. Bandera<sup>1</sup>, M. Fabbiani<sup>1</sup>, A. Ammassari<sup>2</sup>, A. Antinori<sup>2</sup>, A. Calcagno<sup>3</sup>, **M. Ferrara**<sup>3</sup>, B.M. Celesia<sup>4</sup>, L. Cosco<sup>5</sup>, G. D’Ettore<sup>6</sup>, A. Di Biagio<sup>7</sup>, E. Focà<sup>8</sup>, A. Franco<sup>9</sup>, A. Gori<sup>1</sup>, R. Gulminetti<sup>10</sup>, G. Marchetti<sup>11</sup>, S. Nozza<sup>12</sup>, G. Orofino<sup>13</sup>, M. Ripa<sup>12</sup>, D. Ripamonti<sup>14</sup>, S. Rusconi<sup>15</sup>, G. Tambussi<sup>12</sup>, C. Torti<sup>16</sup> on behalf of INACTION study group. “Results of Italian Network of ACuTe HIV InfectiON (INACTION) retrospective study” ICAR 2016, OC; ICAR 2017, OC
- Antonella Castagna <sup>1,2</sup>, Laura Galli<sup>1</sup>, **Micol Ferrara**<sup>3</sup>, Mauro Zaccarelli<sup>4</sup>, Antonio Di Biagio<sup>5</sup>, Marianna Menozzi<sup>6</sup>, Annachiara Cericola<sup>7</sup>, Eleonora Magistrelli<sup>8</sup>, Antonio Muscatello<sup>9</sup>, Andrea Rocadori<sup>10</sup>, Giuseppe Forastieri<sup>11</sup>, Paolo Rizzini<sup>11</sup> on behalf of the PRESTIGIO National Database “Durability of Dolutegravir (50 mg BID) including regimens in INI-resistant failing HIV-1 infected subjects in Italy: data from the PRESTIGIO National Database” ICAR 2016, OC; SIMIT 2016, PP; CROI 2017, PP
- A. Castagna, R. Gulminetti, S. Rusconi, A. Riva, A. Poli, G. Mazzola, A. Cascio, G. De Socio, N. Ladisa, S. Carosella, A.M. Cattelan, S. Cavinato, S. di Giambenedetto, M. Mena, V. Spagnuolo, E. Quiros Roldan, D. Cattaneo, L. Galli, L. Pagnucco, **M. Ferrara**, S. Bonora “Durability and safety of a dual antiretroviral regimen with dolutegravir and unboosted atazanavir in HIV-1 infected patients with virological suppression” EACS 2017
- Jessica Cusato; Letizia Marinaro; Martina Fiumanò; Marco Simiele; **Micol Ferrara**; Chiara Alcantarini; Antonio D’Avolio; Giovanni Di Perri; Stefano Bonora “Predicting Drug Discontinuation in TDF-Tolerant Patients: A Prospective PK/PG Study”. CROI 2016
- C. Alcantarini, L. Marinaro, **M. Ferrara**, A. Barco, M. Milesi, F. Patti, L. Trentini, M.C. Tettoni, J. Cusato, A. De Nicolò, F. Favata, A. Ariaudo, A. D’Avolio, G. Di Perri and S. Bonora Acute Renal Tubular Dysfunction in two HIV/HCV-coinfected Patients Treated with ledipasvir /sofosbuvir and Tenofovir-containing HAART.P198 ICAR 2016
- L. Marinaro, G. Vendemiati, A. Calcagno, C. Montrucchio, **M. Ferrara**, M. Fiumanò, J. Cusato, C. Alcantarini, M. Simiele, S. Raviolo, M.C. Tettoni, L. Trentini, A. D’Avolio, G. Di Perri and S. Bonora Pharmacokinetics and Tubular Safety of Tenofovir/Emtricitabine/ Rilpivirine ICAR 2016
- C. Alcantarini, A. Calcagno, L. Marinaro, **M. Ferrara**, M. Milesi, A. Trentalange, A. Barco, C. Montrucchio, A. De Nicolò, A. Ariaudo, F. Favata, A. D’Avolio, G. Di Perri, S. Bonora “Determinants of dolutegravir plasma concentrations in the clinical setting” HIV Drug Therapy –Glasgow 2016
- S. Rusconi<sup>1</sup>, V. Di Cristo<sup>1</sup>, F. Adorni<sup>2</sup>, R. Maserati<sup>3</sup>, M. Annovazzi Lodi<sup>3</sup>, N. Ladisa<sup>4</sup>, P. Maggi<sup>4</sup>, P. Vitiello<sup>5</sup>, C. Abeli<sup>5</sup>, S. Bonora<sup>6</sup>, **M. Ferrara**<sup>6</sup>, M.V. Cossu<sup>7</sup>, E. Colella<sup>1</sup>, M. Galli<sup>1</sup> “48-week results of a dual therapy with Darunavir/rtv plus Rilpivirine QD vs triple therapy in patients with suppressed viraemia: virological efficacy and non-HIV related morbidity evaluation” ICAR 2017, OC
- **M. Ferrara**, L. Marinaro, C. Alcantarini, C. Montrucchio, M. Milesi,

- A. Barco, C. Costa, B. Granozzi, M.C. Tettoni, G. Orofino, A. Ariaudo, A. De Nicolò, A. D'Avolio, G. Di Perri, S. Bonora Efficacy, tolerability and pharmacokinetics of dual therapy based on dolutegravir (DTG) and darunavir/ritonavir (DRV/r) qd in the clinical setting. Poster Discussion ICAR 2017
- C. Alcantarini, **M. Ferrara**, L. Marinaro, B. Granozzi, M.C. Tettoni, C. Montrucchio, M. Milesi, A. Barco, C. Costa, G. Di Perri, S. Bonora Efficacy and Tolerability of dual therapy based on dolutegravir (DTG) and atazanavir/ritonavir (ATV/r) in the clinical setting ICAR 2017
  - **M. Ferrara**, L. Marinaro, A. Ariaudo, C. Alcantarini, A. Barco, C. Montrucchio, A. De Nicolò, M. Tettoni, M. Milesi, C. Costa, A. Calcagno, G. Di Perri, A. D'Avolio, S. Bonora Intracellular penetration of dolutegravir (DTG) and unboosted atazanavir (ATV) administered as dual regimen in the clinical setting ICAR2017
  - F. Patti, A. Barco, L. Marinaro, C. Montrucchio, C. Alcantarini, C. Costa, S. Scabini, M. Milesi, **M. Ferrara**, M. Tettoni, A. D'Avolio, G. Di Perri, S. Bonora Regression of liver fibrosis and stability of steatosis in HIV/HCV co-infected patients treated with DAAs ICAR 2017
  - C. Costa, C. Montrucchio, D. Pensi, S. Sbrulati, C. Alcantarini, A. Barco, **M. Ferrara**, M. Milesi, A. Trentalange, MC. Tettoni, A. D'Avolio, S. Bonora, G. Di Perri, A. Calcagno "Trimethylamine-N-oxide Serum Concentrations in HIV-positive Treated Patients Trimethylamine-N-oxide Serum Concentrations in HIV-positive Treated Patients", ICAR 2017, poster
  - **M. Ferrara**<sup>1</sup>, M. Zazz<sup>2</sup>, L. Comi<sup>3</sup>, E Focà<sup>4</sup>, G. Sterrantino<sup>5</sup>, A. Di Biagio<sup>6</sup>, M. Zaccarelli<sup>7</sup>, S. Rusconi<sup>8</sup>, G. Cenderello<sup>9</sup>, M Gargiulo<sup>10</sup>, E. Schiaroli<sup>11</sup>, F. Fusco<sup>12</sup>, A.M. degli Antoni<sup>13</sup>, M. Tavio<sup>14</sup>, E. Garlassi<sup>15</sup>, B. Rossetti<sup>16</sup>, O. Bargiacchi<sup>17</sup>, G. Maffongelli<sup>18</sup>, M Santoro<sup>19</sup>, C. della Casa<sup>20</sup>, N. Gianotti<sup>21</sup>, A. Pol<sup>21</sup>, F. Rinaldi<sup>22</sup>, L. Gall<sup>21</sup>, A. Castagna<sup>21,23</sup> on behalf of the PRESTIGIO Study Group "Use of NRTIs in salvage therapy of treatment-experienced subjects with HIV-1 NRTI, NNRTI PI and INSTI-drug resistance" ICAR 2018, OC
  - S. Rusconi<sup>1</sup>, R. Gulminetti<sup>2</sup>, S. Bonora<sup>3</sup>, A. Riva<sup>1</sup>, L. Pagnucco<sup>2</sup>, **M. Ferrara**<sup>3</sup>, G. Mazzola<sup>4</sup>, A. Cascio<sup>4</sup>, M.E. Quiros Roldan <sup>5</sup>, A. Ferraresi<sup>5</sup>, G. De Socio<sup>6</sup>, N. Ladisa<sup>7</sup>, S. Carosella<sup>8</sup>, A.M. Cattelan<sup>9</sup>, S. Cavinato<sup>9</sup>, S. Di Giambenedetto<sup>10</sup>, A. Ciccullo<sup>10</sup>, M. Mena<sup>11</sup>, C. Atzori<sup>12</sup>, M. Frigerio<sup>1</sup>, F.S. Falvella<sup>13</sup>, D. Cattaneo<sup>13</sup>, V. Spagnuolo<sup>14</sup>, A. Poli<sup>14</sup>, L. Galli<sup>14</sup>, A. Castagna<sup>14</sup> on behalf of DAU Study Group "Dual regimen with dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy", ICAR 2018, OC
  - N.Forni<sup>1</sup>, C.Alcantarini<sup>2</sup>, C.Montrucchio<sup>3</sup>, A.Trentalange<sup>4</sup>, A. Barco<sup>5</sup>, C.Costa<sup>6</sup>, M.Milesi<sup>7</sup>, **M.Ferrara**<sup>8</sup>, A.Lazzaro<sup>9</sup>, V.Pirriatore<sup>10</sup>, L.Trentini<sup>11</sup>, A.Calcagno<sup>12</sup>, S.Bonora<sup>13</sup>, G.Di Perri<sup>14</sup>, M.Tettoni<sup>15</sup> "Reasons and outcomes of PEP use in a large urban center, the Outpatient Clinic of Turin: a year of observation", ICAR 2018, OC
  - **M. Ferrara**<sup>1</sup>, C. Alcantarini<sup>1</sup>, L. Marinaro<sup>1</sup>, MC Tettoni<sup>1</sup>, A. De Nicolò<sup>1</sup>, A. D'Avolio<sup>1</sup>, S. Bonora<sup>1</sup>. "Ruolo del booster (ritonavir, RTV e cobicistat, COBI) vs unboosted sulla farmacocinetica (PK)

*plasmatica e intracellulare (IC) di dolutegravir (DTG) nel setting clinico di dual therapy con inibitori di proteasi (PIs)” SIMIT 2018, Poster*

- C. Alcantarini, F. Lipani, A. Lucchini, M. Tettoni, L. Trentini, C. Montrucchio, M. Ferrara, V. Pirriatore, N. Forni, A. Barco, A. Lazzaro, M. Milesi, M. Vangeli, M. Merli, M. Puoti, S. Bonora e G. Di Perri “*Cirrosi secondaria a epatite cronica HCV-correlata con sierologia negativa per HCV, ANA e ASMA positivi in donna con infezione da HIV sottoposta a trapianto epatico e trattata con DAAs*” SIMIT 2018, Poster
- Lazzaro A, Angilletta R, Forni, N, Pirriatore V, Alcantarini A, **Ferrara M**, Tettoni M, Bonora S, Di Perri G “*CASO DI IPERSENSIBILITÀ CUTANEA IN SEGUITO A SWITCH DA KIVEXA® AD ABACAVIR/LAMIVUDINA GENERICO*” CISAI 2019, Poster
- Lazzaro A, Montrucchio C, Angilletta R, Forni, N, Pirriatore V, Alcantarini A, **Ferrara M**, Tettoni M, Grosso Marra W, Bonora S, Calcagno A, Di Perri G “*MODELLO DI GESTIONE MULTIDISCIPLINARE DELLE COMORBIDITÀ NON HIV CORRELATE IN UNA POPOLAZIONE DI PAZIENTE CON INFEZIONE DA HIV*” CISAI 2019, Poster
- Calcagno A, Cusato J, **Ferrara M**, De Nicolò A, Lazzaro A, Manca A, D’Avolio A, Di Perri G and Bonora S. “*Valproic Acid Co-administration Is Not Associated With Lower Non-Dolutegravir Antiretrovirals’ Exposures*” 20th international workshop on clinical pharmacology of hiv, hepatitis & other antiviral drugs 2019, Poster
- L. Marinaro, V. Pirriatore, R. Angilletta, A. Palazzo, A. Barco, C. Alcantarini, C. Montrucchio 1, **M. Ferrara**, MC. Tettoni, A. De Nicolò, A. D’Avolio 1, A. Calcagno, G. Di Perri 1 and S. Bonora “*Glecaprevir/pibrentasvir pharmacokinetics in HCV/HIV patients co-administered with antiretroviral drugs.*” -20th international workshop on clinical pharmacology of hiv, hepatitis & other antiviral drugs 2019, Poster.  
-ICAR 2019, Poster Discussion
- **M. Ferrara**<sup>1</sup>, A. Trentalange<sup>1</sup>, C. Alcantarini<sup>1</sup>, L. Marinaro<sup>1</sup>, V. Pirriatore<sup>1</sup>, A. Ianniello<sup>1</sup>, A. De Nicolò<sup>1</sup>, A. D’Avolio<sup>1</sup>, A. Calcagno<sup>1</sup>, G. Di Perri<sup>1</sup>, S. Bonora<sup>1</sup>. “*Cobicistat-boosted Protease Inhibitors plasma and intracellular pharmacokinetics in Nicotine Users*” -20th international workshop on clinical pharmacology of hiv, hepatitis & other antiviral drugs 2019, Poster  
-ICAR 2019, Poster.
- **M. Ferrara**<sup>1</sup>, A. Trentalange<sup>1</sup>, C. Alcantarini<sup>1</sup>, A. Lazzaro<sup>1</sup>, N. Forni<sup>1</sup>, A. Ianniello<sup>1</sup>, V. Avataneo<sup>1</sup>, A. D’Avolio<sup>1</sup>, A. Calcagno<sup>1</sup>, G. Di Perri<sup>1</sup>, S. Bonora<sup>1</sup> “*Plasma and intracellular pharmacokinetics of cobicistat in the clinical setting*” -20th international workshop on clinical pharmacology of hiv, hepatitis & other antiviral drugs 2019, Poster.  
-ICAR 2019, Poster Discussion
- N. Forni., C. Alcantarini., R. Angilletta., **M. Ferrara.**, A. Lazzaro., V. Pirriatore., M. Tettoni, A. De Nicolò, A. Ianniello., A. D’Avolio., S. Bonora., G. Di Perri..” *TDF Tubulopathy In A Switchback Patient. A Case Report*” ICAR 2019, Poster

- Canetti D, Galli L. Gianotti N, Gagliardini R, Sacco, Siena, Cenderello G, **Ferrara M**, Santoro M, Zazzi M, Castagna A, on behalf of the PRESTIGIO Study Group.  
“Simplification to high-genetic-barrier 2DR in patients harbouring four-class drug-resistant HIV, enrolled in the PRESTIGIO Registry”  
ICAR 2019, Poster Discussion
  - **M. Ferrara**<sup>1</sup>, L. Marinaro<sup>1</sup>, C. Alcantarini<sup>1</sup>, A. Barco<sup>1</sup>, M. Milesi<sup>1</sup>, MC Tettoni<sup>1</sup>, A. Ianniello<sup>1</sup>, A. De Nicolò<sup>1</sup>, A. D’Avolio<sup>1</sup>, A. Calcagno<sup>1</sup>, G. Di Perri<sup>1</sup>, S. Bonora<sup>1</sup> “Role of boosted vs unboosted protease inhibitors on dolutegravir plasma and intracellular pharmacokinetic in dual therapy clinical setting”  
ICAR 2019, Poster Discussion
  - Alice Ianniello, Amedeo De Nicolò, **Micol Ferrara**, Jessica Cusato, Valeria Avataneo, Miriam Antonucci, Elisa De Vivo, Catriona Waitt, Stefano Bonora, Giovanni Di Perri and Antonio D’Avolio “Validation and application of a UHPLC-MS/MS method for the simultaneous quantification of twelve currently used antiretroviral drugs within peripheral blood mononuclear cells from patients with HIV infection” *51° CONGRESSO NAZIONALE SIBIOC - LA MEDICINA DI LABORATORIO NELLA FRAGILITÀ E LA FRAGILITÀ DELLA MEDICINA DI LABORATORIO 2019*
  - C. Alcantarini 1 , M. Tettoni 1 , F. Lipani 1 , I. Dal Conte 2 , A. Lazzaro 1 , **M. Ferrara** 1 , N. Forni 1 , R. Angilletta 1 , M. Milesi 1 , I. De Benedetto 1 , T. Alice 3 , A. Calcagno 1 , G. Di Perri 1 , S. Bonora 1 “ULCERE SCROTALI DA CMV IN CORSO DI CO-INFEZIONE ACUTA DA CMV E HIV” Simit 2019, Poster
  - Francesco Saladini<sup>1</sup>, Federica Giammarino<sup>1</sup>, Franco Maggiolo<sup>2</sup>, **Micol Ferrara**<sup>3</sup>, Giovanni Cenderello<sup>4</sup>, Benedetto Maurizio Celesia<sup>5</sup>, Ferdinando Martellotta<sup>6</sup>, Vincenzo Spagnuolo<sup>7</sup>, Giulio Maria Corbelli<sup>6</sup>, Nicola Gianotti<sup>8</sup>, Maria M. Santoro<sup>9</sup>, Stefano Rusconi<sup>10</sup>, Maurizio Zazzi<sup>1</sup>, Antonella Castagna<sup>7</sup> “*PHENOTYPIC DORAVIRINE SUSCEPTIBILITY AFTER NNRTI EXPOSURE IN THE PRESTIGIO REGISTRY*” CROI 2020, Poster Presentation
  - *Dolutegravir, emtricitabine/tenofovir alafenamide fumarate absorption in a gastrectomized in HIV-positive patient*
- C. Alcantarini, **M. Ferrara**, M. Tettoni, F. Lipani, S. Biffi, A. Di Stefano, M. Trunfio, A. Lazzaro, V. Avataneo, J. Cusato, A. De Nicolò, A. D’Avolio, A. Calcagno, G. Di Perri and S. Bonora, ICAR 2020 Poster
- A. Celotti<sup>1</sup>, S. Calza<sup>2</sup>, A. Di Biagio<sup>3</sup>, C. Mussini<sup>4</sup>, S. Rusconi<sup>5</sup>, S. Bonora<sup>6</sup>, S. Di Giambenedetto<sup>7</sup>, E. Quiros Roldan<sup>1</sup>, G. Sarteschi<sup>3</sup>, M. Menozzi<sup>4</sup>, **M. Ferrara**<sup>6</sup>, A. Ciccullo<sup>8</sup>, V. Giacomet<sup>9</sup>, A. Ferrari<sup>10</sup>, R. Badolato<sup>10</sup>, I. Izzo<sup>1</sup>, F. Castelli<sup>1</sup>, E. Focà<sup>1</sup>  
*Reduced probability of achieving optimal viro-immunological condition in subjects with vertical transmission of HIV reaching adult age with unsuppressed HIV RNA or incomplete immunological recovery, ICAR 2020, Oral Communication*
  - **M. Ferrara**<sup>1</sup>, C. Alcantarini<sup>1</sup>, MC Tettoni<sup>1</sup>, A. Ianniello<sup>1</sup>, A. De

Nicolò<sup>1</sup>, A. D'Avolio<sup>1</sup>, A. Calcagno<sup>1</sup>, G. D Perri<sup>1</sup>, S. Bonora<sup>1</sup> *"Impact of boosted vs unboosted regimen on dolutegravir plasma and intracellular pharmacokinetic in the clinical setting"*, ICAR 2020 Poster Presentation

- **M. Ferrara<sup>1</sup>**, C. Alcantarini<sup>1</sup>, A. Lazzaro<sup>1</sup>, S. Biffi<sup>1</sup>, A. Di Stefano<sup>1</sup>, M. Trunfio<sup>1</sup>, MC Tettoni<sup>1</sup>, V. Avataneo<sup>1</sup>, A. Ianniello<sup>1</sup>, A. De Nicolò<sup>1</sup>, A. D'Avolio<sup>1</sup>, G. D Perri<sup>1</sup>, S. Bonora *"BICTEGRAVIR PLASMA AND INTRACELLULAR PHARMACOKINETICS IN IN THE CLINICAL SETTING"* , ICAR 2020 Oral Communication
- **M.Ferrara<sup>1</sup>**, A. Trentalange<sup>1</sup>, E.S. Cannizzo<sup>2</sup>, G. Marchetti<sup>2</sup>, S. Nozza<sup>3</sup>, A. De Nicolò<sup>1</sup>, V. Avataneo<sup>1</sup>, A. Ianniello<sup>1</sup>, E. De Vivo<sup>1</sup>, A. D'Avolio<sup>1</sup>, G. Di Perri<sup>1</sup>, S. Bonora<sup>1</sup>, A. Calcagno<sup>1</sup> *"Inflammation Affects Antiretrovirals Plasma and Intracellular Exposure"*, ICAR 2020 Oral Communication, PK Workshop 2020 Oral Communication
- **M. Ferrara<sup>1</sup>**, J. Milic<sup>2</sup>, L. Micai<sup>1</sup>, S. Barbieri<sup>2</sup>, E. Aprile<sup>2</sup>, M. Belli<sup>2</sup>, M. Venuta<sup>2</sup>, S. Arsuffi<sup>3</sup>, C. Fornari<sup>3</sup>, E. Focà<sup>3</sup>, G. Di Perri<sup>1</sup>, S. Bonora<sup>1</sup>, G. Guaraldi<sup>2</sup>, A. Calcagno<sup>1</sup> *"A telephone-based multidimensional interview in elderly people living with HIV from the GEPPPO cohort"* International Workshop on HIV & Aging 2021, oral communication; ICAR 2021, OC; EACS 2021, ePoster
- **M. Ferrara<sup>1</sup>**, E. Salvador<sup>1</sup>, A. Di Stefano<sup>1</sup>, C. Alcantarini<sup>1</sup>, A. Trentalange<sup>1</sup>, S. Biffi<sup>1</sup>, M. Tettoni<sup>1</sup> , E. De Vivo<sup>2</sup>, J. Mula<sup>2</sup>, A. Ianniello<sup>2</sup>, A. De Nicolò<sup>2</sup>, A. D'Avolio<sup>2</sup>, G. Di Perri<sup>1</sup>, A. Calcagno<sup>1</sup> , S. Bonora<sup>1</sup> *"Dolutegravir plasma and intracellular pharmacokinetics according to drug companion in the clinical setting"* International Workshop of Clinical Pharmacology 2021, poster; ICAR 2021, poster
- 
- 

Turin, 01/10/2021



## **Tom Fletcher**

Tom Fletcher è professore di malattie infettive emergenti e ad alto rischio e direttore della Global Health Trials Unit presso la Liverpool School of Tropical Medicine (LSTM). È inoltre consulente onorario in malattie infettive e medicina interna generale presso il Royal Liverpool University Hospital e la UK Health Security Agency. Dopo aver completato la formazione universitaria presso l'Università di Leeds, Tom ha svolto incarichi generali presso i Servizi di Medicina della Difesa e successivamente ha seguito una formazione specialistica superiore a Liverpool, prima di ritirarsi dall'esercito nel 2024. È stato distaccato presso il dipartimento di malattie pandemiche ed epidemiche presso la sede centrale dell'Organizzazione Mondiale della Sanità per un anno prima dell'epidemia di Ebola del 2013-15 in Africa occidentale, durante la quale lui e i colleghi del team clinico dell'Organizzazione Mondiale della Sanità hanno guidato un cambiamento radicale nella gestione dei casi di Ebola. Per il suo dottorato di ricerca, Tom ha usufruito di una borsa di studio del Wellcome Trust per studiare la febbre emorragica Crimea-Congo in Turchia. Durante la pandemia di COVID-19, è tornato al quartier generale dell'Organizzazione Mondiale della Sanità con il team clinico ed è stato inviato in Corea del Sud, prima di tornare a supportare la risposta del Servizio Sanitario Nazionale del Regno Unito. Continua a essere impegnato nelle epidemie di filovirus per l'Organizzazione Mondiale della Sanità, più recentemente in Uganda nel 2022 e in Ruanda nel 2024.

### Interessi di ricerca

La ricerca di Tom presso LSTM si concentra principalmente sulle malattie infettive ad alto rischio, dove è co-direttore della piattaforma ACTIVE - ACcelerating Therapeutics and diagnostics in Viral HaEmorrhagic fever. È attivo in Turchia e nell'Africa occidentale. Tom è un ricercatore senior all'interno della piattaforma di sperimentazione AGILE, guidando AGILE International e il pilastro di laboratorio. È stato candidato a capo ricercatore in 2 studi di fase iniziale di nuove terapie per il COVID-19 nel Regno Unito e in Sudafrica. Per quanto riguarda la febbre emorragica della Crimea-Congo, è il capo ricercatore negli studi terapeutici UMIT-1 e UMIT-2 e, attraverso la sua rete, ha sviluppato e valutato piattaforme diagnostiche vicine al paziente. Le sue altre ricerche si concentrano sulle infezioni emergenti, inclusa la patogenesi della perdita di emostasi nelle febbri emorragiche virali. È il ricercatore capo del programma SAND, un finanziamento "one health" con il Regno dell'Arabia Saudita per lo sviluppo di test diagnostici per le infezioni zoonotiche. Attualmente è presidente del gruppo di sviluppo delle linee guida Mpox dell'Organizzazione mondiale della sanità.

### Insegnamento

Tom gestisce un ampio gruppo di ricerca presso l'LSTM e attualmente supervisiona 10 studenti di dottorato. Insegna al Diploma in Medicina Tropicale e Igiene, al Diploma in Infermieristica Tropicale, al Master in Malattie Tropicali e Infettive e, esternamente, al Master in Medicina Tropicale Militare e Malattie Infettive.



PERSONAL  
INFORMATION

**Emanuele Focà, MD, PhD**



📍 Home: Via Mortirolo 66, Brescia, 25136, Italy  
Office: Clinic of Infectious Diseases, Piazzale Spedali Civili 1, Brescia, 25123, Italy

☎ +390303998603 📠 +393297508493

✉ [emanuele.foca@unibs.it](mailto:emanuele.foca@unibs.it)

Sex Male | Date of birth 22/07/1980 | Nationality Italian

**At present Associate Professor – Chair of Infectious Diseases, University of Brescia and Attending Physician, Unit of Infectious Diseases, Brescia ASST Spedali Civili General Hospital. Brescia, Italy**

**ACADEMIC QUALIFICATIONS**

- Full Professor Qualification: National Scientific Qualification (art.16 of the law 30 December 2010, n.240) for Ordinary Professor obtained on February 8st 2022 (and valid until February 8st 2031).
- Member of the Faculty of Medicine and Surgery of the University of Brescia,
- Lecturer of Dentistry, Nurses and Dieticians Degree Courses.
- Teaching activities at post-graduated school in Infectious and tropical Diseases and Clinical Pharmacology.
- Board Member of the PhD programme in Civil and Environmental Engineering, International Cooperation and Mathematica of the University of Brescia
- Teaching activities at the annual Post-graduated Course on Global Health of the University of Brescia

**WORK EXPERIENCE**

At present: Attending Physician, Unit of Infectious Diseases, Brescia ASST Spedali Civili General Hospital.

- HIV/AIDS outpatient care,
- Infectious Diseases consultancy activities.
- Infectious Diseases consultancy activities in the Penitentiary Medicine Unit at the Brescia Provence Jails. Responsible for the ASST Spedali Civili General Hospital of occupational and accidental exposure to infectious biological agents and post-exposure prophylaxis to prevent HIV infections.
- Medical activity in highly isolated Infectious Diseases ward

Clinical Trial Activities: involvement with the role of sub-investigator in more than 30 studies (phase I, II, III, IV) clinical trials on HIV / AIDS andn SARS-CoV-2 infection, both spontaneous and funded including the 2 Italian trials on the testing of therapeutic HIV vaccines

2008-2009 HIV/AIDS outpatient care and clinical research in Burkina Faso: project ESTHER (*Ensemble pour une Solidarité Therapeutique en Réseau*): Outpatient activities in the prevention of mother to child transmission (PMTCT) program in Ouagadougou (Centre Médicale Saint Camille and Centre de Recherche Biomoleculaire Pietro Annigoni (CERBA)

**EDUCATION AND TRAINING**

- 01 November 2010 – 05 February 2014  
PhD in Methodologies of Clinical Trials, University of Brescia, Italy (EQF level 8)

- 01 November 2005 - 08 March 2010  
Post-graduated school - Specialisation in Infectious Diseases, University of Brescia, Italy (EQF level 8)
- 24 October 2005  
Qualification Degree in Medicine and Surgery, University of Messina, Italy

### **RESEARCH ACTIVITIES AND PUBLICATION SCORES**

The scientific production of Dr. Focà per has focused on HIV/AIDS and other chronic infection and COVID-19; innovative and highly original themes were identified, such as clinical characteristics of the aging population living with HIV, the long-term toxicity of antiretroviral drugs, screening and counselling strategies for HIV infection and other sexually transmitted diseases, HIV/AIDS infection in resources-limited countries, HIV and hepatitis coinfections in prisoners. Moreover Dr. Focà focused his scientific interest on Vaccine and vaccination strategies among frail population. From the beginning of COVID-19 epidemic in Italy, he participated in building a local multidisciplinary group in Brescia to study treatment approach of COVID-19.

He coordinated the working group for the drafting of the guidelines for the treatment of COVID-19 of the Lombardy section of Italian society of infectious and tropical diseases,

- **Author of 131 Publications on peer review Scientific Journal:**
- **Total Impact Factor (ISI 2023): 683.604;**
- **H Index (Scopus 2023): 27;**
- **Total Citations (Scopus 2023): 3248**
- **Author of 23 other Publications (including 11 book chapters)**
- **Author of 15 invited lectures to National and International Conferences**
- **Participation as Faculty members at 51 national Conference in the last 5 years**
- **Author of >200 Abstract accepted on National and International Conferences**
- **ORC-ID: 0000-0003-4395-5379**

### **RESEARCH PROJECTS AND GRANTS**

GEPO (Geriatric Patients living with HIV/AIDS: a Prospective multidimensional cOhort) Consortium: Included in the National Scientific Committee. Principal Investigator of the national coordinating Centre of the entire Cohort.

Gilead Fellowship program 2019: Notice of competition intended to support the conception and implementation of scientific and social projects aimed at improving the outcome and quality of life of patients affected by: HIV, Liver disorders, Onco-haematological disorders. Principal Investigator: Emanuele Focà - Contribution of Euro 25,000.

2020 CARIPO Foundation: Measure to support the development of collaborations for the identification of therapies and diagnostic systems, protection and analysis to counter the Coronavirus emergency and other viral emergencies of the future Funding of 175,600 Euros. Project title: "The effect of frailty on the clinical outcomes of patients infected by COVID-19 and on the risk of infection in the elderly: FraCOVID study ". Dr. Focà was sub-unit Principal Investigator

2021 FISR call for special supplementary fund for research (FISR2020IP\_04373). Title "Tools of Artificial Intelligence to predict the prognosis of Covid-19 patients starting from laboratory and radiological data to support clinical decisions and hospital resource management in emergency situations". The overall loan granted by the Ministry is equal to € 56,518.40. As part of the inter-departmental project, as a participant for the clinical part, Dr. Focà has received a specific contribution of € 6,000

### **PRIZES AND HONORS**

CROI Young Investigator Award 19th Conference on Retroviruses and Opportunistic Infections – March 5-8 2012. Seattle.

ICAR–CROI Awards 2012 for young Italian Research (2012)

“Hippocrates Prize for Scientific and Social Progress” 9th edition. Silver medal award of President of the Republic. Category: Young Doctors. Motivation: “Young Calabrian doctor. For having proposed himself in the field of research, projected towards wider and more authoritative boundaries ”. (2016)

Individual annual funding of basic research activities. LAW 11 December 2016, n. 232, Article 1, paragraphs 295-302. Italian Ministry of Education, University and Research, 2017. Prize of Euro 3,000.

**SCIENTIFIC SOCIETIES MEMBERSHIP**

Member of the following scientific societies: Società Italiana di Malattie Infettive (SIMIT) Società Italiana di Medicina Tropicale (SIMET), International AIDS Society (IAS), European AIDS Clinical Society (EACS) and Medicus Mundi Italia (MMI), non-governative organization (NGO) 2018-2022: Board Member (secretary) of the Lombardy Section of Italian Society of Infectious and Tropical Diseases (SIMIT)

**PERSONAL SKILLS**

Mother tongue: Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C1	C1	B2	B2	B2
French	B2	B2	B2	B2	B2
Spanish	B2	B2	B2	B2	B2

Brescia, Italy, 04 November 2024

\_\_\_\_\_ |  | \_\_\_\_\_


## INFORMAZIONI PERSONALI



Dott.ssa Valeria GHISSETTI

 Via Giacinto Collegno 45, 10138 TORINO, Italia

 011 4393739/  335 529 1363

 Valeria.ghisetti@gmail.com , valeria.ghisetti@aslciittaditorino.it

 <http://www.aslcittaditorino.it>

**Sesso: F | Data di nascita: 28 Aprile, 1958 | Nationalità: Italiana**

## ESPERIENZA PROFESSIONALE

### POSIZIONE ATTUALE

Dal 1° Gennaio 2008 a tutt'oggi

**Direttore Struttura Complessa Laboratorio di Microbiologia e Virologia, Dipartimento dei Servizi, ASL Città di Torino, Centro di Riferimento Virologico della Regione Piemonte per la rete INFLUNET & COVID-NET**  
([https://www.salute.gov.it/imgs/C\\_17\\_pubblicazioni\\_2963\\_allegato.pdf](https://www.salute.gov.it/imgs/C_17_pubblicazioni_2963_allegato.pdf)).

## ISTRUZIONE E FORMAZIONE

### **Dal 2014**

Abilitazione a professore di II fascia Microbiologia e Virologia Med 07

**CORSO DI FORMAZIONE MANAGERIALE ai sensi del D.L 502/92, REGIONE PIEMONTE**, dal 16 settembre al 20 dicembre 2010, organizzato da ARESS Regione Piemonte, n° 21 Crediti Formativi E.C.M. dal 16 al 30 settembre 2010, n° 14 Crediti dal 4 all' 11 ottobre 2010, n° 23 Crediti dal 15 al 22 novembre 2010, n° 23 Crediti dal 26 novembre al 7 dicembre 2010, n° 22 Crediti dal 13 al 20 dicembre 2010. Totale 103 crediti

### **1987-1990**

Specializzazione in Microbiologia e Virologia, Scuola di specializzazione in Microbiologia, Università di Torino, *voto finale 70/70 (durata del corso: anni 4).*

### **1985-1987**

Specializzazione in Igiene e Medicina preventiva, orientamento laboratorio, Scuola di specializzazione in Università di Torino, *voto finale 70/70 (durata del corso: anni 3).*

### **1978-1983**

Laurea in Medicina e Chirurgia, Università di Torino, *voto finale 110/110.*

Abilitazione all'esercizio della professione di medico chirurgo conseguita mediante superamento esame di Stato presso l'Università degli Studi di Torino, seconda sessione relativa all'anno 1983

### **Dal 1984**

Iscrizione all'Albo dell'Ordine dei Medici della Provincia di Torino.

**ESPERIENZE LAVORATIVE  
CONSEGUITE ALL'ESTERO E  
IMPORTATE IN ITALIA****Da Marzo 2004 al 30 Aprile 2004**

Center for Disease Control, Branch of Respiratory Virology, Atlanta, Stati Uniti  
Visiting Professor presso il Center for Disease Control, Branch of Respiratory Virology, ad Atlanta, Stati Uniti. Training sull'identificazione dei virus respiratori e identificazione di nuovi virus, apprendimento di tecniche molecolari avanzate per identificare nuovi patogeni respiratori, utilizzando modelli innovativi di analisi di sequenze e di filogenesi. Studio di modelli organizzativi di laboratorio per diagnosi rapide di patogeni emergenti, livelli di rischio e manipolazione di agenti biologici di classe 3 e 4.

**Da Ottobre 2001 a Dicembre 2002**

Vrije Universiteit, Department of Pathology, Amsterdam, NL e Dipartimento di Scienze Biomediche e Oncologia Umana, Epidemiologia dei Tumori, Centro Oncologico ed Epidemiologico Subalpino dell'Università di Torino

Attività di supervisor nell'ambito di studio Multicentrico Italiano (progetto finanziato dal Ministero della Sanità e CEE) per la prevenzione del carcinoma della cervice uterina e infezione da virus Papilloma umano e collaborazione al progetto ministeriale "Identificazione e tipizzazione del virus Papilloma umano e correlazione con il carcinoma della cervice uterina".

**Dal 1°Ottobre al 30 Novembre 2001**

Vrije Universiteit, Department of Pathology, Amsterdam, NL  
Apprendimento di tecniche molecolari per studio della rilevazione e genotipizzazione del virus Papilloma Umano (HPV) sulla base di progetto IARC- WHO e Università di Torino.

**Dal 1° Ottobre 1999 a 1°Ottobre 2000**

Brown University, School of Medicine, Liver Research Center, Providence, RI, USA  
Invio in missione da parte dell'Ospedale Molinette come Visiting professor per lo studio dei processi dell'infezione da virus dell'epatite B e C (HCV) e sviluppo del progetto "Identification of hepatitis C viral/cellular protein interactions in the pathogenesis of hepatocellular carcinoma".

**Aprile 1996**

Visiting Doctor presso il Dipartimento di Gastroenterologia, Cleveland Clinic Foundation, International Center, Cleveland, USA.  
2010-2013

**COMPETENZE PERSONALI**

Direttore del Laboratorio di Microbiologia e Virologia, Ospedale Amedeo di Savoia, Dipartimento di Malattie Infettive, TO, dal 1°Gennaio 2008 a tutt'oggi, in possesso dei requisiti per la direzione di Struttura Complessa, ai sensi del D.L 502/92, mediante CORSO DI FORMAZIONE MANAGERIALE della REGIONE PIEMONTE, anno 2010.

Laurea in Medicina e Chirurgia, Università di Torino, specializzazioni in Igiene e Medicina Preventiva e in Microbiologia e Virologia. Ha lavorato dal 1990 fino al 2007 nel Laboratorio di Microbiologia dell'Ospedale Molinette di Torino, come responsabile dell'Unità Semplice di Biologia Molecolare e Virologia Clinica sviluppando il campo della diagnosi, terapia e prevenzione delle infezioni virali nei pazienti sottoposti a trapianto di organo solido e di midollo e nei pazienti affetti da malattie oncoematologiche. Dal primo Gennaio 2008 dirige il Laboratorio di Microbiologia e Virologia dell'ospedale Amedeo di Savoia di Torino, centro di riferimento regionale per le Malattie Infettive dove ha dato ampio sviluppo alla diagnosi e monitoraggio dell'infezione da SARS CoV-2, HIV, virus epatitici b e XC, e allo studio della farmaco resistenza e variabilità genetica virali (SARS CoV-2, HIV, HBV, HCV e CMV). Le infezioni virali nel paziente immunocompromesso e le infezioni da virus emergenti Coronavirus, virus delle febbri emorragiche e di meningo-encefaliti sono da sempre ambito di lavoro specifico, con particolare rilievo alla diagnosi precoce con metodi molecolari ultrasensibili, allo studio della variabilità genetica, delle interazioni tra ospite e virus immunomodulati (virus dell'epatite B, C, HIV e virus erpetici Citomegalovirus, Epstein Barr,

Herpesvirus 6, 7, 8), e allo sviluppo di piattaforme molecolari avanzate per l'identificazione di nuove varianti e pattern di resistenza agli antivirali nell'ambito di virus respiratori, Coronavirus, virus dell'influenza e HIV. Ha partecipato a studi clinici randomizzati per la valutazione di terapie contro HIV, il virus dell'epatite B e C e a studi di oncogenesi correlata all'infezione da virus del Papilloma umano, collaborando con i Dipartimenti di Malattie Infettive, Gastroenterologia e Epidemiologia dei tumori della facoltà di Medicina dell'Università di Torino. Partecipa in qualità di Laboratorio di Riferimento della Regione Piemonte ai programmi nazionali ed europei di sorveglianza dell'influenza, del COVID-19, delle febbri emorragiche di origine virale e della Tuberculosis. Ha approfondito anni tecniche di analisi mediante next generation sequencing e di fingerprinting per SARS CoV-2, M.tuberculosis ai fini di analisi di filogenesi e identificazione di cluster di trasmissione. Il laboratorio è diventato con DGR della Regione Piemonte N.5524 del 14 marzo 2013 Centro di Riferimento Regionale per l'epidemiologia della tubercolosi e laboratorio di livello III secondo gli standard OMS per la Tuberculosis. Collabora con il Centro OMS Patogeni Emergenti dell'ospedale San Raffaele di Milano e con il progetto SMIRA sulla Tuberculosis Multi-Drug-Resistant con l'Istituto Superiore di Sanità dal 2008. Ha sviluppato programmi di controllo di qualità esterni ed interni per HIV, HBV, HCV, tubercolosi, Dengue e Chikungunia partecipando all'allestimento dello standard internazionali per CMV. Aderisce al network europeo dei laboratori di Biosicurezza 3 e 4 ENIVD ([www.enivd.de](http://www.enivd.de)) dal 2008.

Visiting Professor dal 1999 al 2001 presso il Liver Research Center, Brown University, School of Medicine, Providence, RI, USA, dove ha lavorato sui processi di carcinogenesi epatica conseguenti all'infezione da virus dell'epatite C.

Visiting Professor nel 2004 presso i Centre for Disease Control, Branch of Respiratory Virology, Atlanta, Stati Uniti, per l'apprendimento di modelli innovativi di analisi di sequenze e di studi di filogenesi virale per identificare nuovi patogeni respiratori, occupandosi specificamente di Coronavirus e SARS CoV e di tecniche di lavorazione in laboratorio di Biosicurezza di livello 3 e 4, per patogeni di classe 3 e 4 ai sensi del TU 81/2008.

Da dicembre 2019 ha predisposto e organizzato il laboratorio di diagnostica molecolare per la pandemia COVID-19 del Centro di Riferimento Regionale per le Malattie Infettive (produttività media circa 1000-1200 tamponi al giorno 7giorni/7), implementando l'analisi e identificazione di varianti virali mediante tecniche di Next generation sequencing secondo protocolli nazionali e internazionali e lo studio e monitoraggio della carica virale in pazienti sottoposti a terapia con anticorpi monoclonali (circa 600 nel 2021) e antivirali. Ha predisposto il laboratorio di cellulari per SARS CoV-2 e l'allestimento dei test di neutralizzazione virale per la valutazione della risposta anticorpale neutralizzante nell'ambito di trial vaccinali anti-SARS CoV-. Ha inserito il laboratorio in network nazionali e europei (WHO, ECDC, ENVID) per lo sviluppo di controlli di qualità per SARS CoV-2 e ha predisposto la piattaforma integrata di test di screening per COVID-19 ad uso assistenziale mediante test antigenici rapidi per i presidi ospedalieri ASL Città di Torino, Pronto Soccorso (DEA I° e II° livello), PS pediatrico e ostetrico (N.60 installazioni interconnesse tra loro e con la piattaforma regionale COVID-19).

## INSEGNAMENTI E ATTIVITA' DIDATTICA

### **2010-presente**

Università di Torino: Conferimento incarico di insegnamento di Virologia Clinica alla specializzazione in Malattie Infettive, facoltà di Medicina, Università di Torino

### **2007-presente**

Insegnamento di Virologia Clinica alla Scuola di Specializzazione in Microbiologia e Virologia, Università di Torino.

### **2008-2013**

Insegnamento di Microbiologia alla Scuola di Specializzazione in Patologia Clinica, Università di Torino.

**2002-2004**

Insegnamento di Microbiologia Clinica, Corso di laurea per Dietisti, Università di Torino, per un totale di 20 ore di insegnamento/anno.

**1998-2002**

Insegnamento di Microbiologia Clinica, Scuola di Diploma per Infermieri Professionali, Università di Torino, per un totale di 20 ore di insegnamento/anno.

**1984-1986**

Insegnamento di Epidemiologia al Corso per Abilitazione a Funzioni Direttive, Scuola Infermieri Professionali "E.Nasi", Ospedale Martini-Torino, per un totale di 20 ore di insegnamento/anno.

**1983 –1985**

Insegnamento di Microbiologia, Immunologia, e Patologia generale, Scuola per Tecnici di laboratorio Medico, Ospedale Molinette, Torino, per un totale di 50 ore di insegnamento/anno.

**NETWORKS e ADVISORY BOARD**

---

Componente del gruppo di lavoro regionale per la sorveglianza. La prevenzione e il controllo delle infezioni correlate all'Assistenza (ICA), istituito con DD 12 settembre 2016, rinnovato con DD 286 del 3 maggio 2017 a tutt'oggi.

Riferimento regionale della rete INFLUNET e quindi INFLUNET-COVIDNET per la sorveglianza virologica dell'Influenza, dell'Istituto Superiore di Sanità- National Influenza Centre, dal 2008 a tutt'oggi.

Componente del Gruppo di studio sulle epatiti virali (ESGHV) della European Society of Clinical Microbiology and Infectious Diseases dal 2001 a tutt'oggi

Componente del Board Scientifico del Progetto OSCAR (Optimizing Susceptibility to CCR5 Antagonist response) per lo sviluppo del test genotipico per la valutazione del tropismo di HIV-1, 2010-2012.

Componente del Gruppo di lavoro DIVA "Progetto sviluppo test tropismo di HIV-1 su DNA provirale", 2010-2012.

Componente del Direttivo della Società Associazione Microbiologi Clinici Italiani (AMCLI): dal 2009 al 2018

Componente della Commissione AMCLI-SIV (Società Italiana di Virologia) per la standardizzazione dei metodi relativi alla diagnostica delle infezione da Cytomegalovirus ed Epstein Barr virus nel trapianto d'organo e di midollo, 2007-2008.

Componente del Gruppo di lavoro regionale per "Lotta alla diffusione dell'infezione da HIV/AIDS: l'offerta del test HIV", Determina della Regione Piemonte n.189, 19 luglio 2007.

**ATTIVITÀ EDITORIALE****Revisore per le seguenti riviste scientifiche internazionali**

Journal of Medical Virology

Journal of Virological Methods

Journal of Travel Medicine

Journal of Clinical Virology

Membro dell'Editorial Board di The American Journal of Virology

## **SOCIETA' SCIENTIFICHE**

---

Membro della società europea di Malattie infettive e Microbiologia Clinica ESCMID dal 2000  
Membro dell'ESCMID Study Group of Viral hepatitis (ESGHV)  
Membro del Direttivo dell'Associazione Italiana Microbiologi Clinici (AMCLI) dal 2005 al 2010

## **CONFERENZE, CONGRESSI E PUBBLICAZIONI**

### **MEETING INTERNAZIONALI E NAZIONALI**

Dal 2003 a metà 2020 ha partecipato a più di 200 meeting nazionali e internazionali (ASM, ESCMID, ESCV, AASLD, EASL) di cui in 110 di essi in qualità di RELATORE.

### **PUBBLICAZIONI**

#### **H-FACTOR: 31**

ALLEGATO Pubblicazioni periodo 01/01/2018-31/10/2022

**Pubblicazioni internazionali e nazionali dal 2018 al 2022**  
**Abilitazione a professore di II fascia Microbiologia e Virologia Med 07**

1. Lai A, Bergna A, Toppo S, Morganti M, Menzo S, **Ghisetti V**, Bruzzone B, Codeluppi M, Fiore V, Rullo EV, Antonelli G, Sarmati L, Brindicci G, Callegaro et al. SCIRE-SARS-CoV-2 Italian Research Enterprise-Collaborative Group. Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020. *Sci Rep.* 2022 Apr 6;12(1):5736. doi: 10.1038/s41598-022-09738-0. PMID: 35388091; PMCID: PMC8986836.
2. Burdino E, Cerutti F, Milia MG, Alice T, Gregori G, Aprà F, De Iaco F, Aluffi E, Micca G, **Ghisetti V**. Fast and reliable real life data on COVID-19 triaging with ID NOW. *J Clin Virol Plus.* 2022 Feb;2(1):100065. doi: 10.1016/j.jcvp.2022.100065. Epub 2022 Jan 15. PMID: 35262036; PMCID: PMC8760098.
3. Sartelli M, Labricciosa FM, Coccolini F, Coimbra R, Abu-Zidan FM, Ansaloni L, Al-Hasan MN, Ansari S, Barie PS, Caínzos MA, Ceresoli M, Chiarugi M, Claridge JA, Cicuttin E, et al. It is time to define an organizational model for the prevention and management of infections along the surgical pathway: a worldwide cross-sectional survey. *World J Emerg Surg.* 2022 Mar 17;17(1):17. doi: 10.1186/s13017-022-00420-4. PMID: 35300731; PMCID: PMC8928018.
4. Trunfio M, Richiardi L, Alladio F, Staffilano E, Longo B, Venuti F, **Ghisetti V**, Burdino E, Bonora S, Vineis P, Di Perri G, Calcagno A. Determinants of SARS-CoV-2 Contagiousness in Household Contacts of Symptomatic Adult Index Cases. *Front Microbiol.* 2022 Apr 1;13:829393. doi: 10.3389/fmicb.2022.829393. PMID: 35432272; PMCID: PMC9010948.
5. De Francia S, Ferretti A, Chiara F, Allegra S, Mancardi D, Alice TG, Milia MG, Gregori G, Burdino E, Avanzini C, **Ghisetti V**, Durio A. The Influence of Sex, Gender, and Age on COVID-19 Data in the Piedmont Region (Northwest Italy): The Virus Prefers Men. *Life (Basel).* 2022 Apr 26;12(5):643. doi: 10.3390/life12050643. PMID: 35629311; PMCID: PMC9148110.
6. Ochoa-Azze R, Chang-Monteagudo A, Climent-Ruiz Y, Macías-Abraham C, Valenzuela-Silva C, de Los Ángeles García-García M, Jerez-Barceló Y, Triana-Marrero Y, Ruiz-Villegas L, Dairon Rodríguez-Prieto L, Guerra-Chaviano PP, Sánchez-Ramírez B, Hernández-García T, Orosa-Vázquez I, Díaz-Hernández M, Chiodo F, Calcagno A, **Ghisetti V**, et al. Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial. *Lancet Respir Med.* 2022 Aug;10(8):785-795. doi: 10.1016/S2213-2600(22)00100-X. Epub 2022 Jun 9. PMID: 35691295; PMCID: PMC9183216.
7. Burdino E, Cerutti F, Panero F, Alice T, Gregori G, Milia MG, Cavalot G, Altavilla A, Aprà F, **Ghisetti V**. SARS-CoV-2 microfluidic antigen point-of-care testing in Emergency Room patients during COVID-19 pandemic. *J Virol Methods.* 2022 Jan;299:114337. doi: 10.1016/j.jviromet.2021.114337. Epub 2021 Oct 20. PMID: 34687785; PMCID: PMC8527643.
8. Stefanelli P, Trentini F, Guzzetta G, Marziano V, Mammone A, Sane Schepisi M, Poletti P, Molina Grané C, Manica M, Del Manso M, Andrianou X, Ajelli M, Rezza G, Brusafferro S, Merler S; **COVID-19 National Microbiology Surveillance Study Group**. Co-circulation of SARS-CoV-2 Alpha and Gamma variants in Italy, February and March 2021. *Euro Surveill.* 2022 Feb;27(5). doi: 10.2807/1560-7917.ES.2022.27.5.2100429. PMID: 35115077.
9. Cosma S, Carosso AR, Cusato J, Borella F, Bertero L, Bovetti M, Bevilacqua F, Mengozzi G, Mazzone R, **Ghisetti V**, Di Perri G, Benedetto C. Obstetric and neonatal outcomes after SARS-CoV-2 infection in the first trimester of pregnancy: A prospective comparative study. *J Obstet Gynaecol Res.* 2022 Feb;48(2):393-401. doi: 10.1111/jog.15105. Epub 2021 Nov 23. PMID: 34814234.
10. Romagnoli R, Gruttadauria S, Tisone G, Maria Ettore G, De Carlis L, Martini S, Tandoi F, Trapani S, Saracco M, Luca A, Manzia TM, Visco Comandini U, De Carlis R, **Ghisetti V**, Cavallo R, Cardillo M, Grossi PA. Liver transplantation from active COVID-19 donors: A lifesaving opportunity worth grasping? *Am J Transplant.* 2021. Dec;21(12):3919-3925. doi: 10.1111/ajt.16823. Epub 2021 Sep 13. PMID: 34467627; PMCID: PMC8653300.
11. Trunfio M, Verga F, **Ghisetti V**, Burdino E, Emanuele T, Bonora S, Di Perri G, Calcagno A. Clinical Phenotype and Contagiousness of Early Breakthrough SARS-CoV-2 Infections after BNT162b2 COVID-19 mRNA Vaccine: A Parallel Cohort Study in Healthcare Workers. *Vaccines (Basel).* 2021 Nov 23;9(12):1377. doi: 10.3390/vaccines9121377. PMID: 34960123; PMCID: PMC8705309.

12. Mandras N, Roana J, Scalas D, Del Re S, Cavallo L, **Ghisetti V**, Tullio V. The Inhibition of Non-albicans Candida Species and Uncommon Yeast Pathogens by Selected Essential Oils and Their Major Compounds. *Molecules*. 2021 Aug 15;26(16):4937. doi: 10.3390/molecules26164937. PMID: 34443525; PMCID:PMC8400735.
13. Lai A, Bergna A, Menzo S, Zehender G, Caucci S, **Ghisetti V**, Rizzo F, Maggi F, Cerutti F, Giurato G, Weisz A, Turchi C, Bruzzone B, Ceccherini Silberstein F, Clementi N, Callegaro A, Sagradi F, Francisci D, Venanzi Rullo E, Vicenti I, Clementi M, Galli M; Collaborative group SCIRE SARS-CoV-2 Italian Research Enterprise. Circulating SARS-CoV-2 variants in Italy, October 2020-March 2021. *Virol J*. 2021 Aug 14;18(1):168. doi: 10.1186/s12985-021-01638-5. PMID: 34391446, PMCID: PMC8364297.
14. Cosma S, Carosso AR, Cusato J, Borella F, Carosso M, Gervasoni F, Stura I, Preti M, **Ghisetti V**, Di Perri G, Benedetto C. reterm birth is not associated with asymptomatic/mild SARS-CoV-2 infection per se: Pre-pregnancy state is what matters. *PLoS One*. 2021 Aug 5;16(8):e0254875. doi: 10.1371/journal.pone.0254875. PMID: 34351922; PMCID: PMC8341509.
15. Ginocchio CC, Garcia-Mondragon C, Mauerhofer B, Rindlisbacher C; and the **EME Evaluation Program Collaborative**. Multinational evaluation of the BioFire® FilmArray® Pneumonia plus Panel as compared to standard of care testing. *Eur J Clin Microbiol Infect Dis*. 2021 Aug;40(8):1609-1622. doi: 10.1007/s10096-021-04195-5. Epub 2021 Mar 2. PMID: 33655440; PMCID: PMC7924818.
16. Di Maio VC, Barbaliscia S, Teti E, Fiorentino G, Milana M, Paolucci S, Pollicino T, Morsica G, Starace M, Bruzzone B, Gennari W, Micheli V, Yu La Rosa K, Foroghi L, Calvaruso V, Lenci I, Polilli E, Babudieri S, Aghemo A, Raimondo G, Sarmati L, Coppola N, Pasquazzi C, Baldanti F, Parruti G, Perno CF, Angelico M, Craxi A, Andreoni M, Ceccherini-Silberstein F; **HCV Virology Italian Resistance Network Group (Vironet C)**. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C. *Liver Int*. 2021 Aug;41(8):1802-1814. doi: 10.1111/liv.14797. Epub 2021 Feb 8. PMID: 33497016.
17. Simonetti M, Zhang N, Harbers L, Milia MG, Brossa S, Huong Nguyen TT, Cerutti F, Berrino E, Sapino A, Bienko M, Sottile A, **Ghisetti V**, Crosetto N. COVseq is a cost-effective workflow for mass-scale SARS-CoV-2 genomic surveillance. *Nat Commun*. 2021 Jun 23;12(1):3903. doi: 10.1038/s41467-021-24078-9. PMID: 34162869; PMCID: PMC8222401. Caligaris G, Trunfio M, Ghisetti V, Cusato J, Nigra M, Atzori C, Imperiale D, Bonora S, Di Perri G, Calcagno A. Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated Biomarkers. *Diagnostics (Basel)*. 2021 May 12;11(5):867. doi: 10.3390/diagnostics11050867. PMID: 34065785; PMCID: PMC8151579.
18. Cosma S, Carosso AR, Corcione S, Cusato J, Borella F, Antonucci M, Marozio L, Revelli A, Preti M, **Ghisetti V**, Di Perri G, Benedetto C. Longitudinal analysis of antibody response following SARS-CoV-2 infection in pregnancy: From the first trimester to delivery. *J Reprod Immunol*. 2021 Apr;144:103285. doi: 10.1016/j.jri.2021.103285. Epub 2021 Feb 2. PMID: 33582489; PMCID: PMC7973007
19. Dietz J, Di Maio VC, de Salazar A, Merino D, Vermehren J, Paolucci S, Kremer AE, Lara M, Pardo MR, Zoller H, Degasperis E, Peiffer KH, Sighinolfi L, Téllez F, Graf C, **Ghisetti V**, Schreiber J, Fernández-Fuertes E, Boglione L, Muñoz-Medina L, Stauber R, Gennari W, Figueruela B, Santos J, Lampertico P, Zeuzem S, Ceccherini-Silberstein F, García F, Sarrazin C; HCV Virology Italian Resistance Network (VIRONET-C) collaborators; Spanish GEHEP-004 Collaborators; Members of the German HCV resistance study group. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. *J Hepatol*. 2021 Apr;74(4):801-810. doi: 10.1016/j.jhep.2020.11.017. Epub 2020 Nov 19. PMID: 33220331.
20. Trunfio M, Longo BM, Alladio F, Venuti F, Cerutti F, **Ghisetti V**, Bonora S, Di Perri G, Calcagno A. On the SARS-CoV-2 "Variolation Hypothesis": No Association Between Viral Load of Index Cases and COVID-19 Severity of Secondary Cases. *Front Microbiol*. 2021 Mar 16;12:646679. doi: 10.3389/fmicb.2021.646679. PMID: 33815334; PMCID: PMC8010676.
21. Cosma S, Carosso AR, Borella F, Cusato J, Bovetti M, Bevilacqua F, Carosso M, Gervasoni F, Sciarrone A, Marozio L, Revelli A, Rolfo A, Filippini C, **Ghisetti V**, Di Perri G, Benedetto C. Prenatal Biochemical and Ultrasound Markers in COVID-19 Pregnant Patients: A Prospective Case-Control Study. *Diagnostics (Basel)*. 2021 Feb 26;11(3):398. doi: 10.3390/diagnostics11030398. PMID: 33652805; PMCID: PMC7996827.
22. Trunfio M, Venuti F, Alladio F, Longo BM, Burdino E, Cerutti F, **Ghisetti V**, Bertucci R, Picco C, Bonora S, Di Perri G, Calcagno A.

- Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. *Viruses*. 2021 Feb 11;13(2):281. doi: 10.3390/v13020281. PMID: 33670360; PMCID: PMC7917896.
23. Cosma S, Carosso AR, Cusato J, Borella F, Carosso M, Bovetti M, Filippini C, D'Avolio A, **Ghisetti V**, Di Perri G, Benedetto C. Coronavirus disease 2019 and first-trimester spontaneous abortion: a case-control study of 225 pregnant patients. *Am J Obstet Gynecol*. 2020 Oct 8;. doi: 10.1016/j.ajog.2020.10.005. PubMed PMID: 33039396; PubMed Central PMCID: PMC7543983.
  24. Calcagno A, **Ghisetti V**, Emanuele T, Trunfio M, Faraoni S, Boglione L, Burdino E, Audagnotto S, Lipani F, Nigra M, D'Avolio A, Bonora S, Di Perri G. Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy. *Emerg Infect Dis*. 2020 Oct 6;27(1). doi: 10.3201/eid2701.203027. PubMed PMID: 33021927.
  25. Cerutti F, Burdino E, Milia MG, Alice T, Gregori G, Bruzzone B, **Ghisetti V**. Urgent need of rapid tests for SARS CoV-2 antigen detection: Evaluation of the SD-Biosensor antigen test for SARS-CoV-2. *J Clin Virol*. 2020 Sep 29;132:104654. doi: 10.1016/j.jcv.2020.104654. PubMed PMID: 33053494; PubMed Central PMCID: PMC7522649.
  26. Calcagno A, **Ghisetti V**, Burdino E, Trunfio M, Alice T, Boglione L, Bonora S, Di Perri G. Coinfection with other respiratory pathogens in COVID-19 patients. *Clin Microbiol Infect*. 2020 Aug 19;. doi: 10.1016/j.cmi.2020.08.012. [Epub ahead of print] PubMed PMID: 32822882; PubMed Central PMCID: PMC7434691.
  27. Carosso A, Cosma S, Borella F, Marozio L, Coscia A, **Ghisetti V**, Di Perri G, Benedetto C. Pre-labor anorectal swab for SARS-CoV-2 in COVID-19 pregnant patients: is it time to think about it? *Eur J Obstet Gynecol Reprod Biol*. 2020 Jun;249:98-99. doi: 10.1016/j.ejogrb.2020.04.023. Epub 2020 Apr 14. PubMed PMID: 32327266; PubMed Central PMCID: PMC7194541.
  28. Venturi G, Aberle SW, Avšič-Županc T, Barzon L, Batejat C, Burdino E, Carletti F, Charrel R, Christova I, Connell J, Corman VM, Emmanouil M, Jääskeläinen AJ, Kurolt I, Lustig Y, Martinez MJ, Koopmans M, Nagy O, Nguyen T, Papa A, Pérez-Ruiz M, Pfeffer M, Protic J, Reimerink J, Rossini G, Sánchez-Seco Fariñas MP, Schmidt-Chanasit J, Söderholm S, Sudre B, Van Esbroeck M, Reusken CB. Specialist laboratory networks as preparedness and response tool - the Emerging Viral Diseases-Expert **Laboratory Network** and the Chikungunya outbreak, Thailand, 2019. *Euro Surveill*. 2020 Apr;25(13). doi: 10.2807/1560-7917.ES.2020.25.13.1900438. PubMed PMID: 32265004; PubMed Central PMCID: PMC7140599.
  29. Lupia T, Milia MG, Atzori C, Gianella S, Audagnotto S, Imperiale D, Mighetto L, Pirriatore V, Gregori G, Lipani F, **Ghisetti V**, Bonora S, Di Perri G, Calcagno A. Presence of Epstein-Barr virus DNA in cerebrospinal fluid is associated with greater HIV RNA and inflammation. *AIDS*. 2020 Mar 1;34(3):373-380. doi: 10.1097/QAD.0000000000002442. PubMed PMID: 31764071.
  30. Puzelli S, Di Martino A, Facchini M, Fabiani C, Calzoletti L, Di Mario G, Palmieri A, Affanni P, Camilloni B, Chironna M, D'Agaro P, Gianneccchini S, Pariani E, Serra C, Rizzo C, Bella A, Donatelli I, Castrucci MR. Co-circulation of the two influenza B lineages during 13 consecutive influenza surveillance seasons in Italy, 2004-2017. *BMC Infect Dis*. 2019 Nov 21;19(1):990. doi: 10.1186/s12879-019-4621-z. PubMed PMID: 31752738; PubMed Central PMCID: PMC6873537.
  31. Burdino E, Calleri G, **Ghisetti V**. Added value of loop-mediated isothermal amplification technology (LAMP) in real life for the diagnosis of malaria in travellers. *J Travel Med*. 2019 Oct 14;26(7). doi: 10.1093/jtm/taz052. Review. PubMed PMID: 31411701.
  32. Boglione L, Lupia T, Cariti G, **Ghisetti V**, Milia MG, Burdino E, Di Perri G. Antiviral treatment with pegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis. *J Med Virol*. 2019 Jul;91(7):1329-1334. doi: 10.1002/jmv.25438. Epub 2019 Mar 4. PubMed PMID: 30794324.
  33. Bertero L, Joseph SB, Trunfio M, Alice T, Catera S, Imperiale D, Cassoni P, Kincer LP, Pirriatore V, **Ghisetti V**, Amasio E, Zanusso G, Bonora S, Di Perri G, Calcagno A. HIV-1 detection in the olfactory mucosa of HIV-1-infected participants. *AIDS*. 2019 Mar 15;33(4):665-674. doi: 10.1097/QAD.0000000000002102. PubMed PMID: 30608272.
  34. Gagliardini R, Ciccullo A, Borghetti A, Maggiolo F, Bartolozzi D, Borghi V, Pecorari M, Di Biagio A, Callegaro AP, Bruzzone B, Saladini F, Paolucci S, Maserati R, Zazzi M, Di Giambenedetto S, De Luca A. Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: **A Cohort Study**. *Open Forum Infect Dis*. 2018 Jun;5(6):ofy113. doi: 10.1093/ofid/ofy113.

eCollection 2018 Jun. PubMed PMID: 29977967; PubMed Central PMCID: PMC6016422.

35. Boglione L, Cariti G, **Ghisetti V**, Burdino E, Di Perri G. Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: A retrospective analysis. *J Med Virol*. 2018 Jun;90(6):1047-1052. doi: 10.1002/jmv.25038. Epub 2018 Mar 15. PubMed PMID: 29384201.
36. Stefanelli P, Carannante A, Bonanno CL, Cusini M, **Ghisetti V**, Mencacci A, Barbui AM, Prignano G, Vocale C, Vacca P. Molecular Characterization of Penicillinase-Producing *Neisseria gonorrhoeae* Isolated in Two Time Periods, 2003-2004 and 2014-2015, in Italy. *Microb Drug Resist*. 2018 Jun;24(5):621-626. doi: 10.1089/mdr.2017.0218. Epub 2018 Jan 2. PubMed PMID: 29293395.
37. Burdino E, Milia MG, Alice T, Gregori G, Ruggiero T, Calleri G, Lipani F, Lucchini A, Venturi G, Di Perri G, **Ghisetti V**. Laboratory findings in Zika infection: The experience of a reference centre in North-West Italy. *J Clin Virol*. 2018 Apr;101:18-22. doi: 10.1016/j.jcv.2018.01.010. Epub 2018 Jan 31. PubMed PMID: 29414182.
38. Trunfio M, Joseph SB, **Ghisetti V**, Romito A, Martini C, Cusato J, Audagnotto S, Pesci Kincer L, Ferrara M, Sala A, Imperiale D, Di Perri G, Calcagno A. Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia. *J Neurovirol*. 2018 Feb;24(1):132-136. doi: 10.1007/s13365-017-0605-1. Epub 2017 Dec 14. PubMed PMID: 29243133.
39. Bigliano P, Calcagno A, Lucchini A, Audagnotto S, Montrucchio C, Marinaro L, Alcantarini C, **Ghisetti V**, Di Perri G, Bonora S. The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment. *Antivir Ther*. 2018;23(5):451-456. doi: 10.3851/IMP3221. PubMed PMID: 29372886.

**Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 196/2003, coordinato con il Decreto Legislativo 101/2018, e dell'art. 13 del GDPR (Regolamento UE 2016/679) ai fini della ricerca e selezione del personale.**

Torino, 19 Ottobre 2022

PERSONAL INFORMATION

Andrea Gori



📍 University of Milan  
 Department Biomedical and Clinical Sciences "L. Sacco"  
 Via GB Grassi 74,  
 20157, Milan, Italy

☎ +39 02 34042454  
✉ [andrea.gori@unimi.it](mailto:andrea.gori@unimi.it)

Sex Male | Date of birth 19/03/1963 | Nationality Italian

Enterprise	University	EPR
<input type="checkbox"/> Management Level	<input checked="" type="checkbox"/> Full professor	<input type="checkbox"/> Research Director and 1st level Technologist / First Researcher and 2nd level Technologist / Principal Investigator
<input type="checkbox"/> Mid-Management Level	<input type="checkbox"/> Associate Professor	<input type="checkbox"/> Level III Researcher and Technologist
<input type="checkbox"/> Employee / worker level	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator

WORK EXPERIENCE

March 2024 – to date	<b>Director of Department of Infectious Diseases</b> , Ospedale “Luigi Sacco”, Milan, Italy
March 2024 – to date	<b>Director Infectious Diseases I Unit</b> , Department of Infectious Diseases, Ospedale “Luigi Sacco”, Milan, Italy
2022 – to date	<b>Director Infectious Diseases II Unit</b> , Department of Infectious Diseases, Ospedale “Luigi Sacco”, Milan, Italy
2018 – to date	<b>Full Professor of Infectious Diseases</b> , University of Milan, Department Biomedical and Clinical Sciences “L. Sacco”, Milan, Italy
2018 – 2022	<b>Director Infectious Diseases Unit</b> , Department of Infectious Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
2018 – to date	<b>Head of Centre for Multidisciplinary Research, in Health Science (MACH)</b> , University of Milan, Italy
2014 – 2018	<b>Co-Director, Master in Global Health</b> , University of Milan, Italy <b>Full Professor of Infectious Diseases</b> , University of Milano-Bicocca, Department of Health Sciences, Milan, Italy
2016 – 2018	<b>Chief of Department of Internal Medicine</b> , “San Gerardo” Hospital, Monza, Italy
2007 – 2018	<b>Director Infectious Diseases Unit</b> , Department of Internal Medicine, “San Gerardo” Hospital, Monza, Italy
2006 – 2007	<b>Senior physician, Infectious and Tropical Diseases Clinic</b> , “San Paolo” Hospital, Department of Internal Medicine, University of Milan, Italy
1994 – 2006	<b>Medical assistant</b> , Infectious and Tropical Diseases Clinic, “Luigi Sacco” Hospital, University of Milan, Italy

EDUCATION AND TRAINING

- 2014 **National Scientific Enabling**, scientific-disciplinary sector MED/17
- 2011 **School of Health Management (SDS)**. Bocconi University, Milan
- 1995 **Specialization in Infectious Diseases**, University of Milan, Italy
- 1994 **Researcher Fellow**, Department of Mycobacteriology and Molecular Microbiology, National Institute of Public Health and Environmental Protection, RIVM, Bilthoven, The Netherlands
- 1991-1992 **Researcher Fellow**, Clinique des Maladies Infectieuses, Hopital Universitaire Saint-Pierre, Université Libre de Bruxelles, Bruxelles, Belgium
- 1991-1992 **Researcher Fellow**, Institute de Microbiologie, Hopital Académique Erasme, Université Libre de Bruxelles, Bruxelles, Belgio
- 1991 **Qualification to practice as physician**, Faculty of Medicine, University of Milan, Italy
- 1991 **Degree in Medicine and Surgery**, University of Milan, Faculty of Medicine, University of Milan, Italy

**AWARDS**

- 2023 Premio" Milano cultura 2023"
- 2023 Gilead Fellowship Program Winner
- 2019 Gilead Fellowship Program Winner; Best Ethics Project Award Winner
- 2019 Camuna Rose medal, highest honor in the field of health of the Lombardy Region
- 2018 Gilead Fellowship Program Winner; Best Ethics Project Award Winner
- 2017 Winner of the Research Award, SITA - Italian Society of Anti-infective Therapy
- 1995 Young investigator award winner, American College of Chest Physicians, NYC, USA
- 1992 Fabrizio Rocca Award, National Association for the Fight against AIDS, Italy
- 1991 Scholarship winner, International University Specialization in Foreign Countries, University of Milan

**MANAGEMENT ACTIVITIES**

- 2022 Member of several committees and boards of the Lombardy regional government, including those on sepsis, HIV infection control, antimicrobial resistance, vaccines, and COVID-19
- 2021 Member AIFA-OPERA working group, Italian Drug Agency
- 2021 Member "COVID-19 patient management" AGENAS working group, Ministry of Health
- From 2020 Member National AIDS Commission, Ministry of Health
- From 2020 Member of the Steering Committee of the "Italian guidelines on the use of antiretroviral drugs and diagnostic-clinical management of people with HIV-1 infection", Ministry of Health
- From 2020 Member of the Board of Directors as well of The Bridge Foundation
- From 2020 Member of the Board of Directors of Convivio Fondation
- From 2019 Member of the Board of Directors, ICONA Foundation, Italian Cohortm Naive Antiretrovirals
- From 2019 Member of the Steering Committee, TB Group - Italian Society of Infectious and Tropical Diseases (SIMIT)
- From 2018 President of ANLAIDS Lombardy (National Association for the Fight against AIDS)
- From 2018 Member of the Antimicrobial Resistance Working Group - Association of Italian Clinical Microbiologists (AMCLI)
- From 2016 Member of the Board of Directors of Sita - Italian Society of Anti-infective Therapy
- From 2015 Member of the Scientific Committee of the national guidelines for tuberculosis control and HIV infection management. National Ministry of Health
- 2006-2019 National Coordinator of the tuberculosis working group- Italian Society of Infectious and Tropical Diseases (SIMIT)
- 2006-2019 Member of the Steering Committees of StopTB Italy
- 2002-2016 Member of the Regional Tuberculosis Commission, Lombardy Region

- 2019 Fonder and Member of the Executive Committee of the Italian non-tuberculous mycobacteria – NTM - Registry (IRENE)
- 2016 Founder and Chairman of the Collaborating Group for Surveillance of Multidrug Resistance in the region Lombardy
- 2015 Member of the Steering Committee, International Medical School, University Milano-Bicocca
- 2014 Founder and member of the Steering Committee, "Italian network acute HIV infection (INACTION)

#### EDITORIAL ACTIVITY

*Ad hoc reviewer.* Nature Communications, New England Journal of Medicine, Lancet, Lancet HIV, Lancet ID, AIDS, Clinical Infection Diseases, Journal of Infection Diseases, Journal of Clinical Microbiology, European Respiratory Journal, Journal of AIDS, PLoS Medicine, PLoS One, Frontiers Immunology, Frontiers Medicine (Editor), Frontiers Public Health (Editor)

2021 Author of the "Tuberculosis" Chapter of the 21st edition of the Harrison's Principles of Internal Medicine textbook

#### GRANTS

- HORIZON-HLTH-2021-CORONA-01 "END-VOC: Ending COVID 19 variants of concern through cohort studies". 2022-2025. (€ 432.115,00)
- HORIZON-2020-SC1-2020 "pREvention and management tools for rEducing antibiotic Resistance in high prevalence Settings (REVERSE)". 2021-2026. (€ 300.000)
- Italian Ministry of Health, IRCCS Network on Infectious Diseases "National collaborative network for the creation of an adaptive clinical-management model for the implementation and evaluation of antimicrobial drug use optimization programs (Antimicrobial Stewardship)" 2022-2024. (€ 499.939,11)
- Italian Ministry of Health RF Network 2018 12366982-4 "Research Strategies for implementing Antimicrobial Stewardship: Health Communication, Diagnostic-Therapeutic Interventions and Cost-Effectiveness Analysis: WP4 cost-effectiveness analysis of an antimicrobial stewardship program in Lombardy Area" 2020-2024. (€ 600.000)
- Italian Ministry of Education and Research (MIUR) PRIN-2017: "Immuno virological dynamics triggered by anti HIV-IMVIDYS" 2020-2023. (€ 90.000)
- Fondo di Beneficenza Intesa San Paolo "END-COVID: "Translational research on biological material from COVID19 patients to understand disease mechanisms and identify therapeutic targets also to face future epidemics" 2020-2022. (€ 245.500)
- Bolton Foundation "Assessment of public health response to COVID-19 epidemic (PREP-COVID)" 2021-2023. (€ 200.002,68)
- Merck Sharp & Dohme. 2018 call "In vitro activity of imipenem-relebactam against Klebsiella pneumoniae strains producing KPC B-lactamases isolated in Italy in the period 2016-2018" 2021. (\$ 115.910,90)
- AIFA 2018 "Strategies to contain HIV drug resistance. Unravelling the role of mutation burden in PBMCs" 2019-2022. (€ 60.000)
- Lombardia Region Covid call 2020 ID 1842163 "Characterization of the protective immune response in patients affected by COVID-19 and realization of an immuno-diagnostic assay - CO-iMMUNITY", 2020. (€ 111.730,50)
- Italian Ministry of Health RF GR-2018-12365988 "Pulmonary microbiota and related immunity role in predicting ventilator associated-pneumonia (VAP) development in mechanical ventilated patients" 2020-2024. (€ 450.000,00)
- Italian Ministry of Health RF GR-2018-12365699 "CD4 T memory stem cells in the context of HIV infection" 2020-2024. (€ 435.000,00)
- Italian Ministry of Health RF GR-2016-02362572 "A multidisciplinary approach to counteract multidrug resistant bacterial infection: integrating immunity, bacterial virulence factors and clinical care" 2018-2023. (€ 375.320,30)
- Italian Ministry of Health RF NET-2013-02355333 "Implication of strategies of long-term control of viral replication in patients with primary HIV infection (PHI) treated with

**PERSONAL SKILLS**

- multitarget antiviral therapy (MT-ART): kinetic of viral reservoir, immunological response and drug penetration in lymphoid tissues" 2015-2020. (€ 438.354,98)
  - Italian Ministry of Health RF GR-2011-02351728 "Management of the activities related to the Multicenter Study "Containment of a region-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in seven Lombardy hospitals: molecular characterization, epidemiology and outcome" 2013-2018. (€ 468.340,314)
  - FP7-HEALTH-2007-B "Molecular epidemiology of drug resistant strains in selected metropolitan settings in Western and Eastern Europe" 2008-2014. (€ 472.659,17)
  - Concerted Action, Biomed 2, EU "Molecular epidemiology of tuberculosis in Europe" 1997-2002. (€ 369.672,00)
- Mother tongue** Italian, mother tongue
- Other languages** English, Excellent  
French, Excellent
- Job-related skills** Leadership, communication, human resources management
- Digital skills** Excellent knowledge of Microsoft Office products (Word, Excel, PowerPoint)

**ADDITIONAL INFORMATION**

**Statement of Research Interests** The main focus of my research activity has been the immunological pathogenesis of viral and bacterial infections and the interplay between pathogens and host. My main focus is understanding how to translate information learned from pathogenetic studies into clinical work. I approached the study of immune system interactions with microbial colonization/infection, particular dissecting human T cell the phenotype and function, T cell activation, and immune reconstitution. I'm involved in several antimicrobial stewardship projects developing a deep experience in the managing epidemiological and clinical aspect of antimicrobial resistant infections. I have conducted more than 150 clinical studies as Principal Investigator in national and international multicenter clinical trials (Phase I, II, III, IV) in particular for the development of new drugs for the treatment of HIV infection, antimicrobial agents, immunomodulants and vaccines.

**Publications** Total number of publications in peer-review journals: 366  
Total number of citations: 16071  
H index (Scopus): 54  
H index (Google Scholar): 67

Novembre 2024

Andrea Gori





INFORMAZIONI PERSONALI

Nome / Cognome	<b>LORETA KONDILI</b>
E-mail	loreta.kondili@iss.it
Nazionalità	Italiana
Sesso	Femminile
• Date	Dal 2018 ad oggi
• Tipo di azienda o settore	Istituto Superiore di Sanità Organismo Notificato 0373
• Tipo di impiego	Ricercatore di Ruolo Esperto della Valutazione Clinica
• Principali mansioni e responsabilità	Espletare per l'ON0373 ISS le attività pertinenti la certificazione CE dei Dispositivi Medico-Diagnostici in vitro
• Date	Dal 2014 ad oggi
• Tipo di azienda o settore	Istituto Superiore di Sanità Centro Nazionale per la Salute Globale
• Tipo di impiego	Ricercatore di ruolo
• Principali mansioni e responsabilità	Responsabile Scientifico Piattaforma Italia per lo studio delle Terapie delle epatiti Virali (PITER). Esperto AIFA EMA. Attività tecnico-scientifica nell'ambito della valutazione della efficacia e sicurezza post marketing dei prodotti immunobiologici,
• Date	Dal 2009 a 2014
• Tipo di azienda o settore	Istituto Superiore di Sanità Centro per la Ricerca e la Valutazione dei Prodotti Immunobiologici
• Tipo di impiego	Ricercatore
• Principali mansioni e responsabilità	Esperto AIFA EMA. Attività tecnico-scientifica nell'ambito della valutazione della efficacia e sicurezza post marketing dei prodotti immunobiologici
• Date	Dal 2003-al 2009
• Tipo di azienda o settore	Istituto Superiore di Sanità Dipartimento di Malattie Infettive, Parasitarie ed Immunomediate
• Tipo di impiego	Ricercatore
Principali mansioni e responsabilità	Progetti di ricerca applicando tecniche di rilevamento e caratterizzazione molecolare di marcatori virali di virus epatitici, Programma di Valutazione Esterna Della Qualità del test NAT per la ricerca di HCV-RNA presso i Servizi Trasfusionali,
• Date	Dal 1997- al 2003
• Tipo di azienda o settore	Istituto Superiore di Sanità Laboratorio di Virologia e Laboratorio di Epidemiologia e Biostatistica
• Tipo di impiego	Ricercatore
• Principali mansioni e responsabilità	Progetti di ricerca clinici, virologici e di terapia delle infezioni da virus epatitici Valutazione e gestione di dati clinici e di laboratorio nell'ambito di studi clinici, di epidemiologia e di infezioni

## ISTRUZIONE E FORMAZIONE

- Date 14 Gennaio 2020
- Nome e tipo di istituto di istruzione o formazione Bando D.D. 1532/2016 Settore concorsuale 06/D4 Malattie cutanee malattie infettive malattie dell'apparato digerente **Fascia: II**
- Principali materie / abilità professionali oggetto dello studio
- Qualifica conseguita
- Date
- Nome e tipo di istituto di istruzione o formazione
- Principali materie / abilità professionali oggetto dello studio
- Qualifica conseguita
- Titolo tesi
- Date
- Nome e tipo di istituto di istruzione o formazione
- Principali materie / abilità professionali oggetto dello studio
- Qualifica conseguita
- Titolo tesi
- Date
- Nome e tipo di istituto di istruzione o formazione
- Principali materie / abilità professionali oggetto dello studio
- Qualifica conseguita
- Titolo tesi
- Date
- Nome e tipo di istituto di istruzione o formazione
- Principali materie / abilità professionali oggetto dello studio
- Qualifica conseguita
- Titolo tesi
- Date
- Nome e tipo di istituto di istruzione o formazione
- Principali materie / abilità professionali oggetto dello studio
- Qualifica conseguita
- Titolo tesi
- Date
- Nome e tipo di istituto di istruzione o formazione
- Principali materie / abilità professionali oggetto dello studio
- Qualifica conseguita
- Titolo tesi
- Date
- Nome e tipo di istituto di istruzione o formazione
- Principali materie / abilità professionali oggetto dello studio
- Qualifica conseguita
- Titolo tesi
- Date
- Nome e tipo di istituto di istruzione o formazione
- Principali materie / abilità professionali oggetto dello studio
- Qualifica conseguita
- Titolo tesi
- Date
- Nome e tipo di istituto di istruzione o formazione
- Principali materie / abilità professionali oggetto dello studio
- Qualifica conseguita
- Titolo tesi
- Date
- Nome e tipo di istituto di istruzione o formazione
- Principali materie / abilità professionali oggetto dello studio
- Qualifica conseguita
- Titolo tesi

14 Gennaio 2020

Bando D.D. 1532/2016 Settore concorsuale 06/D4 Malattie cutanee malattie infettive malattie dell'apparato digerente **Fascia: II**

### **Abilitazione Scientifica Nazionale Professore associato**

15 Dicembre 2017

Università Cattolica "Sacro Cuore" Roma  
ALTEMS (Alta Scuola di Economia e Management dei Sistemi Sanitari)  
"Valutazione e Gestione delle Tecnologie Sanitarie"

### **Master Universitario di secondo livello**

Creazione di Strumenti real-life per la Valutazione di Politiche Sanitarie nel Trattamento dell'Infezione Cronica da HCV

28 Maggio 2015

Università degli Studi di Roma "La Sapienza"

Dottorato di ricerca in Fisiopatologia Chirurgica ed Epato-Gastroenterologica Sperimentale e Clinica

### **PhD Dottore di Ricerca**

Modelli preclinici per lo studio di meccanismi virali e dell'ospite che inducono la persistenza virale e sviluppo di epatocarcinoma nel modello animale.

19 Luglio 2012

Università di Tirana Albania,

Concorso (titoli e colloquio) per idoneità titolo Professore

### **"Professore" Università di Tirana Albania**

11 gennaio 2007

Università di Tirana Albania,

Docenze in varie Università d'Albania  
Concorso (titoli e colloquio Professore Associato)

### **Professore Associato**

7 Dicembre 2005

Università degli Studi Sapienza

Scuola di Specializzazione in Gastroenterologia ed Endoscopia Digestiva presso il Dipartimento di Medicina Clinica dell'Università degli Studi "La Sapienza"  
**Specialista in Gastroenterologia ed Endoscopia Digestiva**

Dal 1 Ottobre 2002-al 30 Settembre 2003



	<b>INGLESE</b>
• Capacità di lettura	ECCELLENTE
• Capacità di scrittura	OTTIMA
• Capacità di espressione orale	OTTIMA
CAPACITÀ E COMPETENZE RELAZIONALI	Capacità di lavoro in gruppi multidisciplinari: ricercatori sperimentali, operatori sanitari
CAPACITÀ E COMPETENZE TECNICHE	Tecniche di Biologia Molecolare, Primo operatore in endoscopia Digestiva, Primo operatore in Ecografia addominale, , formazione, elaborazione dati statistici, gestione di progetti scientifici nazionali ed internazionali
<b>COMPETENZE INFORMATICHE</b>	Lavoro abitualmente: Sistemi operativi: Windows 95/98/2000/XP/Vista, macOS Pacchetto applicativo Office (WORD, EXCEL, POWER POINT),. Software statistici: SPSS, Epi Info

	In Fede
12/01/2023	Loreta Kondili

Ai sensi e per effetto del **Regolamento (UE) 2016/679 DEL PARLAMENTO EUROPEO E DEL CONSIGLIO** del 27 aprile 2016 relativo alla protezione delle persone fisiche con riguardo al trattamento dei dati personali, autorizzo al trattamento dei dati e delle informazioni contenute nel curriculum vitae.

Roma, 12/01/2023

Loreta Kondili

## **CURRICULUM VITAE Per Ljungman (born 1950-10-17)**

Work address:

Medical Unit Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, M75, SE-14186 Stockholm, Sweden

### **A. Professional preparation**

M.D (Karolinska Institutet, Stockholm, Sweden 1975)

Ph.D (Virology, Karolinska Institutet, Stockholm, Sweden 1985).

Postdoc and fellow in Infectious Diseases, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA 1986-87.

Board certified in Internal Medicine (1985) and Hematology (1988), Sweden.

### **B. Appointments**

Associate Professor in Internal Medicine, Karolinska Institutet 1986

Professor of Hematology (adjunct and affiliated), Karolinska Institutet, Stockholm, Sweden (2000-2017).

### **C. Current positions:**

Professor (emeritus), Karolinska Institutet, Stockholm 2018-ongoing

Process coordinator, haematological malignancies, Regional Cancer Center Stockholm-Gotland, Stockholm, Sweden, 2013-ongoing

Medical Expert, Swedish Health and Social Care Inspectorate (IVO) 2021-ongoing.

Senior physician, temporary, Dept. of Infectious Diseases, Karolinska University Hospital, 2024-09 - ongoing

### **D. Former positions**

Senior physician, Dept. of Cellular Therapy and Allogeneic Stem Cell Transplantation 2014-2023

Acting director, Center for Allogeneic Stem Cell Transplantation, 2014 - 201704 Karolinska University Hospital, Stockholm, Sweden

Director, Dept. of Hematology, Karolinska University Hospital, Stockholm, Sweden (2004-201308)

Acting director, Division of Oncology, Karolinska University Hospital 2008-200902

Director, Dept of Hematology, Huddinge University Hospital 1998-2004, Stockholm, Sweden

Senior physician, Dept. of Hematology, Karolinska University Hospital and Huddinge University Hospital 1992 – 2013

Research Coordinator, Regional Cancer Center Stockholm- Gotland, Stockholm, Sweden 2013-2017

Alternate member, European Medicines Agency Committee on Advanced Therapy (CAT) 2009-2011

Scientific advisor. European Medicines Agency 2012 – 2015, 2017, 2019

Scientific Advisor, Swedish Medical Products Agency, Uppsala, Sweden 2002-2020

Member, ethical advisory board, Karolinska Institutet, Stockholm, Sweden 2018-2024

### **E. Scientific activities**

Tutorships:

*PhD students*

Main tutor (9) and assistant tutor (8) for graduated PhD students at Karolinska Institutet, Stockholm, Sweden

#### **F. Awards and other achievements**

Honorary member, Swedish Society for Hematology 2018

Honorary member, European Society for Blood and Marrow Transplantation (EBMT) 2019

Lifetime Achievement Award, Immunocompromised Host Society 2022

Fellow Infectious Disease Society of America (FIDSA) 2023

Fellow European Society of Microbiology and Infectious Diseases (FESCMID) 2025

#### **G. International appointments/elected positions**

##### Ongoing

Chairman, European Society for Blood and Marrow Transplantation's (EBMT) registry committee 2012- ongoing

Scientific coordinator, EBMT registry update 2023 - ongoing

Swedish representative, Joint Accreditation Committee of International Society of Cellular Therapy and EBMT (JACIE) 2005-

JACIE inspector

Work Package Leader, European Leukemia Net 2012 - ongoing

Academic co-chair, Transplant Associated Virus Forum, Forum for International

Collaborative Research, UC Berkeley School of Public Health, Washington DC, USA

2015 - ongoing

Board member, European Conference on Infections in Leukemia (ECIL) 2018 - ongoing

Advisory Committee Member, Adult Immunization Board, University of Antwerp and

University of Florence 2022 - ongoing

##### Previous

Board member and chairman Infectious Diseases Working Party, EBMT 1992-1998

Chairman, Registry Subcommittee, EBMT 1998-2004

Secretary, European Society for Bone Marrow Transplantation (EBMT) 2004-2010

Member Clinical Trials Committee, EBMT 2004-2014

Council member, International Immunocompromised Host Society 2000-2004

Vice president, International Immunocompromised Host Society 2004-2006

President elect, International Immunocompromised Host Society 2006-2008

President, International Immunocompromised Host Society 2008-2010

Past President, International Immunocompromised Host Society 2010-2012

Member, Scientific Audit Committee, EORTC, 2013 – 2018

Visiting Professor, Dept. of Haematology, University College London, London, UK (1998-2004)

Visiting Professor, University of Amsterdam, the Netherlands, 2005

Courtesy (visiting) professor, Institute of Medicine, University of Florida, Gainesville, USA 2013-2015

## **H. Editorships**

Co-editor – Transplant infections from Lippincott-Raven Publishers 1998, 2003, 2010

Co-editor – Transplant Infections from Springer Publishers 2016

Section Editor – Clinical Bone Marrow and Stem Cell Transplantation, Cambridge publications 2003

Co-Editor/associate editor, Bone Marrow Transplantation, 2005 - ongoing

Member Editorial Boards for Transplant Infectious Disease, Journal of Infectious Diseases, Clinical Infectious Diseases.

## **I. Publications**

Author of >500 peer reviewed papers in international journals. In addition, the author of several reviews and book chapters.

## **J. Clinical Trial and Drug development activities**

PI and co-investigator on vaccine studies FIH, phase I - IV, Huddinge University Hospital/Karolinska University Hospital and Karolinska Institutet 1990 – 2024

PI and co-investigator on antiviral, cellular therapy, and transplant studies, Phase II – IV, Huddinge University Hospital/Karolinska University Hospital and Karolinska Institutet 1985 - 2023

Current chair, DSMB for OctaPharma

Current member, DSMB for Blueprint pharmaceuticals

Chair and/or member of DSMB for several closed clinical trials.

Member, Endpoint Adjudication Committee for Takeda (closed trial).

Member, Disease Adjudication Committee for MSD (ongoing and closed trials)

Chair, DSMB for Enanta Pharmaceuticals

Stockholm 2025-07-15



Per Ljungman

**PAOLO MAGGI:  
CURRICULUM FORMATIVO E PROFESSIONALE.**

**CURRICULUM STUDI:**

Il sottoscritto si è laureato in Medicina e chirurgia il 19/7/1984 con voto 110/110 e lode e tesi di laurea sperimentale in Microbiologia dal titolo "Produzione di attività procoagulante da parte di linfomonociti umani ed ipercoagulabilità plasmatica associata alla immunoterapia con *Corynebacterium parvum*".

Durante l'attività di internato presso l'Istituto di Microbiologia iniziata nel 1983, oltre agli studi concernenti l'argomento della tesi, si è impraticato nella diagnostica virologica, batteriologica, micologica e parassitologica diretta e indiretta.

Il 30/5/1988 si è specializzato in Microbiologia con voto 50/50 e lode con tesi sperimentale dal titolo: "Siero-epidemiologia della leptospirosi: osservazioni personali".

Il 15/7/1991 si è specializzato in Malattie infettive con voto 50/50 e lode con tesi sperimentale dal titolo "Infezioni opportunistiche dell'apparato digerente in HIV-positivi".

Dal 1985 ha collaborato con la Clinica delle Malattie Infettive in qualità prima di specializzando, poi di medico interno e, infine, di medico di Ruolo, svolgendo attività clinica, didattica e di ricerca.

Il 1/12/2005 si è specializzato in Farmacologia con voto 50/50 e lode con tesi sperimentale dal titolo: "Inibitori delle proteasi e danno cardiovascolare: studio comparativo ultrasonografico color-doppler".

**CURRICULUM PROFESSIONALE:**

Le tappe salienti della formazione del candidato in campo infettivologico sono state le seguenti:

Dal 30/7/85 al 31/6/86 ha prestato servizio in qualità di Ufficiale di complemento presso l'Ospedale Militare di Bari quale assistente dei reparti di Medicina, Malattie infettive e Dermatologia, dopo aver prestato il prescritto servizio presso la Scuola allievi Ufficiali Medici di Firenze dal 2/5 al 29/7/85.

Dal 20/4/88 al 19/12/88 ha prestato servizio presso l'Ospedale di Altamura quale assistente incaricato in reparto Medicina.

In questi periodi il candidato ha prodotto lavori editi a stampa allegati alla documentazione.

Dal 20/12/89 al 31/12/89 ha prestato servizio come assistente di area medica presso il laboratorio di analisi del CTO USL BA/10.

Dall'1/1/90 al 31/5/1992 è stato Assistente di ruolo presso il reparto di Nefrologia e Dialisi dell'Ospedale di Altamura. Nell'ambito dell'attività svolta in tale reparto si ritiene di dover segnalare che il candidato si è impegnato nell'attività di ricerca concernente lo studio delle infezioni in dialisi e nel trapiantato renale con particolare riferimento alle infezioni da HIV, da miceti e alle epatiti virali, come documentato dalle pubblicazioni allegate.

Dall' 1/6/1992 al 31/5/93 ha prestato servizio presso la Clinica di Malattie Infettive del Policlinico di Bari, in Comando di servizio (ex art. 44 DPR 761/79) come Assistente Medico, ritornando in Nefrologia e Dialisi dell'Ospedale di Altamura dall'1 al 30/6/93.

Dal 1/7/1993 a tutt'oggi presta servizio presso la stessa Clinica, prima come Assistente Medico di ruolo, successivamente come Dirigente Medico (dall'1/5/2003 con incarico di alta specializzazione).

**STAGE IN OSPEDALI ESTERI**

The Mount Sinai Medical Center. New York, USA. 23-26/2/1998.

The Johns Hopkins University, School of Medicine. Baltimora, USA. 1-4/6/1998.

San Francisco General Hospital, University of California. San Francisco, USA 30/5-1/6/2000.

Southwestern Medical Center, University of Dallas. USA 11-15/9/2000.

### **INCARICHI DIRIGENZIALI:**

Il sottoscritto coordina dal 1998 il Day Hospital della Clinica gestendo in prima persona le seguenti patologie che afferiscono a detto servizio: infezioni da HIV/AIDS epatopatie croniche, tubercolosi accertate, sospette e altre febbri di natura da definire, terapie anti infettive infusionali, monitoraggio di pazienti trapiantati di fegato.

E' responsabile dell'attività di monitoraggio della tossicità cardiaca, renale ed ossea delle terapie antivirali. In particolare svolge in prima persona attività diagnostica con indagini ecografiche ed eco color Doppler specificatamente dirette alla valutazione dello spessore miointimale dei vasi epiaortici.

E' referente dell' Unità Operativa per la parassitologia clinica e per le malattie infettive dei viaggiatori.

E'uno dei due responsabili delle attività di consulenza esterna dell'Unità Operativa presso gli altri Reparti dell'Ospedale, con particolare riferimento alle infezioni in pazienti ricoverati nelle Unità di terapia intensiva e nelle Rianimazioni, alle osteomieliti e alle infezioni di protesi articolari.

### **CURRICULUM MANAGERIALE:**

1. 15/11/97-11/3/98 L'ospedale come azienda. Bari
2. Anno 1999-2000 Corso di formazione manageriale AMOI-SISMIP.

### **CURRICULUM DI INSEGNAMENTO:**

1. Insegnamento di Malattie Infettive presso la Scuola Infermieri Professionale dell'USL BA/7 negli anni scolastici 1989-90, 1990-91, 1991-92.
2. Insegnamento nell'ambito dei corsi di formazione e di aggiornamento per i Reparti di Malattie Infettive (ex legge 135/90) presso l'Ospedale di Triggiano nei corsi dal 1992 al 2000 discipline: Scienze umane e Prevenzione.
3. Insegnamento nell'ambito dei corsi di formazione e di aggiornamento per i Reparti di Malattie Infettive (ex legge 135/90) presso l'Ospedale Miulli di Acquaviva nel corso del 1994. Disciplina: Sorveglianza.
4. Insegnamento in qualità di docente di Malattie infettive presso la Scuola Infermieri professionali annessa alla Clinica Ostetrica dell'Università degli studi di Bari, negli anni accademici 1995-96 e 1996-97 per la sede attivata presso l'Azienda Ospedaliera Policlinico di Bari (35 ore annuali).
5. Insegnamento in qualità di docente di Malattie infettive per il Diploma Universitario di Ostetricia presso la Clinica Ostetrica dell'Università degli studi di Bari negli anni accademici 1997-98, 1998-99, 1999-00, 2000-01 e 2001-02 per la sede attivata presso l'Azienda Ospedaliera Policlinico di Bari (35 ore annuali).
6. Insegnamento in qualità di docente di Malattie infettive per il Corso di Laurea triennale in Ostetricia presso la Clinica Ostetrica dell'Università degli studi di Bari negli anni accademici 2002-03, 2003-04 2004-05 e 2005-2006 per la sede attivata presso l'Azienda Ospedaliera Policlinico di Bari (1 credito annuale).
7. Insegnamento nell'ambito dei corsi di formazione e di aggiornamento per i Reparti di Malattie Infettive (ex legge 135/90) presso Il Policlinico di Bari nei corsi relativi agli anni dal 1991 al 2000.
8. Docenza presso la scuola di specializzazione in malattie infettive dell'Università di Bari:
  - a): didattica integrativa all'insegnamento di "metodologie diagnostiche e di laboratorio" per gli anni accademici 1994-95, 1995-96, 1996-97, 1997-98.
  - b) didattica integrativa all'insegnamento di "patologia e clinica delle malattie infettive" per gli anni accademici 1999-2000, 2000-01.

- c) insegnamento di ruolo di “epidemiologia e profilassi delle malattie infettive” e “clinica delle malattie infettive negli anni accademici 2001-02 e 2002-03.
  - d) insegnamento di ruolo di “microbiologia medica” negli anni accademici 2003-04 e 2004-05 e 2005-2006 (30 ore annuali)
  - e) “Eziologia e patogenesi delle malattie infettive” per gli anni accademici 2007-2008, 2008-2009, 2009-2010, 2010-2011, 2011-2012 2012-2013, 2013-2014 (20 ore annuali).
- 9 Nominato “cultore della materia” per la disciplina di malattie infettive, settore MED 17 giusta deliberazione del Consiglio di Facoltà del 6/4/2005.
- 10 Docenza presso la scuola di specializzazione in chirurgia vascolare:
- a) a)“Malattie Infettive” negli anni accademici 2004-2005 e 2005-2006 (30 ore annuali)
  - b) :”Infezioni in chirurgia vascolare” per l’anno accademico 2009-2010, 2010-2011, 2011-2012, 2012-2013, 2013-2014 (20 ore annuali)
- 11 Docenza presso la Scuola di Specializzazione in Medicina Legale e delle Assicurazioni: insegnamento di “Patologia clinica” (10 ore annuali) per l’anno accademico 2008-2009.
- 12 Docenza nell’ambito del Corso integrato di Medicina Clinica e Farmacologia – Corso di laurea in Infermieristica, Ospedale Di Venere – Carbonara (Bari): Attività didattica opzionale (ADO): seminari di Farmacologia. AA 2011-2012.

#### **CURRICULUM DI RICERCA:**

All’atto della stesura del presente curriculum è autore di circa 300 pubblicazioni scientifiche ed autore di 8 capitoli di testi di Medicina.

## Curriculum Vitae

---

### Contact information

Name: Catia MARZOLINI KRAUSER  
Professional address: Division of Infectious Diseases & Hospital Epidemiology  
Departments of Medicine and Clinical research  
University Hospital of Basel and University of Basel  
E-mail: [catia.marzolini@usb.ch](mailto:catia.marzolini@usb.ch)

Service of Clinical Pharmacology  
Department of Laboratory Medicine and Pathology  
University Hopsital Lausanne  
Email: [catia.marzolini@chuv.ch](mailto:catia.marzolini@chuv.ch)

### Education/Academic recognition

2024 Associate Professor  
University of Lausanne, Switzerland

2023 Honorary Professor  
University of Liverpool, UK

2018 “Titular Professur” (Associate Professor)  
University of Basel, Switzerland

2013 “Venia docendi”, PD  
University of Basel, Switzerland

2006 Fellowship in Clinical Pharmacology  
Vanderbilt University, Nashville, USA

2002 Ph.D. in Pharmaceutical Sciences  
University of Lausanne, Switzerland

1996 Diploma of Hospital Pharmacy  
University hospital, Lausanne, Switzerland

1994 Swiss federal diploma of Pharmacy  
University of Lausanne, Switzerland

### Professional experience

2023 to present Head of the TDM unit  
Service Clinical Pharmacology  
University Hospital Lausanne, Switzerland

2017 to present Research group leader  
Departement Klinische Forschung (DKF)  
Division of Infectious Diseases  
University Hospital Basel, Switzerland

2022 to present Scientific lead & Deputy Director of drug interactions  
websites  
School of Molecular and Clinical Pharmacology  
University of Liverpool, UK

2011 to present	Principal Pharmacist & Lead Website Content Development School of Molecular and Clinical Pharmacology University of Liverpool, UK
2012-2016	Senior research scientist Division of Infectious Diseases University hospital of Basel, Switzerland
2007-2012	Research scientist Division of Infectious Diseases University hospital of Basel, Switzerland
2005-2006	Chief research fellow Division of Clinical Pharmacology Vanderbilt University School of Medicine, Nashville, USA
2002-2005	Research fellow Division of Clinical Pharmacology Vanderbilt University School of Medicine, Nashville, USA
1998-2002	PhD student Division of Clinical Pharmacology University hospital of Lausanne, Switzerland
1996-1998	Clinical pharmacist SOS Pharmaciens (home care), Geneva, Switzerland
1995-1996	Master student Hospital pharmacy University hospital, Lausanne, Switzerland
1993-1995	Substitute pharmacist in retail pharmacies

### **Professional activity and public service**

#### **A) Panel memberships**

2015 to present	Swiss HIV Cohort Study (SHCS) scientific board
2013 to present	European AIDS Clinical Society (EACS) guidelines. Since 2019 Lead of the drug-drug interactions working group.

#### **B) Organization memberships**

2024 to present	Associate Editor of the journal: <i>HIV Medicine</i>
2019 to present	Editorial Board of Clinical Cases DDIs website
2018 to present	Editorial Board of the journal: <i>HIV Medicine</i> .
2012 to present	Editorial Board of the journal: <i>Antiviral Therapy</i> .
2009 to present	Editorial Board, University of Liverpool HIV Drug Interactions database: <a href="http://www.HIV-druginteractions.org">www.HIV-druginteractions.org</a> .
2024	Abstract reviewer for the Conference on Retroviruses and Opportunistic Infections.
2024	Scientific Program committee for the 17 <sup>th</sup> International Congress on drug therapy in HIV infection, (November 2024 10-13, 2024).

2024	Scientific Program committee of the Liverpool course (September 18, 2024).
2024	Scientific Program committee of the 25 <sup>th</sup> International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs, (September 18-20, 2024).
2024	Scientific Program committee of the 13 <sup>th</sup> International Workshop on HIV & Women, (April 12-13, 2024).
2023	Scientific/Abstract Program committee for the 19 <sup>th</sup> European AIDS Conference (October 18-21, 2023).
2023	Scientific Program committee of the Liverpool course (September 13, 2023)
2023	Scientific Program committee of the 24 <sup>th</sup> International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs, (September 11-13, 2023).
2023	Scientific Program committee of the 13 <sup>th</sup> International Workshop on HIV & Women, (February 17-18, 2023).024
2022 to present	Data and safety monitoring board for the DisCoVeRY multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults (Inserm C20-15).
2022	WHO Adult Treatment Working Group Meeting: updates on Tenofovir, lamivudine, dolutegravir transition and dolutegravir associated toxicity and resistance.
2022 to present	WHO pregnancy and breastfeeding therapeutics working group on HIV, hepatitis and STIs.  Development of a toolkit for antiretrovirals in pregnancy research.
2022	Scientific Program committee of the 23 <sup>rd</sup> International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs, (September, 2022).
2022	Scientific Program committee of the 12 <sup>th</sup> International Workshop on HIV & Women, (April 7-8, 2022).
2022	Scientific Program committee for the 11 <sup>th</sup> Conférence Internationale Francophone AFRAVIH (April 6-9, 2022).
2021	Scientific Program committee for the 18 <sup>th</sup> European AIDS Conference (October 27-30, 2021).
2021	Scientific Program committee for the 12 <sup>th</sup> International Workshop on HIV & Aging, (September 23-24, 2021)

2021	Scientific Program committee of the 11 <sup>th</sup> International Workshop on HIV & Women, (April 26-28, 2021).
2020	Scientific Program committee for the 15 <sup>th</sup> International Congress on drug therapy in HIV infection, (October 25-28, 2020).
2019 to present	Member of the Swiss Society of Infectious Diseases
2019	Local co-chair for the 21 <sup>st</sup> International Workshop on Co-morbidities and Adverse Drug Reactions in HIV (November 5-6, 2019).
2019	Scientific Program committee for the 17 <sup>th</sup> European AIDS Conference (November 6-9, 2019).
2018	Scientific Program committee for the 14 <sup>th</sup> International Congress on drug therapy in HIV infection, (October 2018 28-31, 2018).
2015	Scientific Program committee for the 15 <sup>th</sup> European AIDS Conference (October 21-24, 2015).
2013	Scientific Program committee for the 14 <sup>th</sup> European AIDS Conference (October 16-19, 2013).

## Publications

**H-index = 34** (34 items that have 34 citations or more)

### A) Peer-reviewed journals

- 1) Seydoux C, Briki M, Wagner DA, Choong E, Guidi M, Carrara S, Thoma Y, Livio F, Girardin F, **Marzolini C**, Buclin T, Decosterd LA. Importance of sex-dependent differences for dosing selection and optimization of cancer drugs [accepted].
- 2) **Marzolini C**, Gibbons S, Seddon D, Khoo S. Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir. *Expert Opin Drug Metab Toxicol.* 2024; 16:1-12.
- 3) Abela I, Chammartin F, Amstutz A, Surial B, Ballif M, **Marzolini C**, Aebi-Popp K, Notter J, Segeral O, Stoeckle M, Cavassini M, Bernasconi E, Günthard HF, Kouyos R, Pasin C and the Swiss HIV Cohort Study. Gender disparities in statins prescriptions in people with HIV with low/moderate to high cardiovascular risk. *Open Forum Infectious Diseases.* 2024; 11(9):ofae502.
- 4) Bongiovanni M, Thoueille P, Barda B, Mercier T, **Marzolini C**, Ramponi N, Choong E, Cantu M, Decosterd LA, Bernasconi E. Oritavancin use in patients with recurrent bone infections by methicillin-resistant *Staphylococcus aureus* with monitoring of concentrations. *Eur J Clin Microbiol Infect Dis.* 2024; 43(7):1503-1504.
- 5) Thoueille P, Alves Saldanha S, Schaller F, Choong E, Veuve F, Munting A, Cavassini M, Braun D, Günthard H, Duran Ramirez J, Surial B, Furrer H, Rauch A, Ustero P, Calmy A, Stoeckle M, Di Benedetto C, Bernasconi E, Schmid P, **Marzolini C**, Girardin FR, Buclin T, Decosterd LA, Guidi M, on behalf of the Swiss HIV Cohort Study. Population pharmacokinetic of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV. *Front Pharmacol.* 2024 [epub ahead of print].

- 6) Thoueille P, Alves Saldanha S, Schaller F, Choong E, Veuve F, Munting A, Cavassini M, Braun D, Gunthard H, Kusejko K, Surial B, Furrer H, Rauch A, Ustero P, Calmy A, Stoeckle M, Di Benedetto C, Bernasconi E, Schmid P, **Marzolini C**, Girardin FR, Buclin T, Decosterd LA, Guidi M, on behalf of the Swiss HIV Cohort Study. Population pharmacokinetic modelling of cabotegravir following oral administration and long-acting intramuscular injection in real-world people with HIV. *Clin Pharmacol Ther.* 2024; 115(6):1450-1459.
- 7) Berton M, Stader F, Bettonte S, Battegay M, **Marzolini C**. Ideal time to conduct a pharmacokinetic investigation after delivery in order to fully capture the effect of pregnancy on drug exposure. *Open Forum Infect Dis.* 2024; 11(10):ofae585.
- 8) Briki M, Murisier A, Guidi M, Seydoux C, Buclin T, **Marzolini C**, Girardin FR, Thoma Y, Carrara S, Choong E, Decosterd LA. Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) methods for the therapeutic drug monitoring of cytotoxic anticancer drugs: an update. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2024; 1236:124039.
- 9) Ambrosioni J, Diaz NA, **Marzolini C**, Dragovic G, Imaz A, Calcagno A, Luque S, Curran A, Troya J, Tuset M, Khoo S, Burger D, Cortes CP, Naous N, Molto J. Outcomes of drug interactions between antiretrovirals and co-medications, including over-the-counter drugs: a real-world study. *Infect Dis Ther.* 2024; 13(3):609-17.
- 10) Haefliger D, Rodriguez-Veiga V, Livio F, Diezi L, **Marzolini C**, Chehade H. Case report: optimization of vancomycin dosing strategy for the treatment of peritonitis in a child on automated peritoneal dialysis using therapeutic drug monitoring. *Semin Dial.* 2024 [epub ahead of print].
- 11) Thoueille P, Cavassini M, Guidi M, Buclin T, Girardin FR, Decosterd LA, **Marzolini C**. Guidance for the interpretation of long-acting concentrations based on real-world TDM data and documented failures. *Open Forum Infectious Diseases.* 2024; 11(2):ofae023.
- 12) Bettonte S, Berton M, Stader F, Battegay M, **Marzolini C**. Effect of obesity on the exposure of long-acting cabotegravir and rilpivirine: a modelling study. *Clin Infect Dis.* 2024 [epub ahead of print]
- 13) Damas J, Munting A, Fellay J, Haerry D, **Marzolini C**, Tarr PE, Steffen A, Brain DL, Stoeckle M, Bernasconi E, Calmy A, Fux CA, Darling KA, Böguelin C, Wandeler G, Cavassini M, Surial B and the Swiss HIV Cohort Study. Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide (TAF) in people with HIV . *Clin Infect Dis.* 2024; 79(4):990-998.
- 14) Thoueille P, Delarive L, Cavassini M, Buclin T, Decosterd LA, **Marzolini C**, Girardin FR, Guidi M, on behalf of the Swiss HIV Cohort Study. Population pharmacokinetic analysis of doravirine in real-world people with HIV. *Br J Clin Pharmacol.* 2023; 90(4):1058-65.
- 15) Bettonte S, Berton M, Stader F, Battegay M, **Marzolini C**. Drug exposure of long-acting cabotegravir and rilpivirine in elderly individuals: a modelling study. *Open Forum Infect Dis.* 2024; 11(4):ofae171.
- 16) Pham T, Ghafoor M, Granana-Castillo S, **Marzolini C**, Gibbons S, Khoo S, Chiong J, Wang D, Siccardi M. DeepARV: ensemble deep learning to predict drug-drug interaction of clinical relevance with antiretroviral therapy. *NPJ Syst Biol Appl.* 2024; 10(1):48.
- 17) Ambrosioni J, Levi L, Alagaratnam J, van Bremen K, Mastrangelo A, Waalewijn H, Molina JM, Guaraldi G, Winston A, Boesecke C, Cinque P, Bamford A, Calmy A, **Marzolini C**, Martinez E, Oprea C, Welch S, Koval A, Mendao L, Rockstroh JK, the EACS Governing Board. Major revision version 12.0 of the European AIDS Clinical Society Guidelines 2023. *HIV Medicine.* 2023; 24(11):1126-36.

- 18) Thoueille P, Alves Saldanha S, Schaller F, Choong E, Munting A, Cavassini M, Braun D, Günthard HF, Kusejko K, Surial B, Furrer H, Rauch A, Rougemont M, Ustero P, Calmy A, Stockle M, **Marzolini C**, Di Benedetto C, Bernasconi E, Schmid P, Piso RP, Andre P, Guidi M, Buclin T, Decosterd LA. Real-world plasma trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland. *Lancet Reg Health Eur*. 2023; 36:1000793.
- 19) Berton M, Bettonte S, Stader F, Decosterd L, Tarr P, Livio F, Cavassini M, Braun D, Kusejko K, Hachfeld A, Bernasconi E, Calmy A, Schmid P, Battegay M, **Marzolini C**. Antiretroviral drugs exposure and response in obese and morbidly obese people with HIV: a study combining modelling and Swiss HIV Cohort data. *Clin Infect Dis*. 2024; 78(1):98-110.
- 20) Bettonte S, Berton M, Battegay M, Stader F, **Marzolini C**. Development of a physiologically based pharmacokinetic model to simulate the pharmacokinetics after intramuscular drug administration. *Pharmacometrics & Systems Pharmacology*. 2024; 13(5):781-94.
- 21) Bettonte S, Berton M, **Marzolini C**. What is the significance of the pharmacokinetic profile and potential drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine. *Expert Opin Drug Metab Toxicol*. 2023; 19(5):243-47.
- 22) Berton M, Bettonte S, Stader F, Battegay M, **Marzolini C**. Impact of obesity on the drug-drug interaction between dolutegravir and rifampicin or any other strong inducers. *Open Forum Infectious Diseases*. 2023; 10(7):ofad361.
- 23) Sebastiani G, Milic J, Tsochatzis EA, **Marzolini C**, Betel M, Bhagani S, Morse CG, Cinque F, Maurice JB, Ingiliz P, Price J, Lemoine M, Rockstroh JK, Guaraldi G on behalf of the Steatohepatitis in HIV Emerging Research (SHIVER) Network. Letter to the Editor: People living with HIV and NAFLD: a population left behind in the global effort for liver fibrosis screening? *Hepatology*. 2023; 78(5):E87-E88.
- 24) **Marzolini C**, Cavassini M, Braun D, Hachfeld A, Bernasconi E, Calmy A, Schmid P, Battegay M, Elzi L and the Swiss HIV Cohort Study. Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor containing regimen. *Br J Clin Pharmacol*. 2023; 89(9):2739-46.
- 25) Erba A, **Marzolini C**, Rentsch K, Stoeckle M, Battegay M, Mayr M, Weisser M. Switch from a ritonavir to a cobicistat containing antiretroviral regimen and impact on tacrolimus levels in a kidney transplant recipient. *Virology J*. 2023;20(1):89.
- 26) Bettonte S, Berton M, Stader F, Battegay M, **Marzolini C**. Management of drug interactions with inducers: onset and disappearance of induction on CYP3A4 and UGT1A1 substrates. *Eur J Drug Metab Pharmacokinet*. 2023;48(4):353-362.
- 27) Schwenke JM, Thorball CW, Schoepf IC, Ryom L, Hasse B, Lamy O, Calmy A, Wandeler G, **Marzolini C**, Kahlert CR, Bernasconi E, Kouyos R, Günthard HF, Ledergerber B, Fellay J, Burkhalter F, Tarr PE for the Swiss HIV Cohort Study. Association of a polygenic risk score with osteoporosis in people living with HIV: the Swiss HIV Cohort Study. *J Infect Dis*. 2023;228(6):742-750.
- 28) Haefliger D, **Marzolini C**, Lamoth F, Pabst T, Buclin T, Livio F. Clinically relevant bidirectional drug-drug interaction between midostaurin and voriconazole. *Br J Clin Pharmacol*. 2023;89(7):2304-08.
- 29) Schoepf IC, Esteban-Cantos A, Thorball CW, Rodes B, Reiss P, Rodriguez-Centeno J, Riebensahm C, Braun DL, **Marzolini C**, Seneghini M, Bernasconi E, Cavassini M, Buvelot H, Thurnheer MC, Kouyos RD, Fellay J, Günthard HF, Arribas JR, Ledergerber B, Tarr PE and the Swiss HIV Cohort Study. Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV: a longitudinal study over >17 years. *Lancet Healthy Longev*. 2023;4(5):e211-218.

- 30) Bettonte S, Berton M, Stader F, Battegay M, **Marzolini C**. Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz containing regimen. *Br J Clin Pharmacol*. 2023;89(12):3618-28.
- 31) **Marzolini C**, Khoo S. Response to “ a case report of safe co-administration of amiodarone with short-term treatment nirmatrevir/ritonavir”. *Clin Pharmacol Ther*. 2023;113(4):770.
- 32) Bettonte S, Berton M, Stader F, Battegay M, **Marzolini C**. Management of drug-drug interactions between long-acting cabotegravir and rilpivirine and comedications with inducing properties: a modelling study. *Clin Infect Dis*. 2023;76(7):1225-1236.
- 33) Berton M, Bettonte S, Stader F, Battegay M, **Marzolini C**. Physiologically based pharmacokinetic modelling to identify physiological and drug parameters driving pharmacokinetics in obese individuals. *Clin Pharmacokinet*. 2023;62(2):277-295.
- 34) Jakeman B, Scherrer AU, Darling KEA, Damas J, Bieler-Aeschlimann M, Hasse B, Schlosser L, Hacheld A, Gutbrod K, Tarr PE, Calmy A, Assal F, Kunze U, Stoeckle M, Schmid P, Toller G, Rossi S, Di Benedetto C, Du Pasquier R, Cavassini M, **Marzolini C** for the NAMACO study group, a Swiss HIV Cohort Study. Anticholinergic and sedative medications are associated with neurocognitive performance of well-treated people living with HIV. *Open Forum Infect Dis*. 2022;9(9):ofac457.
- 35) Avery EF, Kleynhans JN, Ledergerber B, Schoepf IC, Thorball CW, Kootstra NA, Reiss P, Ryom L, Braun DL, Thrnheer MC, **Marzolini C**, Seneghini M, Bernasconi E, Cavassini M, Buvelot H, Kouyos D, Fellay J, Gunthard HF, Tarr PE for the Swiss HIV Cohort Study. Leukocyte count and coronary artery disease events in persons living with HIV: a longitudinal study. *Clin Infect Dis*. 2023;76(11):1969-79.
- 36) Thoueille P, Alves Saldanha S, Schaller F, Munting A, Cavassini M, Braun D, Gunthard HF, Kusejko K, Surial B, Furrer H, Rauch A, Ustero P, Calmy A, Stoeckle M, Battegay M, **Marzolini C**, Andre P, Guidi M., Buclin T, Decosterd LA and the Swiss HIV Cohort Study. Real-life therapeutic concentration monitoring of long-acting cabotegravir and rilpivirine: preliminary results of an ongoing prospective observational study in Switzerland. *Pharmaceutics*. 2022;14(8):1588.
- 37) Aebi-Popp K, Crisinel PA, Decosterd L, Saldanha SA, Hoesli I, Martinez de Tejada B, Kahlert CR, Duppenenthaler A, Rauch A, **Marzolini C** for the Swiss HIV Mother and Child HIV Cohort Study. Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study. *J Antimicrob Chemother*. 2022;77(12):3436-42.
- 38) Hodge D, Hodel EM, Hughes E, Hazenberg P, Granana-Castillo S, Gibbons S, Wang D, Marra F, **Marzolini C**, Back D, Khoo S. Prevalence of potentially clinically significant drug-drug interactions with antiretrovirals against HIV over three decades: a systematic review of the literature. *J Acquir Immun Defic*. 2023;92(2):97-105.
- 39) Bettonte S, Berton M, **Marzolini C**. Magnitude of drug-drug interactions in special populations. *Pharmaceutics*. 2022;14(4):789
- 40) Girardin F, Oriol M, **Marzolini C**, Buclin T. Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent progression to severe COVID-19. *Clin Microbiol Infect*. 2022;28(8):1044-1046.
- 41) Berton M, Bettonte S, Stader F, Battegay M, **Marzolini C**. Repository describing the anatomical, physiological, and biological changes in an obese population to inform physiologically based pharmacokinetic models. *Clin Pharmacokinet*. 2022;61(9):1251-70.
- 42) **Marzolini C\***, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, Pozniak A, Boffito M, Waters L, Burger D, Back DJ, Khoo S. Prescribing nirmatrelvir/ritonavir (Paxlovid): how to recognize and manage drug-drug interactions. *Annals Intern Med*. 2022;175(5):744-746.\*corresponding author.

- 43) **Marzolini C\***, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, Pozniak A, Boffito M, Waters L, Burger D, Back DJ, Khoo S. Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir/ritonavir (Paxlovid) and comedications. *Clin Pharmacol Ther.* 2022; 112(6):1191-1200.\*corresponding author. Most downloaded article in *Clin Pharmacol Ther* in 2022.
- 44) **Marzolini C\***, Marra F, Boyle A, Khoo S, Back DJ. Fluvoxamine for the treatment of COVID-19: awareness of drug-drug interactions. *Lancet Global Health.* 2022;10(3):e331.\*corresponding author.
- 45) Otten LS, Piet B, van den Heuvel MM, **Marzolini C**, van Geel RMJM, Gulikers JL, Burger DM, Leentjes J, ter Heine R. Practical recommendations to combine small molecule inhibitors and direct oral anticoagulants in patients with non-small cell lung cancer. *Eur Respir Rev.* 2022;31(164):220004.
- 46) Franchini F, Kusejko K, **Marzolini C**, Tellenbach C, Rossi S, Stamf S, Koller M, Stoyanov J, Moller B, Leichtle AB. Collaborative challenges of multi-cohort project in pharmacogenetics – Why time is essential for meaningful collaborations. *JMIR Form Res.* 2022;6(9):e36759.
- 47) Zino L, Kingma JS, **Marzolini C**, Richel O, Burger DM, Colbers A. Implications of bariatric surgery on the pharmacokinetics of antiretroviral agents in people living with HIV. *Clin Pharmacokinet.* 2022;61(5):619-635.
- 48) Ryom L, De Miguel R, Cotter AG, Podlekareva D, Beguelin C, Waakewijn H, Arribas JR, Mallon PGM, **Marzolini C**, Kirk O, Bamford A, Rauch A, Molina JM, Kowalska JD, Guaraldi G, Winston A, Boesecke C, Cinque P, Welch S, Collins S, Behrens GMN on behalf of the EACS Governing Board. Major Revision Version 11.0 of the European AIDS Clinical Society Guidelines 2021. *HIV Medicine.* 2022;23(8):849-858.
- 49) Allavena C, **Marzolini C**. Polypharmacy and risk of admission to hospital in people ageing with HIV: what is the contribution of drug-drug interactions? *Lancet Healthy Longev.* 2021:e606.
- 50) Schoepf IC, Thorball CW, Ledergerber B, Kootstra NA, Reiss P, Raffenberg M, Engel T, Braun D, Hasse B, Thurnheer C, **Marzolini C**, Seneghini M, Bernasconi E, Cavassini M, Buvelot H, Arribas JR, Kouyos RD, Fellay J, Gunthard HF, Tarr PE and the Swiss HIV Cohort Study. Telomere length declines in persons living with HIV before antiretroviral therapy start but not after viral suppression: a longitudinal study over >17 years. *J Infect Dis.* 2022;225(9):1581-91.
- 51) Jakeman B, Scherrer A, Battegay M, Günthard H, Hachfeld A, Calmy A, Schmid P, Bernasconi E, Cavassini M, **Marzolini C\*** for the Swiss HIV Cohort Study. Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study. *J Antimicrob Chemother.* 2022;77(2):492-99. \*corresponding author
- 52) **Marzolini C\***, Gibbons S, van Oosterhout J, Khoo S. Drug-drug interaction potential with once-weekly rifapentine/isoniazid (3HP) for the treatment of latent tuberculosis infection. *Clin Pharmacokinet.* 2022;61:339-46. \*corresponding author
- 53) Stader F, **Marzolini C\***. Sex-related pharmacokinetic differences with aging. *Eur Geriatr Med.* 2021;13(3):559-565. \*corresponding author
- 54) Jacobs TG, **Marzolini C**, Back DJ, Burger DM. Dexamethasone is a dose dependent perpetrator: implications for use in people living with HIV. *J Antimicrob Chemother.* 2022;77(3):568-73.
- 55) Hollinger A, Cueni N, **Marzolini C**, Dickenmann M, Landmann E, Battegay M, Martinez AE, Siegemund M, Leuppi-Taegtmeier A. Lactic acidosis and hyperlactatemia associated with lamivudine accumulation and sepsis in a kidney transplant recipient – A case report and review of the literature. *AIDS Res Ther.* 2021;18(1):56.

- 56) Kuemmerle A, Sikalengo G, Vanobberghen F, Ndege RC, Foe G, Schlaeppi C, Burri C, Battegay M, Paris DH, Glass TR, Weisser M, **Marzolini C\*** on behalf of the KIULARCO study group. Recognition and management of clinically significant drug-drug interactions between antiretrovirals and co-medications in a cohort of people living with HIV in rural Tanzania: a prospective questionnaire-based study. *J Antimicrob Chemother.* 2021;76(10):2681-89. \*corresponding author
- 57) Schoepf IC, Thorball CW, Ledergerber B, Engel T, Raffenberg M, Kootstra NA, Reiss P, Hasse B, **Marzolini C**, Thurnheer C, Seneghini M, Bernasconi E, Cavassini M, Buvelot H, Kouyos R, Gunthard HF, Fellay J, Tarr PE and the Swiss HIV Cohort Study. Coronary artery disease-associated and longevity-associated polygenic risk scores for prediction of coronary artery disease events in persons living with HIV: the Swiss HIV Cohort Study. *Clin Infect Dis.* 2021;73(9):1597-1604.
- 58) Stader F, Battegay M, Sendi P, **Marzolini C**. Physiologically based pharmacokinetic modelling to investigate the impact of the cytokine storm on CYP3A drug pharmacokinetics in COVID-19 patients. *Clin Pharmacol Ther.* 2022;113(3):579-84.
- 59) Istampoulouoglou I, Zimmermanns B, Grandinetti T, **Marzolini C**, Harings-Kaim A, Koechlin-Lemke S, Scholz I, Bassetti S, Leuppi-Taegtmeyer AB. Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: cases from a single pharmacovigilance centre. *Global Cardiol Science Practice.* 2021:e202111.
- 60) Mari A, Roloff TC, Stange M, Sogaard KK, Asllanaj E, Tauriello G, Alexander LT, Schweitzer M, Leuzinger K, Gensch A, Martinez AE, Bielicki J, Pargger H, Siegemund M, Nickel CH, Bingisser R, Osthoff M, Bassetti S, Sendi P, Battegay M, **Marzolini C**, Seth-Smith HMB, Schwede T, Hirsch HH, Egli A. Global genomic analysis of SARS-CoV-2 RNA dependent polymerase evolution and antiviral drug resistance. *Microorganisms.* 2021;9(5):1094.
- 61) Hodge CE, Back DJ, Gibbons S, Khoo SH, **Marzolini C\***. Pharmacokinetics and drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine. *Clin Pharmacokinet.* 2021;60(7):835-53. \*corresponding author
- 62) **Marzolini C\***, Stader F, Leuppi-Taegtmeyer A, Stoeckle M, Battegay M, Sendi P. Sex differences in lopinavir levels and occurrence of marked QTc prolongation episodes in COVID-19 patients. *Drug Safety.* 2021;44(2):255-257. \*corresponding author
- 63) Livio F, Deutschmann E, Moffa G, Rrustemi F, Stader F, Elzi L, Braun D, Calmy A, Hachfeld A, Cavassini M, Tarr P, Wissel K, Battegay, **Marzolini C\*** and the Swiss HIV Cohort Study. Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity. *J Antimicrob Agents.* 2021;76(3):758-764 \*corresponding author. Article selected by editor of JAC (editor's choice).
- 64) Stader F, Battegay M, **Marzolini C**. Physiologically based pharmacokinetic modelling to support the clinical management of DDIs with bictegravir. *Clin Pharmacol Ther.* 2021;110(5):1231-1239.
- 65) Scherrer AU, Traytel A, Braun DL, Calmy A, Battegay M, Cavassini M, Furrer H, Schmid P, Bernasconi E, Stoeckle M, Kahlert C, Trkola A, Kouyos RD, Tarr P, **Marzolini C**, Wandeler G, Fellay J, Bucher H, Yerly S, Suter F, Hirsch H, Huber M, Dollenmaier G, Perreau M, Martinetti G, Rauch A, Günthard HF and the Swiss HIV Cohort Study. Cohort profile update: The Swiss HIV Cohort Study (SHCS). *Int J Epidemiol.* 2022;51(1):33-34j.
- 66) **Marzolini C\***, Battegay M, Sendi P, Back DJ. Prescribing in COVID19 patients: should we take into account inflammation? *Br J Clin Pharmacol.* 2021;87(3):719-721. \* corresponding author
- 67) **Marzolini C\***, Stader F, Stoeckle M, Franzeck F, Egli A, Bassetti S, Hollinger A, Osthoff M, Weisser M, Gebhard CE, Baettig V, Geenen J, Khanna N, Tschudin-Sutter S, Mueller D, Hirsch HH, Battegay M, Sendi P. Effect of systemic inflammatory response to SARS-CoV-2 on lopinavir and

hydroxychloroquine plasma concentrations. *Antimicrob Agents Chemother.* 2020;64(9):e01177-20. \* corresponding author

- 68) Marra F, Smolders E, El-Sherif O, Boyle A, Davidson K, Sommerville AJ, **Marzolini C**, Siccardi M, Burger D, Gibbons S, Khoo S, Back DJ. Recommendations for dosing of repurposed COVID-medications in patients with renal and hepatic impairment. *Drugs in R&D.* 2021;21(1):9-27.
- 69) Courlet P, Guidi M, Alves Saldanha S, Stader F, Traytel AK, Cavassini M, Stoeckle M, Buclin T, **Marzolini C**, Decosterd LA, Csajka C and the Swiss HIV Cohort Study. Pharmacokinetic/pharmacodynamic modelling to describe the cholesterol lowering effect of rosuvastatin in people living with HIV. *Clin Pharmacokinet.* 2021;60(83):379-90.
- 70) Stader F, Courlet P, Decosterd LA, Battegay M, **Marzolini C**. Physiologically based pharmacokinetic modelling combined with Swiss HIV Cohort Study data supports no dose adjustment of bicittegravir in elderly individuals living with HIV. *Clin Pharmacol Ther.* 2021;109(4):1025-29.
- 71) Back D, **Marzolini C**, Hodge C, Marra F, Boyle A, Gibbons S, Burger D, Khoo S. COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions. *Br J Clin Pharmacol.* 2021;87(1):212-213.
- 72) Stader F, Khoo S, Stoeckle M, Back DJ, Hirsch HH, Battegay M, **Marzolini C**. Stopping lopinavir/ritonavir in COVID-19 patients: Duration of the drug interacting effect. *J Antimicrob Chemother.* 2020;75(10):3084-6.
- 73) Hodge CE, Marra F, **Marzolini C**, Boyle A, Gibbons S, Siccardi M, Burger D, Back D, Khoo S. Drug interactions: a review of the unseen danger of experimental COVID19 therapies. *J Antimicrob Chemother.* 2020;75(12):3417-3424.
- 74) Deutschmann E, Bucher HC, Jaekel S, Gibbons S, McAllister K, Scherrer A, Braun D, Cavassini M, Hachfeld H, Calmy A, Battegay M, Cipriani M, Elzi L, Young J, Lopez-Centeno B, Berenguer J, Khoo S, Moffa G, **Marzolini C** and the Swiss HIV Cohort Study. Prevalence of potential drug-drug interactions in patients of the Swiss HIV Cohort Study in the era of HIV integrase inhibitors. *Clin Infect Dis.* 2021;73(7):2145-52.
- 75) Courlet P, Guidi M, Alves Saldanha S, Cavassini M, Stoeckle M, Buclin T, **Marzolini C**, Decosterd L, Csajka C. Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs. *Eur J Clin Pharmacol.* 2021;77(7):979-87.
- 76) Lopez-Centeno B, Badenes-Olmedo C, Mataix-Sanjuan A, Bellon JM, Perez-Latorre L, Lopez JC, Benedi J, Khoo S, **Marzolini C**, Calvo-Alcantara MJ, Berenguer J. Potentially inappropriate medications in older adults living with HIV. *HIV Medicine.* 2020;21(8):541-6.
- 77) Courlet P, Alves Saldanha S, Cavassini M, **Marzolini C**, Choong E, Csajka C, Gunthard HF, Andre P, Buclin T, Desfontaine V, Decosterd LA. Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bicittegravir, cabotegravir, doravirine and rilpivirine in plasma of people living with HIV. *J Mass Spectrom.* 2020;55(6):e4506.
- 78) Bukkems VE, Colbers A, **Marzolini C**, Molto J, Burger DM. Drug-drug interactions with antiretroviral drugs in pregnant women living with HIV: are they different from non-pregnant subjects? *Clin Pharmacokinet.* 2020;59(10):1217-36.
- 79) Courlet P, Livio F, Alves Saldanha S, Scherrer A, Battegay M, Cavassini M, Stoeckle M, Decosterd LA, **Marzolini C\*** and the Swiss HIV Cohort Study. Real-life management of drug-drug interactions between antiretrovirals and statins. *J Antimicrob Chemother.* 2020;75(7):1972-1980. \* corresponding author.

- 80) Burger DM, Calmy A, **Marzolini C**. Cobicistat: a case of mislabeled drug-drug interaction risk? *B J Clin Pharmacol* 2020;86:834-836.
- 81) Ryom L, Cotter A, Buckley RDM, Béguelin C, Podlekareva D, Arribas J, **Marzolini C**, Mallon PGM, Rauch A, Kirk O, Molina JM, Guaraldi G, Winston A, Bhagani S, Cinque P, Kowalska J, Collins S, Battegay M on behalf of the EACS Governing Board. 2019 update of the European AIDS Clinical Society (EACS) Guidelines for treatment of people living with HIV (PLWHV) version 10.0. *HIV Medicine*. 2020;21(10):617-24.
- 82) Stader F, Courlet P, Kinvig H, Penny MA, Decosterd LA, Battegay M, Siccardi M, **Marzolini C**. Clinical data combined with modelling and simulation indicate unchanged drug-drug interaction magnitudes in the elderly. *Clin Pharmacol Ther*. 2021;109(2):471-484.
- 83) Roth JA, Radevski G, **Marzolini C**, Rauch A, Günthard HF, Kouyos RD, Fux CA, Scherrer AU, Calmy A, Cavassini M, Kahlert CR, Bernasconi E, Bogojeska J, Battegay M. Cohort-derived machine learning models for individual prediction of chronic kidney disease in people living with HIV: a prospective multicenter cohort study. *J Infect Dis*. 2021;224(7):1198-1208.
- 84) Guaraldi G, Maurice J, **Marzolini C**, Monteith K, Milic J, Tsochatzis E, Bhagani S, Morse CG, Price JC, Ingiliz P, Lemoine M, Sebastiani G; SHIVER Network. New drugs for NASH and HIV infection: Great expectations for a great need. *Hepatology*. 2020;71:1831-44.
- 85) Courlet P, Decosterd LA, Alves Saldanha S, Cavassini M, Stader S, Stoeckle M, Buclin T, **Marzolini C**, Csajka C, Guidi M and the Swiss HIV Cohort Study. Influence of drug-drug interactions on the pharmacokinetics of atorvastatin and its major active metabolite ortho-OH-atorvastatin in aging people living with HIV. *Clin Pharmacokinet*. 2020;59:1037-1048.
- 86) Courlet P, Livio F, Guidi M, Cavassini M, Battegay M, Stoeckle M, Buclin T, Alves Saldanha S, Csajka C, **Marzolini C\*\***, Decosterd L and the Swiss HIV Cohort Study. Polypharmacy, inappropriate drugs and drug-drug interactions in people living with HIV. *Open Forum Infect Dis*. 2019;6(12):ofz531. \*\*equal last author contribution.
- 87) Stader F, Decosterd L, Stoeckle M, Cavassini M, Battegay M, Alves Saldanha S, **Marzolini C**, Courlet P and the Swiss HIV Cohort Study. Aging does not impact drug-drug interaction magnitudes with antiretrovirals: a Swiss HIV Cohort Study. *AIDS* 2020;34(6):949-952.
- 88) Stader F, Courlet P, Kinvig H, Battegay M, Decosterd LA, Penny MA, Siccardi M, **Marzolini C**. Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation. *Br J Clin Pharmacol* 2021;87(2):458-70.
- 89) Back DJ, **Marzolini C**. The challenge of HIV treatment in an era of polypharmacy. *J Int AIDS Soc*. 2020;23:e25449.
- 90) Courlet P, Stader F, Guidi M, Alves Saldanha SA, Stoeckle M, Cavassini M, Battegay M, Buclin T, Decosterd LA, **Marzolini C**. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging patients enrolled in the Swiss HIV Cohort Study. *AIDS*. 2020;34:103-108. \* corresponding author
- 91) Schlaeppi C, Vanobberghen F, Sikalengo G, Glass TR, Ndege RC, Foe G, Kuemmerle A, Paris D, Battegay, **Marzolini C**, Weisser M on behalf of the KIULARCO study group. Prevalence and management of drug-drug interactions with antiretroviral treatment in 2069 people living with HIV in rural Tanzania. A prospective cohort study. *HIV Medicine*. 2020;21(1):53-63.
- 92) Courlet P, Spaggiari D, Desfontaine V, Cavassini M, Alves Saldanha S, Buclin T, **Marzolini C**, Csajka C, Decosterd L. UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV. *J Chromatogr B*. 2019;1125:121733.

- 93) Lopez-Centeno B, Badenes-Olmedo C, Mataix-Sanjuan A, McAllister K, Bellon JM, Gibbons S, Balsalobre P, Perez-Latorre L, Benedi J, **Marzolini C**, Aranguren-Oyarzabal A, Khoo S, Calvo-Alcantara MF, Berenguer J. Polypharmacy and drug-drug interactions in HIV infected subjects in the region of Madrid, Spain: a population-based study. *Clin Infect Dis*. 2020;71(2):353-62.
- 94) Stader F, Kinvig H, Penny MA, Battegay M, Siccardi M, **Marzolini C**. Physiologically based pharmacokinetic modelling to identify pharmacokinetic parameters driving drug exposure changes in the elderly. *Clin Pharmacokinet*. 2020;59(3):383-401.
- 95) Boyle A, Moss CE, **Marzolini C**, Khoo S. Clinical pharmacodynamics, pharmacokinetics and drug interaction profile of doravirine. *Clin Pharmacokinet*. 2019;58(12):1553-1565.
- 96) Livio F, **Marzolini C\***. Prescribing issues in elderly individuals living with HIV: thinking beyond drug-drug interactions with antiretroviral drugs. *Ther Adv Drug Saf*. 2019;10:1-7. \* corresponding author
- 97) Sundermann EE, Erlandson KM, Pope C, Rubtsova A, Montoya J, Moore A, **Marzolini C**, O'Brien K, Pahwa S, Payne B, Rubin LH, Walmsley S, Haughey NJ, Montano M, Margolick J, Moore DJ. Current challenges and solutions in research and clinical care of the older persons living with HIV: findings presented at the 9<sup>th</sup> International Workshop of HIV and Aging. *AIDS Res Hum Retroviruses*. 2019;35(11/12):985-998.
- 98) **Marzolini C\***, Livio F. Prescribing issues in elderly individuals living with HIV. *Expert Rev Clin Pharmacol*. 2019;12:643-659. \* corresponding author
- 99) Courlet P, Guidi M, Glatard A, Alves Saldanha S, Cavassini M, Buclin T, **Marzolini C**, Eap CB, Decosterd L, Csajka C and the Swiss HIV Cohort Study. Escitalopram population pharmacokinetics in people living with HIV and psychiatric population: drug-drug interactions and probability of target attainment. *Br J Clin Pharmacol*. 2019;85(9):2022-2032.
- 100) Courlet P, Decosterd LA, Brown JA, Alves Saldanha S, **Marzolini C**, Cavassini M, Stoeckle M, Csajka C, Labhardt N, Calmy A and the Swiss HIV Cohort Study. Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence. *J Antimicrob Chemother*. 2019;74:2468-2470.
- 101) Brockhaus L, Goldblum D, Eggenschwiler L, Zimmerli S, **Marzolini C**. Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration of systemic antibiotics. *Clin Microbiol Infect*. 2019;25(11):1364-1369.
- 102) Ruffieux Y, Lemsalu L, Aebi-Popp K, Calmy A, Cavassini M, Fux C, Günthard H, **Marzolini C**, Scherrer A, Vernazza P, Keiser O, Egger M for the Swiss HIV Cohort Study. Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017. *J Int AIDS Soc*. 2019; 22(8):e25339.
- 103) Stader F, Penny M, Siccardi M, **Marzolini C**. A comprehensive framework for physiologically based pharmacokinetic modelling in Matlab. *CPT Pharmacometrics Syst Pharmacol*. 2019;8:444-459.
- 104) Hodel EM, **Marzolini C**, Waitt C, Rakhmanina N. Pharmacokinetics, placental and breastmilk transfer of antiretroviral drugs in pregnant and lactating women living with HIV. *Curr Pharm Des*. 2019;25:556-576.
- 105) Stader F, Siccardi M, Battegay M, Kinvig H, Penny MA, **Marzolini C**. Repository describing an aging population to inform physiologically based pharmacokinetic models considering anatomical, physiological and biological age-dependent changes. *Clin Pharmacokinet*. 2019;58:483-501.

- 106) Baettig V, Courlet P, Delko T, Battegay M, **Marzolini C\***. Boosted darunavir, emtricitabine and tenofovir pharmacokinetics in the early and late post-gastric bypass surgery periods. *AIDS*. 2018;32:1903-1905. \*corresponding author
- 107) Stader F, Kinvig H, Battegay M, Khoo S, Owen A, Siccardi M, **Marzolini C\***. Analysis of clinical drug-drug interaction data to predict uncharacterized interaction magnitudes between antiretroviral drugs and co-medications. *Antimicrob Agents Chemother*. 2018;62:e00717-18. \*corresponding author
- 108) Ryom L, Boesecke C, Bracchi M, Ambrosioni J, Pozniak A, Arribas J, Behrens G, Mallon PGM, Puoti M, Rauch A, Miro JM, Kirik O, **Marzolini C**, Lundgren JD, Battegay M. Highlights of the 2017 European AIDS Clinical Society Guidelines for the treatment of adult HIV positive persons Version 9.0. *HIV Med*. 2018;19:309-315.
- 109) Engel T, Raffenberg M, **Marzolini C**, Cavassini M, Kovari H, Hasse B, Tarr PE. HIV and Aging – perhaps not quite as bad as we feared?. *Gerontology*. 2018;15:1-11
- 110) Courlet P, Spaggiari D, Cavassini M, Du Pasquier R, Alves Saldanha S, Buclin T, **Marzolini C**, Csajka C, Decosterd L. Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry. *Clinical Mass Spectrometry*. 2018;8:8-20.
- 111) Bartels H, Decosterd L, Battegay M, **Marzolini C\***. Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir. *J Antimicrob Chemother*. 2017; 72:2574-2577. \*corresponding author
- 112) **Marzolini C\***, Decosterd L, Winterfeld U, Tissot F, Francini K, Buclin T, Livio F. Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum. *Br J Clin Pharmacol*. 2017; 83:2835-2838. \* corresponding author
- 113) Piso R, Battegay M, **Marzolini C**. Dolutegravir plasma levels after gastric bypass surgery. *AIDS*. 2017; 31:1052-1054.
- 114) Seden K, Gibbons S, **Marzolini C**, Schapiro JM, Burger DM, Back DJ, Khoo S. Development of an Evidence Evaluation and Synthesis System for Drug-Drug Interactions, and its Application to a Systematic Review of HIV and Malaria Co-infection. *PLoS One*. 2017; 12:e0173509.
- 115) Erb S, Letang E, Glass TR, Natamatungiro A, Mnzava D, Mapesi E, Haschke M, Duthalder U, Berger B, Muri L, Bader J, **Marzolini C**, Elzi L, Klimkait T, Langewitz W, Battegay M for the Kiularco Study Group. Health care provider communication training in rural Tanzania empowers HIV-infected patients on antiretroviral therapy to discuss adherence problems. *HIV Medicine*. 2017; 18:623-634.
- 116) **Marzolini C\***, Rajoli RK, Battegay M, Elzi L, Back D, Siccardi M. Physiologically based pharmacokinetic modeling to predict drug-drug interactions with efavirenz involving simultaneous inducing and inhibitory effects on cytochromes. *Clin Pharmacokinet*. 2017; 56:409-420. \* corresponding author
- 117) **Marzolini C\***, Gibbons S, Khoo S, Back D. Cobicistat versus ritonavir boosting and differences in the drug-drug interactions profile with co-medications. *J Antimicrob Chemother*. 2016; 71:1755-8. \* corresponding author
- 118) McLaren PJ, Raisaro JL, Aouri M, Rotger M, Ayday E, Bartha I, Delgado MB, Vallet Y, Gunthard H, Cavassini M, Furrer H, Lecompte T, **Marzolini C**, Schmid P, Di Benedetto C, Decosterd LA, Fellay J, Hubaux JP, Telenti A and the Swiss HIV Cohort Study. Privacy preserving pharmacogenetic testing in the clinic – a real-life implementation in HIV treatment. *Genetics in Medicine*. 2016; 18:814-22.

- 119) Moss DM, **Marzolini C**, Rajoli RKR, Siccardi M. Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies. *Expert Opin Drug Metab Toxicol.* 2015; 11:1203-17.
- 120) **Marzolini C\***, Sabin C, Raffi F, Siccardi M, Mussini C, Launay O, Burger D, Roca J, Fehr J, Bonora S, Mocroft A, Obel N, Dauchy FA, Zangerle R, Gogos C, Gianotti N, Ammassari A, Torti C, Ghosn J, Chêne G, Grarup J, Battegay M for the Efavirenz and Obesity Project Team on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment naive adults. *AIDS.* 2015; 29: 193-200. \* corresponding author
- 121) Hasse B, Iff M, Ledergerber B, Calmy A, Schmid P, Hauser C, Cavassini M, Bernasconi E, **Marzolini C**, Tarr P. Obesity trends and body mass index changes after starting antiretroviral treatment: the Swiss HIV Cohort Study. *Open Forum Infect Dis* 2014; 1 (2).
- 122) Kurz M, Stoeckle M, Krasniqi F, Battegay M, **Marzolini C\***. Etravirine: a good option for concomitant use with chemotherapy for Hodgkin's lymphoma. *Int J STD AIDS.* 2015; 26:212-214. \* corresponding author
- 123) Lakatos B, Stoeckle M, Elzi L, Battegay M, **Marzolini C\***. Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus. *Swiss Med Wkly.* 2014; 144:w13906. \* corresponding author
- 124) **Marzolini C\***, Mueller R, Li-Blatter X, Battegay M, Seelig A. The brain entry of HIV-1 protease inhibitors is facilitated when used in combination. *Mol Pharm.* 2013; 10:2340-2349. \* corresponding author
- 125) Siccardi M, **Marzolini C**, Seden K, Almond L, Kirov A, Khoo S, Owen A, Back D. Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. *Clin Pharmacokinet.* 2013; 52:583-92.
- 126) Lubomirov R, Arab-Alameddine M, Rotger M, Fayet-Mello A, Martinez R, di Iulio J, Cavassini M, Gunthard H, Furrer H, **Marzolini C**, Bernasconi E, Calmy A, Buclin T, Decosterd L, Csajka C, Telenti A and the Swiss HIV Cohort Study. Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. *Pharmacogenet Genomics.* 2013; 23:9-18.
- 127) **Marzolini C\***, Gray G. Maternal antiretroviral prophylaxis and breastfeeding. *Antivir Ther.* 2012; 17:1503-1506. \* corresponding author
- 128) de Roche, Siccardi M, Stoeckle M, Livio F, Back D, Battegay M, **Marzolini C\***. Efavirenz in an obese HIV-infected patient – case report and *in vitro in vivo* extrapolation model indicate risk of underdosing. *Antivir Ther.* 2012; 17:1381-1384. \* corresponding author
- 129) Siccardi M, Almond L, Schipani A, Csajka C, **Marzolini C**, Wyen C, Brockmeyer NH, Boffito M, Owen A, Back D. Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model. *Clin Pharm Ther.* 2012; 92:494-502.
- 130) Glass TR, Rotger M, Telenti A, Decosterd L, Bucher H, Rickenback M, Günthard H, Vernazza P, Hirschel B, Bernasconi E, Furrer H, Battegay M, **Marzolini C\*** and the Swiss HIV Cohort Study. Determinants of virological suppression in HIV positive patients on antiretroviral therapy with self-reported poor adherence. *PLoS One.* 2012; 7:e29186. \* corresponding author
- 131) Mossdorf E, **Marzolini C**, Fasel D, Mello Fayet A, Blum C, Donath M, Battegay M. Drug-drug interactions with HIV treatments. *Praxis (Bern 1994).* 2011; 100:1193-6.
- 132) **Marzolini C\***, Back D, Weber R, Furrer H, Cavassini M, Calmy A, Vernazza P, Bernasconi E, Khoo S, Battegay M, Elzi L and the Swiss HIV Cohort Study. Aging with HIV: medication use and

risk for potential drug-drug interactions. *J Antimicrob Chemother.* 2011; 66:2107-2111. \* corresponding author

- 133) **Marzolini C\***, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, Chave JP, Cavassini M, Bernasconi E, Calmy A, Vernazza P, Khoo S, Ledergerber B, Back DJ, Battegay M and the Swiss HIV Cohort Study. Prevalence of co-medications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. *AntivirTher.* 2010; 15:413-423. \* corresponding author
- 134) Lubomirov R, di Iulio J, Fayet A, Colombo S, Martinez R, **Marzolini C**, Furrer H, Vernazza P, Calmy A, Cavassini M, Ledergerber B, Rentsch K, Descombes P, Buclin T, Decosterd L, Csajka C, Telenti A. and the Swiss HIV Cohort Study. ADME pharmacogenetics – investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. *Pharmacogenetics and Genomics.* 2010; 20:217-30.
- 135) Elzi L, **Marzolini C**, Furrer H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Weber R, Battegay M. Treatment modification in HIV-infected individuals starting combination antiretroviral therapy between 2005-2008: rates, time point and regimen specific aspects. *Arch Intern Med.* 2010; 170:57-65.
- 136) Mertz D, Battegay M, **Marzolini C**, Mayr M. Drug-drug interaction in a kidney transplant recipient with HIV salvage therapy and tacrolimus. *Am J Kidney Dis.* 2009; 54:e1-4.
- 137) Krishnamurthy P, Schwab M, Takenaka K, Nachagari D, Morgan J, Leslie M, Du W, Boyd K, Cheek M, Nakauchi H, **Marzolini C**, Kim RB, Poonkuzhali B, Schuetz E, Evans W, Relling M, Schuetz JD: Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. *Cancer Res.* 2008; 68:4983-9.
- 138) **Marzolini C**, Tirona R, Gervasini G, Poonkuzhali B, Assem M, Lee W, Leake B, Schuetz J, Schuetz E, Kim RB: A common polymorphism in the bile acid receptor FXR is associated with decreased hepatic target gene expression. *Mol Endocrinol.* 2007; 21:1769-1780.
- 139) Ribaldo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, Clifford DB, **Marzolini C**, Fletcher CV, Tashima KT, Kuritzkes DR, Acosta EP. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an adult AIDS clinical trials group study. *Clin Infect Dis.* 2006; 42: 401-407.
- 140) Colombo S, Beguin A, **Marzolini C**, Telenti A, Biollaz J, Decosterd L. Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction. *J Chromatograph B.* 2006; 832: 138-143.
- 141) **Marzolini C**, Kim RB. Placental transfer of antiretroviral drugs. *Clin Pharm Ther.* 2005; 78: 118-122.
- 142) Fellay J, **Marzolini C**, Decosterd L, Powell Golay K, Baumann P, Buclin T, Telenti A, Eap CB. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. *Eur J Clin Pharmacol.* 2005; 60:865-873.
- 143) Haas DW, Ribaldo HJ, Kim RB, Tierney C, Wilkinson GR, Clifford DB, Gulick RM, Hulgand T, **Marzolini C**, Acosta EP. Pharmacogenetics of efavirenz and central nervous system side effects: an adult aids clinical trial group study. *AIDS.* 2004; 18:2391-2400.
- 144) Colombo S, Guignard N, **Marzolini C**, Telenti A, Biollaz J, Decosterd LA. Determination of the new HIV-protease inhibitor atazanavir by HPLC after solid-phase extraction. *J Chromatograph B.* 2004; 810:25-34.
- 145) Csajka C, **Marzolini C**, Fattinger K, Decosterd LA, Telenti A, Biollaz J, Buclin T. Population pharmacokinetics and effects of indinavir in patients with human immunodeficiency virus infection. *Antimicrob Agent Chemother.* 2004; 48: 3226-3232.

- 146) **Marzolini C**, Tirona R, Kim RB. Pharmacogenomics of organic anion transporting polypeptide (OATP) and organic anion transporter (OAT) families. *Pharmacogenomics*. 2004; 5: 273-282.
- 147) Bleiber G, May M, Suarez C, Martinez R, **Marzolini C**, Egger M, Telenti A and the Swiss HIV Cohort Study: MDR1 genetic polymorphism does not modify cell permissiveness to HIV-1 or disease progression before treatment. *J Infect Dis*. 2004; 189: 583-586.
- 148) **Marzolini C**, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. *Clin Pharm Ther*. 2004; 75: 13-33.
- 149) Csajka C, **Marzolini C**, Fattinger K, Decosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. *Clin Pharm Ther*. 2003; 73: 20-30.
- 150) Doser N, Kübli S, Telenti A, **Marzolini C**, Chave JP, Feihl F, Buclin T, Pannatier A, Darioli R, Nicod P, Waeber B, Mooser V. Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. *AIDS*. 2002; 16: 1982-1983.
- 151) **Marzolini C**, Béguin A, Telenti A, Schreyer A, Buclin T, Biollaz J, Decosterd LA. Determination of lopinavir and nevirapine by HPLC after solid-phase extraction: application for the assessment of their transplacental passage at delivery. *J Chromatograph B*. 2002; 774: 127-140.
- 152) **Marzolini C**, Rudin C, Decosterd LA, Telenti A, Schreyer A, Biollaz J, Buclin T and the MoCHiV. Transplacental passage of protease inhibitors at delivery. *AIDS*. 2002; 16: 889-893.
- 153) Fellay J, **Marzolini C**, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel A, Vernazza P, Eap CB, Telenti A, for the Swiss HIV Cohort Study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. *Lancet*. 2002; 359: 30-36.
- 154) **Marzolini C**, Chave JP, Telenti A, Brenas-Chinchon L, Biollaz J. Impaired absorption of rifabutin by concomitant administration of didanosine. *AIDS*. 2001; 15: 2203-2204.
- 155) **Marzolini C**, Buclin T, Decosterd LA, Biollaz J, Telenti A. Nelfinavir plasma levels under TID and BID regimens: high inter- and low intra-patient variability. *Ther Drug Monit*. 2001; 23: 394-398.
- 156) **Marzolini C**, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. *AIDS* 2001; 15: p71-75 + response to a letter *AIDS*. 2001; 15: 1193-1194.
- 157) **Marzolini C**, Troillet N, Telenti A, Baumann P, Decosterd LA, Eap CB. Efavirenz decreases methadone blood concentrations. *AIDS*. 2000; 14: 1291-1292.
- 158) **Marzolini C**, Telenti A, Buclin T, Biollaz J, Decosterd LA. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high performance liquid chromatography after solid-phase extraction. *J Chromatograph B*. 2000; 740: 43-58.
- 159) Gander M, Leyvraz S, Decosterd L, Bonfanti M, **Marzolini C**, Shen F, Liénard D, Perey L, Colella G, Biollaz J, Lejeune F, Yarosh D, Belanich M and D'Incalci M. Sequential administration of temozolomide and fotemustine: Depletion of O<sup>6</sup>-alkylguanine-DNA transferase in blood lymphocytes and in tumours. *Annals of Oncology*. 1999; 10: 831-838.
- 160) **Marzolini C**, Decosterd LA, Shen F, Gander M, Leyvraz S, Bauer J, Buclin T, Biollaz J and Lejeune F. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous and hepatic intra-arterial administration. *Cancer Chemother Pharmacol*. 1998; 42: 433-440.

## **B) Non-peer reviewed journals**

- 1) **Marzolini C.** Arzneimittelinteraktionen mit antiretroviralen Medikamenten: immer noch ein Problem?. *Jatros Infektiologie & Gastroenterologie-Hepatologie.* 2021.

## **C) Book chapters**

- 1) **Marzolini C\***: Les interactions médicamenteuses. In *VIH, Hépatites virales et Santé sexuelle.* 2020
- 2) Moss D, Siccardi M, **Marzolini C\***: Mechanisms of drug interactions II: transport proteins. In *Drug interactions in Infectious Diseases.* Edited by Pai M, Kiser J, Gubbins P, Rodvold K. Humana Press. 2018 \* corresponding author.
- 3) **Marzolini C\***, Battegay M, Back DJ: Mechanisms of drug interactions II: transport proteins. In *Drug interactions in Infectious Diseases.* Edited by Piscitelli S, Rodvold KA, Pai MP. Humana Press. 2011: 43-72. \* corresponding author
- 4) **Marzolini C**, Kim RB, Telenti A. Pharmacogenetics of antiretroviral agents. In *HIV Therapy.* Edited by Dolin R, Masur H, Saag MS. Churchill Livingstone. 2008: 513-538.
- 5) **Marzolini C**, Tirona R, Kim RB. Pharmacogenetics of drug transporters. In *Pharmacogenomics.* Edited by Kalow W, Meyer UA and Tyndale RF. Taylor & Francis. 2005: 109-156.

## **D) HIV treatment guidelines**

- 1) European AIDS Clinical Society treatment guidelines since 2013 (yearly updates)
- 2) World Health Organization consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. 2021
- 3) Faculty of Sexual & Reproductive Healthcare: clinical guidance on drug interactions between HIV antiretroviral therapy and contraception. 2023
- 4) WHO think tank on treatment optimization of HIV. 2023
- 5) Toolkit for studies in pregnancy. 2024
- 6) WHO guidelines development group for medical eligibility criteria and selected practice recommendations for the contraception use. 2024

*Marzolini*

Basel, November 11<sup>th</sup>, 2024



## Curriculum Vitae Europass

### Informazioni personali

Cognome/Nome **MUSSINI CRISTINA**  
Indirizzo Via Zurlini 61, 41125 Modena  
Telefono 059 359957  
cellulare 333 2494376  
E-mail personale cristina.mussini@unimore.it  
Cittadinanza Italiana  
Data di nascita 05 Settembre 1962  
Codice Fiscale MSS CST 62P45 F257U

### Occupazione desiderata/Settore professionale

**Dal 1/11/2011, Professore Ordinario di Malattie Infettive, Università degli Studi di Modena e Reggio Emilia e Direttore della Clinica delle Malattie Infettive, Azienda Ospedaliero Universitaria Policlinico di Modena**

Dal 1988 si è occupata di infezione da HIV e dal 2008 è membro del Governing Board dell'EACS (European AIDS Clinical Society) ed è membro del panel delle Linee Guida EACS sulla terapia antiretrovirale. Dal 2018 è membro del Governing Council dell'International AIDS Society. Dal 2019 del Consiglio Direttivo della SIMIT e del Consiglio Direttivo di ICAR. Dal 2011 si occupa anche di infezioni, soprattutto di prevenzione delle infezioni nosocomiali e ha conseguito importanti risultati nel suo ospedale come testimoniato da pubblicazioni scientifiche. In tale settore è stata Chair dal 2017 al 2019 del Gruppo di Studio ESCMID sulle infezioni dell'anziano e fa tuttora parte del direttivo (ESGIE). E' membro del Consiglio Direttivo di SIMIT. Dal 2021 è nuovamente membro della Commissione Ministeriale AIDS.

Dal 2009 al 2016 è stata membro della Commissione Nazionale AIDS del Ministero della Salute.

Ha organizzato come co-chair 2 Congressi ICAR nel 2015 e nel 2021 e ha fatto parte del comitato Scientifico di numerosi Congressi Internazionali.

Come collaborazioni nazionali e internazionali è membro della Segreteria Scientifica di ICONA, del Comitato Scientifico delle coorti internazionali COHERE, RESPOND e CASCADE.

Come attività d'insegnamento internazionale ha svolto lezioni in corsi e master quali: EACS HIV advanced course, Izmir advanced HIV course in Turkey, HIV course in

Nairobi Kenyatta University in Kenya, San Petersburg HIV Course and Irkutsk HIV course in Russia, Teheran and Birjan HIV course in Iran, Austrian-American Society Salzburg HIV course.

## Istruzione e formazione

Date Liceo Classico A. Muratori, Modena: Maturità Classica (1981)

Università di Modena: Laurea *cum laude* in Medicina e Chirurgia (1987)

Università di Modena: Specializzazione *cum laude* in Malattie Infettive (1990).

Titolo della qualifica rilasciata  
Principali tematiche/competenza professionali possedute  
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione

## Capacità e competenze personali

Madrelingua **Italiano**

Altra(e) lingua(e) **Inglese**

Capacità di lettura Ottimo

Capacità di scrittura Ottimo

Altra(e) lingua(e) **Francese**

Capacità di lettura Buono

Capacità di scrittura Buono

Capacità e competenze organizzative

Capacità e  
competenze  
informatiche

Ottima conoscenza di numerosissimi programmi e sistemi operativi in ambiente Windows, OS per Mac.

Altre capacità e  
competenze

Sport praticati: sci.

Patente

B

**Ulteriori  
informazioni**

A tutt'oggi ha pubblicato più di 500 lavori a stampa, su riviste internazionali con Impact Factor per un Impact Factor totale di **1010**.

Figura nell'elenco dei Top Italian Scientists con un H index di **58**.

La sottoscritta è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 196/03.

Si autorizza la pubblicazione dei dati sul sito del Ministero



CRISTINA MUSSINI

Modena, 12/06/2023

## INFORMAZIONI PERSONALI

**GIUSEPPE NUNNARI M.D., Ph.D, MPH****Born in:** Catania  
**D.O.B.:** August 1<sup>st</sup>, 1972**Phone number:** +393381448363**Fax:** +390902212069**Email:** [giuseppe.nunnari@unime.it](mailto:giuseppe.nunnari@unime.it)[giuseppe.nunnari@polime.it](mailto:giuseppe.nunnari@polime.it)POSITIONS AND  
EMPLOYEMENT

- July 1<sup>st</sup>, 2020 - today  
**Chief of Infectious Diseases**  
Azienda Ospedaliera Universitaria Policlinico "Gaetano Martino", Messina, Italy
- October 2020 - today  
**Chief of COVID-19 Hospital**  
Azienda Ospedaliera Universitaria Policlinico "Gaetano Martino", Messina, Italy
- October 14<sup>th</sup>, 2020 - today  
**Member of the Scientific and Technical Committee for COVID-19 emergency of the Sicilian Region**
- Dec 2018 - today  
**Sicilian Region delegate at the Health Minister for the National Plan against AIDS**
- July 2017 - today  
**Dean's delegate for the Medical Specialization Schools**  
University of Messina, Messina, Italy
- 2020-2021  
**Chief of the 2<sup>nd</sup> level Master program in "Hospital Acquired Infections, Antimicrobial Stewardship and Pandemics: control, prevention and preparedness"**  
Department of Clinical and Experimental Medicine  
University of Messina
- Dec 2015 - today  
**Full Professor of Infectious Diseases, MED/17**  
University of Messina  
Department of Clinical and Experimental Medicine
- Dec 2015 - today  
**Chief of the Residency program in Infectious Diseases and Tropical Medicine**  
University of Messina  
Department of Clinical and Experimental Medicine
- Feb-Sep 2020  
**Coordinator of the Working Group for Medical Care at the COVID-hospital for adults**  
Azienda Ospedaliera Universitaria Policlinico "Gaetano Martino", Messina, Italy
- 1 Dec. 2015 – 30 Jun 2020  
**Acting Chief of the Unit of Infectious Diseases**  
Azienda Ospedaliera Universitaria Policlinico "Gaetano Martino", Messina, Italy
- 2008 - today  
**Adjunct Assistant Professor of Microbiology and Immunology,**  
Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, USA
- 2020 – today  
**Chief of the 2<sup>nd</sup> level Master program in "Hospital Acquired Infections, Antimicrobial Stewardship and Pandemics: Prevention, Control and Preparedness"**  
Department of Clinical and Experimental Medicine  
University of Messina
- 2018-2019  
**Chief of the 2<sup>nd</sup> level Master program in "Hospital Infection Control and Antimicrobial Stewardship"**  
Department of Clinical and Experimental Medicine  
University of Messina
- 2017-2018  
**Chief of the 2<sup>nd</sup> level Master program in "Hospital Infection Control"**  
Department of Clinical and Experimental Medicine

- Oct 2016-Dec 2018 University of Messina  
**Member of the National Scientific Qualification Committee**  
Sector 06/D4: Infectious Diseases, Gastroenterology and Dermatology
- Dec 2014-Nov.2015  
**Associate Professor of Infectious Diseases, MED/17**  
Department of Clinical and Experimental Medicine  
University of Catania
- Nov 2006-Dec 2014  
**Clinical Assistant Professor of Infectious Diseases, MED/17**  
Department of Clinical and Experimental Medicine
- 2002-June 2006  
**Senior Research Associate, Clinical Research Director**  
Center for Human Virology, Division of Infectious Diseases, Department of Medicine, Thomas Jefferson University, Philadelphia PA, USA.

## EDUCATION AND TRAINING

- Dec 2014 **National Scientific Qualification as Full Professor**  
Sector 06/D4 – MED/17
- 2008-2009 **Master in Ultrasound diagnostics and ultrasound-guided treatment**  
Università Cattolica del Sacro Cuore  
Medicine and Surgery  
Fondazione Policlinico “Agostino Gemelli”, Roma  
22/12/2009
- 2008 **ECFMG/USMLE: Medical license**  
“United States Medical Licensing Examination (USMLE step 1, 2CK, 2 CS), Educational Commission for Foreign Medical Graduates (ECFMG)  
**ECFMG/USMLE certificate, issued Feb 1<sup>st</sup> 2008**  
**certification number 0-681-277-0**
- 2004-2006 **Master in Public Health (M.P.H)**  
Thomas Jefferson University, Philadelphia, Pennsylvania, USA  
June 2006
- 2003-2005 **Graduate Certificate in Public Health**  
Thomas Jefferson University, Philadelphia, Pennsylvania, USA,  
March 2005.
- 2001/02-2005 **Ph.D. in Microbiology**  
XVII cycle, 2001/2002-24/02/2005  
University of Catania
- Dec 1999-Oct 2000 **Post-doc in Infectious Diseases and Human Virology**  
Thomas Jefferson University, Philadelphia, Pennsylvania, USA
- 1996/97-2001 **Specialist in Infectious Diseases**  
University of Catania, Catania, Italy  
70/70 cum laude, on July 9<sup>th</sup>, 2001
- 1997 **License to practice Medicine and Surgery**  
Votazione 220/220
- 1990-1996 **Degree in Medicine and Surgery**  
University of Catania, Catania, Italy  
110/110 cum laude
- Aug 1996 **Clerkship**  
Department of Infectious Disease, Hospital Clinico, Malaga University, Spain, August 1996.

## PERSONAL SKILLS

Mother tongue Italian

Other language(s)	COMPRESIONE	PARLATO	PRODUZIONE SCRITTA

	Ascolto	Lettura	Interazione	Produzione orale	
inglese	C2	C2	C2	C2	C2

Livelli: A1/A2: Livello base - B1/B2: Livello intermedio - C1/C2: Livello avanzato  
[Quadro Comune Europeo di Riferimento delle Lingue](#)

Communication skills Excellent

Organizational/Managerial skills

**Chief of Infectious Diseases**  
**Chief of the Residency program in Infectious Diseases and Tropical Medicine**  
**Senior Research Associate, Clinical Research Director**  
 Center for Human Virology, Division of Infectious Diseases, Department of Medicine, Thomas Jefferson University, Philadelphia PA, USA.  
**Editor in Chief** of the journal "Infectious Diseases and Tropical Medicine", Verduci editore, <http://www.infectiousjournal.com/>. ISSN (ISSN 2379-4054)  
**Reviewer** for Journal of Infectious Diseases, Clinical Infectious Diseases, Journal of Virology, Journal of Antimicrobial Chemotherapy, Virology Journal, World Journal of AIDS  
**Prin Reviewer (2008, 2009)**

Other competences

Basic and clinical research

Laboratory techniques:

- Cell cultures;
- Cell line separation from peripheral blood
- Molecular biology
- Cellular DNA and RNA extraction and purification, PCR, RT-PCR, Southern Blot, siRNA, Microarray

RESEARCH GRANTS

1

**Gilead Sciences Srl. Fellowship Program 2019:** "Lymphocyte-activation gene 3 (CD223) come marcatore immunologico di ridotta durability terapeutica"  
**Principal Investigator**  
**Grant:** 25,000 €

2

**Gilead Sciences Srl. Fellowship Program 2016:** Promozione dello screening tumorale nei soggetti coinfezione da HIV: "Remind the doctor-remind the patient software-based strategy". Studio retrospettivo-prospettico multicentrico multidisciplinare  
**Principal Investigator**  
**Grant:** 25,000 €

3

PRA, ex 60%, annuali, dal 2006-2013

4

**Departmental Research Grant** in collaborazione con altri docenti dell'Università degli Studi di Catania e con ricercatori italiani e stranieri in risposta al bando intra-universitario per lo svolgimento del progetto di ricerca dal titolo: "Il ruolo del selenio nelle patologie da RNA virus (HIV, HCV, Coxsackie virus): possibili implicazioni terapeutiche".  
**Co-investigator**  
**Grant:** 20,000.00 €

5

**Research Collaboration Grant of the University of Catania**  
 "Il ruolo del nuovo pattern immunologico T-helper 17 nell'infezione da virus dell'immunodeficienza acquisita (HIV)".  
**Principal Investigator**  
**Grant:** 92,000.00 € (23,000.00 €/year)

6

**The Voice Grants Programme:** Coordinatore del finanziamento per lo studio "Are soluble CD14 and immune activation markers associated with immune recovery in HIV-positive patients on suppressive cART?"  
**Grant:** 20,000.00 €

7

**Gilead Sciences Srl. Fellowship Program 2014** “HIV DNA integrato e 2-LTR e HIV RNA intracellulare come predittori di mancato successo immunovirologico in pazienti con stabile soppressione virologica: studio retrospettivo-prospettico multicentrico siciliano”.

**Principal Investigator**

**Grant:** 25.000,00 €

8

**PON Hippocrates:** Sviluppo di Micro e Nano-Tecnologie e Sistemi Avanzati per la Salute dell’Uomo (Ruolo delle nanotecnologie nella diagnostica della tubercolosi polmonare)

**Co-investigator**

9

**Italian Ministry of Health, Grant for AIDS research**

**Principal Investigator**

**Grant:** 97,000.00 €

## PATENTS

**US Patent:**

Cellular targets for treatment of retroviral infection US Patent N°: 7,736,848 B2 June 15<sup>th</sup> 2010

## HONORS

**“Clinical Infectious Disease Award for Outstanding Review”.**

**Fellow travel grant award**

8th conference on retrovirus and opportunistic infections: February 4-8 Chicago, 2001.

## SCIENTIFIC SOCIETIES

1

**Member of the “Standards and Practice Guidelines Committee, Infectious Diseases Society of America”**

Since October 23<sup>rd</sup>, 2010 for 3 years

2

**Member of the “Infectious Diseases Society of America”**

since 2006

3

**Member of the Italian Society of Infectious and Tropical Diseases (ISITD)**

President of the “Sicilia” Regional Section (2022-2025)

## TEACHING EXPERIENCE

**Teacher and Mentor** of the Ph.D. Program in “Translational Molecular Medicine and Surgery”, University of Messina, since the Academic Year 2019/2020, Cycles XXXV, XXXVI

**Teacher and Mentor** of the Ph.D. Program in “Biotecnologie Mediche e Chirurgiche”, University of Messina, since the Academic Year 2016/2017, Cycles XXXII, XXXIII, XXXIV

**Teacher of** Infectious Diseases, for the Medicine and Surgery course, University of Messina

**Teacher of** Infectious Diseases, for the Dentistry course, University of Messina

**Teacher of** Infectious Diseases, for the Nurse Training course, University of Messina

**Chief and Teacher** of the 2<sup>nd</sup> Level Master program in Hospital Acquired Infections, Antimicrobial Stewardship and Pandemics: Prevention, Control and Preparedness, University of Messina, AY 2020/2021

**Chief and Teacher** of the 2<sup>nd</sup> level Master Program in Hospital Infection Control and Antimicrobial Stewardship, University of Messina, AY 2018/2019, 2019/2020

**Chief and Teacher** of the 2<sup>nd</sup> level Master program in Hospital Infection Control, University of Messina, AY 2017/2018

**Teacher** of Infectious Diseases, for the Medicine and Surgery course, University of Catania

**Mentor** for the “Scuola Superiore di Catania”, University of Catania

**Teacher of Molecular Biology in Infectious Diseases**, Residency Program in Infectious Diseases, University of Catania

**Teacher of Viral Disease Pathogenesis**, Ph.D program in Microbiology and Immunology, Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, USA

**Teacher of the Ph.D. program in:** “Epatogastroenterologia e clinica e biomolecolare dell’età evolutiva ed adulta” Università of Messina, AY 2009/2010, Cycle XXV.

**Supervisor, Teacher and Mentor** of the Master Program in Microbiology and Immunology, of Medicine and Surgery students and residents in Infectious Diseases at the Department of Internal Medicine, Unit of Infectious Diseases, Center for Human Virology and Biodefense, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

**Supervisor and Mentor of a Post-doc in Infectious Diseases, in quality of Project Manager** University of Catania, 01/11/2010 for 4 years

**Supervisor and Mentor for the Residency Program in Infectious Diseases** University of Catania (10/2007-2015)

**Supervisor and Mentor for the Medicine and Surgery Degree program students.** University of Catania (10/2007-2015)

**Teacher of Infectious Diseases for the Residency program in Dermatology and Venereology** University of Catania

**Teacher of Infectious Diseases for the Residency program in Nephrology** University of Catania

## PUBLICATIONS

---

### Summary:

225 Publications  
5 book chapters  
H-index 34  
Total citations 3383

1. Motolese, Alfonso; Ceccarelli, Manuela; Macca, Laura; Li Pomi, Federica; Ingrasciotta, Ylenia; Nunnari, Giuseppe; Guarneri, Claudio. Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease. BIOMEDICINES 2022; 10: 228-228. DOI: 10.3390/biomedicines10020228
2. Ceccarelli, M.; Marino, A.; Cosentino, F.; Moscatt, V.; Celesia, B. M.; Gussio, M.; Bruno, R.; Venanzi Rullo, E.; Nunnari, G.; Cacopardo, B. S.. Post-infectious ST elevation myocardial infarction following a COVID-19 infection: A case report. BIOMEDICAL REPORTS 2022; 16: 10-10. DOI: 10.3892/br.2021.1493
3. Micali, Cristina; Russotto, Ylenia; Caci, Grazia; Ceccarelli, Manuela; Marino, Andrea; Celesia, Benedetto Maurizio; Pellicanò, Giovanni Francesco; Nunnari, Giuseppe; Venanzi Rullo, Emmanuele. Loco-Regional Treatments for Hepatocellular Carcinoma in People Living with HIV. INFECTIOUS DISEASE REPORTS 2022; 14: 43-55. DOI: 10.3390/idr14010006
4. Longhitano, Elisa; Nardi, Chiara; Calabrese, Vincenzo; Messina, Roberta; Mazzeo, Giuliana; Rullo, Emmanuele Venanzi; Ceccarelli, Manuela; Chatrenet, Antoine; Saulnier, Patrick; Torreggiani, Massimo; Nunnari, Giuseppe; Piccoli, Giorgina B; Santoro, Domenico. Hyponatremia and low eGFR at

hospitalization in COVID-19 patients: a deadly combination. *CLINICAL KIDNEY JOURNAL* 2021; : 1-26. DOI: 10.1093/ckj/sfab122

5. Bonaccorsi, Irene; Carrega, Paolo; Rullo, Emmanuele Venanzi; Ducatelli, Rosaria; Falco, Michela; Freni, Josè; Miceli, Massimiliano; Cavaliere, Riccardo; Fontana, Vincenzo; Versace, Antonio; Caramori, Gaetano; David, Antonio; Nunnari, Giuseppe; Ferlazzo, Guido. HLA-C\*17 in COVID-19 patients: hints for associations with severe clinical outcome and cardiovascular risk. *IMMUNOLOGY LETTERS* 2021; 234: 44-46. DOI: 10.1016/j.imlet.2021.04.007
6. Esther, Merlini; Alessandro, Cozzi-Lepri; Antonella, Castagna; Andrea, Costantini; Sergio Lo, Caputo; Stefania, Carrara; Eugenia Quiros, Roldan; Maria A, Ursitti; Andrea, Antinori; Antonella, D'Arminio Monforte; Giulia, Marchetti; Pellicanò, G. F.; Nunnari, Giuseppe. Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV. *BMC INFECTIOUS DISEASES* 2021; 21: 557-568. DOI: 10.1186/s12879-021-06330-1
7. Giordano, Madeddu; Andrea, De Vito; Alessandro, Cozzi-Lepri; Antonella, Cingolani; Franco, Maggiolo; Carlo Federico, Perno; Roberta, Gagliardini; Giulia, Marchetti; Annalisa, Saracino; Antonella, d' Arminio Monforte; Andrea, Antinori; Enrico, Girardi; Nunnari, G.; Pellicanò, G. F. Time spent with viral load $\leq$ 200copies/mL in a cohort of people with HIV seen for care in Italy during the U=U prevention campaign era. *AIDS* 2021; 35: 1103-1112. DOI: 10.1097/QAD.0000000000002825
8. Ceccarelli M, Pavone P, Venanzi Rullo E, Nunnari G. Comment on safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis. *Eur Rev Med Pharmacol Sci.* 2021 Mar;25(6):2473-2474. doi: 10.26355/eurev\_202103\_25408. PMID: 33829431.
9. Pampaloni A, Locatelli ME, Venanzi Rullo E, Alaimo S, Cosentino F, Marino A, Moscatt V, Scuderi D, Puglisi S, Lupo G, Celesia BM, Pintaudi S, Pulvirenti C, Ceccarelli M, Nunnari G, Pulvirenti A, Cacopardo B. "Diagnosis on the Dock" project: A proactive screening program for diagnosing pulmonary tuberculosis in disembarking refugees and new SEI model. *Int J Infect Dis.* 2021 Mar 15;106:98-104. doi: 10.1016/j.ijid.2021.03.032. Epub ahead of print. PMID: 33737130.
10. Bandera A, Lorenzini P, Taramasso L, Cozzi-Lepri A, Lapadula G, Mussini C, Saracino A, Ceccherini-Silberstein F, Puoti M, Quiros-Roldan E, Montagnani F, Antinori A, d'Arminio Monforte A, Gori A; ICONA Foundation Cohort. The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfecting patients: Data from the ICONA Foundation Cohort. *J Viral Hepat.* 2021 May;28(5):779-786. doi: 10.1111/jvh.13488. Epub 2021 Mar 11. PMID: 33600068.
11. Malagnino V, Cerva C, Cingolani A, Ceccherini-Silberstein F, Vergori A, Cuomo G, Perno CF, Puoti M, d'Arminio Monforte A, Cozzi-Lepri A, Andreoni M, Sarmati L; ICONA Foundation Study Group. HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients. *Open Forum Infect Dis.* 2020 Nov 18;8(1):ofaa566. doi: 10.1093/ofid/ofaa566. PMID: 33447635; PMCID: PMC7781466.
12. Buccafusca M, Micali C, Autunno M, Versace AG, Nunnari G, Musumeci O. Favourable course in a cohort of Parkinson's disease patients infected by SARS- CoV-2: a single-centre experience. *Neurol Sci.* 2021 Mar;42(3):811-816. doi: 10.1007/s10072-020-05001-4. Epub 2021 Jan 13. PMID: 33439387; PMCID: PMC7803661.
13. Guarneri C, Ceccarelli M, Rinaldi L, Cacopardo B, Nunnari G, Guarneri F. Helicobacter pylori and skin disorders: a comprehensive review of the available literature. *Eur Rev Med Pharmacol Sci.* 2020 Dec;24(23):12267-12287. doi: 10.26355/eurev\_202012\_24019. PMID: 33336746.
14. Ceccarelli M, Venanzi Rullo E, Berretta M, Cacopardo B, Pellicanò GF, Nunnari G, Guarneri C. New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations

- about the risk of infection. *Dermatol Ther.* 2021 Jan;34(1):e14660. doi: 10.1111/dth.14660. Epub 2020 Dec 25. PMID: 33301216.
15. Berretta M, Quagliariello V, Maurea N, Di Francia R, Sharifi S, Facchini G, Rinaldi L, Piezzo M, Ceccarelli M, Nunnari G, Montopoli M. Multiple Effects of Ascorbic Acid against Chronic Diseases: Updated Evidence from Preclinical and Clinical Studies. *Antioxidants (Basel).* 2020 Nov 26;9(12):1182. doi: 10.3390/antiox9121182. PMID: 33256059; PMCID: PMC7761324.
  16. Berretta M, Facchini G, Fiorica F, Nunnari G, Morra A, Tirelli U. Asymptomatic COVID-19 infection in patients with cancer at a cancer-specialized hospital in Wuhan, China - Preliminary results. *Eur Rev Med Pharmacol Sci.* 2020 Nov;24(21):10924-10925. doi: 10.26355/eurrev\_202011\_23573. PMID: 33215469.
  17. Meduri A, Oliverio GW, Mancuso G, Giuffrida A, Guarneri C, Venanzi Rullo E, Nunnari G, Aragona P. Ocular surface manifestation of COVID-19 and tear film analysis. *Sci Rep.* 2020 Nov 19;10(1):20178. doi: 10.1038/s41598-020-77194-9. PMID: 33214658; PMCID: PMC7677531.
  18. Pavone P, Marino S, Marino L, Cacciaguerra G, Guarneri C, Nunnari G, Taibi R, Marletta L, Falsaperla R. Chilblains-like lesions and SARS-CoV-2 in children: An overview in therapeutic approach. *Dermatol Ther.* 2021 Jan;34(1):e14502. doi: 10.1111/dth.14502. Epub 2020 Nov 10. PMID: 33141476.
  19. Currò M, Visalli G, Pellicanò GF, Ferlazzo N, Costanzo MG, D'Andrea F, Caccamo D, Nunnari G, Ientile R. Vitamin D Status Modulates Inflammatory Response in HIV+ Subjects: Evidence for Involvement of Autophagy and TG2 Expression in PBMC. *Int J Mol Sci.* 2020 Oct 13;21(20):7558. doi: 10.3390/ijms21207558. PMID: 33066266; PMCID: PMC7588966.
  20. Venanzi Rullo E, Pinzone MR, Cannon L, Weissman S, Ceccarelli M, Zurakowski R, Nunnari G, O'Doherty U. Persistence of an intact HIV reservoir in phenotypically naive T cells. *JCI Insight* 2020;5:133157
  21. Vella F, Senia P, Ceccarelli M, Vitale E, Maltezou H, Taibi R, Lleshi A, Venanzi Rullo E, Pellicanò GF, Rapisarda V, Nunnari G, Ledda C. Transmission mode associated with Coronavirus disease 2019: a review. *Eur Rev Med Pharmacol Sci* 2020; 24: 7889-7904.
  22. Guarneri C, Venanzi Rullo E, Gallizzi R, Ceccarelli M, Cannavò SP, Nunnari G. Diversity of Clinical Appearance of Cutaneous Manifestations in the course of COVID-19. *J Eur Acad Dermatol Venereol* 2020; 34(9): e449-e450
  23. Ceccarelli M, Nunnari G, Celesia BM, Pellicanò GF, Venanzi Rullo E, Berretta M, Cacopardo BS. Editorial – Coronavirus disease 2019 and people living with HIV: clinical considerations. *Eur Rev Med Pharmacol Sci* 2020; 24(13): 7534-7539
  24. Berretta M, Rinaldi L, Taibi R, Tralongo P, Fulvi A, Montesarchio V, Madeddu G, Magistri P, Bimonte S, Trovò M, Gnagnarella P, Cuomo A, Cascella M, Lleshi A, Nasti G, Facchini S, Fiorica F, Di Francia R, Nunnari G, Pellicanò GF, Guglielmino A, Danova M, Rossetti S, Amore A, Crispo A, Facchini G. Physician Attitudes and Perceptions of Complementary and Alternative Medicine (CAM): A Multicentre Italian Study. *Front Oncol* 2020; 10: 594.
  25. Pavone P, Ceccarelli M, Taibi R, La Rocca G, Nunnari G. Outbreak of COVID-19 infection in children: fear and serenity. *Eur Rev Med Pharmacol Sci* 2020; 24 (8): 4572-4575
  26. Vaccaro M, Marafioti I, Nunnari G, Pellicanò GF, Vaccaro F, Trombetta CJ, Cannavò SP. When the eye does not see, the bone can grieve: an unusual presentation of secondary syphilis. *Indian J Dermatol Venereol Leprol* 2020; 86 (2): 184-186
  27. d'Arminio Monforte A, Tavelli A, Cozzi-Lepri A, et al. Virological response and retention in care according to time of starting ART in Italy: data from the Iona Foundation Study cohort. *J Antimicrob Chemother.* 2020;75(3):681-689. doi:10.1093/jac/dkz512
  28. Ceccarelli M, Berretta M, Venanzi Rullo E, Nunnari G, Cacopardo B. Editorial – Differences and similarities between Severe Acute Respiratory Syndrome (SARS)-Coronavirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet? *Eur Rev Med Pharmacol Sci* 2020; 24 (5); 2781-2783

29. Guarneri C, Venanzi Rullo E, Pavone P, Berretta M, Ceccarelli M, Natale A, Nunnari G. Silent COVID-19: what your skin can reveal. *Lancet Infect Dis* 2020. In press.
30. Carta MG, Orrù G, Scano A, Coghe F, Nunnari G, Facchini G, Numis FG, Berretta M. In the face of the SARS-CoV-2 outbreak, do people suffering from oncological disease need specific attention? *Eur Rev Med Pharmacol Sci* 2020; 27 (4): 3434-3436
31. Pampaloni A, Tosto S, Locatelli ME, Gentile A, Scuderi D, Marino A, Cosentino F, Moscatt V, Nunnari G, Cacopardo B. Skin and soft tissue infection by *Mycobacterium intracellulare* in an immunocompetent patient. *IDCases* 2020; 19: e00720
32. Marino A, Scuderi D, Locatelli ME, Gentile A, Pampaloni A, Cosentino F, Ceccarelli M, Celesia BM, Benanti F, Nunnari G, Montineri A, Cacopardo B. Modification of serum brain-derived neurotrophic factor levels following anti-HCV therapy with direct antiviral agents: a new marker of neurocognitive disorders. *Hepatitis Monthly* 2020; 20 (2): e95101
33. Ceccarelli M, Venanzi Rullo E, Marino MA, d'Aleo F, Pellicanò GF, D'Andrea F, Marino A, Cacopardo B, Celesia BM, La Rocca G, Di Rosa M, Condorelli F, Berretta M, Nunnari G. Non-AIDS defining cancers: a comprehensive update on diagnosis and management. *Eur Rev Med Pharmacol Sci* 2020; 24 (7): 3849-3875
34. Diurno F, Numis FG, Porta G, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. *Eur Rev Med Pharmacol Sci*. 2020;24(7):4040-4047. doi:10.26355/eurrev\_202004\_20875
35. D'Andrea F, Venanzi Rullo E, Marino A, Moscatt V, Celesia BM, Cacopardo B, Condorelli F, La Rocca G, Di Rosa M, Pellicanò GF, Nunnari G, Ceccarelli M. Hepatitis B virus infection and hepatocellular carcinoma in PLWH: epidemiology, pathogenesis and treatment. *World Cancer Res J* 2020; 7: e1537.
36. D'Andrea F, Venanzi Rullo E, Facciola A, Di Rosa M, Condorelli F, Marino A, Cacopardo B, Pellicanò GF, Nunnari G, Ceccarelli M. Epstein Barr Virus related cancer in people living with HIV: a review of the literature. *World Cancer Res J* 2020; 7: e1512.
37. Trentalange A, Prochet A, Imperiale D, Cusato J, Tettoni M, Nunnari G, Barco A, Bonora S, Di Perri G, Calcagno A. Cerebral white matter Hyperintensities in HIV-positive patients. *Brain Imaging Behav*. 2020; 14 (1): 10-18. doi: 10.1007/s11682-018-9966-1. PubMed PMID: 30238207
38. Facciola A, Venanzi Rullo E, Ceccarelli M, D'Andrea F, Coco M, Micali C, Cacopardo B, Marino A, Cannavò SP, Di Rosa M, Condorelli F, Pellicanò GF, Guarneri C, Nunnari G. Malignant Melanoma in HIV: Epidemiology, Pathogenesis and management. *Dermatol Ther* 2020; 33 (1): e13180. DOI: 10.1111/dth.13180
39. Celesia BM, Marino A, Fontana del Vecchio R, Bruno R, Palermo F, Gussio M, Nunnari G, Cacopardo B. Is it safe and cost saving to defer the CD4+ cell count monitoring in stable patients on ART with more than 350 or 500 cells/ $\mu$ L? *Mediterranean J Hematol Infect Dis* 2019; 11(1):e2019063
40. Rapisarda V, Nunnari G, Senia P, Vella F, Vitale E, Murabito P, Salerno M, Ledda C. Hepatitis B Vaccination coverage among medical residents from Catania University Hospital, Italy. *Future Microbiol* 2019; 14(9s):41-44
41. Facciola A, Visalli G, Laganà P, La Fauci V, Squeri R, Pellicanò GF, Nunnari G, Trovato M, Di Pietro A. The new era of vaccines: the "nanovaccinology". *Eur Rev Med Pharmacol Sci* 2019; 23(16):7163-7182
42. Ledda C, Cinà D, Garozzo SF, Senia P, Consoli A, Marconi A, Scialfa V, Nunnari G, Rapisarda V. Tuberculosis screening among healthcare workers in Sicily, Italy. *Future Microbiol* 2019; 14(9s):37-40
43. Ledda C, Cinà D, Garozzo SF, Vella F, Consoli A, Scialfa V, Proietti L, Nunnari G, Rapisarda V. Vaccine-preventable diseases in healthcare workers in Sicily (Italy): Seroprevalence against measles. *Future Microbiol* (2019); 14(9s):33-36

44. Vadini F, Sozio F, Madeddu G, et al. Alexithymia Predicts Carotid Atherosclerosis, Vascular Events, and All-Cause Mortality in Human Immunodeficiency Virus-Infected Patients: An Italian Multisite Prospective Cohort Study. *Open Forum Infect Dis.* 2019;6(9):ofz331. Published 2019 Jul 27. doi:10.1093/ofid/ofz331
45. Taramasso L, Ricci E, Cascio A, et al. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA). *AIDS Res Ther.* 2019;16(1):21. Published 2019 Aug 26. doi:10.1186/s12981-019-0236-0
46. Maggi P, De Socio GV, Cicalini S, et al. Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: review of the literature and suggestions for a friendly use. *AIDS Res Ther.* 2019;16(1):11. Published 2019 May 24. doi:10.1186/s12981-019-0226-2
47. Ceccarelli M, Facciola A, Taibi R, Pellicanò GF, Nunnari G, Venanzi Rullo E. The treatment of Kaposi's sarcoma: present and future options, a review of the literature. *Eur Rev Med Pharmacol Sci* 2019; 23(17): 7488-7497
48. Larné D, D'Andrea F, Facciola A, Paolucci IA, Ceccarelli M, Venanzi Rullo E, Pellicanò GF. Pasteurella multocida septic shock in an immunocompromised woman *Infect Dis Trop Med* 2019; 5: e541
49. Cosentino F, Marino A, Onorante A, Gussio M, Zagami A, Torrisi S, Locatelli ME, Pampaloni A, Scuderi D, Gentile A, Ceccarelli M, Nunnari G, Cacopardo B. Cervical and lumbar diffuse Brucella spondylodiscitis: an uncommon case report. *Infect Dis Trop Med* 2019; 5: e545
50. d'Aleo F, Ceccarelli M, Venanzi Rullo E, Facciola A, D'Andrea F, Micali C, Coco M, Pinzone MR, Focà E, Condorelli F, Picerno I, Visalli G, Cacopardo B, Nunnari G, Pellicanò GF. Anal cancer in people living with HIV: the importance of screening and early diagnosis. *WCRJ* 2019; 6: e1319
51. D'Andrea F, Ceccarelli M, Venanzi Rullo E, Facciola A, Marino A, Cacopardo B, Pellicanò GF, Nunnari G. Vaccines against HPV in people living with HIV: a review. *WCRJ* 2019; 6: e1348
52. Rusconi S, Santoro MM, Gianotti N, et al. Is the rate of virological failure to cART continuing to decline in recent calendar years?. *J Clin Virol.* 2019;116:23-28. doi:10.1016/j.jcv.2019.04.009
53. D'Andrea F, Pellicanò GF, Venanzi Rullo E, d'Aleo F, Facciola A, Micali C, Coco M, Visalli G, Picerno I, Condorelli F, Pinzone MR, Cacopardo B, Nunnari G, Ceccarelli M. Cervical cancer in women living with HIV: a review of the literature. *World Cancer Res J* 2019; 6:e1224
54. Facciola A, Venanzi Rullo E, Ceccarelli M, d'Aleo F, D'Andrea F, Visalli G, Pinzone MR, Picerno I, Cacopardo B, Condorelli F, Madeddu G, Nunnari G, Pellicanò GF. Hodgkin's lymphoma in people living with HIV: epidemiology and clinical management. *WCRJ* 2019; 6: e1295. DOI: 10.32113/wcrj\_20195\_1295
55. Venanzi Rullo E, Cannon L, Pinzone MR, Ceccarelli M, Nunnari G, O'Doherty U. Genetic evidence that Naïve T cells can contribute significantly to the HIV intact reservoir: time to re-evaluate their role. *Clin Infect Dis* 2019; ciz378
57. Cama BAV, Ceccarelli M, Venanzi Rullo E, Ferraiolo F, Paolucci IA, Maranto D, Mondello P, Lo Presti Costantino MR, Marano F, D'Andrea G, Di Marco V, Puglisi G, Valenzise M, D'Angelo G, Mondello L, Strano G, Condorelli F, Spicola D, Nunnari G, Pellicanò GF. Outbreak of Brucella melitensis infection in Eastern Sicily: risk factors, clinical characteristics and complication rate. *New Microbiol.* 2019 Jan;42(1):43-48. PubMed PMID: 30957869.
58. Facciola A, Pellicanò GF, Visalli G, Paolucci IA, Venanzi Rullo E, Ceccarelli M, D'Aleo F, Di Pietro A, Squeri R, Nunnari G, La Fauci V. The role of the hospital environment in the healthcare-associated infections: a general review of the literature. *Eur Rev Med Pharmacol Sci.* 2019 Feb;23(3):1266-1278. doi: 10.26355/eurrev\_201902\_17020. PubMed PMID: 30779096.
59. D'Andrea F, Ceccarelli M, Facciola A, Nunnari G, Pellicanò GF, Venanzi Rullo E. Breast cancer in women living with HIV. *Eur Rev Med Pharmacol Sci.* 2019 Feb;23(3):1158-1164. doi: 10.26355/eurrev\_201902\_17007. PubMed PMID: 30779085.

60. Pinzone MR, VanBelzen DJ, Weissman S, Bertuccio MP, Cannon L, Venanzi-Rullo E, Migueles S, Jones RB, Mota T, Joseph SB, Groen K, Pasternak AO, Hwang WT, Sherman B, Vourekas A, Nunnari G, O'Doherty U. Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion. *Nat Commun.* 2019 Feb 13;10(1):728. doi: 10.1038/s41467-019-08431-7. PubMed PMID: 30760706; PubMed Central PMCID: PMC6374386.
61. d'Arminio Monforte A, Cozzi-Lepri A, Di Biagio A, Marchetti G, Lo Caputo S, Rusconi S, Gianotti N, Mazzotta V, Mazzarello G, Costantini A, Castagna A, Antinori A; ICONA Foundation Study Group. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. *J Antimicrob Chemother.* 2019 Jan 29. doi: 10.1093/jac/dky566. [Epub ahead of print] PubMed PMID: 30698801.
62. Pinzone MR, Ceccarelli M, Venanzi Rullo E, Maresca M, Bruno R, Condorelli F, Di Rosa M, Madeddu G, Focà E, Calcagno A, Celesia BM, Cacopardo B, Nunnari G, Pellicanò GF. Circulating angiopoietin-like protein 2 levels are associated with decreased renal function in HIV+ subjects on cART: A potential marker of kidney disease. *Biomed Rep.* 2019 Feb;10(2):140-144. doi: 10.3892/br.2019.1183. Epub 2019 Jan 7. PubMed PMID: 30675354; PubMed Central PMCID: PMC6341407
63. Mondì A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, Calcagno A, De Luca A, Maggiolo F, Marchetti G, Antinori A, d'Arminio Monforte A; Icona Foundation Study Group. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. *J Int AIDS Soc.* 2019 Jan;22(1):e25227. doi: 10.1002/jia2.25227. PubMed PMID: 30663278; PubMed Central PMCID: PMC6340053
64. Venanzi Rullo E, Ceccarelli M, Condorelli F, Facciola A, Visalli G, D'Aleo F, Paolucci I, Cacopardo B, Pinzone MR, Di Rosa M, Nunnari G, Pellicanò GF. Investigational drugs in HIV: Pros and cons of entry and fusion inhibitors (Review). *Mol Med Rep.* 2019 Mar;19(3):1987-1995. doi: 10.3892/mmr.2019.9840. Epub 2019 Jan 10. PubMed PMID: 30628713
65. Ceccarelli M, Venanzi Rullo E, Vaccaro M, Facciola A, d'Aleo F, Paolucci IA, Cannavò SP, Cacopardo B, Pinzone MR, Pellicanò GF, Condorelli F, Nunnari G, Guarneri C. HIV-associated psoriasis: Epidemiology, pathogenesis, and management. *Dermatol Ther.* 2019 Mar;32(2):e12806. doi: 10.1111/dth.12806. Epub 2019 Jan 6. Review. PubMed PMID: 30588732
66. Taramasso L, Lorenzini P, Di Biagio A, et al. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. *J Antimicrob Chemother.* 2019;74(11):3295-3304. doi:10.1093/jac/dkz353
67. Leone S, Lorenzini P, Cozzi-Lepri A, et al. Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study. *Eur J Clin Microbiol Infect Dis.* 2019;38(10):1857-1865. doi:10.1007/s10096-019-03618-8
68. Facciola A, Visalli G, La Maestra S, Ceccarelli M, D'Aleo F, Nunnari G, Pellicanò GF, Di Pietro A. Carbon nanotubes and central nervous system: Environmental risks, toxicological aspects and future perspectives. *Environ Toxicol Pharmacol.* 2019 Jan;65:23-30. doi: 10.1016/j.etap.2018.11.006. Epub 2018 Nov 22. Review. PubMed PMID: 30500734
69. d'Arminio Monforte A, Diaz-Cuervo H, De Luca A, Maggiolo F, Cingolani A, Bonora S, Castagna A, Girardi E, Antinori A, Lo Caputo S, Guaraldi G, Cozzi-Lepri A; ICONA Foundation Study Group. Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014. *HIV Med.* 2019 Feb;20(2):99-109. doi: 10.1111/hiv.12683. Epub 2018 Nov 21. PubMed PMID: 30461158
70. Facciola A, Ceccarelli M, Venanzi Rullo E, d'Aleo F, Condorelli F, Visalli G, Cacopardo B, Pinzone MR, di Rosa M, Nunnari G, Pellicanò GF. Prostate cancer in HIV-positive patients: a review of the literature. *World Cancer Res J* 2018; 5 (3): e1136
71. d'Aleo F, Venanzi Rullo E, Ceccarelli M, Facciola A, Condorelli F, Pinzone MR, Cacopardo B, Di Rosa M, Nunnari G, Pellicanò GF. HIV and colorectal cancer. New insights and review of the literature. *World Cancer Res J* 2018; 5 (3): e1122

72. D'Aleo F, Cama BAV, Paolucci IA, Venanzi Rullo E, Condorelli F, Facciola A, Di Francia R, Savasta A, Pinzone MR, Picerno I, Visalli G, Nunnari G, Pellicano GF, Ceccarelli M. New and old assumptions on lung cancer in people living with HIV. *World Cancer Res J* 2018; 5:e1036
73. D'Andrea F, Ceccarelli M, Venanzi Rullo E, Facciola A, d'Aleo F, Cacopardo B, Iacobello C, Costa A, Altavilla G, Pellicano GF, Nunnari G. Cancer screening in HIV-infected patients: early diagnosis in a high-risk population. *World Cancer Res J* 2018; 5 (3): e1130
74. Visalli G, Facciola A, D'Aleo F, Pinzone MR, Condorelli F, Picerno I, Nunnari G, Pellicano GF, Ceccarelli M, Venanzi Rullo E. HPV and urinary bladder carcinoma: a review of the literature. *World Cancer Res J* 2018; 5:e1038
75. Lamè D, Ceccarelli M, Condorelli F, Venanzi Rullo E, Nunnari G, Pellicano GF. Bacteremic meningitis due to *Pasteurella multocida* resistant to first line antibiotic therapy. *Infect Dis Rep* 2018; 10(2):7632
76. Ceccherini-Silberstein F, Cozzi Lepri A, Alteri C, Merlini E, Surdo M, Marchetti G, Capobianchi MR, De Luca A, Gianotti N, Viale P, Andreoni M, Antinori A, Perno CF, d'Arminio Monforte A; ICONA Foundation Study Group. Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. *J Antimicrob Chemother.* 2018 Dec 1;73(12):3460-3470. doi: 10.1093/jac/dky350. PubMed PMID: 30247724
77. Musumeci G, Castrogiovanni P, Barbagallo I, Tibullo D, Sanfilippo C, Nunnari G, Pellicano GF, Pavone P, Caltabiano R, Di Marco R, Imbesi R, Di Rosa M. Expression of the OAS Gene Family Is Highly Modulated in Subjects Affected by Juvenile Dermatomyositis, Resembling an Immune Response to a dsRNA Virus Infection. *Int J Mol Sci.* 2018 Sep 17;19(9). pii: E2786. doi: 10.3390/ijms19092786. PubMed PMID: 30227596; PubMed Central PMCID: PMC6163680
78. Ceccarelli M, Rullo EV, Condorelli F, Vitale F, Marco VD, Nunnari G, Pellicano GF. Unusual Signs and Symptoms in HIV-Positive Patients Coinfected with *Leishmania* spp: The Importance of Neglected Tropical Disease in Differential Diagnosis. *Open Access Maced J Med Sci.* 2018 Apr 25;6(5):843-847. doi: 10.3889/oamjms.2018.186. eCollection 2018 May 20. PubMed PMID: 29875857; PubMed Central PMCID: PMC5985878.
79. Ceccarelli M, Rullo EV, Facciola A, Madeddu G, Cacopardo B, Taibi R, D'Aleo F, Pinzone MR, Picerno I, di Rosa M, Visalli G, Condorelli F, Nunnari G, Pellicano GF. Head and neck squamous cell carcinoma and its correlation with human papillomavirus in people living with HIV: a systematic review. *Oncotarget.* 2018Mar 30;9(24):17171-17180. doi: 10.18632/oncotarget.24660. eCollection 2018 Mar 30. Review. PubMed PMID: 29682214; PubMed Central PMCID: PMC5908315.
80. Ceccarelli M, Venanzi Rullo E, Nunnari G. Risk factors of venous thrombo-embolism during cytomegalovirus infection in immunocompetent individuals. A systematic review. *Eur J Clin Microbiol Infect Dis.* 2018 Mar;37(3):381-390. doi: 10.1007/s10096-018-3185-y. Epub 2018 Jan 18. Review. PubMed PMID: 29344839.
81. Fiore V, Mancini F, Ciervo A, Bagella P, Peruzzo F, Nunnari G, Deiana GA, Rezza G, Babudieri S, Madeddu G. Tache Noire in a Patient with Acute Q Fever. *Med Princ Pract.* 2018;27(1):92-94. doi: 10.1159/000486573. Epub 2018 Jan 3. PubMed PMID: 29298443.
82. Facciola A, Venanzi Rullo E, Ceccarelli M, D'Aleo F, Di Rosa M, Pinzone MR, Condorelli F, Visalli G, Picerno I, Fisichella R, Nunnari G, Pellicano GF. Kaposi's sarcoma in HIV-infected patients in the era of new antiretrovirals. *Eur Rev Med Pharmacol Sci.* 2017 Dec;21(24):5868-5869. doi: 10.26355/eurrev\_201712\_14036. PubMed PMID: 29272026.
83. D'Aleo F, Ceccarelli M, Venanzi Rullo E, Facciola A, Di Rosa M, Pinzone MR, Condorelli F, Visalli G, Picerno I, Berretta M, Pellicano GF, Nunnari G. Hepatitis C-related hepatocellular carcinoma: diagnostic and therapeutic management in HIV-patients. *Eur Rev Med Pharmacol Sci.* 2017 Dec;21(24):5859-5867. doi: 10.26355/eurrev\_201712\_14035. PubMed PMID: 29272025.
84. Svicher V, Marchetti G, Ammassari A, Ceccherini-Silberstein F, Sarmati L; Impact Study Group. Novelty in Evaluation and Monitoring of Human Immunodeficiency Virus-1 Infection: Is Standard Virological Suppression

Enough for Measuring Antiretroviral Treatment Success? *AIDS Rev.* 2017 Oct-Dec;19(3):119-133. PubMed PMID: 28926559.

85. Sanfilippo C, Cambria D, Longo A, Palumbo M, Avola R, Pinzone M, Nunnari G, Condorelli F, Musumeci G, Imbesi R, Castogiovanni P, Malaguamera L, Di Rosa M. SERPING1 mRNA overexpression in monocytes from HIV+ patients. *Inflamm Res.* 2017 Dec;66(12):1107-1116. doi: 10.1007/s00011-017-1091-x. Epub 2017 Sep 9. PubMed PMID: 28889214.
86. Maggi P, Di Biagio A, Rusconi S, Cicalini S, D'Abbraccio M, d'Ettorre G, Martinelli C, Nunnari G, Sighinolfi L, Spagnuolo V, Squillace N. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. *BMC Infect Dis.* 2017 Aug 9;17(1):551. doi: 10.1186/s12879-017-2626-z. Review. PubMed PMID: 28793863; PubMed Central PMCID: PMC5550957.
87. Di Biagio A, Riccardi N, Signori A, Maserati R, Nozza S, Gori A, Bonora S, Borderi M, Ripamonti D, Rossi MC, Orofino G, Quirino T, Nunnari G, Celesia BM, Martini S, Sagnelli C, Mazzola G, Colletti P, Bartolozzi D, Bini T, Ladisa N, Castelnuovo F, Saracino A, Lo Caputo S. PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection. *PLoS One.* 2017 Jul 20;12(7):e0181433. doi: 10.1371/journal.pone.0181433. doi
88. Ledda C, Cicciù F, Puglisi B, Ramaci T, Nunnari G, Rapisarda V. Attitude of Health Care Workers (HCWs) toward Patients Affected by HIV/AIDS and Drug Users: A Cross-Sectional Study. *Int J Environ Res Public Health.* 2017 Mar 9;14(3). pii: E284. doi: 10.3390/ijerph14030284. PubMed PMID: 28282937. I.F.2.035
89. Sanfilippo C, Pinzone MR, Cambria D, Longo A, Palumbo M, Di Marco R, Condorelli F, Nunnari G, Malaguamera L, Di Rosa M. OAS Gene Family Expression Is Associated with HIV-Related Neurocognitive Disorders. *Mol Neurobiol.* 2017 Feb 24. doi: 10.1007/s12035-017-0460-3. [Epub ahead of print] PubMed PMID: 28236279. I.F.5.397
90. Maggi P, De Socio GV, Cicalini S, D'Abbraccio M, D'Ettorre G, Di Biagio A, Martinelli C, Nunnari G, Rusconi S, Sighinolfi L, Spagnuolo V, Squillace N. Use of statins and aspirin to prevent cardiovascular disease among HIV-positive patients. A survey among Italian HIV physicians. *New Microbiol.* 2017 Jan 10;40(1). [Epub ahead of print] PubMed PMID: 28072892. I.F.1.629
91. Malaguamera G, Bertino G, Chisari G, Motta M, Vecchio M, Vacante M, Caraci F, Greco C, Drago F, Nunnari G, Malaguamera M. Silybin supplementation during HCV therapy with pegylated interferon- $\alpha$  plus ribavirin reduces depression and anxiety and increases work ability. *BMC Psychiatry.* 2016 Nov 15;16(1):398. PubMed PMID: 27842532. I.F.2.576
92. Sanfilippo C, Nunnari G, Calcagno A, Malaguamera L, Blennow K, Zetterberg H, Di Rosa M. The chitinases expression is related to Simian Immunodeficiency Virus Encephalitis (SIVE) and in HIV encephalitis (HIVE). *Virus Res.* 2017 Jan 2;227:220-230. doi: 10.1016/j.virusres.2016.10.012. Epub 2016 Oct 26. PubMed PMID: 27794455. I.F.2.526
93. Raffi F, Esser S, Nunnari G, Pérez-Valero I, Waters L. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens. *HIV Med.* 2016 Oct;17 Suppl 5:3-16. doi: 10.1111/hiv.12440. Review. PubMed PMID: 27714978. I.F.3.341
94. Pinzone MR, Graf E, Lynch L, McLaughlin B, Hecht FM, Connors M, Migueles SA, Hwang WT, Nunnari G, O'Doherty U. Monitoring Integration over Time Supports a Role for Cytotoxic T Lymphocytes and Ongoing Replication as Determinants of Reservoir Size. *J Virol.* 2016 Nov 14;90(23):10436-10445. Print 2016 Dec 1. PubMed PMID: 27630237; PubMed Central PMCID: PMC5110192. I.F.4.439
95. Madeddu G, Fiore V, Mancini F, Caddeo A, Ciervo A, Babudieri S, Masala G, Bagella P, Nunnari G, Rezza G, Mura MS. Mediterranean spotted fever-like illness in Sardinia, Italy: a clinical and microbiological study. *Infection.* 2016 Dec;44(6):733-738. Epub 2016 Jul 5. PubMed PMID: 27380385. I.F.2.294
96. Malaguamera L, Nunnari G, Di Rosa M. Nuclear import sequence identification in hOAS3 protein. *Inflamm Res.* 2016 Nov;65(11):895-904. Epub 2016 Jul 5. PubMed PMID: 27379722. I.F.2.557
97. Nunnari G, Fagone P, Lazzara F, Longo A, Cambria D, Di Stefano G, Palumbo M, Malaguamera L, Di Rosa M.

- Vitamin D3 inhibits TNF $\alpha$ -induced latent HIV reactivation in J-LAT cells. *Mol Cell Biochem.* 2016 Jul;418(1-2):49-57. doi: 10.1007/s11010-016-2732-z. Epub 2016 Jun 13. PubMed PMID: 27295094. I.F. 2.613
98. Nunnari G, Fagone P, Condorelli F, Nicoletti F, Malaguamera L, Di Rosa M. CD4+ T-cell gene Immunological chaos. *Cytokine.* 2016Apr 21;83:127-135.
  99. Emanuele Focà, Giuseppe Nunnari & Andrea Calcagno. The good, the bad and the ugly: determinants of antiretroviral-associated toxicities. *Future Virol.* 2016 (Epub ahead of print). I.F. 1.01
  100. La Ferla L. , Pinzone M. R. , Pellicanò G. F. , Nunnari G. Kaposi's sarcoma in HIV-infected patients: a review of the literature. *Infect Dis Trop Med* 2016; 2 (1): e239
  101. Fagone P, Nunnari G, Lazzara F, Longo A, Cambria D, Distefano G, Palumbo M, Nicoletti F, Malaguamera L, Di Rosa M. Induction of OAS gene family in HIV monocyte infected patients with high and low viral load. *Antiviral Res.* 2016 Apr 20. pii:S0166-3542(16)30217-0. doi: 10.1016/j.antiviral.2016.04.009. [Epub ahead of print] PubMed PMID: 27107898. I.F.3.938
  102. Bellissimo F, Pinzone MR, Celesia BM, Cacopardo B, Nunnari G. Baseline CD4/CD8T-cell Ratio Predicts Prompt Immune Restoration upon cART Initiation. *Curr HIV Res.* 2016 Apr 14. [Epub ahead of print] PubMed PMID: 27074946. I.F.1.757
  103. Di Rosa M. , Fagone P. , Pinzone M. R. , Nunnari G. Cathepsin A levels in CD4+ T cells from HIV-positive patients. *Infect Dis Trop Med* 2016; 2 (1): e245
  104. Pinzone MR, Castronuovo D, Di Gregorio A, Celesia BM, Gussio M, Borderi M, Maggi P, Santoro CR, Madeddu G, Cacopardo B, Nunnari G. Heel quantitative ultrasound in HIV-infected patients: a cross-sectional study. *Infection.* 2015 Sep 9. [Epub ahead of print] PubMed PMID: 26349915. I.F. 2.618
  105. Malaguamera M, Motta M, Vacante M, Malaguamera G, Caraci F, Nunnari G, Gagliano C, Greco C, Chisari G, Drago F, Bertino G. Silybin-vitaminE-phospholipids complex reduces liver fibrosis in patients with chronic epatiti C treated with pegylated interferon  $\alpha$  and ribavirin. *Am J Transl Res.* 2015 Nov 15;7(11):2510-8. eCollection 2015. PubMed PMID: 26807195; PubMed Central PMCID: PMC4697727. I.F. 3.4
  106. Nunnari G. , Malaguamera L. , Lazzara F. , Cambria D. , Distefano G. , Longo A. , Palumbo M. , Fagone P. , Di Rosa M. Th17 common genes in CD4 T-cells of HIV-1-infected naïve patients and elite controllers. *Infect Dis Trop Med* 2015; 1 (2): e121
  107. Guameri C, Tchernev G, Bevelacqua V, Lotti T, Nunnari G. The unwelcome trio: HIV plus cutaneous and visceral leishmaniasis. *Dermatol Ther.* 2015 Nov 2. doi:10.1111/dth.12303. [Epub ahead of print] PubMed PMID: 26555699. I.F.1.59
  108. Castronuovo D. , Pinzone M. R. , Moreno S. , Cacopardo B. , Nunnari G. HIV infection and bone disease: a review of the literature. *Infect Dis Trop Med* 2015; 1 (2): e116
  109. Bellissimo F, Pinzone MR, Cacopardo B, Nunnari G. Diagnostic and therapeutic management of hepatocellular carcinoma. *World J Gastroenterol.* 2015 Nov 14;21(42):12003-21. doi: 10.3748/wjg.v21.i42.12003. Review. PubMed PMID: 26576088; PubMed Central PMCID: PMC4641121. I.F.2.36
  110. Gabriella D'ettore, Giancarlo Ceccarelli, Mauro Andreotti, Carla Selvaggi, Ivan Schietroma, Giuseppe Nunnari, Guido Antonelli, Vincenzo Vullo, Carolina Scagnolari, Sara Serafino and Noemi Giustini. Analysis of Th17 and Tc17 frequencies and antiviral defenses in gut-associated lymphoid tissue of chronic HIV-1 positive patients," *Mediators of Inflammation* (2015) (in press) I.F. 2.417
  111. Pinzone MR, Nunnari G. Prevalence of comorbidities in a cohort of women living with HIV *Infect Dis Trop Med* 2015; 1 (3): e165
  112. Pinzone MR, Berretta M, Cacopardo B, Nunnari G. Epstein-Barr Virus- and Kaposi Sarcoma-Associated Herpesvirus-Related Malignancies in the Setting of Human Immunodeficiency Virus Infection. *Semin Oncol.* 2015 Apr;42(2):258-271. I.F. 3.943

113. Gussio M. , Pinzone M. , Cacopardo B. , Cocuzza S. , Nunnari G. Primary isolated nasopharyngeal tuberculosis in an otherwise healthy individual: a case report and mini review of the literature. *Infect Dis Trop Med* 2015; 1 (3): e136
114. Cacopardo B. , Maresca M. , Sofia S. , Pinzone M. R. , Nunnari G. IL-15 Serum Levels In Acute And Chronic Brucellosis. *Infect Dis Trop Med* 2015; 1 (1): E35
115. Sofia S. , Scarvaglieri E. , Pinzone M. R. , Maresca M. , Cacopardo B. , Nunnari G. Photoquiz – Chronic Back Pain And An Inguinal Mass: What Is Your Diagnosis? *Infect Dis Trop Med* 2015; 1 (1): E32
116. Fontana Del Vecchio R. , Pinzone M. R. , Celesia B. M. , Palermo F. , Cacopardo B. , Nunnari G. ZDV/3TC To ABC/3TC Switch And Bone Marrow Toxicity In The Post-HAART Era. *Infect Dis Trop Med* 2015; 1 (1): E39
117. Giuseppe Nunnari. Introduction To Infectious Diseases And Tropical Medicine. *Infect Dis Trop Med* 2015; 1 (1): E59
118. R. Fontana Del Vecchio, B.M. Celesia, M.R. Pinzone, B. Cacopardo, G. Nunnari. A Relapsing Case Of Kaposi's Sarcoma. *WCRJ* 2014; 1 (3): E282
119. Pinzone MR, Zanghi AM, Rapisarda L, D'Agata V, Benanti F, Spartà D, Nunnari G, Cacopardo B. Cirrhotic patients are still at risk of developing hepatocellular carcinoma despite Interferon-induced sustained virological response. *Eur Rev Med Pharmacol Sci.* 2014 Dec;18(2 Suppl):11-5. PMID:25535185. I.F.: 1.089
120. Malaguamera G, Giordano M, Nunnari G, Bertino G, Malaguamera M. Gut microbiota in alcoholic liver disease: Pathogenetic role and therapeutic perspectives. *World J Gastroenterol.* 2014 Nov 28;20(44):16639-16648. PMID: 25469033 I.F: 2.433
121. Vitaliti G, Falsaperla R, Lubrano R, Rapisarda V, Cocuzza S, Nunnari G, Pavone P. Incidence of Mediterranean Spotted Fever in Sicilian children: a clinical-epidemiological observational retrospective study from 1987 to 2010. *Int J Infect Dis.* 2014 Nov 6. pii: S12019712(14)01676-2. doi: 10.1016/j.ijid.2014.11.001. [Epub ahead of print]. PMID:25461654. I.F.: 2.330
122. Vitaliti G, Pavone P, Mahmood F, Nunnari G, Falsaperla R. Targeting inflammation as a therapeutic strategy for drug-resistant epilepsies: An update of new immune-modulating approaches. *Hum Vaccin Immunother.* 2014 Mar 7;10(4). [Epub ahead of print] Review. PubMed PMID: 24609096. I.F.: 3.643
123. Pinzone MR, Cacopardo B, Nunnari G. Relapsed nodular sclerosis Hodgkin lymphoma in a patient with HIV infection. *WCRJ* 2014; 1(4):e389
124. Pinzone MR, Cacopardo B, Nunnari G. Comment about "Lymphomas and other cancers in HIV-infected patients". *WCRJ* 2014; 1(4):e345
125. Fontana Del Vecchio R, Pinzone MR, Cacopardo B, Nunnari G. Anal cancer in HIV-positive patients. *WCRJ* 2014; 1 (4): e405
126. Pinzone MR, Cacopardo B, Abbo L, Nunnari G. Optimal duration of antimicrobial therapy in ventilator-associated pneumonia: What is the role for procalcitonin? *JGAR* 2014 (Epub ahead of print)
127. Pinzone MR, Moreno S, Cacopardo B, Nunnari G. Is there enough evidence to use bisphosphonates in HIV-infected patients? A systematic review and meta-analysis. *AIDS Reviews* 2014;16(4). I.F.: 4.023
128. BM Celesia, R Fontana, MR Pinzone, M Cuccia, F Bellissimo, L Rapisarda, S Rinnone, V Rapisarda, P Pavone, B Cacopardo, G Nunnari. A measles outbreak in Catania, Sicily: the importance of high vaccination coverage and early notification of cases for health and economic reasons. *Infez Med* 2014; 22(3):222-6.
129. BM Celesia, B Cacopardo, D Massimino, M Gussio, S Tosto, G Nunnari, MR Pinzone. Atypical Presentation of PKDL due to *Leishmania infantum* in an HIV-Infected Patient with Relapsing Visceral Leishmaniasis. *Case Rep Infect Dis* 2014; 2014:370286.
130. Pinzone MR, Cacopardo B, Abbo L, Nunnari G. Duration of antimicrobial therapy in community acquired

pneumonia: Less is more (2014) The Scientific World Journal 2014 doi: 10.1155/2014/759138

131. Malaguarnera G, Pennisi M, Gagliano C, Vacante M, Malaguarnera M, Salomone S, Drago F, Bertino G, Caraci F, Nunnari G, Malaguarnera M. Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon- $\alpha$  2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial. *Hepat Mon.* 2014 May 5;14(5):e11608. doi: 10.5812/hepatmon.11608. eCollection 2014 May. PubMed PMID:24910702. I.F.: 1.796
132. Madeddu G, Mameli G, Capobianco G, Babudieri S, Maida I, Bagella P, Rocca G, Cherchi PL, Sechi LA, Zanetti S, Nunnari G, Dessole S, Mura MS. HPV infection in HIV-positive females: the need for cervical cancer screening including HPV-DNA detection despite successful HAART. *Eur Rev Med Pharmacol Sci.* 2014 Apr;18(8):1277-85. PubMed PMID: 24817305.I.F.: 1.089
133. Bearz A, Vaccher E, Martellotta F, Spina M, Talamini R, Lleshi A, Cacopardo B, Nunnari G, Berretta M, Tirelli For The Italian Cooperative Group On Aids And Tumors U. Lung cancer in HIV positive patients: the GICAT experience. *Eur Rev Med Pharmacol Sci.* 2014 Feb;18(4):500-8. PubMed PMID: 24610616. I.F.: 1.089
134. Cacopardo B, Pinzone MR, Gussio M, Nunnari G. High prevalence of parotidial abnormalities among HCV infected patients. *Infez Med.* 2014 Mar;22(1):31-5. PubMed PMID: 24651088.
135. Rapisarda V, Bracci M, Nunnari G, Ferrante M, Ledda C. Tetanus immunity in construction workers in Italy. *Occup Med (Lond).* 2014 Apr;64(3):217-9. doi: 10.1093/occmed/kqu019. PubMed PMID: 24706467. I.F. 1.472
136. Rizzo L, Attanasio M, Pinzone MR, Berretta M, Malaguarnera M, Morra A, L'Abbate L, Balestrieri L, Nunnari G, Cacopardo B. A New Sampling Method For Spleen Stiffness Measurement Based On Quantitative Acoustic Radiation Force Impulse Elastography For Noninvasive Assessment Of Esophageal Varices In Newly Diagnosed HCV-Related Cirrhosis. *Biomed Res Int.* 2014;2014:365982. doi: 10.1155/2014/365982. Epub 2014 Mar 4. PubMed PMID: 24729970; PubMed Central PMCID: PMC3960519. I.F.:2.706
137. Vecchio RF, Pinzone MR, Nunnari G, Cacopardo B. Neurocysticercosis in a 23-year-old Chinese man. *Am J Case Rep.* 2014 Jan 18;15:31-4. doi:10.12659/AJCR.889807. eCollection 2014 Jan 18. PubMed PMID: 24459541; PubMed Central PMCID: PMC3899174.
138. Di Rosa M, Tibullo D, Vecchio M, Nunnari G, Saccone S, Di Raimondo F, Malaguarnera L. Determination of chitinases family during osteoclastogenesis. *Bone.* 2014 Jan 16;61C:55-63. doi: 10.1016/j.bone.2014.01.005. [Epub ahead ofprint] PubMed PMID: 24440516. I.F.: 4.461
139. Madeddu G, Fiori ML, Ena P, Riu F, Lovigu C, Nunnari G, Bagella P, Maida I, Babudieri S, Mura MS. Mucocutaneous leishmaniasis as presentation of HIV infection in Sardinia, insular Italy. *Parasitol Int.* 2014 Feb;63(1):35-6. doi:10.1016/j.parint.2013.10.002. Epub 2013 Oct 11. PubMed PMID: 24126182. I.F.: 2.111
140. De Socio GV, Ricci E, Maggi P, Parruti G, Pucci G, Di Biagio A, Calza L, Orofino G, Carezzi L, Cecchini E, Madeddu G, Quirino T, Schillaci G; CISA Study Group. Prevalence, awareness, treatment, and control rate of hypertension in HIV-infected patients: the HIV-HY study. *Am J Hypertens.* 2014 Feb;27(2):222-8. doi: 10.1093/ajh/hpt182. Epub 2013 Sep 27. PubMed PMID: 24077828. I.F.: 3.402
141. Serra A, Andaloro C, Castro V, Gigante F, Cassarà G, Martines F, Nunnari G, Cocuzza S (2013). Atypical Presentation Of Ramsay Hunt Syndrome Without Facial Palsy In An immunocompetent Young Male. *Acta Medica Mediterranea*, Issn: 0393-6384/2013. I.F.: 0.333
142. Strazzulla A, Cocuzza S, Pinzone MR, Martines F, Serra A, Cosentino S, Cacopardo B, Nunnari G (2013). Isolated Laryngeal Leishmaniasis In A 55-Year-Old Man With Dysphonia And Rheumatoid Arthritis: Case Report And Literature Review. *Acta Medica Mediterranea*, P. 77-80, Issn: 0393-6384 I.F.: 0.333
143. Cacopardo B, Pinzone M, Berretta S, Fisichella R, Di Vita M, Zanghì G, Cappellani A, Nunnari G, Zanghì A. Localized and systemic bacterial infections in necrotizing pancreatitis submitted to surgical necrosectomy or percutaneous drainage of necrotic secretions. *BMC Surg.* 2013;13 Suppl 2:S50. doi:10.1186/1471-2482-13-S2-S50. Epub 2013 Oct 8. PubMed PMID: 24267612; PubMed Central PMCID: PMC3851131.I.F.: 1.24
144. Cacopardo B, Benanti F, Pinzone MR, Nunnari G. Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature. *BMC Res Notes.* 2013 Oct

- 30;6:437. doi:10.1186/1756-0500-6-437. PubMed PMID: 24171974; PubMed Central PMCID: PMC3815306.
145. Scarpino M, Pinzone MR, Di Rosa M, Madeddu G, Focà E, Martellotta F, Schioppa O, Ceccarelli G, Celesia BM, d'Ettore G, Vullo V, Berretta S, Cacopardo B, Nunnari G. Kidney disease in HIV-infected patients. *Eur Rev Med Pharmacol Sci.* 2013 Oct;17(19):2660-7. PubMed PMID: 24142615. I.F.: 1.089
  146. Pinzone MR, Berretta M, Doerr HW, Nunnari G, Cacopardo B. The complexity of aging: cancer risk among elderly people and infectious risk among those with cancer. *Anticancer Agents Med Chem.* 2013 Nov;13(9):1444-8. PubMed PMID:24102281. I.F.: 2.939
  147. Castronuovo D, Cacopardo B, Pinzone MR, Di Rosa M, Martellotta F, Schioppa O, Moreno S, Nunnari G. Bone disease in the setting of HIV infection: update and review of the literature. *Eur Rev Med Pharmacol Sci.* 2013 Sep;17(18):2413-9. Review. PubMed PMID: 24089217. I.F.: 1.089
  148. La Ferla L, Pinzone MR, Nunnari G, Martellotta F, Lleshi A, Tirelli U, DePaoli P, Berretta M, Cacopardo B. Kaposi's sarcoma in HIV-positive patients: the state of art in the HAART-era. *Eur Rev Med Pharmacol Sci.* 2013 Sep;17(17):2354-65. Review. PubMed PMID: 24065230. I.F.: 1.089
  149. Vitaliti G, Falsaperla R, Giunta L, Spataro G, Rapisarda V, Velardita M, Nunnari G, Pavone P. Acute Glomerulonephritis in a Child with Chlamydia pneumoniae Infection: A Case Report. *Case Rep Med.* 2013;2013:570921. doi:10.1155/2013/570921. Epub 2013 Jul 18. PubMed PMID: 23970901; PubMed Central PMCID: PMC3732622.
  150. Bellissimo F, Pinzone MR, Tosto S, Nunnari G, Cacopardo B. *Achromobacter xylosoxidans* meningitis in an immunosuppressed patient. *QJM.* 2014 Jan;107(1):65-6. doi: 10.1093/qjmed/hct170. Epub 2013 Aug 22. PubMed PMID: 23970185. I.F.: 2.460
  151. Celesia BM, Castronuovo D, Pinzone MR, Bellissimo F, Mughini MT, Lupo G, Scarpino MR, Gussio M, Palermo F, Cosentino S, Cacopardo B, Nunnari G. Late presentation of HIV infection: predictors of delayed diagnosis and survival in Eastern Sicily. *Eur Rev Med Pharmacol Sci.* 2013 Aug;17(16):2218-24. PubMed PMID: 23893189. I.F.: 1.089
  152. Celesia BM, Nigro L, Pinzone MR, Coco C, La Rosa R, Bisicchia F, Mavilla S, Gussio M, Pellicanò G, Milioni V, Palermo F, Russo R, Mughini MT, Martellotta F, Taibi R, Cacopardo B, Nunnari G. High prevalence of undiagnosed anxiety symptoms among HIV-positive individuals on cART: a cross-sectional study. *Eur Rev Med Pharmacol Sci.* 2013 Aug;17(15):2040-6. PubMed PMID: 23884824. I.F.: 1.089
  153. Pinzone MR, Di Rosa M, Celesia BM, Condorelli F, Malaguarrera M, Madeddu G, Martellotta F, Castronuovo D, Gussio M, Coco C, Palermo F, Cosentino S, Cacopardo B, Nunnari G. LPS and HIV gp120 modulate monocyte/macrophage CYP27B1 and CYP24A1 expression leading to vitamin D consumption and hypovitaminosis D in HIV-infected individuals. *Eur Rev Med Pharmacol Sci.* 2013 Jul;17(14):1938-50. PubMed PMID:23877860. I.F.: 1.089
  154. Strazzulla A, Cocuzza S, Pinzone MR, Postorino MC, Cosentino S, Serra A, Cacopardo B, Nunnari G. Mucosal leishmaniasis: an underestimated presentation of a neglected disease. *Biomed Res Int.* 2013;2013:805108. doi: 10.1155/2013/805108. Epub 2013 Jun 18. Review. PubMed PMID: 23853773; PubMed Central PMCID: PMC3703408. I.F.:2.706
  155. Cacopardo B, Stefani S, Cardì F, Cardì C, Pinzone MR, Nunnari G. Surgical Site Infection by *Corynebacterium macginleyi* in a Patient with Neurofibromatosis Type 1. *Case Rep Infect Dis.* 2013;2013:970678. doi: 10.1155/2013/970678. Epub 2013 May 30. PubMed PMID: 23819079; PubMed Central PMCID: PMC3683466.
  156. Antoci E, Pinzone MR, Nunnari G, Stefani S, Cacopardo B. Prevalence and molecular characteristics of methicillin-resistant *Staphylococcus aureus* (MRSA) among subjects working on bovine dairy farms. *Infez Med.* 2013 Jun;21(2):125-9. PubMed PMID: 23774976.
  157. Nunnari G, Gussio M, Pinzone MR, Martellotta F, Cosentino S, Cacopardo B, Celesia BM. Cryptococcal meningitis in an HIV-1-infected person: relapses or IRIS? Case report and review of the literature. *Eur Rev Med Pharmacol Sci.* 2013 Jun;17(11):1555-9. Review. PubMed PMID: 23771547. I.F.: 1.089

158. Pinzone MR, Di Rosa M, Malaguamera M, Madeddu G, Focà E, Ceccarelli G, d'Ettore G, Vullo V, Fisichella R, Cacopardo B, Nunnari G. Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic. *Eur Rev Med Pharmacol Sci.* 2013 May;17(9):1218-32. Review. PubMed PMID: 23690192. I.F.: 1.089
159. Cocuzza S, Strazzulla A, Pinzone MR, Cosentino S, Serra A, Caltabiano R, Lanzafame S, Cacopardo B, Nunnari G. Isolated laryngeal leishmaniasis in immunocompetent patients: an underdiagnosed disease. *Case Rep Infect Dis.* 2013;2013:165409. doi: 10.1155/2013/165409. Epub 2013 Apr 15. PubMed PMID: 23662221; PubMed Central PMCID: PMC3639709.
160. Pavone P, Cocuzza S, Passaniti E, Longo MR, Verrotti A, Serra A, Romano C, Nunnari G, Falsaperla R. Otorrhea in Kawasaki disease diagnosis complicated by an EBV infection: coincidental disease or a true association. *Eur Rev Med Pharmacol Sci.* 2013 Apr;17(7):989-93. PubMed PMID: 23640449. I.F.: 1.089
161. Pinzone MR, Cacopardo B, Condorelli F, Di Rosa M, Nunnari G. Sirtuin-1 and HIV-1: an overview. *Curr Drug Targets.* 2013 Jun 1;14(6):648-52. Review. PubMed PMID: 23547809. I.F.: 3.597
162. Nunnari G, Pinzone MR, Vancheri C, Palermo F, Cacopardo B. Interferon- $\gamma$  and interleukin-17 production from PPD-stimulated PBMCs of patients with pulmonary tuberculosis. *Clin Invest Med.* 2013 Apr 1;36(2):E64-71. PubMed PMID: 23544607. I.F.: 0.971
163. Cacopardo B, Pinzone MR, Nunnari G. [Development of sarcoidosis during treatment for chronic hepatitis C with pegylated interferon alfa-2a and ribavirin: case report and literature review]. *Infez Med.* 2013 Mar;21(1):40-44. Review. Italian. PubMed PMID: 23524900.
164. Nunnari G, Pinzone MR, Cacopardo B. Lack of clinical and histological progression of chronic hepatitis C in individuals with true persistently normal ALT: the result of a 17-year follow-up. *J Viral Hepat.* 2013 Apr;20(4):e131-7. doi: 10.1111/jvh.12029. Epub 2012 Dec 5. PubMed PMID: 23490382. I.F.: 3.307
165. Schillaci G, Maggi P, Madeddu G, Pucci G, Mazzotta E, Penco G, Orofino G, Menzaghi B, Rusconi S, Carenci L, Celesia BM, Martinelli C, Bonfanti P, De Socio GV; CISA Study Group. Symmetric ambulatory arterial stiffness index and 24-h pulse pressure in HIV infection: results of a nationwide cross-sectional study. *J Hypertens.* 2013 Mar;31(3):560-7; discussion 567. Doi:10.1097/HJH.0b013e32835ca949. PubMed PMID: 23282895. I.F.: 4.222
166. Di Rosa M, Malaguamera L, Nicolosi A, Sanfilippo C, Mazzarino C, Pavone P, Berretta M, Cosentino S, Cacopardo B, Pinzone MR, Nunnari G. Vitamin D3: an ever green molecule. *Front Biosci (Schol Ed).* 2013 Jan 1;5:247-60. Review. PubMed PMID: 23277049. I.F.: 4.249
167. Pavone P, Passaniti E, Taibi R, Longo MR, Nunnari G, Verrotti A, Serra A, Falsaperla R, Cocuzza S. Intravenous immunoglobulin therapy when plasmapheresis fails in thrombotic thrombocytopenic purpura associated with severe ADAMTS-13 deficiency in childhood: a case report. *Eur J Inflamm* 2013; 11(1):291-296
168. Guameri C, Bevelacqua V, Nunnari G. Nail pigmentation and fatigue. *Cleve Clin J Med.* 2012 Nov;79(11):785-6. doi: 10.3949/ccjm.79a.12011. PubMed PMID: 23125328. I.F.: 3.37
169. Bruno Cacopardo, Marilia Rita Pinzone, Filippo Palermo, Giuseppe Nunnari. Changes in serum Interleukin-33 concentration before and after treatment with pegylated interferon alfa-2a plus ribavirin in patients with chronic hepatitis C genotype 1b infection. *Hepatitis Monthly.* 2012, Volume 12, Issue 12, Dec: e7611. | DOI: 10.5812/hepatmon.7611 I.F.: 1.796
170. Nunnari G, Berretta M, Pinzone MR, Di Rosa M, Berretta S, Cunsolo G, Malaguamera M, Cosentino S, De Paoli P, Schnell JM, Cacopardo B. Hepatocellular carcinoma in HIV positive patients. *Eur Rev Med Pharmacol Sci.* 2012 Sep;16(9):1257-70. Review. PubMed PMID: 23047511. I.F.: 1.089
171. Rizzo L, Nunnari G, Berretta M, Cacopardo B. Acoustic Radial Force Impulse as an effective tool for a prompt and reliable diagnosis of hepatocellular carcinoma - preliminary data. *Eur Rev Med Pharmacol Sci.* 2012 Oct;16(11):1596-8. PubMed PMID: 23111977. I.F.: 1.089
172. Pinzone MR, Fiorica F, Di Rosa M, Malaguamera G, Malaguamera L, Cacopardo B, Zanghi G, Nunnari G. Non-AIDS-defining cancers among HIV-infected people. *Eur Rev Med Pharmacol Sci.* 2012 Oct;16(10):1377-88.

Review. PubMed PMID: 23104654. I.F.: 1.089

173. Di Rosa M, Malaguarnera G, De Gregorio C, Palumbo M, Nunnari G, Malaguarnera L. Immuno-modulatory effects of vitamin D3 in human monocyte and macrophages. *Cell Immunol.* 2012 Nov 29;280(1):36-43. doi: 10.1016/j.cellimm.2012.10.009. [Epub ahead of print] PubMed PMID: 23261827. I.F.: 1.874
174. Celesia B, Gussio M, Franco A, Scifo G, Prestileo T, Di Lorenzo F, La Rosa R, Nigro L, Colomba C, Ingrassia D, Galvagna S, Mannino G, Storaci N, Migliore S, Salvo A, Todaro G, Portelli V, Sturniolo G, Davi' A, Bruno S, Bellissima P, Guameri L, Palermo F, Zagami A, Nunnari G, Cosentino S. Test for CCR5 tropism and treatment with maraviroc in Sicily: an observational retrospective multicentre study. *J Int AIDS Soc.* 2012 Nov 11;15(6):18216. doi: 10.7448/IAS.15.6.18216. PubMed PMID: 23234888. I.F.: 4.207
175. Nunnari G, Montineri A, Portelli V, Savalli F, Fatuzzo F, Cacopardo B. The use of peginterferon in monotherapy or in combination with ribavirin for the treatment of acute hepatitis C. *Eur Rev Med Pharmacol Sci.* 2012 Aug;16(8):1013-6. PubMed PMID: 22913149. I.F.: 1.089
176. Pinzone MR, Celesia BM, Di Rosa M, Cacopardo B, Nunnari G. Microbial translocation in chronic liver diseases. *Int J Microbiol.* 2012;2012:694629. Epub 2012 Jul 17. PubMed PMID: 22848224; PubMed Central PMCID: PMC3405644.
177. Malaguarnera G, Cataudella E, Giordano M, Nunnari G, Chisari G, Malaguarnera M. Toxic hepatitis in occupational exposure to solvents. *World J Gastroenterol.* 2012 Jun 14;18(22):2756-66. PubMed PMID: 22719183; PubMed Central PMCID: PMC3374978. I.F.: 2.433
178. Zanet E, Berretta M, Benedetto FD, Talamini R, Ballarin R, Nunnari G, Berretta S, Ridolfo A, Lleshi A, Zanghi A, Cappellani A, Tirelli U. Pancreatic cancer in HIV-positive patients: a clinical case-control study. *Pancreas.* 2012 Nov;41(8):1331-5. doi: 10.1097/MPA.0b013e31824a0e40. PubMed PMID: 22695133. I.F.: 3.008
179. Nunnari G, Coco C, Pinzone MR, Pavone P, Berretta M, Di Rosa M, Schnell M, Calabrese G, Cacopardo B. The role of micronutrients in the diet of HIV-1-infected individuals. *Front Biosci (Elite Ed).* 2012 Jun 1;4:2442-56. PubMed PMID: 22652651. I.F.: 4.249
180. Nunnari G, Pinzone MR, Gruttadauria S, Celesia BM, Madeddu G, Malaguarnera G, Pavone P, Cappellani A, Cacopardo B. Hepatic echinococcosis: clinical and therapeutic aspects. *World J Gastroenterol.* 2012 Apr 7;18(13):1448-58. Review. PubMed PMID: 22509076; PubMed Central PMCID: PMC3319940. I.F.: 2.433
181. Pinzone MR, Di Rosa M, Cacopardo B, Nunnari G. HIV RNA suppression and immune restoration: can we do better? *Clin Dev Immunol.* 2012;2012:515962. Epub 2012 Mar PubMed PMID: 22489250; PubMed Central PMCID: PMC3318265. I.F.: 2.934
182. Cacopardo B, Camma C, Petta S, Pinzone MR, Cappellani A, Zanghi A, Nicolosi A, Nunnari G. Diagnostic and therapeutical role of vitamin D in chronic hepatitis C virus infection. *Front Biosci (Elite Ed).* 2012 Jan 1;4:1276-86. Review. PubMed PMID: 22201953. I.F.: 4.249
183. Guameri C, Mughini M, Celesia B, Massimino D, Nunnari G. The undesired fellow traveller. *QJM.* 2012 Jul;105(7):697-8. Epub 2011 May 4. PubMed PMID: 21543448. I.F.: 2.460
184. B. M. Celesia, F. Bellissimo, M. R. Pinzone, R. La Rosa, C. Coco, M. Gussio, P. Nicotra, F. Palermo, L. Nigro, S. Cosentino, Nunnari G. Predictive criteria of sustained virological response (more than 60 months) to Nevirapine-based antiretroviral treatment. *HAART AND CORRELATED PATHOLOGIES.* 2011, 424-427
185. Ciuni R, Biondi A, Grosso G, Nunnari G, Panascia E, Randisi L, Volpes R, Arcadipane A, Basile F, Gridelli B, Gruttadauria S. Nutritional aspects inpatient undergoing liver resection. *Updates Surg.* 2011 Dec;63(4):249-52. Epub 2011 Nov 9. Review. PubMed PMID: 22068963.
186. Rizzo L, Calvaruso V, Cacopardo B, Alessi N, Attanasio M, Petta S, Fatuzzo F, Montineri A, Mazzola A, L'abbate L, Nunnari G, Bronte F, Di Marco V, Craxi A, Cammà C. Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. *Am J Gastroenterol.* 2011 Dec;106(12):2112-20. doi:10.1038/ajg.2011.341. Epub 2011 Oct 4. PubMed PMID: 21971536. I.F.: 9.213

187. Malaguarnera M, Vacante M, Motta M, Giordano M, Malaguarnera G, Bella R, Nunnari G, Rampello L, Pennisi G. Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial. *Metab Brain Dis.* 2011 Dec;26(4):281-9. Epub 2011 Aug 26. PubMed PMID: 21870121. I.F.: 2.398
188. Pavone P, Longo MR, Taibi R, Nunnari G, Romano C, Passaniti E, Falsaperla R. Acute asthma in children: treatment in emergency. *Eur Rev Med Pharmacol Sci.* 2011 Jun;15(6):711-6. PubMed PMID: 21796876. I.F.: 1.089
189. Nunnari G, Schnell MJ. MicroRNA-122: a therapeutic target for hepatitis C virus (HCV) infection. *Front Biosci (Schol Ed).* 2011 Jun 1;3:1032-7. PubMed PMID: 21622252. I.F.: 4.249
190. Nunnari G, Celesia BM, Bellissimo F, Tosto S, La Rocca M, Giarratana F, Benanti F, Caltabiano E, Russo R, Cacopardo B. Trimethoprim-sulfamethoxazole-associated severe hypoglycaemia: a sulfonyleurea-like effect. *Eur Rev Med Pharmacol Sci.* 2010 Dec;14(12):1015-8. PubMed PMID: 21375132. I.F.: 1.089
191. Nunnari G, Vancheri C, Gilli E, Migliore S, Palermo F, La Rosa C, Nicotra P, Russo R, Cacopardo B. Circulating fibrocytes as a marker of liver fibrosis in chronic hepatitis C. *Front Biosci (Elite Ed).* 2010 Jun 1;2:1241-5. PubMed PMID: 20515796. I.F.: 4.249
192. Berretta M, Lleshi A, Cappellani A, Bearz A, Spina M, Talamini R, Cacopardo B, Nunnari G, Montesarchio V, Izzi I, Lanzafame M, Nasti G, Basile F, Berretta S, Fisichella R, Schiantarelli C C, Garlassi E, Ridolfo A, Guella L, Tirelli U. Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection. *Curr HIV Res.* 2010 Apr;8(3):218-22. PubMed PMID: 20158458. I.F.: 2.135
193. Guameri C, Polimeni G, Nunnari G. Pityriasis rosea during etanercept therapy. *Eur Rev Med Pharmacol Sci.* 2009 Sep-Oct;13(5):383-7. PubMed PMID: 19961045. I.F.: 1.089
194. Cacopardo B, Nunnari G, Nigro L. Clearance of HCV RNA following acute hepatitis A superinfection. *Dig Liver Dis.* 2009 May;41(5):371-4. Epub 2008 Jan 7. PubMed PMID: 18182335. I.F.: 2.889
195. Cacopardo B, Nunnari G, Benanti F, Cappellani A, Onorante A, Caltabiano E, Russo R. Leukocyte interferon alpha early retreatment for Child A HCV genotype 1b-infected cirrhotics intolerant to pegylated interferons. *Infection.* 2009 Jun;37(3):210-5. Epub 2008 Dec 5. PubMed PMID: 19139808. I.F.: 2.864
196. Cacopardo B, Nigro L, Nunnari G, La Medica G, Cappellani A, Palermo F, Cappello E, Russo R. [Association between raised IL-8 serum levels and resistance to combined peg-interferon plus ribavirin therapy in HCV+ active chronic hepatitis]. *Infez Med.* 2008 Jun;16(2):80-5. Italian. PubMed PMID: 18622147.
197. Nunnari G, Smith JA, Daniel R. HIV-1 Tat and AIDS-associated cancer: targeting the cellular anti-cancer barrier? *J Exp Clin Cancer Res.* 2008 May 15;27:3. Review. PubMed PMID: 18577246; PubMed Central PMCID: PMC2438332. I.F.: 3.27
198. Nunnari G. Do Vgamma2Vdelta2 T cells influence HIV disease progression? *Clin Infect Dis.* 2008 May 1;46(9):1473-5. PubMed PMID: 18419458. I.F.: 9.416
199. Smith JA, Nunnari G, Preuss M, Pomerantz RJ, Daniel R. Pentoxifylline suppresses transduction by HIV-1-based vectors. *Intervirology.* 2007;50(5):377-86. Epub 2007 Oct 15. PubMed PMID: 17938572. I.F.: 1.773
200. Celesia BM, Onorante A, Nunnari G, Mughini MT, Mavilla S, Massimino SD, Russo R. Porphyria cutanea tarda in an HIV-1-infected patient after the initiation of tipranavir/ritonavir: case report. *AIDS.* 2007 Jul 11;21(11):1495-6. PubMed PMID: 17589203. I.F.: 6.557
201. Pavone P, Nicolini E, Greco F, Taibi R and G. Nunnari. Peripheral neuropathy in a child with *Mycoplasma pneumoniae* infections. *Journal of Pediatric Infectious Diseases*, 2007, Volume 2, Number 3, 163-66.
202. Modica A, Nicolini E; Nicolini A; D'Orazio A; Nunnari G; Pavone P. Chronic *Yersinia enterocolitica* Infection Presenting as Intestinal Obstruction. *Infectious Diseases in Clinical Practice.* January 2007. 15(1):68-69.
203. Argyris EG, Dornadula G, Nunnari G, Acheampong E, Zhang C, Mehlman K, Pomerantz RJ, Zhang H. Inhibition of endogenous reverse transcription of human and nonhuman primate lentiviruses: potential for development of

- lentivirucides. *Virology*. 2006 Sep 30;353(2):482-90. Epub 2006 Jul 21. PubMed PMID: 16859727; PubMed Central PMCID: PMC1626530. I.F.: 3.278
204. Chen K, Huang J, Zhang C, Huang S, Nunnari G, Wang FX, Tong X, Gao L, Nikisher K, Zhang H. Alpha interferon potentially enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. *J Virol*. 2006 Aug;80(15):7645-57. PubMed PMID: 16840343; PubMed Central mPMCID: PMC1563726. I.F.: 4.648
205. Pavone P, Nicolini A, Armenia R, D'Orazio A, Nunnari G, Nicolini E. Kawasaki's disease with paralytic ileus. A case report. *Minerva Pediatr*. 2006 Apr;58(2):193-7. PubMed PMID: 16835578. I.F.: 0.723
206. Dave RS, McGettigan JP, Qureshi T, Schnell MJ, Nunnari G, Pomerantz RJ. siRNA targeting vaccinia virus double-stranded RNA binding protein [E3L] exerts potent antiviral effects. *Virology*. 2006 May 10;348(2):489-97. Epub 2006 Feb 9. PubMed PMID: 16480752. I.F.: 3.278
207. Nunnari G, Pomerantz RJ. IL-7 as a potential therapy for HIV-1-infected individuals. *Expert Opin Biol Ther*. 2005 Nov;5(11):1421-6. Review. PubMed PMID: 16255646. I.F.: 3.653
208. Nunnari G, Leto D, Sullivan J, Xu Y, Mehlman KE, Kulkosky J, Pomerantz RJ. Seminal reservoirs during an HIV type 1 eradication trial. *AIDS Res Hum Retroviruses*. 2005 Sep;21(9):768-75. PubMed PMID: 16218800. I.F.: 2.457
209. Nunnari G, Xu Y, Acheampong EA, Fang J, Daniel R, Zhang C, Zhang H, Mukhtar M, Pomerantz RJ. Exogenous IL-7 induces Fas-mediated human neuronal apoptosis: potential effects during human immunodeficiency virus type 1 infection. *J Neurovirol*. 2005 Aug;11(4):319-28. PubMed PMID: 16162475. I.F.: 3.323
210. Nunnari G, Sullivan J, Xu Y, Nyirjesy P, Kulkosky J, Cavert W, Frank I, Pomerantz RJ. HIV type 1 cervicovaginal reservoirs in the era of HAART. *AIDS Res Hum Retroviruses*. 2005 Aug;21(8):714-8. PubMed PMID: 16131311. I.F.: 2.457
211. Nunnari G, Argyris E, Fang J, Mehlman KE, Pomerantz RJ, Daniel R. Inhibition of HIV-1 replication by caffeine and caffeine-related methylxanthines. *Virology*. 2005 May 10;335(2):177-84. PubMed PMID: 15840517. I.F.: 3.278
212. Wang FX, Xu Y, Sullivan J, Souder E, Argyris EG, Acheampong EA, Fisher J, Sierra M, Thomson MM, Najera R, Frank I, Kulkosky J, Pomerantz RJ, Nunnari G. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. *J Clin Invest*. 2005 Jan;115(1):128-37. PubMed PMID: 15630452; PubMed Central PMCID: PMC539197. I.F.: 13.765
213. Xu Y, Kulkosky J, Acheampong E, Nunnari G, Sullivan J, Pomerantz RJ. HIV-1-mediated apoptosis of neuronal cells: Proximal molecular mechanisms of HIV-1-induced encephalopathy. *Proc Natl Acad Sci U S A*. 2004 May 4;101(18):7070-5. Epub 2004 Apr 21. PubMed PMID: 15103018; PubMed Central PMCID: PMC406467. I.F.: 9.809
214. Pomerantz RJ, Nunnari G. HIV and GB virus C--can two viruses be better than one? *N Engl J Med*. 2004 Mar 4;350(10):963-5. PubMed PMID: 14999105. I.F.: 54.42
215. Cacopardo B, Nunnari G, Mughini MT, Tosto S, Benanti F, Nigro L. Fatal hepatitis during Epstein-Barr virus reactivation. *Eur Rev Med Pharmacol Sci*. 2003 Jul-Aug;7(4):107-9. PubMed PMID: 15068233. I.F.: 1.089
216. Nunnari G, Nigro L, Palermo F, Leto D, Pomerantz RJ, Cacopardo B. Reduction of serum melatonin levels in HIV-1-infected individuals' parallel disease progression: correlation with serum interleukin-12 levels. *Infection*. 2003 Dec;31(6):379-82. PubMed PMID: 14735378. I.F.: 2.864
217. Pavone P, Leonardi S, Nunnari G, Greco F, La Rosa G, Sorge G. Thrombocytopenia and scrotal swelling: an association in early Kawasaki's disease? Trombocitopenia e tumefazione scrotale: una manifestazione precoce della malattia di Kawasaki? *ITAL J PEDIATR*. 2003;29:363-366. I.F.: 1.24
218. Otero M, Nunnari G, Leto D, Sullivan J, Wang FX, Frank I, Xu Y, Patel C, Dornadula G, Kulkosky J, Pomerantz RJ. Peripheral blood Dendritic cells are not a major reservoir for HIV type 1 in infected individuals on virally suppressive HAART. *AIDS Res Hum Retroviruses*. 2003 Dec;19(12):1097-103. PubMed PMID: 14709246. I.F.: 2.864

**2.457**

219. Argyris EG, Acheampong E, **Nunnari G**, Mukhtar M, Williams KJ, Pomerantz RJ. Human immunodeficiency virus type 1 enters primary human brain microvascular endothelial cells by a mechanism involving cell surface proteoglycans independent of lipid rafts. *J Virol.* 2003 Nov;77(22):12140-51. PubMed PMID: 14581551; PubMed Central PMCID: PMC254292. **I.F.: 4.648**
220. **Nunnari G**, Nigro L, Palermo F, Attanasio M, Berger A, Doerr HW, Pomerantz RJ, Cacopardo B. Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profile. *Ann Intern Med.* 2003 Jul 1;139(1):26-30. PubMed PMID: 12834315. **I.F.: 16.104**
221. Kulkosky J, **Nunnari G**, Otero M, Calarota S, Dornadula G, Zhang H, Malin A, Sullivan J, Xu Y, DeSimone J, Babinchak T, Stern J, Cavert W, Haase A, Pomerantz RJ. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. *J Infect Dis.* 2002 Nov 15;186(10):1403-11. Epub 2002 Oct 29. PubMed PMID: 12404155. **I.F.: 5.778**
222. **Nunnari G**, Otero M, Dornadula G, Vanella M, Zhang H, Frank I, Pomerantz RJ. Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections. *AIDS.* 2002 Jan 4;16(1):39-45. PubMed PMID: 11741161. **I.F.: 6.557**
223. Dornadula G, **Nunnari G**, Vanella M, Roman J, Babinchak T, DeSimone J, Stern J, Braffman M, Zhang H, Pomerantz RJ. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups. *J Infect Dis.* 2001 Jun 1;183(11):1682-7. Epub 2001 Apr 27. PubMed PMID: 11343220. **I.F.: 5.778**
224. Cacopardo B, **Nunnari G**, Berger A, Doer HW, Russo R. Acute non A-E hepatitis in eastern Sicily: the natural history and the role of hepatitis G virus. *Eur Rev Med Pharmacol Sci.* 2000 Sep Dec;4(5-6):117-21. PubMed PMID: 11710508. **I.F.: 1.089**
225. Kulkosky J, Bouhamdan M, Geist A, **Nunnari G**, Phinney DG, Pomerantz RJ. Pathogenesis of HIV-1 infection within bone marrow cells. *Leuk Lymphoma.* 2000 May;37(5-6):497-515. PubMed PMID: 11042510. **I.F.: 2.605**

**CAPITOLI DI LIBRO:**

1. Musumeci S, Nunnari G, Polizzi A, Pavone P. "Le malattie infettive del sistema nervoso" in *Neurologia Pediatrica*, Pavone-Ruggieri. MASSON. 2006, CAP 17 pag 583-604.
2. Roger J Pomerantz and Giuseppe Nunnari. HIV-1 Reservoirs and Residual Viral Replication During Highly active Antiretroviral Therapy. In "Cell death During HIV Infection". Chapter 26 433- 448 2005, Taylor and Francis Group, LLC.
3. Pinzone MR, Cacopardo B, Nunnari G. Micronutrients in HIV infection without HAART: a focus on resource-limited settings *Health of HIV Infected People: Food, Nutrition and Lifestyle without Antiretroviral Drugs*. Elsevier Editor 2015 [In press]
4. Pinzone MR, Nunnari G, Cacopardo B. Risk Factors for Hepatocellular Carcinoma. *Hepatocellular carcinoma in the 3rd Millennium*. Nova Science Publishers 2015 [In press]
5. Pinzone MR, Nunnari G, Cacopardo B. The Epidemiology of Hepatocellular Carcinoma. *Hepatocellular carcinoma in the 3rd Millennium*. Nova Science Publishers 2015 [In press]

**ABSTRACT, POSTER E PRESENTAZIONI ORALI:**

1. Schietroma, C. Scagnolari, G. Ceccarelli, M. Andreotti, N. Giustini, S. Serafino, C. Selvaggi, G. Nunnari, G. Antonelli, G. d'Ettore, V. Vullo. Highly frequencies of Th17 and Tc17 in gut associated lymphoid tissue despite sustained immune-activation and type I interferon response in chronic HIV-1 positive patients. ICAR 2015, 17-19 Maggio 2015

2. Chairs: G. Nunnari (Catania), Oral Poster Basic Science, ICAR 2015, 17-19 Maggio 2015, Riccione, Italy
3. B.M. Celesia, M. Gussio, R. Bruno, M. Maresca, G. Nunnari, S. Piacenti, S. Sofia, F. Palermo, B. Cacopardo. It's safe to defer the CD4 cell count monitoring in stable patients on HAART with more than 350 or 500 CD4 lymphocyte/ul?. ICAR 2015, 17-19 Maggio 2015
4. M. Di Rosa, M.R. Pinzone, F. Condorelli, B. Cacopardo, G. Nunnari. CD4+ T-cell Gene Expression of HIV-1 Elite Controllers: Immunological Chaos. ICAR 2015, 17-19 Maggio 2015
5. Marilia Pinzone, Maria Gussio, Daniela Castronuovo, Adriana Di Gregorio, Benedetto Celesia, Bruno Cacopardo, Giuseppe Nunnari. Heel Quantitative Ultrasound to Cut Down on DXA Costs in HIV-infected Patients. CROI 2015, Seattle February 23-26 2015
6. L. Rizzo, M. Pinzone, L. L'Abbate, G. Nunnari, S. Piacenti, S. Sofia, L. Rapisarda, D. Castronuovo, R. Fontana Del Vecchio, B. Cacopardo. Nella Epatite Cronica C, La Valutazione Elastometrica Con Arfi Consente Di Intercettare La Disomogeneità Della Fibrosi Epatica E Di Ottenere Un Utile Assessment Clinico. Simit, Genova 26-29 Ottobre 2014
7. S. Sofia, M.R. Pinzone, B. Cacopardo, G. Nunnari, B.M. Celesia. Alessitimia E Metacognizione In Soggetti Con Infezione Da Hiv: Effetti Sulla Aderenza Alla Haart. Simit, Genova 26-29 Ottobre 2014
8. Chair-Corso Aggiornamento: Disturbi neurocognitivi nella pratica clinica: metodi e strumenti diagnostici e algoritmi clinico-terapeutici. 6° Congresso ICAR. Roma. 25-27 maggio 2014.
9. M.R. Pinzone, B.M. Celesia, B. Cacopardo, G. Nunnari. Quantitative ultrasound of the heel to assess bone mineral density in HIV-infected patients. ICAR 2014, Roma 25-27 Maggio 2014
10. M.R. Pinzone, B.M. Celesia, B. Cacopardo, G. Nunnari. Quantitative ultrasound of the heel to assess bone mineral density in HIV-infected patients. Unità Operativa di Malattie Infettive, Dipartimento di Biomedicina. 6° Congresso ICAR. Roma. 25-27 maggio 2014.
11. R. Fontana Del Vecchio, B.M. Celesia, M.R. Pinzone, F. Palermo, B. Cacopardo, G. Nunnari. ZDV/3TC to ABC/3TC switch and bone marrow toxicity in the post HAART era Unit of Infectious Diseases, University of Catania; ARNAS Garibaldi Catania. 6° Congresso ICAR. Roma. 25-27 maggio 2014.
12. F. Bellissimo, B.M. Celesia, G. Strano, G. Nunnari, M. Attanasio, S. Stefani, S. Cosentino, S. Coniglio, M. Gussio, B. Cacopardo. Epidemiologia e suscettibilità agli antibiotici dei principali patogeni in una ICU di Catania. 12° Congresso Nazionale SIMIT. Milano 27-30 ottobre 2013 (abs 147) F. Bellissimo, B. Cacopardo, B.M. Celesia, G. Lupo, M.T. Mughini, M. Gussio, S. Cosentino, G. Nunnari. Impatto della normalizzazione del rapporto CD4/CD8 in una coorte di pazienti di Catania 12° Congresso Nazionale SIMIT. Milano 27-30 ottobre 2013 (abs149)
13. M. Gussio, F. Bellissimo, G. Strano, A. Cusplisci, G. Nunnari, S. Cosentino, B.M. Celesia. Offerta del test per la ricerca degli anticorpi anti-HIV ai pazienti ricoverati nell'ARNAS Garibaldi di Catania nel biennio 2010-2011. 12° Congresso Nazionale SIMIT. Milano 27-30 ottobre 2013. (abs144)
14. M.R. Pinzone, L. Rapisarda, F. Palermo, F. Bellissimo, M. Gussio, S. Cosentino, G. Nunnari, B.M. Celesia. La terapia antiretrovirale basata sugli NNRTI è associata ad una maggiore probabilità di mantenere valori di viremia stabilmente <20 copie/ml nel corso di un follow up quadriennale 12° Congresso Nazionale SIMIT. Milano 27-30 ottobre 2013 (abs155)
15. S. Piacenti, C.M. Frasca, L. La Ferla, S.A. Sofia, M. Maresca, M.R. Scarpino, M. Scarvaglieri, M.R. Pinzone, D. Castronuovo, B.M. Celesia, S. Cosentino, B. Cacopardo, G. Nunnari. L'insulino-resistenza in una coorte di soggetti HIV positivi in terapia HAART 12° Congresso Nazionale SIMIT. Milano 27-30 ottobre 2013 (abs 337)
16. M.R. Pinzone, L. Rapisarda, F. Palermo, F. Bellissimo, M. Gussio, S. Cosentino, G. Nunnari, B.M. Celesia. NNRTI-based cART is Associated with Higher Probability of Mantaining Stable HIV RNA below 20 copies/mL in a 4-year Follow up. 14 th EACS Brussels, Belgium 16-19 october 2013 (abs PE8/27)
17. B.M. Celesia, D. Castronuovo, M.R. Pinzone, G. Nunnari, M.T. Mughini, G. Lupo, F. Benanti, M. Gussio, F. Bellissimo, F. Palermo, S. Cosentino. Rates and Reasons for HAART Switch over a 6-year Period (2007-2012) in a Cohort of Patients Living in Eastern Sicily. 14 th EACS Brussels, Belgium 16-19 october 2013 (abs PE11/22)

18. Nunnari-Moderatore-V International Meeting NEURO HIV 2013. Palermo 3-5 ottobre 2013
19. G. Nunnari, R. Fontana Del Vecchio, D. Spadaro, F. Ferlito, G. Scifo, B.M. Celesia, B. Cacopardo, Franco. Neurocognitive impairment and ART modulation. V International Meeting NEURO HIV 2013. Palermo 3-5 ottobre 2013
20. M. Scarvaglieri, R. La Rosa, S. Galvagna, L. Nigro, M. Gussio, G. Nunnari, S. Rinnone, F. Palermo, M. Cuccia, S. Cosentino, B.M. Celesia. New HIV diagnosis in the district of Catania (ETNA COHORT) in years 2007-2012.V ICAR Torino 12-14 maggio 2013 (abs P102)
21. Bandiera, B.M. Celesia, M. Maresca, S. Tosto, F. Giarratana, R.S. Grasso, P. Bonaventura, A. Onorante, M. La Rocca, V. D'Agata, G. Nunnari, M. Gussio, M. Cuccia, F. Palermo, B. Cacopardo, S. Cosentino. Aspetti epidemiologici e clinici della tubercolosi nella provincia di Catania: studio retrospettivo osservazionale anni 2006-2011. XI congresso nazionale SIMIT Pescara 17-20 ottobre 2012 (Abstract 147)
22. Nunnari-RELATORE-HIVgp120 Vitamina D ed immunoattivazione. Achilles. Siracusa Aprile 2012-07-10, presentazione orale
23. G. Nunnari, M. R. Pinzone, C. Coco, M. Gussio, F. Palermo, M. Di Rosa, S. Cosentino, B. M. Celesia. Low Vitamin D in a cohort of HIV-infected patients in Eastern Sicily: risk factors for hypovitaminosis D and association with markers of immune activation. IAC Washington DC USA 22.27 luglio 2012 (poster)
24. B.M. Celesia, M.R. Pinzone, C. Coco, M. Gussio, F. Palermo, S. Cosentino, G. Nunnari. Evaluation of renal function by CKD-EPI and risk factors for reduced eGFR in a cohort of HIV-infected subjects. ITALIAN CONFERENCE ON AIDS AND RETROVIRUSES (ICAR) Napoli 10-12 giugno 2012 (P77)
25. B.M. Celesia, L. Nigro, C. Coco, R. La Rosa, S. Mavilla, F. Bisicchia, M. Gussio, G. Nunnari, G. Pellicanò, L. Larocca, V. Milioni, F. Palermo, R. Russo, M.T. Mughini. Il disturbo d'ansia nella popolazione HIV+ in terapia antiretrovirale. V workshop nazionale CISA. Pescara 20-21 gennaio 2011. (abs O14)
26. B.M. Celesia, D. Castronuovo, F. Bellissimo, M.T. Mughini, G. Lupo, M.R. Scarpino, F. Palermo, S. Cosentino, G. Nunnari: Late and very late presenters: predictors of delayed HIV diagnosis in Eastern Sicily. IAS Rome 17-20 July 2011.
27. B.M. Celesia, C.A. Coco, F. Bisicchia, G. Pellicanò, Nunnari G, M.T. Mughini, F. Palermo, R. Russo (2010). Anxiety Disorders And Adherence To Haart. In: XVIII International Aids Conference 18-23 Luglio 2010 Vienna, Austria. Journal Of The International Aids Society (Jias) (Tupe0192). P. 0192 B. M. Celesia, G. Nunnari, F. Bellissimo, Liliana Rapisarda, S. Tosto, F. Zipper, G. La Medica, S. Rinnone, M. Cuccia, R. Russo. Descrizione di un'epidemia di morbillo a Catania. Importanza della copertura vaccinale e della notifica dei casi. IX congresso nazionale SIMIT. Roma 24-27 novembre 2010. (abs P221)
28. Nunnari G, C. Vancheri, E. Gilli, S. Migliore, C. La Rosa, R. Russo, B. Cacopardo (2010). Circulating Fibrocytes. As A Potential Non Invasive Marker Of Liver Fibrosis In Patients With Chronic Hepatitis C Virus Infection. In: Easl: Session Title: Category 5f. Viral Hepatitis: F. Hepatitis C. P. 321
29. Giuseppe Nunnari, Carlo Vancheri, Elisa Gilli, Simona Migliore, Cristina La Rosa, Rosario Russo, Bruno Cacopardo. La Concentrazione Dei Fibrociti Circolanti Nel Sangue Periferico Di Soggetti Con Infezione Da Hcv È Aumentata E Correla Positivamente Con La Fibrosi Epatica: Ruolo E Significato Di Un Test Surrogato, Non Invasivo, Di Fibrosi. Simit 2009, Modena, Italy
30. BM Celesia, L Nigro, G Nunnari, S Mavilla R La Rosa , F Bisicchia, M T Mughini, L Larocca, V Milioni, R Russo. Anxiety in HIV patients on HAART is associated with regimen failures. IAS 2007 Sidney 22-25 July 2007 (abs CDB218)
31. B.M. Celesia, G. Nunnari, G. Fuduli, M.L. Occhipinti, L. Nigro, R. La Rosa, G. Lupo, M. Cuccia, R. Russo. Significant increase of HIV-siphilis co-infection in Catania (Italy). IAS 2007 Sidney 22-25 July 2007 (abs CDB180)
32. B.M. Celesia, G. Nunnari, G. Fuduli, M.L. Occhipinti, L. Nigro, R. La Rosa, G. Lupo, M. Cuccia, R. Russo. HIV-siphilis co-infection and increase of unsafe sex practice in Catania (Italy). Il International workshop on HIV transmission. Washington DC USA 26-28 august 2007

33. B.M. Celesia, G. Nunnari, G. Fuduli, M.L. Occhipinti, L. Nigro, R. La Rosa, G. Lupo, M. Cuccia, R. Russo. Significativo incremento della confezione HIV-sifilide e delle pratiche di sesso non sicuro nella provincia di Catania. XXI congresso nazionale AIDS e sindromi correlate. ICAR. Rimini 17-20 ottobre 2007 (abs)
34. B.M. Celesia, B. Autino, M. Nicotra, G. Nunnari, S. Mavilla, M.T. Mughini, S. Galvagna, G. Lupo, G. Russo. Tolerability, satisfaction and adherence to Lopinavir/ritonavir tablets in subjects switching from soft gel formulation. 11<sup>th</sup> European AIDS conference/EACS October 24-27 2007, Madrid Spain (abs 9.8/02)
35. B.M. Celesia, M. Gussio, S. Mavilla, F. Bisicchia, Giuseppe Nunnari, M.T. Mughini, G. Lupo R. Russo Virological and immunological response to HAART in HIV elderly patients 11<sup>th</sup> European AIDS conference/EACS October 24-27 2007, Madrid Spain (abs 7.9/03)
36. B.M. Celesia, M. Gussio, Giuseppe Nunnari, M.T. Mughini, G. Lupo, F. Palermo, R. Russo. Rischio di progressione clinica e/o morte in soggetti HIV+ con viremia plasmatica rilevabile. VI congresso nazionale SIMIT. Napoli 20-23 novembre 2007 (abs)
37. S. Perloff, Nunnari G., D. Neofytos, D Jungkind, J. Desimone (2006). Infections Due To Staphylococcus Lugdunensis And The Emergence Of Antimicrobial Resistance. In: 44th Annual Meeting Of Ilsa, October 12– 15, 2006 – Toronto, P. 395, 2006
38. Nunnari G.-Relatore: Statins potently block enhanced transmigration of HIV-infected cells: a novel therapeutic approach for HIV neuroinvasion. VI Conference on Cerebral Vascular Biology- 8<sup>th</sup> International Symposium on Signal Transduction in the Blood Brain Barrier. Munster Germany 2005.
39. Dave S Rajnish, James P Mcgettigan, Nunnari G., Matthias J Shnell, Roger J. Pomerantz (2005). Sima-Mediated Interference Of Double-Stranded Rna Binding Protein (E3l) Is An Effective Strategy To Inhibit Vaccinia Virus. In: Abstract From The American Society Of Gene Therapy's, St. Louis, Mo, Usa June 1-5. 8th Annual Meeting, June 1-5, 2005 Poster # 999, P. 9992005
40. Muhammad Mukhtar, A Mengistu, E Acheampong, J Sullivan, Nunnari G., E Argyris, M Kalayeh, Williams, And R Pomerantz (2005). Title: Statins Block Enhanced Transvascular Migration Of Hiv-1-Infected Cells: A Novel Therapeutic Approach For Hiv-1 Neuroinvasion. In: 12th Conference On Retroviruses And Opportunistic Infections CROI. February 22 -February 25, 2005, Boston, Ma, Usa Paper #: 391, P. 203, 2005
41. Roger Pomerantz, F X Wang, Y Xu, J Sullivan, E Sounder, E Argyris, E Acheampong, J Fisher, M Sierra, R Najera, J Kulkosky, Nunnari G. (2005). Title: Il-7 As A Potent Inducer Of Viral Strain-Specific Hiv-1 Reservoirs. In: 12th Conference On Retroviruses And Opportunistic Infections CROI. February 22 -February 25, 2005, Boston, Ma, Usa Paper #: 299, P. 299
42. Yan Xu, E Acheampong, R Daniel, J Fang, C Zhang, M Mukhtar, Nunnari G., And R Pomerantz (2005). Title: Exogenous Il-7 Induces Neuronal Apoptosis: Molecular Mechanisms During Hiv-1 Infection. In: 12th Conference On Retroviruses And Opportunistic Infections February CROI. 22 - February 25, 2005, Boston, Ma, Usa Paper #: 390, P. 390
43. A Mengistu, E Acheampong, Nunnari G., E Argyris, M Kalayeh, K J Williams, R J Pomerantz, And M Mukhtar (2004). Title: Effects Of Statins On The Transmigration Of Monocytes And T Cells Across The Blood Brain Barrier. In: 11th Conference On Retroviruses And Opportunistic Infections CROI. February 8-11, 2004, San Francisco, Ca, Usa Paper #: 481, P. 481
44. E G Argyris, E Acheampong, Nunnari G., M Mukhtar, K J Williams, And R J Pomerantz (2004). Title: Hiv-1 Enters Primary Human Brain Microvascular Endothelial Cells By A Mechanism Involving Cell-Surface Proteoglycans Independent Of Lipid Rafts. In: 11th Conference On Retroviruses And Opportunistic Infections CROI. February 8-11, 2004, San Francisco, Ca, Usa Paper #: 484, P. 484
45. F X Wang, Y Xu, J Sullivan, J Fisher, E Souder, E Acheampong, E Argyris, I Frank, J Kulkosky, R J Pomerantz, Nunnari G. (2004). Title: The Role Of Il-7 In Purging Hiv-1 Virus Cellular Reservoirs In Hiv-1-Infected Patients On Virally Suppressive Haart. In: Keystone Symposia, April 11-18, 2004, Whistler Resort, Whistler, British Columbia, Canada. Poster: # 360, P. 360
46. F X Wang, Y Xu, J Sullivan, J Fisher, E Souder, E Acheampong, E Argyris, I Frank, J Kulkosky, R J Pomerantz, Nunnari

- G. (2004). Title: Purging Hiv-1 Viral Reservoirs: The Role Of Il-7. In: 11th Conference On Retroviruses And Opportunistic Infections CROI. February 8-11, 2004, San Francisco, Ca, Usa Paper #: 424, P. 421
47. Nunnari G., J Kulkosky, J Sullivan, Y Xu, W Cavert, P Nyirjesy, I Frank, And R J Pomerantz (2004). Title: Hiv-1 Cervicovaginal Reservoirs In The Era Of Haart. In: 11th Conference On Retroviruses And Opportunistic Infections CROI. February 8-11, 2004, San Francisco, Ca, Usa Paper #: 421, P. 421
48. Nunnari-G: Relatore: Cervical-Vaginal Reservoir In The Era Of Haart. First International Workshop On Hiv Persistence During Therapy. Saint Martin, Fwi, December 10-12, 2003. Pp 2.10., P. 10, Oral Presentation
49. Nunnari G., J Kulkosky, D Leto, J Sullivan, Y Xu, Rj Pomerantz (2003). Title: Seminal Reservoirs During An Hiv-1 Eradication Trial. In: First International Workshop On Hiv Persistence During Therapy. Saint Martin, Fwi, December 10-12, 2003. Pp 2.10., P. 10
50. Nunnari G: Cervical-Vaginal Reservoir In The Era Of Haart. First International Workshop On Hiv Persistence During Therapy. Saint Martin, Fwi, December 10-12, 2003. Pp 2.10., P. 10, Oral Presentation
51. Nunnari G., J Kulkosky, D Leto, J Sullivan, Y Xu, Rj Pomerantz (2003). Title: Seminal Reservoirs During An Hiv-1 Eradication Approach. In: 10th Conference On Retroviruses And Opportunistic Infections CROI. February 10-14, 2003, Boston Ma, Usa Paper #: 455, P. 455
52. Nunnari G., L. Nigro, F. Palermo, D. Leto, R. J. Pomerantz, B. Cacopardo (2003). Title: Reductions Of Serum Melatonin Levels In Hiv-1 Infected Individuals Parallel Disease Progression: Correlation With Serum Interleukin-12 Levels. In: 10th Conference On Retroviruses And Opportunistic Infections CROI. February 10-14, 2003, Boston Ma, Usa Paper #: 383, P. 383
53. Roger J Pomerantz, Nunnari G., Michele Dimascio, Alan Perelson, And Joseph Kulkosky (2003). Title: Purging Hiv-1 Reservoirs. In: Keystone Symposia, March 28-April-4, 2003, Fairmont Banff Springs Hotel. Banff, Alberta, Canada. Poster: # 251, P. 251
54. M. Otero, Nunnari G., G. Dornadula, C. Patel, I. Frank, And R. J. Pomerantz (2002). Title: Peripheral Blood Dendritic Cells Are Not A Major Reservoir For Hiv-1-Infected Individuals On Virally Suppressive Haart. In: 9th Conference On Retroviruses And Opportunistic Infections CROI. February 24-28, 2002, Seattle Paper #: 494-M, P. 494
55. Nunnari G., L. Nigro, F. Palermo, A. Berger, H. W. Doerr, R. Russo, R. J. Pomerantz, And B. Cacopardo (2002). Title: Slower Progression Of Hiv-1 Infection In Hgv Co-Infected Individuals Correlates With An Intact T-Helper-1 Cytokine Profile. In: 9th Conference On Retroviruses And Opportunistic Infections CROI. February 24-28, 2002, Seattle Paper #: 667-M, P. 667
56. Pomerantz R, Dornadula G, Nunnari G., Zhang H (2002). Title: Stratifying Residual Hiv-1 Disease And Viral Reservoirs: Virological And Immunological Delineation Of Subgroups Of Hiv-1- Infected Individuals On Suppressive Haart. In: The 1st Ias Conference On Hiv Pathogenesis And Treatment, July 8-11, Buenos Aires, Argentina. Poster 257, P. 257
57. R. J. Pomerantz, M. Otero, Nunnari G., A. Malin, C. Coates, C. Dascenzo, J. Desimone, T. Babinchak, H. Zhang, G. Dornadula, D. Culnan, J. Sullivan, Y. Xu, J. Stern, W. Cavert, A. Haase, And J. Kulkosky (2002). Title: Residual Hiv-1 Eradication (Rhide) Trial: An Hiv-1 Reservoir Eradication Approach In Humans Using Stimulatory And Novel Intensification Therapy. In: XIV International Aids Conference, 2002, July 7-12, Barcelona, Spain Poster: Wepeb5894, P. 5894
58. R. J. Pomerantz, M. Otero, Nunnari G., A. Malin, C. Coates, C. Dascenzo, J. Desimone, T. Babinchak, H. Zhang, G. Dornadula, D. Culnan, J. Sullivan, Y. Xu, J. Stern, W. Cavert, A. Haase, And J. Kulkosky (2002). Title: Residual Hiv-1 Disease Eradication (Rhide) Trial: An Hiv-1 Reservoir Eradication Approach In Humans Using A Novel And Stimulatory Intensification Therapy. In: 9th Conference On Retroviruses And Opportunistic Infections CROI. February 24-28, 2002, Seattle Paper #: 405-T, P. 405
59. R. J. Pomerantz, M. Otero, Nunnari G., W. Cavert, A. Haase, And J. Kulkosky (2002). Title: Residual Hiv-1 Disease Eradication (Rhide) Using Stimulatory And Novel Intensification Therapy: Dissecting Residual Disease Pathogenesis. In: Keystone Symposia, April 5-11, Keystone Resort, Keystone, Colorado, Usa Poster: # 426, P. 426

60. G. Dornadula, Nunnari G., H. Zhang, And R. J. Pomerantz (2001). Title: Virological And Immunological Delineation Of Subgroups Of Hiv-1-Infected Individuals On Suppressive Haart: Defining Residual Hiv-1 Disease And Reservoirs. In: 8th Conference On Retrovirus And Opportunistic Infections CROI. February 4-8, 2001, Chicago. Paper #: 393
61. Nunnari G., G. Dornadula, M. Otero, M. Vanella, H. Zhang, I. Frank, And R. J. Pomerantz (2001). Title: Seminal Cells In Hiv-1- Infected Men On Suppressive Haart Have Latent Infection But Lack On-Going Viral Replication in Vivo: A Divergent, Compartment-Specific Reservoir And Mechanism Of Residual Hiv-1 Disease. In: 8th Conference On Retrovirus And Opportunistic Infections CROI. February 4-8, 2001, Chicago. Paper #: 391

I hereby authorize the use of my personal data in accordance to the GDPR 679/16 - "European regulation on the protection of personal data".

The undersigned is aware that, pursuant to art. 76 of Presidential Decree 445/2000, false declarations, false documents and the use of false deeds are punished according to the Penal Code and special laws. All this stated, states the preceding facts and personal qualities.

Messina, 17 October 2022

In fede

Giuseppe Nunnari



PERSONAL INFORMATION

## Carlo Federico Perno

📍 Children Hospital Bambino Gesù'  
Microbiology and Diagnostic Immunology  
Piazza S. Onofrio 4 - 00165 Rome, Lazio (RM)

☎ +39 320-7986567

✉ [carlofederico.perno@opbg.net](mailto:carlofederico.perno@opbg.net) , [carlofederico.perno@unicamillus.org](mailto:carlofederico.perno@unicamillus.org)

Sex Male | Date of birth 27/03/1956 | Nationality Italian

WORK EXPERIENCE

From 2020 up today

### Director of Microbiology, Research Area of Multimodal Medicine

Children Hospital Bambino Gesù', Rome, Italy

Business or sector: Hospital

### Professor of Microbiology

UniCamillus — International Medical University in Rome

Business or sector: University

### President of the Scientific Committee of the Center of International Research Chantal Biya

Center of International Research Chantal Biya, Yaounde', Cameroon

From 1998 to 2020

### Virology consultant

IRCCS Spallanzani Hospital for Infectious Diseases

Business or sector: Hospital

From 2003 to 2017

### Director, Virology UOC

Policlinico Tor Vergata Hospital

Business or sector: Hospital

From 2018 to 2020

### Director, Department of Laboratory Medicine

ASST Niguarda Hospital, Milan

Business or sector: Hospital

From 1989 to 2017

### Assistant, Associate, and from 2001, Professor of Microbiology and Virology

University of Rome Tor Vergata, Department of Experimental Medicine and Surgery

Basic and clinical research of diseases driven by viruses and bacteria; oncogenic retroviruses

Business or sector: University

From 1986 to 1989

### Fogarty Fellow – National Institutes of Health, USA

National Cancer Institute – USA

Development of new anti-HIV/AIDS drug

From 1983 to 1985  
**Adjunct Professor**  
University of Rome Tor Vergata  
Oncogenic Virus  
Business or sector: University

From 1980 to 1983  
**Scholarship**  
Regina Elena Institute for Cancer Care  
Treatment protocols for advanced cancer – Oncogenic retroviruses  
Business or sector: Hospital

## EDUCATION AND TRAINING

---

From 1980 to 1983  
**Ph. D. In Oncology, Degree cum laude** *Degree cum laude*  
Catholic University of Rome  
Therapy of cancer, oncogenic retroviruses

From 1974 to 1980  
**Medical Degree cum laude** *110 cum laude*  
University of Rome “La Sapienza”  
Medical Doctor

## WORK ACTIVITIES

---

**Awards** 2001: European community Descartes Award winner, best 2001 European biomedical research group

**Invited presentations** Invited speaker at more than 100 international conferences over all 5 Continents

- Research**
- Decennial experience in basic and applied clinical Microbiology
  - Basic and clinical research of viral and bacterial driven-diseases with a special focus on oncogenic retroviruses and HIV
  - Ad hoc consultant and speaker for several pharma and diagnostic companies (Merck, Bristol Myers Squibb, Gilead, ViiV, Janssen, Abbvie, Elitech, and others) in the field of virology, clinical virology and infectious diseases
  - Expert on technology transfer in developing countries, and improving the clinical approach to diseases prevalent in Africa. From 2002 to 2010 he participated to the Project Dream, for the improvement of antiviral therapy in AIDS field, and in teaching to health personnel. So far, he has visited 6 different African sub Saharan countries, in more than 30 missions there

### Achievements

- Expert in patent litigations from 2013 in US, UK
- Contributor to the discovery and development of the first anti-AIDS drugs, AZT, ddC, ddI
- President or Member of numerous Commissions of the Ministry of Health, of the Ministry of University and vResearch, of the University of Rome Tor Vergata, over the last decade
- President or member of Commissions for the evaluation of Research of some Italian Regions, and of the Ministry of Education, University and Research (Research funded by public (Europe, Italian Ministries, National Research Council, etc) and private (Pharma and Diagnostic Companies, Private Foundations, etc) Institutions
- President, Scientific Committee, International Center for AIDS Research, Cameroon
- Coordinator of the Unit of Monitoring antiviral and antineoplastic drugs, INMI L. Spallanzani, Rome

### PERSONAL SKILLS

---

Mother tongue(s)

**Italian**

Other language(s)

English, French, Spanish

Digital skills

Excellent knowledge of Office packages (Word, Excel, Power Point, Access), Internet browsers (Edge, Chrome, Safari) and e-mail management system.

### ADDITIONAL INFORMATION

---

#### Statement of Research Interests

The major lines of interest over the years have been dedicated to the research on the pathogenesis, genetic evolution and drug development referring to viruses, including mostly HIV, HBV, HCV. More recently, attention has been dedicated to viruses of major relevance in acute infections, such as respiratory viruses, beta-herpesviruses, and, in the last two years, SARS-CoV-2 (that became prevalent in this latter period). Data produced in this frame have been published in many journals, including Science, Nature, PNAS, Lancet, etc). Beside this focus on selected viruses, an extensive interest of the last years has been directed toward drug-resistant bacteria and fungi in immunocompromised hosts, with focus on oncohaematological patients, transplanted, and immunosuppressed children. Identification of resistant genes in bacteria, as well as new and innovative methods for diagnosis of multidrug-resistant bacteria and of fungi, occupied a substantial part of the research effort of the last years. These areas of interest are consistent with the spoke 1, 3, and 4, whom the OPBG will be dedicated to in this project.

## Publications

total number of publications in peer-review journals: **624**total number of citations: **16962**H index (Scopus): **64**

**Twenty papers have been selected among >200 papers published in the last 10 years, by caring mostly about time (last 3 years), topic correlated to the project (Genomic surveillance & control of human pathogens) and role of the researcher in the publications**

1. Alteri C, Scutari R, Costabile V, Colagrossi L, Yu La Rosa K, Agolini E, Lanari V, Chiurchiù S, Romani L, Markowich AH, Bernaschi P, Russo C, Novelli A, Bernardi S, Campana A, Villani A, **Perno CF. Epidemiological characterization of SARS-CoV-2 variants in children over the four COVID-19 waves and correlation with clinical presentation.** *Sci Rep.* 2022 Jun 17;12(1):10194. doi: 10.1038/s41598-022-14426-0. Erratum in: *Sci Rep.* 2022 Jul 27;12(1):12814. PMID: 35715488; PMCID: PMC9204374.
2. Fokam J, Takou D, Nka AD, Ka'e AC, Yagai B, Ambe Chenwi C, Ngoufack Jagni Semengue E, Angong Beloumou G, Djupsa Ndjeyep SC, Abba A, Pabo W, Gouissi D, Tommo Tchouaket MC, Yatchou L, Zam K, Mama L, Ekitti RC, Fainguem N, Kamgaing R, Sosso SM, Ndembi N, Colizzi V, **Perno CF, Ndjolo A. Epidemiological, virological and clinical features of SARS-CoV-2 among individuals during the first wave in Cameroon: Baseline analysis for the EDCTP PERFECT-Study RIA2020EF-3000.** *J Public Health Afr.* 2022 May 24;13(1):2142. doi: 10.4081/jphia.2022.2142. PMID: 35720804; PMCID: PMC9202463.
3. Colagrossi L, Costabile V, Scutari R, Agosta M, Onori M, Mancinelli L, Lucignano B, Onetti Muda A, Del Baldo G, Mastronuzzi A, Locatelli F, Trua G, Montanari M, Alteri C, Bernaschi P, **Perno CF. Evidence of pediatric sepsis caused by a drug resistant Lactococcus garvieae contaminated platelet concentrate.** *Emerg Microbes Infect.* 2022 Dec;11(1):1325-1334. doi: 10.1080/22221751.2022.2071174. PMID: 35475418; PMCID: PMC9132404.
4. Agosta M, Bencardino D, Argentieri M, Pansani L, Sisto A, Ciofi Degli Atti ML, D'Amore C, Putignani L, Bagolan P, Iacobelli BD, Dotta A, Martini L, Di Chiara L, Magnani M, **Perno CF, Andreoni F, Bernaschi P. Prevalence and Molecular Typing of Carbapenemase-Producing Enterobacterales among Newborn Patients in Italy.** *Antibiotics (Basel).* 2022 Mar 23;11(4):431. doi: 10.3390/antibiotics11040431. PMID: 35453183; PMCID: PMC9032973.
5. Mattana G, Albitar-Nehme S, Cento V, Colagrossi L, Piccioni L, Raponi M, Raucci U, Vittucci AC, Reale A, Villani A, Bernaschi P, **Perno CF. Back to the future (of common respiratory viruses).** *J Glob Antimicrob Resist.* 2022 Mar;28:223-225. doi: 10.1016/j.jgar.2022.01.010. Epub 2022 Jan 21. PMID: 35074567; PMCID: PMC8779783.
6. Coltella L, Ranno S, Piccioni L, Linardos G, Colagrossi L, Agosta M, Russo C, Concato C, Campana A, Onetti Muda A, Villani A, **Perno CF. Quantitative SARS-CoV-2 antigen test as a tool able to predict the stage of the infection.** *J Infect.* 2022 Mar;84(3):418-467. doi: 10.1016/j.jinf.2021.12.013. Epub 2021 Dec 22. PMID: 34953907.
7. Colagrossi L, Mattana G, Piccioni L, Cento V, **Perno CF. Viral Respiratory Infections: New Tools for a Rapid Diagnosis.** *Semin Respir Crit Care Med.* 2021 Dec;42(6):747-758. doi: 10.1055/s-0041-1739306. Epub 2021 Dec 16. PMID: 34918318.
8. Antonello M, Scutari R, Lauricella C, Renica S, Motta V, Torri S, Russo C, Gentile L, Cento V, Colagrossi L, Mattana G, Codecasa LR, Vismara C, Scaglione F, Veronese SM, Bonoldi E, Bandera A, Gori A, Mazzola E, **Perno CF, Alteri C. Rapid Detection and Quantification of Mycobacterium tuberculosis DNA in Paraffinized Samples by Droplet Digital PCR: A Preliminary Study.** *Front Microbiol.* 2021 Sep 13;12:727774. doi: 10.3389/fmicb.2021.727774. PMID: 34589075; PMCID: PMC8475183.
9. Colagrossi L, Antonello M, Renica S, Merli M, Matarazzo E, Travi G, Vecchi M, Colombo J, Muscatello A, Grasselli G, Molteni SN, Scaravilli V, Cattaneo E, Fanti D, Vismara C, Bandera A, Gori A, Puoti M, Cento V, Alteri C, **Perno CF. SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study.** *BMC Infect Dis.* 2021 Feb 17;21(1):184. doi: 10.1186/s12879-021-05886-2. PMID: 33596855; PMCID: PMC7887543.
10. Marcuccilli F, Chevaliez S, Muller T, Colagrossi L, Abbondanza G, Beyser K, Wlassow M, Ortonne V, **Perno CF, Ciotti M. Multicenter Evaluation of the Cepheid Xpert® HBV Viral Load Test.** *Diagnostics (Basel).* 2021 Feb 12;11(2):297. doi: 10.3390/diagnostics11020297. PMID: 33673365; PMCID: PMC7917951.
11. Alteri C, Cento V, Piralla A, Costabile V, Tallarita M, Colagrossi L, Renica S, Giardina F, Novazzi F, Gaiarsa S, Matarazzo E, Antonello M, Vismara C, Fumagalli R, Epis OM, Puoti M, **Perno CF, Baldanti F. Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy.** *Nat Commun.* 2021 Jan 19;12(1):434. doi: 10.1038/s41467-020-20688-x. PMID: 33469026; PMCID: PMC7815831.
12. Cento V, Alteri C, Merli M, Di Ruscio F, Tartaglione L, Rossotti R, Travi G, Vecchi M, Raimondi A, Nava A, Colagrossi L, Fumagalli R, Ughi N, Epis OM, Fanti D, Beretta A, Galbiati F, Scaglione F,

- Vismara C, Puoti M, Campisi D, Perno CF. **Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy.** PLoS One. 2020 Nov 20;15(11):e0242765. doi: 10.1371/journal.pone.0242765. PMID: 33216817; PMCID: PMC7679019.
13. Alteri C, Cento V, Antonello M, Colagrossi L, Merli M, Ughi N, Renica S, Matarazzo E, Di Ruscio F, Tartaglione L, Colombo J, Grimaldi C, Carta S, Nava A, Costabile V, Baiguera C, Campisi D, Fanti D, Vismara C, Fumagalli R, Scaglione F, Epis OM, Puoti M, Perno CF. **Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients.** PLoS One. 2020 Sep 8;15(9):e0236311. doi: 10.1371/journal.pone.0236311. PMID: 32898153; PMCID: PMC7478621.
  14. Cento V, Alteri C, Mancini V, Gatti M, Lepera V, Mazza E, Moioli MC, Merli M, Colombo J, Orcese CA, Bielli A, Torri S, Gasparini LE, Vismara C, De Gasperi A, Brioschi P, Puoti M, Cairoli R, Lombardi G, Perno CF. **Quantification of 1,3- $\beta$ -d-glucan by Wako  $\beta$ -glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study.** Mycoses. 2020 Dec;63(12):1299-1310. doi: 10.1111/myc.13170. Epub 2020 Sep 17. PMID: 32810888.
  15. Langer T, Favarato M, Giudici R, Bassi G, Garberi R, Villa F, Gay H, Zeduri A, Bragagnolo S, Molteni A, Beretta A, Corradin M, Moreno M, Vismara C, Perno CF, Buscema M, Grossi E, Fumagalli R. **Development of machine learning models to predict RT-PCR results for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with influenza-like symptoms using only basic clinical data.** Scand J Trauma Resusc Emerg Med. 2020 Dec 1;28(1):113. doi: 10.1186/s13049-020-00808-8. PMID: 33261629; PMCID: PMC7705856.
  16. Svicher V, Salpini R, Piermatteo L, Carioti L, Battisti A, Colagrossi L, Scutari R, Surdo M, Cacciafesta V, Nuccitelli A, Hansi N, Ceccherini Silberstein F, Perno CF, Gill US, Kennedy PTF. **Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B.** Gut. 2021 Dec;70(12):2337-2348. doi: 10.1136/gutjnl-2020-323300. Epub 2020 Dec 21. PMID: 33402415; PMCID: PMC8588301.
  17. Alteri C, Cento V, Vecchi M, Colagrossi L, Fanti D, Vismara C, Puoti M, Perno CF; SCoVA Study Group. **Nasopharyngeal SARS-CoV-2 Load at Hospital Admission as a Predictor of Mortality.** Clin Infect Dis. 2021 May 18;72(10):1868-1869. doi: 10.1093/cid/ciaa956. PMID: 32674129; PMCID: PMC7454479.
  18. Bonelli F, Sarasini A, Zierold C, Calleri M, Bonetti A, Vismara C, Blocki FA, Pallavicini L, Chinali A, Campisi D, Percivalle E, DiNapoli AP, Perno CF, Baldanti F. **Clinical and Analytical Performance of an Automated Serological Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively.** J Clin Microbiol. 2020 Aug 24;58(9):e01224-20. doi: 10.1128/JCM.01224-20. PMID: 32580948; PMCID: PMC7448652.
  19. Cento V, Colagrossi L, Nava A, Lamberti A, Senatore S, Travi G, Rossotti R, Vecchi M, Casati O, Matarazzo E, Bielli A, Casalicchio G, Antonello M, Renica S, Costabile V, Scaglione F, Fumagalli R, Ughi N, Epis OM, Puoti M, Vismara C, Faccini M, Fanti D, Alteri C, Perno CF. **Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients.** J Infect. 2020 Sep;81(3):e90-e92. doi: 10.1016/j.jinf.2020.06.024. Epub 2020 Jun 20. PMID: 32574567; PMCID: PMC7836522.
  20. Bielli A, Piazza A, Cento V, Comandatore F, Lepera V, Gatti M, Brioschi P, Vismara C, Bandi C, Perno CF. **In vivo acquisition and risk of inter-species spread of blaKPC-3-plasmid from Klebsiella pneumoniae to Serratia marcescens in the lower respiratory tract.** J Med Microbiol. 2020 Jan;69(1):82-86. doi: 10.1099/jmm.0.001113. PMID: 31904319.

Date, July 5<sup>th</sup>, 2024

Signature



INFORMAZIONI PERSONALI

Francesco Saladini



📍 Via Marco Biagi 154A, 53014 Monteroni d'Arbia (SI), Italia

☎ +39 3398139851

✉ saladini6@unisi.it; france.saladini@gmail.com

Sesso maschile | Data di nascita 25/03/1983 | Nazionalità italiana

POSIZIONE ATTUALE

**Ricercatore di tipo B (RTD-B)** presso il Dipartimento di Biotecnologie Mediche dell'Università di Siena (Italia) dal 01/06/2023. In possesso di abilitazione per il ruolo di professore di seconda fascia per le classi di insegnamento 06/A3 (Microbiologia e Microbiologia Clinica, validità 09/01/2020-09/01/2029) e 05/I2 (Microbiologia, validità 19/01/2021-19/01/2030)

ESPERIENZA PROFESSIONALE

15/02/2019-14/02/2022

**Ricercatore a tempo determinato tipo A (RTD-A)**

Dipartimento di Biotecnologie mediche, Università di Siena

Attività: "Supporto virologico avanzato per lo studio ed il trattamento dell'infezione da HIV"

15/05/2012-14/05/2018

**Assegnista di ricerca**

Dipartimento di Biotecnologie mediche, Università di Siena

▪ Attività: sviluppo di sistemi diagnostici per il monitoraggio di infezioni virali umane causate da HIV, HBV, HCV, ZIKV, DENV, WNV

ISTRUZIONE E FORMAZIONE

02/11/2017 – 18/10/2021

**Scuola di specializzazione in Microbiologia e Virologia**

Università di Siena (Italia)

▪ Titolo della tesi: "Evaluation of the Intact Proviral DNA Assay for monitoring HIV-1 reservoir in individuals under successful antiretroviral therapy"

▪ Votazione: 70/70 e lode

01/10/2007 – 30/09/2011

**Dottorato di Ricerca in Biotecnologie Mediche**

Sezione "Biotecnologie microbiche, vaccini e malattie infettive"

Università di Siena (Italia)

▪ Titolo della tesi di dottorato: "Advanced monitoring of HIV drug resistance"

01/10/2005 – 28/09/2007

**Laurea magistrale in Biotecnologie per la salute umana (classe 9/S)**

Università di Siena (Italia)

▪ Titolo della tesi: "Development of a system for the identification of drug resistant minority species of HIV-1"

▪ Votazione: 110/110 e lode

01/10/2003 – 30/09/2005

**Laurea triennale in Biotecnologie (classe L-2)**

Università di Siena (Italia)

▪ Titolo della tesi: "Utilizzo dei test genotipici di resistenza per la caratterizzazione dei sottotipi non-B di HIV-1"

▪ Votazione: 110/110 e lode


## COMPETENZE PERSONALI

Lingua madre	Italiano				
Altre lingue	COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Letture	Interazione	Produzione orale	
Inglese	B1	B1	B1	B1	B1
2004 – Preliminary English Test, livello B2					

## ULTERIORI INFORMAZIONI

<b>Pubblicazioni</b>	Autore di 82 pubblicazioni su riviste peer-reviewed, le pubblicazioni indicizzate su Pubmed sono consultabili al link <a href="https://www.ncbi.nlm.nih.gov/myncbi/francesco.saladini.1/bibliography/public/">https://www.ncbi.nlm.nih.gov/myncbi/francesco.saladini.1/bibliography/public/</a> Scopus ID 1630213870 ORCID ID 0000-0002-9934-377X H-index 21 (Scopus)
<b>Progetti</b>	Partecipazione in progetti finanziati a livello regionale (“UNAVIR”, 2014; “PANVIR.NET”, 2017; “TUSCAVIR.NET”, 2018; finanziati da Regione Toscana), nazionale (PRIN 2008/2018/2021, Programma AIDS 2009, Gilead Fellowship 2012 e 2017) e internazionale (“EURESIST”, 2006; “CHAIN”, 2009; “THINPAD”, 2013; “CARE”, 2018; “EuCARE”, 2021; “AVITHRAPID”, 2023) finanziati dalla Comunità Europea)
<b>Brevetti</b>	Co-inventore del brevetto Europeo intitolato “HIV-1 Nucleocapsid Inhibitors” (numero applicazione EP16186511.8, data di sottomissione 11 Ottobre 2016)
<b>Riconoscimenti e premi</b>	<ul style="list-style-type: none"> <li>▪ Miglior abstract accettato come comunicazione orale in Virologia/Immunopatologia al 10° Congresso ICAR, 22-24 Maggio, Roma</li> <li>▪ Miglior poster al 16° European Meeting on HIV and Hepatitis, 30 Maggio – 1 Giugno 2018, Roma.</li> <li>▪ CROI-ICAR award, Seattle (USA), 4-7 Marzo 2019</li> <li>▪ CROI-ICAR award, Boston (Usa), 8-11 Marzo 2020</li> </ul>
<b>Attività didattica</b>	<p>Anno accademico 2024/25:</p> <ul style="list-style-type: none"> <li>• Docente del corso “Anti-infective drugs, antimicrobial resistance and One Health Approach, Corso di Laurea Magistrale in Medical Biotechnologies, Università di Siena</li> </ul> <p>Anno accademico 2021/22:</p> <ul style="list-style-type: none"> <li>• Docente del modulo di Microbiologia, Corso Integrato in Basi Morfologiche, Corso di Laurea in Dietistica, Università di Siena</li> </ul> <p>Anno accademico 2020/21:</p> <ul style="list-style-type: none"> <li>• Docente del modulo di Microbiologia, Corso Integrato in Basi Morfologiche, Corso di Laurea in Dietistica, Università di Siena</li> <li>• Docente del modulo di Virologia, Corso Integrato in Microbiologia, Corso di Laurea in Tecniche di Laboratorio Biomedico, Università di Siena</li> </ul> <p>Anno accademico 2019/2020:</p> <ul style="list-style-type: none"> <li>• Docente del modulo di Microbiologia, Corso integrato in Microbiologia, Corso di Laurea in Tecniche di Laboratorio Biomedico, Università di Siena</li> </ul>
<b>Incarichi istituzionali</b>	<p>Membro del Collegio dei Docenti della Scuola di Dottorato in Biotechnologie Mediche, Università di Siena, per gli anni accademici 2019/2020, 2020/2021 e 2021/2022.</p>
<b>Dati personali</b>	Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 “Codice in materia di protezione dei dati personali”.

Siena, li 13/11/2025  
In fede,  
Francesco Saladini



# **CURRICULUM VITAE**

	<b>TRUNFIO, MATTIA GIOVANNI CARLO</b>
<b>Place of birth</b>	Milan, Italy
<b>Date of birth</b>	January 1 <sup>st</sup> , 1989
<b>Email</b>	<a href="mailto:mtrunfio@health.ucsd.edu">mtrunfio@health.ucsd.edu</a> <a href="mailto:mattia.trunfio@edu.unito.it">mattia.trunfio@edu.unito.it</a>
<b>Phone</b>	+39 338 3309546 (IT) +1 (619) 983-9239 (US)
<b>Memberships</b>	European AIDS Clinical Society (EACS) Società Italiana di Malattie Infettive e Tropicali (SIMIT) NeuroHIV Aging and Advocacy Group Last Gift CNS Working group
<b>Medical License</b>	17/02/2015 – present Ordine dei Medici & Chirurghi di Milano
<b>National Scientific Qualification (Abilitazione Scientifica Nazionale)</b>	Associate Professor (II Fascia), Area 06/D4 Valid from 12/12/2023 to 12/12/2035

## **EDUCATION & DEGREES**

<b>Title</b>	<b>Philosophiae Doctor, PhD</b>
<b>PhD School</b>	<u>Experimental Medicine and Therapy, XXXVI cycle</u>
<b>Institution</b>	<u>University of Torino, Italy</u>
<b>Achievement date</b>	April 29, 2024
<b>Period</b>	October 2020 – April 2024
<b>Final evaluation</b>	PhD defense cum laude
<b>Supervisor</b>	Prof Giovanni Di Perri, Prof Andrea Calcagno
<b>Title</b>	<b>Specialization in Infectious Diseases and Tropical Medicine</b>
<b>Institution</b>	<u>University of Torino, Italy</u>
<b>Achievement date</b>	November 4, 2019
<b>Period</b>	a.y. 2015/2016 – a.y. 2018/2019
<b>Final evaluation</b>	70/70 cum laude, honors, and recommendation for publication
<b>School Director</b>	Prof Giovanni Di Perri
<b>Title</b>	<b>Professional Diploma in Tropical Medicine and Hygiene, DTM&amp;H</b>
<b>Institution</b>	<u>Liverpool School of Tropical Medicine (LSTM), UK</u>
<b>Achievement date</b>	April 2018
<b>Period</b>	January 2018 – April 2018
<b>Final evaluation</b>	Distinction and WarringtonYorke Prize in International Community Health
<b>Title</b>	<b>Doctor of Medicine, MD</b>
<b>Institution</b>	<u>University of Milan, Milano, Italy</u>
<b>Achievement date</b>	July 16, 2014
<b>Period</b>	a.y. 2008/2009 – a.y. 2013/2014
<b>Final evaluation</b>	110/110 cum laude
<b>Supervisor</b>	Prof Antonella d'Arminio Monforte
<b>Title</b>	<b>High School Diploma of Classical Studies, Baccalaureate</b>
<b>Institution</b>	<u>Liceo Classico Primo Levi, San Donato Milanese, Milano, Italy</u>
<b>Achievement date</b>	July 2008
<b>Period</b>	September 2003 - July 2008
<b>Final evaluation</b>	100/100

## OTHER EDUCATION

- **Translational Regenerative Medicine**, Clinical Research Enhancement through Supplemental Training (CREST) Program, University of California San Diego (La Jolla, CA, US, Jan–Apr 2025)  
Course on design, regulation, and clinical applications of regenerative medicine products (e.g., CAR cells, stem cells, small molecules) – final project *CAR NK T cells for XDR-Tuberculosis*
- **The VOICE program**, Gilead Sciences Europe, University College London, UK, and University College Dublin, IR (Lisbon and Munich, 2019)  
Competitive, international course in clinical research and medical statistics for HIV-focused investigators.
- **International English Language Testing System (IELTS)**, British Council (Turin, Italy, Nov 2017) - overall level C1 (Advanced).
- **30<sup>th</sup> European Educational Program in Epidemiology (EEPE)**, International Epidemiological Association, World Health Organization, Associazione Italiana di Epidemiologia, London School of Hygiene and Tropical Medicine, Swiss Tropical and Public Health Institute, Barcelona Institute for Global Health, and Aarhus University (Florence, IT, Jun-Jul 2017)  
International, residential course in epidemiology and research methodology.
- **Residential Tutorship Master/Training course in Tropical Medicine and Global Health**, Ivo de Carneri Foundation and Zanzibar Ministry of Health (Pemba, Tanzania, Jul-Aug 2016).  
International, residential course combining field-based training, public health strategies, clinical rotations, and laboratory practice in the control and management of tropical and neglected infectious diseases – final project *Implementation of Geographic Information Systems in Leprosy Control and Elimination Programs in Zanzibar*
- **Advanced Life Support (ALS)**, Italian Resuscitation Council (IRC) (Turin, IT, Nov 2016)

## RESEARCH & ACADEMIC APPOINTMENTS

**Position** Postdoctoral Scholar  
**Institution** Division of Infectious Diseases and Global Health, Department of Medicine, University of California San Diego (UCSD), CA, US  
**Period** June 1<sup>st</sup>, 2024 – present  
**Mentor** Prof Sara Gianella, Prof Antoine Chaillon, Prof Scott Lee Letendre

**Position** **Research Fellow - Sanford Stem Cell Clinical Scientist Fellowship**  
**Institution** Sanford Stem Cell Clinical Center, UCSD, California Institute for Regenerative Medicine  
**Period** July 1<sup>st</sup>, 2024 – June 30, 2025  
**Mentor** Prof Davey Smith, Prof Karine Dubé

**Position** **Junior Research Specialist**  
**Employer** Department of Medicine, University of California San Diego, CA, US  
**Period** October 1<sup>st</sup>, 2023 – May 31<sup>st</sup>, 2024  
**Referee** Prof Sara Gianella

**Position** **Research fellow - Interdisciplinary Research Fellowship in NeuroAIDS**  
**Institution** Department of Psychiatry, University of California San Diego (UCSD), CA, US  
**Period** September 1<sup>st</sup>, 2022 – August 31, 2024  
**Mentor** Prof Scott Lee Letendre, Prof Ronald J Ellis

**Position** **Temporary Research Assistant (Assegnista di Ricerca), XXII cycle**  
**Employer** University of Torino, Italy  
**Period** January 1<sup>st</sup>, 2020 – December 31, 2022  
**Referee** Prof Andrea Calcagno

**Position** **Visiting Research Fellow**  
**Institution** University of Sussex, Brighton, UK  
**Period** October – November 2021  
**Supervisor** Prof Jaime Vera

**Position** **Visiting Research Fellow**  
**Institution** Infectious Diseases Institute, Makerere University, Kampala, Uganda  
**Period** January 2019 – March 2019  
**Supervisor** Dr Mohammed Lamorde, Dr Barbara Castelnuovo

## CLINICAL EXPERIENCE

**Position** **Consultant in Infectious Diseases (libera professione – contratti emergenza COVID-19)**  
**Employer** ASL Città di Torino – Unit of Infectious Diseases, Amedeo di Savoia Hospital, Turin, IT  
**Period** March 18, 2020 – March 31, 2022  
**Duty** Inpatient management in the high-intensity COVID-19 ward  
Inpatient management in the Infectious Diseases ward  
Hospitalist care with rotation in night/weekend shifts for hospital-wide coverage  
In-person and remote ID consultations across affiliated hospitals and departments (e.g., internal medicine, ICU, cardiology at Maria Vittoria Hospital; geriatrics and psychiatry at Birago di Vische)  
Clinical supervision, responsibility and mentoring of ID fellow trainees  
**Referee** Prof Giovanni Di Perri: [giovanni.diperri@unito.it](mailto:giovanni.diperri@unito.it)  
Prof Andrea Calcagno: [andrea.calcagno@unito.it](mailto:andrea.calcagno@unito.it)

**Position** **On-call Consultant in Infectious diseases (libera professione)**  
**Employer** Koelliker Hospital, Torino, Italy  
**Period** March 28, 2020 - December 31, 2020  
**Duty** In-person ID consultations for both inpatient and outpatient cases upon request from all the hospital units (e.g., orthopedics, internal medicine) (libera professione)  
**Referee** [direzione.sanitaria@osp-koelliker.it](mailto:direzione.sanitaria@osp-koelliker.it)

**Employer** Cottolengo Hospital, Torino, Italy  
**Period** July 2020 - August 2020  
**Duty** Temporary summer coverage: in-person ID consultations for both inpatient and outpatient cases upon request from all the hospital units (e.g., surgery, internal medicine)  
**Referee** [Direzione.Sanitaria@ospedalecottolengo.it](mailto:Direzione.Sanitaria@ospedalecottolengo.it)

**Employer** Cellini Humanitas Hospital - Fornaca Clinic, Torino, Italy  
**Period** July 16, 2020 – July 31, 2022  
**Duty** In-person ID consultations for inpatient and outpatient cases upon request from all the hospital units (e.g., surgery, internal medicine)  
**Referee** [zahara.aveta@clinicacellini.it](mailto:zahara.aveta@clinicacellini.it)

**Position** **Missionary Doctor**  
**Institution** Dr. Ambrosoli Memorial Hospital, Kalongo, Uganda  
**Period** October 2018 – January 2019  
**Duty** Rotations as attending physician in charge of the adult medical ward, tuberculosis unit, and emergency department, managing patients with primarily infectious and internal medicine conditions. Clinical supervision and bedside training of clinical officers and nursing and medical staff.  
**Referee** Prof Giorgia Montrucchio for IDEA Onlus: [giorgiagiuseppina.montrucchio@unito.it](mailto:giorgiagiuseppina.montrucchio@unito.it)

## LANGUAGES

**ITALIAN** Native speaker – **ENGLISH** Advanced (IELTS C1) – **FRENCH** Basic proficiency

## GRANTS & FELLOWSHIPS

1. **Sanford Stem Cell Clinical Scientist Fellowship**, California Institute for Regenerative Medicine (CIRM), University of California San Diego, CA, US  
Project “*Feasibility and Safety of Cytomegalovirus-specific anti-HIV Chimeric Antigen Receptor T cells in people living with HIV*”  
Role: Fellow - stipend, Amount: \$94.000, Duration: 1 year, Start: July 2024
2. **Basic Biomedical Sciences Discovery Initiative Grant**, California HIV/AIDS Research Program (CHRP), CA, US  
Project “*Spinal cord as a distinct site of HIV persistence and dispersal*”  
Role: Principal Investigator, Amount: \$270.000, Duration: 2 years, Start: June 2024
3. **Interdisciplinary Research Fellowship in NeuroAIDS**, University of California San Diego, CA, US  
Role: Fellow - stipend, Amount: \$60.000, Duration: 2 years, Start: September 2022
4. **Gilead Research Fellowship 2021**, Gilead Science Inc., IT  
Project “*Pathocoenosis of Cerebrospinal fluid Virome in People living with HIV and its relationship with HIV-related Central Nervous System outcomes*”  
Role: Principal Investigator, Amount: €29.035, Duration: 1 year, Start: September 2021

## SKILLS & OTHER EXPERIENCES

### Scholarly Editorial and Reviewing Activities

- **Editorial Board Member** for *BMC Infectious Diseases* (2021-present; impact factor: 3.8)
- **Academic Editor** for *PLOS One* (2024-present; impact factor: 2.9)
- **Guest editor** for the special issue “*Neurocognitive Dynamics and Biomarkers in HIV*”, *Viruses* (2024-present), and “*HIV: comorbidities, aging, and polypharmacy*”, *Frontiers in Tropical Diseases* (2022)
- **Invited peer reviewer** for high-impact, indexed journals, including *Lancet HIV*, *Clinical Infectious Diseases*, *Nature Communications*, *Journal of Infectious Diseases*, *Cell Reports Medicine*
- **Book chapter author**, *Methicillin-resistant Staphylococcus aureus*, in *Clinical Approach to Difficult-to-Treat Pathogens in Intensive Care*, Eds. L. Brazzi & G. Montrucchio, Edizioni Minerva Medica (2023)
- **Section curator** (chapters 350–359, tropical and parasitic infections), Italian edition of *Goldman-Cecil Internal Medicine*, 25th ed. (2016)

### Lectures and Conference Participation

- **Invited lecturer** at national and international meetings (past 5 years, selected):
  - *Joint National Institute of Mental Health (NIMH) Center Seminar Series* by John Hopkins University, Temple University, and HNRC at University of California San Diego, US (2023, 2024)
  - *California Center for AIDS Research (CFAR) Seminars*, La Jolla, CA, US (2023, 2024)
  - *Residential Course on Clinical Pharmacology of Antiretrovirals*, Torino, IT (2020, 2021, 2023, 2024, 2025)
  - *AIDS course - ex legge 135/90*, ASL Città di Torino, IT (2020, 2021, 2022)
  - *TOAfrica Summer School* by University of Turin, Makerere University, ErasmusPlus, Torino World Affairs Institute, Turin, IT (2020)
- **Presenter of original research** at national and international conferences (past 5 years, selected first author):
  - *Conference on Retroviruses and Opportunistic Infections (CROI)* – Seattle, US (2023; abstracts n.462, 488) – Boston, US (2020; abstract n.430) – San Francisco, US (2025; abstracts n.168 -oral communication, 522, 608) – virtual (2022; abstract n.411)
  - *European AIDS Clinical Society Conference (EACS)* – Warsaw, Poland (2023; abstracts n.B2.029, B2.040)
  - *International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs* – virtual (2021; oral communication n.9)

- *Italian Conference on AIDS and Antiviral Research (ICAR)* – virtual (2020; P137, 141)
- *NextGen HIV Research*, Center for AIDS Research (CFAR) - La Jolla, CA, US (2024; oral communication, *Identification of a Core Bacteriome that is associated with HIV Reservoir Size and Activity Across the Human Gut Segments*)

## Teaching and Mentoring Activity

### University of California San Diego (UCSD), US

- Teaching and mentoring activities for graduate and undergraduate students at the Stein Clinical Research Building, Translational Virology Core, and the San Diego Center for AIDS Research (CFAR) (2023–present):
  - Mentees: Meghaan Bovee, Alexander Georgian, Marissa Borochoff, Alec Guerra, Noah Gaitan, Brady Lapke, Vanessa Gomez-Moreno.
  - Activities: Summer Bootcamp 2024, clinical lectures, manuscript writing and supervision, scientific presentations, transferable skills development, laboratory training and supervision.
- Teaching assistant (frontal and practical classes -fungal, viral, and protozoa infections), Microbiology Lab Course, School of Medicine (spring 2025)

### University of Turin, Italy

- MD thesis tutoring, School of Medicine:
  - Mentees: Serena Miglietta (2025); Francesca Balbo, Miriam Vercellone (2023); Elisa Vuaran, Marco Russo (2022); Laura Napoli (2021); Marta Pasquero (2020); Caterina Medina (2019)
- Residency thesis tutoring, Postgraduate School in Infectious Diseases and Tropical Medicine:
  - Mentee: Alessandro Di Stefano (2022)
- Lecturer at the Master Program in Infectious Diseases, director Prof. Giovanni Di Perri (a.y. 2023/2024)
- Teaching and mentoring for fellow residents, Postgraduate School in Infectious Diseases and Tropical Medicine, director Prof. Giovanni Di Perri (a.y. 2020/2021, 2021/2022)
- Supervised teaching activities (Prof. Giovanni Di Perri, Prof. Andrea Calcagno) for the Infectious Diseases course, School of Medicine, and School of Nursing Science (a.y. 2016/2017, 2027/2018, 2018/2019, 2019/2020, 2020/2021, 2021/2022)

### Other Institutions, Italy

- Travel Medicine at the United Nations Fellows Orientation Workshop, The International Training Centre of the International Labour Organization (ITCILO), Turin (2022)
- Infectious Diseases and Microbiology, Professional Nursing course, Italian Red Cross, Turin (2016; Dr. Roberto Bertucci)
- Clinical case discussion, interactive frontal lectures as a supplement to the course of Infectious Diseases, School of Medicine, University of Milan, IT (a.y. 2014/2015; Prof. Antonella D'Arminio Monforte)

## Statistical and Data Analysis Skills

- Excellent command of SPSS and Stata; ongoing training in R Studio
- Advanced expertise in statistical methods for clinical research, including mixed-effects and generalized modeling, cluster analysis (e.g., k-means, hierarchical clustering, latent profile analysis), factor analysis, principal component analysis and principal coordinate analysis, interaction, mediation and moderation models, ROC curve analysis and diagnostic performance metrics, random forests and recursive partitioning, validation methods (e.g., bootstrapping)
- Moderate proficiency in microbiome bioinformatics, including MaAsLin3 and phyloseq R, filtering techniques, alpha and beta diversity analyses and related indices
- All statistical analyses in my first- and co-first-author publications were performed personally

## Wet Lab Skills

- Microscopic diagnosis of parasitic, protozoal and other common pathogens through interpretation of blood films and fecal smears
- Independent execution of tissue processing, DNA/RNA extraction, ELISA and Luminex assays
- Basic training in Olink assays, ddPCR, viral primer design, library preparation, single-cell RNA sequencing, tissue-derived cell sorting (e.g., magnetic beads), and flow cytometry

## Research Network and Active Scientific Collaborations

These projects are investigator-initiated collaborations in which I serve as scientific lead or key contributor, though without a formally appointed or funded role:

- **NCT06252402 Trial *Feasibility and Safety of CMV-Specific, Anti-HIV CAR T Cells in People with HIV***  
**Partner institution:** City of Hope, Duarte, CA, US
  - Key role in the socio-behavioral sub-study - qualitative research on participants' lived experiences in the trial
- **CNS HIV Antiretroviral Therapy Effects Research (CHARTER) cohort**  
**Partner institutions:** Johns Hopkins University, Baltimore, MD; Mount Sinai School of Medicine, New York, NY; University of Texas Medical Branch at Galveston, Galveston, TX; University of Washington, Seattle, WA; Washington University in St. Louis, St. Louis, MO, US
  - Scientific lead in the study *Single-copy HIV suppression, neuroinflammation, and depressive symptoms*
  - Scientific lead in the study *Dissecting trait- and state-like biomarkers in CSF and blood to predict cognitive trajectories in people with HIV in the CHARTER Aging Cohort*
  - Involvement in the study *CSF and plasma proteomics across Neurobehavioral phenotypes* (preliminary findings presented at CROI 2025, abstract n.610).
  - Involvement in the study *Genetic determinants and SNPs in biomarkers trajectory in CHARTER Aging*
  - PI for the HIV Neurobehavioral Research Center Developmental Core Grant (\$18,000, 1 year), *The Cerebrospinal fluid Immunological landscape of HIV-1 CSF Controllers* – pending post-review approval
  - Scientific lead in the study *Role of co-infections in brain and mental health of people living with HIV*
- **Igor Koralnik's laboratory, Neuro-Infectious Disease and Global Neurology**  
**Partner institution:** Northwestern University, Feinberg School of Medicine, Chicago, IL, US
  - Scientific lead in the pilot study *Longitudinal analysis of CSF virome in people with HIV through ViroFind*
- **NeuroHIV Aging and Advocacy Group**  
**Partner institutions:** Global multi-institutional collaboration lead by Prof Lucette Cysique, University of New South Wales, Sidney, Australia, and Prof Sean Rourke, University of Toronto, Toronto, Canada
  - Scientific lead for an online survey of healthcare professionals' literacy about brain and mental health in people with HIV
- **Guochun Jiang's lab, HIV Cure Center, Institute for Global Health and Infectious Diseases**  
**Partner institution:** University of North Carolina at Chapel Hill, NC, US
  - Involvement in a project investigating microglial cells sorting from human spinal cord tissues and their role as source for HIV reactivation and reseeding
- **Primary Infection Resource Consortium (PIRC) in San Diego (PI Dr. Susan Little)**  
**Partner Institution:** UC San Diego Health, University of California San Diego, La Jolla, CA, US
  - Scientific lead for the project *Minimal Disruption of the Rectal Microbiome in Acute and Early Untreated HIV Infection* (submitted, under review)
- **INACTION - Italian Network ACuTe HIV Infection**  
**Partner Institutions:** Italian multi-institutional collaboration lead by Dr Silvia Nozza, Vita-Salute San Raffaele University, Milan, Italy (including University of Turin)
  - Co-investigator for the clinical trial NCT04225325 *HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens* and involvement in the prospective studies of the cohort since 2020 (e.g., PMID:38768738, PMID:39171829)
- **CNS Infectious Diseases Study Group, Director Prof Andrea Calcagno**  
**Partner Institution:** Department of Medical Sciences, University of Turin, Italy
  - Involvement in the projects of the research group since 2016, such as the trials NCT02951559 and EudraCT Number 2016-003741-29 (e.g., PMID:30608272, PMID:39250652), and ricerca finalizzata RF-2019-12371089

## MERITS & OTHER ACHIEVEMENTS

- **Editorial Contribution Award 2025**, *Springer Nature* Editor of Distinction awards for *BMC Infectious Diseases*, May 2025
- **Honorary Mention for Career Achievement during the Infectious Diseases Residency**, University of Turin, Nov 4, 2019
- Selected among the top six highest-scoring students for the Viva examination and awarded the **Warrington Yorke Prize for International Community Health**, as one of the three best students of the Diploma in Tropical Medicine and Hygiene 2018, Liverpool School of Tropical Medicine (LSTM), UK
- **Invited Expert Interviews on research findings**: invited to discuss findings from “*Symptomatic and Asymptomatic Neurocognitive Impairment, ART Adherence and HIV Control: A 4-Year Observational Study*” in *Physician’s Weekly*, September 2024; invited to discuss findings from “*Bacterial Coinfections in Dengue Virus Disease*” in *Embo Reports*, July 2018
- **ICAR-CROI Award for Young Italian Researchers**: years 2017, 2018, 2019, 2020, 2023
- **CROI New Investigators Scholarship**, 2017, Seattle, USA; 2025, San Francisco, USA
- Winner of the **Scholarship by Società Italiana di Malattie Infettive e Tropicali (SIMIT) 2014 for research in the field of HIV, HCV, and fungal infections**. Winning research project: “Correlation between monocytic-macrophagic immune activation, viral reservoir and neurocognitive impairment among HIV-positive HAART-naive patients”; mentor, Prof Antonella D’Arminio Monforte
- Winner of the **Scholarship for Excellence, University of Milan**, IT, for the academic years 2009/2010, 2010/2011, 2011/2012, 2012/2013, 2013/2014

## PUBLICATIONS

ORCID: <https://orcid.org/0000-0001-8663-719X> - first year of publication 2017 – H-index:

Google Scholar **20** <https://scholar.google.com/citations?user=bMzSHAgAAAAJ&hl=en>

ResearchGate **19** <https://www.researchgate.net/profile/Mattia-Trunfio>

SCOPUS **17** <https://www.scopus.com/authid/detail.uri?authorId=57190343786>

### All First and Co-First Authorships\* - 43.4% of total published work:

1. Trunfio M, Iudicello J, Riggs PK, Kallianpur AR, Hulgan T, Ellis RJ, Letendre SL. Relationships Between Estimated Drug Distribution of Antiretroviral Therapy and Immune Proteins in Cerebrospinal Fluid during Chronic HIV suppression. **Viruses**. 2025, 17(6), 749; <https://doi.org/10.3390/v17060749>.
2. Mazzitelli M\*, Trunfio M\*, Scaglione V, Sasset L, Leoni D, Gasparini G, Marini M, Favaro A, Cattelan A. Multidimensional program for insomnia in a cohort of people with HIV. **AIDS**. 2024 Dec 1;38(15):2040-2049. doi: 10.1097/QAD.0000000000004019. Epub 2024 Sep 18. PMID: 39715493.
3. Longo BM\*, Trunfio M\*, Calcagno A. Dual  $\beta$ -lactams for the treatment of Mycobacterium abscessus: a review of the evidence and a call to act against an antibiotic nightmare. **J Antimicrob Chemother**. 2024 Nov 4;79(11):2731-2741. doi: 10.1093/jac/dkae288. PMID: 39150384; PMCID: PMC11932079.
4. Trunfio M, Vuaran E, Vai D, Quarta C, Di Stefano A, Imperiale D, Cinnirella G, Bonora S, Di Perri G, Letendre SL, Calcagno A. Symptomatic and Asymptomatic Neurocognitive Impairment, ART Adherence and HIV Control: A 4-Year Observational Study. **AIDS Behav**. 2024 Nov;28(11):3643-3654. doi: 10.1007/s10461-024-04440-w. Epub 2024 Jul 30. PMID: 39080201.
5. Trunfio M, Bonora S, di Perri G, Calcagno A. Further considerations on the use of cerebrospinal fluid C-X-C motif chemokine ligand 13 in the diagnosis of neurosyphilis among people with HIV. **AIDS**. 2024 Jul 1;38(8):1273-1275. doi: 10.1097/QAD.0000000000003902. Epub 2024 May 30. PMID: 38814718.
6. Trunfio M, Tang B, Okwuegbuna O, Iudicello JE, Bharti A, Moore DJ, Gelman BB, Morgello S, Patel PB, Rubin LH, Ances BM, Gianella S, Heaton RK, Ellis RJ, Letendre SL. Longitudinal analysis of CSF HIV RNA in untreated people with HIV: Identification of CSF controllers. **J Med Virol**. 2024 Mar;96(3):e29550. doi: 10.1002/jmv.29550. PMID: 38511593; PMCID: PMC11139255.
7. Trunfio M, Tang B, Iudicello JE, Ma Q, Franklin DR, Cookson D, Riggs PK, Cherner M, Moore DJ, Heaton RK, Letendre SL, Ellis RJ. Distinct Effects of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors on Soluble Biomarkers in Blood and Cerebrospinal Fluid of People With HIV. **J Infect Dis**. 2024 May 15;229(5):1266-1276. doi: 10.1093/infdis/jiad558. PMID: 38059529; PMCID: PMC11095536.
8. Trunfio M, Sacchi A, Vai D, Pittaluga F, Croce M, Cavallo R, Imperiale D, Bonora S, Di Perri G, Letendre SL, Calcagno A. Intrathecal production of anti-Epstein-Barr virus viral capsid antigen IgG is associated with neurocognition and tau proteins in people with HIV. **AIDS**. 2024 Mar 15;38(4):477-486. doi: 10.1097/QAD.0000000000003775. Epub

2023 Nov 7. PMID: 37939156; PMCID: PMC12077805.

9. Trunfio M, Chaillon A, Beliakova-Bethell N, Deiss R, Letendre SL, Riggs PK, Higgins N, Gianella S. Beyond the Syndemic of Opioid Use Disorders and HIV: The Impact of Opioids on Viral Reservoirs. **Viruses**. 2023 Aug 9;15(8):1712. doi: 10.3390/v15081712. PMID: 37632053; PMCID: PMC10458944.
10. Venuti F\*, Trunfio M\*, Martson AG, Lipani F, Audagnotto S, Di Perri G, Calcagno A. Extended and Continuous Infusion of Novel Protected  $\beta$ -Lactam Antibiotics: A Narrative Review. **Drugs**. 2023 Jul;83(11):967-983. doi: 10.1007/s40265-023-01893-6. Epub 2023 Jun 14. PMID: 37314633.
11. Trunfio M, Mighetto L, Napoli L, Atzori C, Nigra M, Guastamacchia G, Bonora S, Di Perri G, Calcagno A. Cerebrospinal Fluid CXCL13 as Candidate Biomarker of Intrathecal Immune Activation, IgG Synthesis and Neurocognitive Impairment in People with HIV. **J Neuroimmune Pharmacol**. 2023 Jun;18(1-2):169-182. doi: 10.1007/s11481-023-10066-x. Epub 2023 May 11. PMID: 37166552.
12. Trunfio M, Pinnetti C, Arsuffi S, Bai F, Celani L, D'Ettorre G, Vera JH, D'Arminio Monforte A, Focà E, Ghisetti V, Bonora S, Antinori A, Calcagno A. The presence of resistance-associated mutations in reverse transcriptase gene is associated with cerebrospinal fluid HIV-1 escape: A multicentric retrospective analysis. **J Med Virol**. 2023 Apr;95(4):e28704. doi: 10.1002/jmv.28704. PMID: 36967541.
13. Mazzitelli M\*, Trunfio M\*, Milinkovic A, Castelli E, Sasset L, Leoni D, Salvucci M, Cazzaro R, Calcinoni I, Balducci P, Ribeiro GCQ, Filagrana G, Scaglione V, Cattelan AM. Sleep disturbances and their correlation with cardiovascular risk, obesity, and mood disorders in people with HIV. **AIDS**. 2023 May 1;37(6):925-934. doi: 10.1097/QAD.0000000000003493. Epub 2023 Jan 24. PMID: 36723511.
14. Trunfio M, Di Girolamo L, Ponzetta L, Russo M, Burdino E, Imperiale D, Atzori C, Di Perri G, Calcagno A. Seropositivity and reactivations of HSV-1, but not of HSV-2 nor VZV, associate with altered blood-brain barrier, beta amyloid, and tau proteins in people living with HIV. **J Neurovirol**. 2023 Feb;29(1):100-105. doi: 10.1007/s13365-022-01105-z. Epub 2022 Nov 9. PMID: 36352195.
15. Trunfio M, Portesani F, Vicinanza S, Nespoli P, Traverso F, Cortese G, Bonora S, Calcagno A, Di Perri G. Real-life Evidence of Lower Lung Virulence in COVID-19 Inpatients Infected with SARS-CoV-2 Omicron Variant Compared to Wild-Type and Delta SARS-CoV-2 Pneumonia. **Lung**. 2022 Oct;200(5):573-577. doi: 10.1007/s00408-022-00566-7. Epub 2022 Sep 17. PMID: 36114845; PMCID: PMC9483268.
16. Mastorino L\*, Dapavo P\*, Trunfio M\*, Avallone G, Rubatto M, Calcagno A, Ribero S, Quaglino P. Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy. **Acta Derm Venereol**. 2022 Nov 29;102:adv00821. doi: 10.2340/actadv.v102.1982. PMID: 36065745; PMCID: PMC9811291.
17. Trunfio M, Scabini S, Ruge W, Bonora S, Di Perri G, Calcagno A. Concurrent and Subsequent Co-Infections of *Clostridioides difficile* Colitis in the Era of Gut Microbiota and Expanding Treatment Options. **Microorganisms**. 2022 Jun 23;10(7):1275. doi: 10.3390/microorganisms10071275. PMID: 35888994; PMCID: PMC9317215.
18. Trunfio M, Atzori C, Pasquero M, Di Stefano A, Vai D, Nigra M, Imperiale D, Bonora S, Di Perri G, Calcagno A. Patterns of Cerebrospinal Fluid Alzheimer's Dementia Biomarkers in People Living with HIV: Cross-Sectional Study on Associated Factors According to Viral Control, Neurological Confounders and Neurocognition. **Viruses**. 2022 Apr 4;14(4):753. doi: 10.3390/v14040753. PMID: 35458483; PMCID: PMC9031633.
19. Trunfio M, Richiardi L, Alladio F, Staffilano E, Longo B, Venuti F, Ghisetti V, Burdino E, Bonora S, Vineis P, Di Perri G, Calcagno A. Determinants of SARS-CoV-2 Contagiousness in Household Contacts of Symptomatic Adult Index Cases. **Front Microbiol**. 2022 Apr 1;13:829393. doi: 10.3389/fmicb.2022.829393. PMID: 35432272; PMCID: PMC9010948.
20. Trunfio M, De Francesco D, Vai D, Medina C, Milesi M, Domini S, Alcantarini C, Imperiale D, Bonora S, Di Perri G, Calcagno A. Screening Accuracy of Mini Addenbrooke's Cognitive Examination Test for HIV-Associated Neurocognitive Disorders in People Ageing with HIV. **AIDS Behav**. 2022 Jul;26(7):2203-2211. doi: 10.1007/s10461-021-03563-8. Epub 2022 Jan 4. PMID: 34982319.
21. Trunfio M, Verga F, Ghisetti V, Burdino E, Emanuele T, Bonora S, Di Perri G, Calcagno A. Clinical Phenotype and Contagiousness of Early Breakthrough SARS-CoV-2 Infections after BNT162b2 COVID-19 mRNA Vaccine: A Parallel Cohort Study in Healthcare Workers. **Vaccines (Basel)**. 2021 Nov 23;9(12):1377. doi: 10.3390/vaccines9121377. PMID: 34960123; PMCID: PMC8705309.
22. Avallone G\*, Trunfio M\*, Mastorino L, Agostini A, Merli M, Rubatto M, Caracciolo D, Calcagno A, Senetta R, Fierro MT, Quaglino P, Ribero S. Case Report: Atypical Cutaneous Presentation of Human T-cell Lymphotropic Virus Type 1-Related Adult T-cell Lymphoma. **Am J Trop Med Hyg**. 2021 Oct 11;105(6):1590-1593. doi: 10.4269/ajtmh.21-0630. PMID: 34634767; PMCID: PMC8641320.
23. Trunfio M, Scabini S, Mornese Pinna S, Ruge W, Alcantarini C, Pirriatore V, Di Perri G, Bonora S, Castelnuovo B, Calcagno A. The Manifesto of Pharmacoenosis: Merging HIV Pharmacology into Pathocoenosis and Syndemics in Developing Countries. **Microorganisms**. 2021 Jul 31;9(8):1648. doi: 10.3390/microorganisms9081648. PMID: 34442727; PMCID: PMC8399770.
24. Trunfio M, Calcagno A, Bonora S, Di Perri G. Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases. **Lancet Infect Dis**. 2021 Jul;21(7):914-915. doi: 10.1016/S1473-3099(21)00205-X. Epub 2021 Apr 14. PMID: 33864803; PMCID: PMC8046410.

25. Trunfio M, Longo BM, Alladio F, Venuti F, Cerutti F, Ghisetti V, Bonora S, Di Perri G, Calcagno A. On the SARS-CoV-2 "Variolation Hypothesis": No Association Between Viral Load of Index Cases and COVID-19 Severity of Secondary Cases. **Front Microbiol.** 2021 Mar 16;12:646679. doi: 10.3389/fmicb.2021.646679. PMID: 33815334; PMCID: PMC8010676.
26. Trunfio M, Venuti F, Alladio F, Longo BM, Burdino E, Cerutti F, Ghisetti V, Bertucci R, Picco C, Bonora S, Di Perri G, Calcagno A. Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. **Viruses.** 2021 Feb 11;13(2):281. doi: 10.3390/v13020281. PMID: 33670360; PMCID: PMC7917896.
27. Trunfio M, Salvador E, Gaviraghi A, Audagnotto S, Marinaro L, Motta I, Casciaro R, Ghisetti V, Fava C, Bonora S, Di Perri G, Calcagno A; e-COVID Study Group. Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity. **Antivir Ther.** 2020;25(6):327-333. doi: 10.3851/IMP3377. PMID: 33506810.
28. Trunfio M, Salvador E, Cabodi D, Marinaro L, Alcantarini C, Gaviraghi A, Trentalange A, Lipani F, Sciascia S, Roccatello D, Bonora S, Di Perri G, Calcagno A; e-COVID Study group. Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection. **Thromb Res.** 2020 Dec;196:432-434. doi: 10.1016/j.thromres.2020.09.039. Epub 2020 Oct 8. PMID: 33049598; PMCID: PMC7543686.
29. Trunfio M, Ruge W, Mighetto L, Vai D, Atzori C, Nigra M, Domini S, Borgogno E, Guastamacchia G, Bonora S, Di Perri G, Calcagno A. Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV. **AIDS.** 2020 Nov 1;34(13):1899-1906. doi: 10.1097/QAD.0000000000002601. PMID: 32701580.
30. Trunfio M, Ribero S, Bonora S, Di Perri G, Quaglino P, Calcagno A. Malignant Melanoma in People Living with HIV/AIDS: Can We Know More, Can We Do Better? **AIDS Rev.** 2019;21(2):65-75. doi: 10.24875/AIDSRev.19000038. PMID: 31332396.
31. Trunfio M, Manini C, Trentalange A, Boghi A, Audagnotto S, Imperiale D, Taraglio S, Bonora S, Di Perri G, Calcagno A. The "milky way" galaxy of HIV-related central nervous system immune reaction syndromes. **J Neurovirol.** 2019 Dec;25(6):887-892. doi: 10.1007/s13365-019-00769-4. Epub 2019 Jun 18. PMID: 31214917.
32. Trunfio M, Pinnetti C, Focà E, Bai F, Maffongelli G, Celani L, Cinque P, Celotti A, Andreoni M, D'Arminio Monforte A, D'Ettorre G, Antinori A, Calcagno A. Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities: is it time to assess the definitions? **AIDS.** 2019 Mar 15;33(4):759-762. doi: 10.1097/QAD.0000000000002091. PMID: 30531317.
33. Trunfio M, Vai D, Montrucchio C, Alcantarini C, Livelli A, Tettoni MC, Orofino G, Audagnotto S, Imperiale D, Bonora S, Di Perri G, Calcagno A. Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders. **HIV Med.** 2018 May 15. doi: 10.1111/hiv.12622. Epub ahead of print. PMID: 29761877.
34. Trunfio M, Scabini S, Bertucci R. Ultrasonography of an Oral Cavity Onchocercidae Nodule. **Am J Trop Med Hyg.** 2018 Mar;98(3):645-646. doi: 10.4269/ajtmh.17-0796. PMID: 29514730; PMCID: PMC5930920.
35. Trunfio M, Joseph SB, Ghisetti V, Romito A, Martini C, Cusato J, Audagnotto S, Pesci Kincer L, Ferrara M, Sala A, Imperiale D, Di Perri G, Calcagno A. Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia. **J Neurovirol.** 2018 Feb;24(1):132-136. doi: 10.1007/s13365-017-0605-1. Epub 2017 Dec 14. PMID: 29243133.
36. Trunfio M, Savoldi A, Viganò O, d'Arminio Monforte A. Bacterial coinfections in dengue virus disease: what we know and what is still obscure about an emerging concern. **Infection.** 2017 Feb;45(1):1-10. doi: 10.1007/s15010-016-0927-6. Epub 2016 Jul 22. PMID: 27448105.
37. **PREPRINT – Under Review.** Trunfio M, Scutari R, Fox V, Vuaran E, Dastgheyb RM, Fini V, Granaglia A, Balbo F, Tortarolo D, Bonora S, Perno CF, Di Perri G, Alteri C, Calcagno A. The cerebrospinal fluid virome in people with HIV: links to neuroinflammation and cognition. **bioRxiv** [Preprint]. 2025 Feb 28:2025.02.28.640732. doi: 10.1101/2025.02.28.640732. PMID: 40060671; PMCID: PMC11888432.

#### All Co-Authorships (notable publications highlighted in bold):

38. Mendez-Lopez A, Burns F, Sullivan A, Deogan C, Darling KEA, Simoes D, Garner A, Del Amo J, Pasanen S, Vaughan E, Verluyten J, Bhagani S, Martinez E, Noori T, for the HIV knowledge and attitudes in Europe and Central Asia study group. Knowledge about biomedical HIV prevention among healthcare workers: A cross-sectional study in Europe and Central Asia. **HIV Med.** 2025 May 19. doi: 10.1111/hiv.70048. Epub ahead of print. PMID: 40390383.
39. **Kamkwalala AR, Matthews A, Garg A, Roy U, Ma Q, Karris M, Sundermann E, Ellis RJ, Riggs PK, Trunfio M, Blanchard J, Moore DJ, Rubin LH, Letendre SL. The Effects of Prescribed Medications on Depressive Symptoms and Neurocognitive Performance in People With HIV. Clin Infect Dis.** 2025 Apr 30;80(4):871-880. doi: 10.1093/cid/ciae518. PMID: 39658021; PMCID: PMC12043063.
40. **Cysique LA, Levin J, Howard C, Taylor J, Rule J, Costello J, Bruning J, Njeri P, Mullens AB, Wright E, Gouse H, Daken K, Trunfio M, Aung HL, Robbins RN, Ferraris CM, Muñoz-Moreno JA, Woods SP, Moore DJ, Power C, Wong PL, Hasmukharay K, Nyamayaro P, Vera J, Rajasuriar R, Heaton RK, Goodkin K, Letendre S, Ellis RJ, Brew BJ, Rourke SB; NeuroHIV and Aging Advocacy Group. Fostering healthy cognitive ageing in people living with HIV.**

**Lancet HIV.** 2025 Jan;12(1):e71-e80. doi: 10.1016/S2352-3018(24)00248-0. Epub 2024 Nov 29. PMID: 39615509.

41. **Kincer LP, Dravid A, Trunfio M, Calcagno A, Zhou S, Vercesi R, Spudich S, Gisslen M, Price RW, Cinque P, Joseph SB. Neurosymptomatic HIV-1 CSF escape is associated with replication in CNS T cells and inflammation. *J Clin Invest.* 2024 Oct 1;134(19):e176358. doi: 10.1172/JCI176358. PMID: 39352388; PMCID: PMC11444166.**
42. Stroffolini G, Atzori C, Imperiale D, Trunfio M, Di Perri G, Calcagno A. Central Nervous System Disorders with Auto-Antibodies in People Living with HIV. ***Microorganisms.*** 2024 Aug 24;12(9):1758. doi: 10.3390/microorganisms12091758. PMID: 39338433; PMCID: PMC11433650.
43. Lazzaro A, Vai D, Barco A, Stroffolini G, Pirriatore V, Guastamacchia G, Nigra M, Ghisetti V, Tettoni MC, Noce G, Giaccone C, Trunfio M, Trentalange A, Bonora S, Di Perri G, Calcagno A. Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical Trial. ***J Acquir Immune Defic Syndr.*** 2024 Oct 1;97(2):180-191. doi: 10.1097/QAI.0000000000003480. PMID: 39250652.
44. **Calcagno A, Cusato J, Cinque P, Marchetti G, Bernasconi D, Trunfio M, Bruzzesi E, Rusconi S, Gabrieli A, Muscatello A, Antinori A, Ripamonti D, Gulminetti R, Antonucci M, Nozza S. Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized study. *Brain.* 2024 Nov 4;147(11):3742-3750. doi: 10.1093/brain/awae271. PMID: 39171829; PMCID: PMC11907231.**
45. De Nicolò A, Palermi A, Dispinseri S, Marchetti G, Trunfio M, De Vivo E, D'Avolio A, Muscatello A, Gori A, Rusconi S, Bruzzesi E, Gabrieli A, Bernasconi DP, Bandera A, Nozza S, Calcagno A; INACTION (Italian Network of Acute HIV Infection) study group. Plasma, intracellular and lymph node antiretroviral concentrations and HIV DNA change during primary HIV infection: Results from the INACTION P25 study. ***Int J Antimicrob Agents.*** 2024 Aug;64(2):107200. doi: 10.1016/j.ijantimicag.2024.107200. Epub 2024 May 18. PMID: 38768738.
46. Bai F, Bono V, Borghi L, Bonazza F, Falcinella C, Vitaletti V, Miraglia F, Trunfio M, Calcagno A, Cusato J, Vegni E, d'Arminio Monforte A, Marchetti G. Association between tight junction proteins and cognitive performance in untreated persons with HIV. ***AIDS.*** 2024 Jul 15;38(9):1292-1303. doi: 10.1097/QAD.0000000000003923. Epub 2024 May 2. PMID: 38704619; PMCID: PMC11216391.
47. Cusato J, Manca A, Palermi A, Mula J, Avataneo V, Antonucci M, Marinaro L, Bonora S, Trunfio M, Di Perri G, D'Avolio A, Calcagno A. Host single nucleotide polymorphisms and biomarkers of neuronal damage and inflammation in people living with HIV. ***Int J Antimicrob Agents.*** 2024 Jun;63(6):107137. doi: 10.1016/j.ijantimicag.2024.107137. Epub 2024 Mar 18. PMID: 38508536.
48. **Cysique LA, Brew BJ, Bruning J, Byrd D, Costello J, Daken K, Ellis RJ, Fazeli PL, Goodkin K, Gouse H, Heaton RK, Letendre S, Levin J, Aung HL, Mindt MR, Moore D, Mullens AB, de Almeida SM, Muñoz-Moreno JA, Power C, Robbins RN, Rule J, Rajasuriar R, Savin MJ, Taylor J, Trunfio M, Vance DE, Wong PL, Woods SP, Wright EJ, Rourke SB. Cognitive criteria in HIV: greater consensus is needed. *Nat Rev Neurol.* 2024 Feb;20(2):127-128. doi: 10.1038/s41582-024-00927-1. PMID: 38228906.**
49. Mazzitelli M, Trunfio M, Coin A, Sasset L, Farina J, Brundu M, Scaglione V, Devita M, Sergi G, Cattelan AM. Use of different anticholinergic scales and their correlation with anticholinergic symptom burden in a cohort of people living with HIV. ***J Antimicrob Chemother.*** 2024 Jan 3;79(1):66-77. doi: 10.1093/jac/dkad348. PMID: 37965917; PMCID: PMC11032244.
50. Stroffolini G, Lazzaro A, Barco A, Pirriatore V, Vai D, Giaccone C, Nigra M, Atzori C, Trunfio M, Bonora S, Di Perri G, Calcagno A. Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment Regimen. ***J Neuroimmune Pharmacol.*** 2023 Dec;18(4):551-562. doi: 10.1007/s11481-023-10086-7. Epub 2023 Oct 31. PMID: 37906406; PMCID: PMC10770227.
51. Mazzitelli M, Sasset L, Gardin S, Leoni D, Trunfio M, Scaglione V, Mengato D, Agostini E, Vania E, Putaggio C, Cattelan A. Real-Life Experience on Dolutegravir and Lamivudine as Initial or Switch Therapy in a Silver Population Living with HIV. ***Viruses.*** 2023 Aug 15;15(8):1740. doi: 10.3390/v15081740. PMID: 37632082; PMCID: PMC10459453.
52. De Vito A, Colpani A, Trunfio M, Fiore V, Moi G, Fois M, Leoni N, Ruii S, Babudieri S, Calcagno A, Madeddu G. Living with HIV and Getting Vaccinated: A Narrative Review. ***Vaccines*** (Basel). 2023 Apr 25;11(5):896. doi: 10.3390/vaccines11050896. PMID: 37243000; PMCID: PMC10220625.
53. Cusato J, Manca A, Palermi A, Mula J, Costanzo M, Antonucci M, Trunfio M, Corcione S, Chiara F, De Vivo ED, Ianniello A, Ferrara M, Di Perri G, De Rosa FG, D'Avolio A, Calcagno A. COVID-19: A Possible Contribution of the MAPK Pathway. ***Biomedicines.*** 2023 May 16;11(5):1459. doi: 10.3390/biomedicines11051459. PMID: 37239131; PMCID: PMC10216575.
54. Mazzitelli M, Trunfio M, Sasset L, Scaglione V, Ferrari A, Mengato D, Gardin S, Bonadiman N, Calandrino L, Agostini E, Cattelan AM. Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and Omicron era: A real-life cohort study. ***J Med Virol.*** 2023 Mar;95(3):e28660. doi: 10.1002/jmv.28660. PMID: 36905216.
55. Avallone G, Cavallo F, Susca S, Mastorino L, Trunfio M, Bonora S, Rugge W, Calleri G, Conti L, Senetta R, Marra E, Fierro MT, Quaglino P, Ribero S. Oral doxycycline in HIV-related synchronous malignant syphilis and condyloma lata. ***Ital J Dermatol Venerol.*** 2022 Dec;157(6):524-525. doi: 10.23736/S2784-8671.22.07232-2. PMID: 36651206.
56. Cusato J, Borghetti A, Teti E, Milesi M, Tettoni MC, Bonora S, Trunfio M, D'Avolio A, Compagno M, Di Giambenedetto

- S, Di Perri G, Calcagno A. Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study. **Metabolites**. 2022 Dec 1;12(12):1202. doi: 10.3390/metabo12121202. PMID: 36557240; PMCID: PMC9781993.
57. **Sciascia S, Arbrile M, Trunfio M, Calcagno A, Radin M, Roccatello D, Lembo D, Civra A. The role of bacteria and viruses in Behçet syndrome: Should we move towards new paradigms? *Autoimmun Rev*. 2023 Feb;22(2):103237. doi: 10.1016/j.autrev.2022.103237. Epub 2022 Nov 19. PMID: 36414220.**
  58. Ferrara M, Cusato J, Salvador E, Trentalange A, Alcantarini C, Trunfio M, Cannizzo ES, Bono V, Nozza S, De Nicolò A, Ianniello A, De Vivo E, D'Avolio A, Di Perri G, Bonora S, Marchetti G, Calcagno A. Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV. **Br J Clin Pharmacol**. 2023 Mar;89(3):1020-1026. doi: 10.1111/bcp.15538. Epub 2022 Oct 11. PMID: 36115063.
  59. Mazzitelli M, Trunfio M, Putaggio C, Sasset L, Leoni D, Lo Menzo S, Mengato D, Cattelan AM. Viro-Immunological, Clinical Outcomes and Costs of Switching to BIC/TAF/FTC in a Cohort of People Living with HIV: A 48-Week Prospective Analysis. **Biomedicines**. 2022 Jul 28;10(8):1823. doi: 10.3390/biomedicines10081823. PMID: 36009370; PMCID: PMC9405513.
  60. Mazzitelli M, Trunfio M, Sasset L, Leoni D, Castelli E, Lo Menzo S, Gardin S, Putaggio C, Brundu M, Garzotto P, Cattelan AM. Factors Associated with Severe COVID-19 and Post-Acute COVID-19 Syndrome in a Cohort of People Living with HIV on Antiretroviral Treatment and with Undetectable HIV RNA. **Viruses**. 2022 Feb 28;14(3):493. doi: 10.3390/v14030493. PMID: 35336900; PMCID: PMC8954437.
  61. Mazzitelli M, Sasset L, Trunfio M, di Meco E, Frater A, Leoni D, Cattelan A. Use of self-prescribed medications and complementary medicines in a cohort of women with HIV. **AIDS**. 2022 Mar 15;36(4):617-619. doi: 10.1097/QAD.0000000000003174. PMID: 35197438.
  62. Bima P, Orlotti C, Smart OG, Morello F, Trunfio M, Brazzi L, Montrucchio G. Norepinephrine may improve survival of septic shock patients in a low-resource setting: a proof-of-concept study on feasibility and efficacy outside the Intensive Care Unit. **Pathog Glob Health**. 2022 Sep;116(6):389-394. doi: 10.1080/20477724.2022.2038051. Epub 2022 Feb 9. PMID: 35138990; PMCID: PMC9387336.
  63. Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, Arena V, d'Ettorre G, Guaraldi G, Gisslen M, Di Perri G. Alzheimer Dementia in People Living With HIV. **Neurol Clin Pract**. 2021 Oct;11(5):e627-e633. doi: 10.1212/CPJ.0000000000001060. PMID: 34840876; PMCID: PMC8610525.
  64. Stroffolini G, Guastamacchia G, Audagnotto S, Atzori C, Trunfio M, Nigra M, Di Stefano A, Di Perri G, Calcagno A. Low cerebrospinal fluid Amyloid- $\beta$  1-42 in patients with tuberculous meningitis. **BMC Neurol**. 2021 Nov 16;21(1):449. doi: 10.1186/s12883-021-02468-2. PMID: 34784880; PMCID: PMC8594191.
  65. Avallone G, Trunfio M, Giura MT, Siliquini N, Viola R, Orofino G, Mastorino L, Ortoncelli M, Quaglino P, Ribero S. Dupilumab in HIV-positive patients with atopic dermatitis: a long-term follow-up patient and a literature review. **Dermatol Online J**. 2021 Aug 15;27(8). doi: 10.5070/D327854709. PMID: 34755964.
  66. **Ulfhammer G, Edén A, Antinori A, Brew BJ, Calcagno A, Cinque P, De Zan V, Hagberg L, Lin A, Nilsson S, Oprea C, Pinnetti C, Spudich S, Trunfio M, Winston A, Price RW, Gisslén M. Cerebrospinal Fluid Viral Load Across the Spectrum of Untreated Human Immunodeficiency Virus Type 1 (HIV-1) Infection: A Cross-Sectional Multicenter Study. *Clin Infect Dis*. 2022 Aug 31;75(3):493-502. doi: 10.1093/cid/ciab943. PMID: 34747481; PMCID: PMC9427147.**
  67. Parietti M, Trunfio M, Delmonte S, Conti L, Trentalange A, Bonora S, Calcagno A, Ribero S. Efflorescence of acquired epidermodysplasia verruciformis due to immune reconstitution inflammatory syndrome-like mechanisms following anti-HPV vaccination in a HIV-positive patient. **Int J STD AIDS**. 2022 Jan;33(1):94-96. doi: 10.1177/09564624211048343. Epub 2021 Oct 11. PMID: 34629004.
  68. Airoidi C, Calcagno A, Di Perri G, Valinotto R, Gallo L, Locana E, Trunfio M, Patrucco F, Vineis P, Faggiano F. Seroprevalence of SARS-CoV-2 Among Workers in Northern Italy. **Ann Work Expo Health**. 2022 Feb 18;66(2):224-232. doi: 10.1093/annweh/wxab062. PMID: 34365502; PMCID: PMC8385866.
  69. Chan TY, De Zan V, Gregg A, Alagaratnam J, Gerevini S, Antinori A, D'Arminio Monforte A, Saracino A, Trunfio M, Everitt A, Rackstraw S, Marta M, Calcagno A, Cinque P, Winston A. The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-series. **AIDS**. 2021 Nov 15;35(14):2341-2346. doi: 10.1097/QAD.0000000000002992. PMID: 34127578.
  70. Caligaris G, Trunfio M, Ghisetti V, Cusato J, Nigra M, Atzori C, Imperiale D, Bonora S, Di Perri G, Calcagno A. Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated Biomarkers. **Diagnostics (Basel)**. 2021 May 12;11(5):867. doi: 10.3390/diagnostics11050867. PMID: 34065785; PMCID: PMC8151579.
  71. Calcagno A, Trunfio M, D'Avolio A, Di Perri G, Bonora S. The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV. **Expert Opin Drug Metab Toxicol**. 2021 Jun;17(6):665-676. doi: 10.1080/17425255.2021.1915285. Epub 2021 Apr 29. PMID: 33913394.
  72. Calcagno A, de Nicolò A, Pizzi C, Trunfio M, Tettoni C, Ferrara M, Alcantarini C, Trentini L, D'Avolio A, Di Perri G, Bonora S. Medication burden and clustering in people living with HIV undergoing therapeutic drug monitoring. **Br J Clin Pharmacol**. 2021 Nov;87(11):4432-4438. doi: 10.1111/bcp.14869. Epub 2021 May 7. PMID: 33890312.
  73. **Nissen CB, Sciascia S, de Andrade D, Atsumi T, Bruce IN, Cron RQ, Hendricks O, Roccatello D, Stach K, Trunfio M, Vinet É, Schreiber K. The role of antirheumatics in patients with COVID-19. *Lancet Rheumatol*. 2021**

Jun;3(6):e447-e459. doi: 10.1016/S2665-9913(21)00062-X. Epub 2021 Mar 30. PMID: 33817665; PMCID: PMC8009617.

74. **Calcagno A, Ghisetti V, Emanuele T, Trunfio M, Faraoni S, Boglione L, Burdino E, Audagnotto S, Lipani F, Nigra M, D'Avolio A, Bonora S, Di Perri G. Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy. *Emerg Infect Dis*. 2021 Jan;27(1):303–5. doi: 10.3201/eid2701.203027. Epub 2020 Oct 6. PMID: 33021927; PMCID: PMC7774556.**
75. **Calcagno A, Ghisetti V, Burdino E, Trunfio M, Allice T, Boglione L, Bonora S, Di Perri G. Co-infection with other respiratory pathogens in COVID-19 patients. *Clin Microbiol Infect*. 2021 Feb;27(2):297-298. doi: 10.1016/j.cmi.2020.08.012. Epub 2020 Aug 19. PMID: 32822882; PMCID: PMC7434691.**
76. De Benedetto I, Trunfio M, Guastamacchia G, Bonora S, Calcagno A. A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs. *J Neurovirol*. 2020 Oct;26(5):642-651. doi: 10.1007/s13365-020-00874-9. Epub 2020 Jul 31. PMID: 32737860.
77. Calcagno A, Moltó J, Borghetti A, Gervasoni C, Milesi M, Valle M, Avataneo V, Alcantarini C, Pla-Junca F, Trunfio M, D'Avolio A, Di Giambenedetto S, Cattaneo D, Di Perri G, Bonora S. Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. *Clin Pharmacokinet*. 2021 Jan;60(1):103-109. doi: 10.1007/s40262-020-00916-9. PMID: 32737820.
78. Mornese Pinna S, Trunfio M, Imperiale D, Calcagno A. JC virus DNA in cerebrospinal fluid: insight into clinical significance. *Diagn Microbiol Infect Dis*. 2020 Jun;97(2):115017. doi: 10.1016/j.diagmicrobio.2020.115017. Epub 2020 Feb 13. PMID: 32201111.
79. Joseph SB, Trunfio M, Kincer LP, Calcagno A, Price RW. What can characterization of cerebrospinal fluid escape populations teach us about viral reservoirs in the central nervous system? *AIDS*. 2019 Dec 1;33 Suppl 2:S171-S179. doi: 10.1097/QAD.0000000000002253. PMID: 31790378.
80. Bertero L, Joseph SB, Trunfio M, Allice T, Catera S, Imperiale D, Cassoni P, Kincer LP, Pirriatore V, Ghisetti V, Amasio E, Zanusso G, Bonora S, Di Perri G, Calcagno A. HIV-1 detection in the olfactory mucosa of HIV-1-infected participants. *AIDS*. 2019 Mar 15;33(4):665-674. doi: 10.1097/QAD.0000000000002102. PMID: 30608272.
81. Scabini S, Trunfio M, Pirriatore V, Imperiale D, Audagnotto S, Bertucci R, Ghisetti V, Cinnirella G, Cistaro A, Perna M, Calcagno A, Di Perri G. Antiviral activity of maraviroc plus mirtazapine in a low-risk HIV-negative patient with progressive multifocal leukoencephalopathy. *Infez Med*. 2018 Jun 1;26(2):160-163. PMID: 29932090.
82. Calcagno A, Barco A, Trunfio M, Bonora S. CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose. *Curr HIV/AIDS Rep*. 2018 Feb;15(1):84-91. doi: 10.1007/s11904-018-0375-2. PMID: 29363025.
83. Palazzo A, Trunfio M, Pirriatore V, Milesi M, De Nicolò A, Alcantarini C, D'Avolio A, Bonora S, Di Perri G, Calcagno A. Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid. *J Antimicrob Chemother*. 2018 Mar 1;73(3):826-827. doi: 10.1093/jac/dkx461. PMID: 29244118.
84. Bai F, Iannuzzi F, Merlini E, Borghi L, Tincati C, Trunfio M, Bini T, Monforte AD, Marchetti G. Clinical and viro-immunological correlates of HIV associated neurocognitive disorders (HAND) in a cohort of antiretroviral-naïve HIV-infected patients. *AIDS*. 2017 Jan 14;31(2):311-314. doi: 10.1097/QAD.0000000000001346. PMID: 28005574.

Tutte le informazioni riportate nel presente curriculum, comprese attività professionali, titoli e pubblicazioni, sono rese ai sensi degli artt. 46 e 47 del D.P.R. n. 445/2000.

01/06/2025,

*Curriculum vitae of Mattia Trunfio*



## INFORMAZIONI PERSONALI

Nome	<b>MAURO VIGANÒ</b>
Data di nascita	24 NOVEMBRE 1972
Qualifica	Medico Chirurgo
Incarico attuale	Dirigente Medico
Amministrazione	Gastroenterologia 1 - Epatologia e Trapiantologia ASST Papa Giovanni XXIII Piazza OMS, 1 - 24127 Bergamo
Telefono	3392354938
E-mail	mvigano72@gmail.com
CF	VGNMRA72S24F205R
Nazionalità	Italiana

## ESPERIENZA LAVORATIVA

DAL DICEMBRE 2022

**Dirigente medico**Gastroenterologia 1 - Epatologia e Trapiantologia  
ASST Papa Giovanni XXIII Piazza OMS, 1 - 24127 Bergamo**Dirigente medico**DAL MAGGIO 2010 AL  
NOVEMBRE 2022

- Nome e indirizzo del datore di lavoro

Unità Operativa Epatologia. Ospedale San Giuseppe Multimedica, Via San Vittore 12, 20123 Milano

- Tipo d'impiego
- Principali mansioni e responsabilità

Incarico a tempo indeterminato

Attività di reparto; Day Hospital con esecuzione di biopsie epatiche e trattamenti ablativi loco regionali di HCC eco-guidati; ambulatorio specialistico di epatologia. Partecipazione a riunioni multidisciplinari per la gestione dei pazienti con lesioni focali epatiche e per l'inserimento in lista di trapianto di fegato. Gestione di trial clinici sulla NASH e su epatite B e C. Attività di ricerca inerente efficacia e sicurezza dei trattamenti antivirali nei pazienti con epatite cronica B e C, dei pazienti con cirrosi ed HCC.

DAL 2010 al novembre 2022 consulente Epatologo del Centro Cardiologico Monzino di Milano

DAL 2013 Consulente medico dell'Associazione EpaC ETS

DAL NOVEMBRE 2006  
ALL'APRILE 2010**Assegno di Ricerca Università degli Studi di Milano**

- Nome e indirizzo del datore di lavoro

Università degli Studi di Milano Via Festa del Perdono, 20122 Milano  
Dipartimento di Scienze Mediche IRCCS Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena. Via Francesco Sforza 35, Milano 20122

- Tipo d'impiego
- Principali mansioni e responsabilità

Assegnista di Ricerca

Attività di ricerca clinica su pazienti con epatite cronica B, identificazione dei predittori di risposta ai trattamenti antivirali, valutazione della storia naturale dei pazienti sottoposti a trapianto di fegato. Attività di ricerca: studi molecolari relativi alle mutazioni indotte dai farmaci antivirali sul virus dell'epatite B.

Attività didattica: lezioni frontali, seminari ed esercitazioni nel Corso di Metodologia Clinica e Corso di Semeiotica e Sistematica II della Facoltà di Medicina e Chirurgia, dell'Università degli Studi di Milano.

DAL GENNAIO 2006 AL  
GENNAIO 2007

- Nome e indirizzo del datore di lavoro
- Tipo d'impiego
- Principali mansioni e responsabilità

DA OTTOBRE 2003 A  
MAGGIO 2010

Nome e indirizzo del datore di lavoro  
Tipo d'impiego  
Principali mansioni e responsabilità

DAL GENNAIO 2002 AL  
GENNAIO 2006

- Nome e indirizzo del datore di lavoro
- Tipo d'impiego
- Principali mansioni e responsabilità

DAL 1998 AL 2002

- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Principali mansioni e responsabilità

**Borsa di ricerca del Consorzio Interuniversitario Trapianti d'Organo, Roma.** "Studio prospettico di coorte di 320 pazienti affetti d cirrosi compensata HCV correlata: incidenza e impatto clinico della comparsa del carcinoma epatocellulare"

IRCCS Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena Via Francesco Sforza 35, Milano 20122

Borsa di studio

Attività di ricerca clinica: creazione e gestione di database. Attività di ricerca sulla storia naturale della cirrosi HCV correlata. Gestione di trial clinici in qualità di sub-investigatore. Attività didattica: esercitazioni nel Corso di Metodologia Clinica, Facoltà di Medicina e Chirurgia, Università degli Studi di Milano.

**Emergenza e Urgenza 118 Lecco**

Centrale Operativa AST Lecco Via dell'Eremo Lecco

Medico c/o SSUEm 118 Lecco

Contratto a tempo determinato

**Dottorato di Ricerca in Gastroenterologia**

Università degli Studi di Milano Via Festa del Perdono, 20122 Milano. Dipartimento di Scienze Mediche, Università degli Studi di Milano. Via Francesco Sforza 35 20122 Milano

Borsa di Studio

Attività clinica: gestione ambulatoriale di pazienti affetti da malattia cronica di fegato. Attività di ricerca clinica: creazione e gestione di database. Gestione di trial clinici in qualità di sub-investigatore.

**Scuola di Specializzazione in Gastroenterologia ed Endoscopia digestiva**

Università degli Studi di Milano Via Festa del Perdono, 20122 Milano. IRCCS Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena. Via Francesco Sforza 35, Milano 20122 0255035432

Dipartimento di Scienze Mediche Via Pace 9, 20122 Milano

Medico in formazione. Attività ambulatoriale di gastroenterologia ed epatologia, servizio di endoscopia digestiva ed attività di reparto. Gestione di trial clinici in qualità di sub-investigatore.

DAL 1995 AL 1998

- Nome e indirizzo del datore di lavoro
- Tipo d'impiego
- Principali mansioni responsabilità

### **Frequentatore volontario**

Ospedale S. Gerardo, Monza

Attività clinica c/o la Clinica Medica e ambulatorio del metabolismo del ferro  
Prima come studente e poi medico interno in formazione

### **ISTRUZIONE E FORMAZIONE**

DAL 2016 A TUTT'OGGI

2013

**Tutore** alla Scuola di Specializzazione di Gastroenterologia ed Endoscopia Digestiva, Università degli Studi di Milano

**Abilitazione Scientifica Nazionale a Professore di II fascia** – settore concorsuale 067D4 “Malattie Cutanee, Malattie Infettive e Malattie dell'Apparato Digerente” con validità dal 1/12/14 al 1/12/25

DAL 2011 A TUTT'OGGI

**Professore a Contratto del Corso Integrato di semeiotica II (insegnamento di Gastroenterologia)** del corso di laurea in Medicina e Chirurgia dell'Università degli Studi di Milano.

2006-2010

**Assegno di Ricerca Università degli Studi di Milano**

2006

**Diploma di Dottorato di Ricerca in Gastroenterologia**, Istituto di Scienze Mediche, Università degli studi di Milano. Votazione: eccellente

2004

**Diploma Nazionale della Società di Ultrasonologia in Medicina e Biologia - SIUMB**

2003

**Certificazione di Qualificazione per Area di Emergenza-Urgenza**

2002

**Specializzazione in Gastroenterologia ed Endoscopia digestiva**, Università degli Studi di Milano. Votazione 70/70 e lode.

1998

**Esame di Stato** con conseguimento idoneità alla professione di Medico Chirurgo e conseguente iscrizione all'Albo dell'Ordine dei Medici Chirurghi e Odontoiatri della Provincia di Lecco con tessera nr. 1228.

1997

**Laurea in Medicina e Chirurgia**, Università degli Studi di Milano. Votazione 110 e lode.

1991

Diploma di Maturità Istituto “A. Greppi” di Monticello. Votazione 60/60.

### **CAPACITÀ E COMPETENZE**

#### **PERSONALI**

*Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.*

Pagina 4 di 28

Data emissione del presente modello: 09/01/2006

PRIMA LINGUA

ITALIANO

ALTRE LINGUE

INGLESE

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

Ottima

Ottima

Ottima

CAPACITÀ E COMPETENZE  
RELAZIONALI

OTTIMA CAPACITÀ E NOTEVOLE INTERESSE NEL VIVERE E LAVORARE CON ALTRE PERSONE, OCCUPANDO POSTI IN CUI LA COMUNICAZIONE È IMPORTANTE E IN SITUAZIONI IN CUI È ESSENZIALE LAVORARE IN SQUADRA.

*Vivere e lavorare con altre persone, in ambiente multiculturale, occupando posti in cui la comunicazione è importante e in situazioni in cui è essenziale lavorare in squadra (ad es. cultura e sport), ecc.*

CAPACITÀ E COMPETENZE  
ORGANIZZATIVE

DAL 2008 AL'APRILE 2015 **DIRETTORE SANITARIO GENERALE** CROCE BIANCA MILANO

*Ad es. coordinamento e amministrazione di persone, progetti, bilanci; sul posto di lavoro, in attività di volontariato (ad es. cultura e sport), a casa, ecc.*

**MEMBRO DEL COMITATO DIRETTIVO DELL'ASSOCIAZIONE ITALIANA STUDIO FEGATO (AISF) DAL 2015 AL 2017**

SOCIO DELLA ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO (AISF) E DELL'ASSOCIAZIONE EUROPEA PER LO STUDIO DEL FEGATO (EASL)

**MEMBRO EDITORIAL BOARD:** JOURNAL OF CLINICAL MEDICINE, CASE REPORTS IN HEPATOLOGY, READFILES, JSM HEPATITIS, JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY RESEARCH

REVIEWER: LANCET INFECTIOUS DISEASES, LIVER INTERNATIONAL, DIGESTIVE AND LIVER DISEASE, ALIMENTARY PHARMACOLOGY AND THERAPEUTICS, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, INTERNATIONAL JOURNAL OF HEPATOLOGY, WORLD JOURNAL OF HEPATOLOGY, WORLD JOURNAL OF GASTROENTEROLOGY

DAL 2015 **MEMBRO DEL CONSIGLIO DI AMMINISTRAZIONE DELLA CDR DI MONTICELLO BRIANZA**

DAL 2021 AL 2023 **MEMBRO DEL CONSIGLIO D'ISTITUTO DELL'ISTITUTO COMPRENSIVO "RITA LEVI MONTALCINI"**

CAPACITÀ E COMPETENZE  
TECNICHE  
*Con computer, attrezzature  
specifiche, macchinari, ecc.*

Buona capacità di utilizzo PC

**ALTRO**  
**PARTECIPAZIONE A**  
**CONGRESSI E CONVEGNI**

SUONARE SAXOFONO.  
HA PARTECIPATO IN QUALITÀ DI RELATORE/MODERATORE A NUMEROSI  
CONGRESSI LOCALI, NAZIONALI E INTERNAZIONALI.

## Capitolo di libri/publicazioni:

- 1) P. Lampertico, **M. Viganò**, M. Colombo. Treatment of HBV drug resistance. International Hepatology Update – Chronic Hepatitis B. Editors: M Buti and R Esteban: Hepatitis B. Eds. Permanyer Publications, Barcelona, 2009;121-132
- 2) P. Lampertico, **M. Viganò**, M. Colombo. Long-term treatment with oral antivirals for HBeAg-negative patients. International Hepatology Update – Chronic Hepatitis B. Editors: M Buti and R Esteban: Hepatitis B. Eds. Permanyer Publications, Barcelona, 2010;49-56
- 3) P. Lampertico, **M. Viganò**. Terapia dell'epatite cronica B. Manuale di Gastroenterologia, UNIGASTRO (ed), EGI, Roma, 2012

Autore delle linee guida Italiane su epatite B negli immunodepressi: **Gestione clinica della epatite B negli immunocompromessi: aggiornamento italiano 2017**. A Marzano, R Bruno, S Fagiuoli, M Marignani, S Madonia, P Toniutto, **M Viganò**.

Revisore delle linee guida Italiane su epatite B: **Terapia della Epatite Cronica B: aggiornamento 2015 delle raccomandazioni Italiane**. MR Brunetto, R Bruno, V Di Marco, G Taliani, GB Gaeta, G Brancaccio, F Ceccherini-Silberstein, M Fasano, P Lampertico, A Marzano, T Santantonio, V Svicher, **M Viganò**.

## Elenco lavori pubblicati su riviste indicizzate con peer review:

- 1) C. Arosio, L. Fossati, **M. Viganò**, P. Trombini, G. Cazzaniga, A. Piperno. Hereditary hyperferritinemia cataract syndrome: a de novo mutation in the iron responsive element of the L-ferritin gene. Haematologica 1999;84:560-561
- 2) **M. Viganò**, A. Vergani, P. Trombini, M. Pozzi, F. Paleari, A. Piperno. Insulin resistance influences iron metabolism and hepatic steatosis in type II diabetes. Gastroenterology 2000;118:986-987
- 3) A. Piperno, C. Arosio, L. Fossati, **M. Viganò**, P. Trombini, A. Vergani and G. Mancia. Two novel nonsense mutations of HFE gene in five unrelated italian patients with hemochromatosis. Gastroenterology 2000;119:441-445
- 4) P. Lampertico, E. Del Ninno, **M. Viganò**, R. Romeo, M.F. Donato, E. Sablon, A. Morabito and M. Colombo. Long-term suppression of hepatitis B e Antigen-negative chronic hepatitis B by 24-month interferon therapy.

Hepatology 2003;37:756-763

5) A. Piperno, A. Vergani, A. Salvioni, P. Trombini, **M. Viganò**, A. Riva, A. Zoppo, G. Boari, G. Mancina. Effects of venesections and restricted diet in patients with insuline resistance hepatic iron overload syndrome. Liver International 2004;24:471-476

6) **M. Viganò**, S. Visentin, A. Aghemo, M.G. Rumi and G. Ronchi. US features of liver surface nodularity as a predictor of severe fibrosis in chronic hepatitis C. Radiology 2005;234:641

7) A. Marzano, P. Lampertico, V. Mazzaferro, S. Carezzi, **M. Viganò**, R. Romito, A. Pulvirenti, A. Franchello, M. Colombo, M. Salizzoni and M. Rizzetto. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transplantation 2005;11:532-538

8) **M. Viganò**, M. Colombo, A. Aroldi, G. Lunghi, E. Manenti, C. Ponticelli and P. Lampertico. Long-term lamivudine monotherapy in renal transplant recipients with hepatitis B-related cirrhosis. Antiviral Therapy 2005;10:709-713

9) P. Lampertico, **M. Viganò**, E. Manenti, G. Lunghi, M. Iavarone, E. Del Ninno and M. Colombo. Adefovir rapidly suppresses hepatitis B in HBeAg negative patients developing genotypic resistance to lamivudine. Hepatology 2005;42:1414-1419

10) A. Cortelezzi, **M. Viganò**, V.R. Zilioli, N.N. Fantini, M.C. Pasquini, G. Lambertenghi Delleris, M. Colombo and P. Lampertico. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with campath-1H. Journal of Clinical Virology 2006;35:467-469

11) **M. Viganò**, P. Lampertico, M.G. Rumi, C. Folli, L. Maggioni, A. Morabito, E. Del Ninno, M. Cicardi and M. Colombo. Natural history and clinical impact of cryoglobulins in chronic hepatitis C: 10-year prospective study of 343 patients. Gastroenterology 2007;133:835-842

12) P. Lampertico, **M. Viganò**, E. Manenti, M. Iavarone, E. Sablon, M. Colombo. Low resistance to adefovir combined with lamivudine: a 3 year study of 145 lamivudine resistant hepatitis B patients. Gastroenterology 2007;133:1445-51

13) **M. Viganò**, A. Aghemo, M. Iavarone. The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis. Gastroenterology 2007;133:2076

14) **M. Viganò**, P. Lampertico, M. Colombo. Acute hepatitis following assumption of a herbal remedy. Eur J Gastroenterol Hepatol 2008;20:364-365

15) **M. Viganò**, P. Lampertico, F. Facchetti, G. Lunghi, M. Colombo. Failure

of adefovir 20 mg to improve suboptimal response in lamivudine resistant hepatitis B patients treated with adefovir 10 mg and lamivudine. *J Viral Hepat* 2008;15:922-924

16) S. Paggi, A. Colli, M. Fraquelli, **M. Viganò**, P. Del Poggio, C. Facciotto, M. Colombo, G. Ronchi, D. Conte. A non-invasive algorithm accurately predicts advanced fibrosis in hepatitis C: a comparison using histology with internal-external validation. *J Hepatol* 2008;49:564-71

17) P. Lampertico, **M. Viganò**, M. Colombo. Management of lamivudine resistance: An overview. *Hep B Annual* 2008;5:66-80

18) **M. Viganò**, A. Aghemo, M. Iavarone, M.G. Rumi, F. Agnelli, P. Lampertico, M.F. Donato, M. Colombo. The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin. *Antivir Ther* 2009;14:789-96

19) P. Lampertico, A. Aghemo, **M. Viganò**, M. Colombo. HBV and HCV therapy. *Viruses* 2009;1:484-509

20) **M. Viganò**, S. Massironi, P. Lampertico, M. Iavarone, S. Paggi, R. Pozzi, D. Conte, M. Colombo. Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B. *Eur J Gastroenterol Hepatol* 2010;22:180-4

21) M. Iavarone, M. Perrino, **M. Viganò**, P. Beck-Peccoz, L. Fugazzola. Sorafenib-induced destructive thyroiditis. *Thyroid* 2010;20:1043-4

22) **M. Viganò**, C. Vener, P. Lampertico, C. Annaloro, C. Pichoud, F. Zoulim, F. Facchetti, F. Poli, M. Scalamogna, G. Lambertenghi Delilieri, M. Colombo. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. *Bone Marrow Transplantation* 2011;46:125-31

23) P. Lampertico, **M. Viganò**, M. Colombo. Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon. *Liver International* 2011;31 Suppl 1:90-4.

24) **M. Viganò**, P. Lampertico. Antiviral drugs for HBV liver disease. *Expert Opin Biol Ther* 2011;11:285-300

25) P. Lampertico, **M. Viganò**, F. Facchetti, F. Invernizzi, A. Aroldi, G. Lunghi G, P.G. Messa, M. Colombo. Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B. *Nephrol Dial Transplant* 2011;26:2037-41

26) **M. Viganò**, P. Lampertico, M. Colombo. Drug safety evaluation of adefovir in HBV infection. *Expert Opin Drug Saf* 2011;10:809-18

27) **M. Viganò**, S. Paggi, P. Lampertico, M. Fraquelli, S. Massironi, G. Ronchi, C. Rigamonti, D. Conte, M. Colombo. Dual cut-off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation. *Aliment Pharmacol Ther* 2011;34:353-362

28) **M. Viganò**, S. Paggi, P. Lampertico. Application of transient elastography

- in chronic hepatitis B. *Aliment Pharmacol Ther* 2011;34:818-819
- 29) P. Lampertico, **M. Viganò**, M. Colombo. Current management of HBV antiviral drug resistance. *Curr Hepatitis Rep* 2011;10:120-127
- 30) G.L. Colombo, G.B. Gaeta, **M. Viganò**, S. Di Matteo. A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. *Clinicoecon Outcomes Res* 2011;3:37-46
- 31) F. Fabrizi, **M. Viganò**, G. Banfi, P. Martin, P.G. Messa, P. Lampertico P. HBV-related liver disease in renal insufficiency: successful antiviral therapy with entecavir. *Int J Artif Organs* 2011;34:1031-5
- 32) **M. Viganò**, E. Degasperis, A. Aghemo, P. Lampertico, M. Colombo. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. *Expert Opin Biol Ther* 2012;12:193-207
- 33) A. Aghemo, M.G. Rumi, S. Monico, M. Banderali, A. Russo, F. Ottaviani, **M. Viganò**, R. D'Ambrosio, M. Colombo. Ribavirin impairs salivary gland function during combination treatment with pegylated interferon alfa-2a in hepatitis C patients. *Hepat Mon* 2011;11:918-24
- 34) A. Penna, D. Laccabue, I. Libri, T. Giuberti, S. Schivazappa, A. Alfieri, C. Mori, D. Canetti, P. Lampertico, **M. Viganò**, M. Colombo, E. Loggi, G. Missale, C. Ferrari. Peginterferon- $\alpha$  does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. *J Hepatol*. 2012;56:1239-46
- 35) **M. Viganò**, P. Lampertico. Clinical implications of HBsAg quantification in patients with chronic hepatitis B. *Saudi J Gastroenterol*. 2012;18:81-6.
- 36) P. Lampertico, **M. Viganò**, M. Colombo. Partial response to entecavir and tenofovir in naive patients with chronic hepatitis B: clinical relevance and management. *Curr Hepatitis Rep* 2012;11:90-94
- 37) C. Boni, D. Laccabue, P. Lampertico, T. Giuberti, **M. Viganò**, S. Schivazappa, A. Alfieri, M. Pesci, G. Gaeta, G. Brancaccio, M. Colombo, G. Missale, C. Ferrari. Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues. *Gastroenterology* 2012;143:963-973
- 38) P. Lampertico, **M. Viganò**, C. Cheroni, F. Facchetti, F. Invernizzi, V. Valveri, R. Soffredini, S. Abrignani, R. De Francesco and M. Colombo. IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg-negative patients with chronic hepatitis B. *Hepatology* 2013;57:890-6.
- 39) P. Lampertico, **M. Viganò**, G.G. Di Costanzo, E. Sagnelli, M. Fasano, V. Di Marco, S. Boninsegna, P. Farci, S. Fargion, T. Giuberti, C. Iannacone, L. Regep, B. Massetto, F. Facchetti, M. Colombo. Randomised study comparing 48 and 96 weeks peginterferon  $\alpha$ -2a therapy in genotype D HBeAg-negative chronic hepatitis B. *Gut*. 2013;62:290-298.

- 40) P. Lampertico, **M. Viganò**, M. Colombo. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon? *Liver Int.* 2013;33 Suppl 1:157-63.
- 41) **M. Viganò**, L. Valenti, P. Lampertico, F. Facchetti, B.M. Motta, R. D'Ambrosio, S. Romagnoli, P. Dongiovanni, B. Donati, S. Fargion, M. Colombo. PNPLA3 I148M affects liver steatosis in patients with chronic hepatitis B. *Hepatology* 2013;58:1245-52.
- 42) E. Degasperi, **M. Viganò**, A. Aghemo, P. Lampertico, M. Colombo M. PegIFN- $\alpha$ 2a for the treatment of chronic hepatitis B and C: a 10-year history. *Expert Rev Anti Infect Ther* 2013;11:459-74.
- 43) **M. Viganò**, G. Mangia, P. Lampertico. Results of treatment of chronic hepatitis B with pegylated interferon. *Clin Liver Dis* 2013;17:425-43.
- 44) **M. Viganò** and P. Lampertico. Hepatitis B virus treatment: which patients should be treated with nucleos(t)ide analogue? *Clinical Liver Disease* 2013;2:21-23.
- 45) **M. Viganò** and P. Lampertico. IL28B polymorphism in interferon-treated patients with chronic hepatitis B. *European Medical Journal-Hepatology* 2013;1:92-99.
- 46) **M. Viganò**, G. Mangia, P. Lampertico. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues? *Liver Int* 2014;34 Suppl 1:120-6.
- 47) E. Galmozzi, **M. Viganò**, P. Lampertico. Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection? *Aliment Pharmacol Ther* 2014; 39:569-78
- 48) E. Galmozzi, **M. Viganò**, P. Lampertico. Letter: do interferon lambda 3 polymorphisms predict the outcome of interferon therapy in hepatitis B infection? Authors' reply. *Aliment Pharmacol Ther* 2014;39:1251-2.
- 49) P.M. Trembling, P. Lampertico, J. Parkes, S. Tanwar, **M. Viganò**, F. Facchetti, M. Colombo, W.M. Rosenberg. Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. *J Viral Hepat* 2014;21:430-8
- 50) **M. Viganò**, G. Mangia, P. Lampertico. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy. *Expert Opin Biol Ther* 2014;14:1019-31
- 51) **M. Viganò**, P. Martin, M. Cappelletti, F. Fabrizi. HBV-Associated Cryoglobulinemic vasculitis: remission after antiviral therapy with Entecavir. *Kidney Blood Press Res* 2014;39:65-73.
- 52) **M. Viganò**, A. Brocchieri, A. Spinetti, S. Zaltron, G Mangia, F. Facchetti,

- A. Fugazza, F. Castelli, M. Colombo, P. Lampertico. Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal. *J Clin Virol* 2014;61:600-3.
- 53) **M. Viganò**, F. Invernizzi, P. Lampertico. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients? *Liver Int* 2015;35 Suppl 1:107-13.
- 54) **M. Viganò**, S. Bhoori, P. Lampertico, M.F. Donato, M. Iavarone, G. Grossi, A. Facciorusso, L. Caccamo, G. Rossi, M. Colombo, V. Mazzaferro. Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma. *Liver Int*. 2015;35:2187-93.
- 55) P. Lampertico, F. Invernizzi, **M. Viganò**, A. Loglio, G. Mangia, F. Facchetti, M. Primignani, M. Jovani, M. Iavarone, M. Fraquelli, G. Casazza, R. de Franchis, M. Colombo. The long-term benefits of nucleos(t)ides analogs on esophageal varices in compensated HBV cirrhotics with non or small esophageal varices: a 12-year prospective cohort study. *J Hepatol* 2015;63:1118-25.
- 56) **M. Viganò**, M. Colombo. Extrahepatic Manifestations of Hepatitis C Virus. *Gastroenterol Clin North Am*. 2015;44:775-91.
- 57) F. Invernizzi, **M. Viganò**, G. Grossi, P. Lampertico. Prognosis and management of inactive carriers. *Liver Int*. 2016;36 Suppl 1:100-4.
- 58) V. Varisco, **M. Viganò**, A. Batticciotto, P. Lampertico, A. Marchesoni, P. Gibertini, R. Pellerito, G. Rovera, R. Caporali, M. Todoerti, M. Covelli, A. Notarnicola, F. Atzeni, P. Sarzi-Puttini. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. *J Rheumatol*. 2016;43(5):869-74.
- 59) **M. Viganò**, Serra G, Casella G, Grossi G, Lampertico P. Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders. *Expert Opin Biol Ther*. 2016;16:917-26
- 60) S. Bruno, V. Di Marco, M. Iavarone, L. Roffi, A. Crosignani, V. Calvaruso, A. Aghemo, G. Cabibbo, **M. Viganò**, V. Boccaccio, A. Craxì, M. Colombo, P. Maisonneuve. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. *J Hepatol*. 2016;64:1217-23.
- 61) A Craxì, CF Perno, **M Viganò**, F Ceccherini-Silberstein, S Petta; AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party. From current status to optimization of HCV treatment: Recommendations from an expert panel. *Dig Liver Dis*. 2016;48:995-1005
- 62) **M Viganò**, F Invernizzi, G Grossi, P Lampertico. Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection. *Aliment Pharmacol Ther*. 2016;44:653-61.

- 63) G Grossi, **M Viganò**, A Loglio, P Lampertico. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs). *Liver Int.* 2017;37:45-51.
- 64) **M Viganò**, CF Perno, A Craxì; AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party. Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. *Dig Liver Dis.* 2017. 49:731-741.
- 65) S Odolini, P Lanza, A Spinetti, S Zaltron, L Urbinati, A Vavassori, P Nasta, E Festa, F Gargiulo, A Rodella, A Caruso, S Casari, F Castelli, **M Viganò**. Hepatitis B virus reactivation after effective sofosbuvir and ribavirin treatment in a patient with occult hepatitis B virus infection. *New Microbiol* 2017;40:218-220
- 66) E Galmozzi, F Facchetti, G Grossi, A Loglio, **M Viganò**, G Lunghi, M Colombo, P Lampertico. IFNL4 rs368234815 and rs117648444 variants predict off treatment HBsAg seroclearance in IFN treated HBeAg negative chronic hepatitis B patients. *Liver Int.* 2017 38:417-423
- 67) G Grossi, **M Viganò**, Facchetti F, Labanca S, Loglio A, Dodero A, Montefusco V, Corradini P, Cafro A, Cairoli R, Colombo M, Lampertico P. Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies: two case reports. *Haematologica*;102:e423-e426.
- 68) **M Viganò**, Grossi G, Loglio A, Lampertico P. Hepatitis B: Is there still a role for interferon? *Liver Int.* 2018 Feb;38 Suppl 1:79-83.
- 69) **M Viganò**, Loglio A, Grossi G, Lampertico P. Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? *Expert Review of Anti-infective Therapy* 2018;16:153-161.
- 70) Loglio A, Iavarone M, Grossi G, **M Viganò**, Rumi MG, Facchetti F, Lunghi G, Sangiovanni A, Colombo M, Lampertico P. Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for Hepatitis B. *Aliment Pharmacol Ther*;48:431-439
- 71) Petta S, Sebastiani G, Bugianesi E, **M Viganò**, Wong VW, Berzigotti A, Fracanzani AL, Anstee QM, Marra F, Barbara M, Calvaruso V, Cammà C, Di Marco V, Craxì A, de Ledinghen V. Noninvasive prediction of esophageal varices in Nonalcoholic Fatty Liver Disease Cirrhosis: A Multicenter Cross-sectional Study. *J Hepatol.* 2018;69:878-885.
- 72) Guarino M, Viganò L, Ponziani FR, Giannini EG, Lai Q, Morisco F; Vitale A, Francesco Paolo R, Cillo U, Burra P, Mescoli C, Gambato M, Sessa A, Cabibbo G, **M Viganò**, Galati G, Villa E, Iavarone M, Brancaccio G, Rendina M, Lupo LG, Losito F, Fucilli F, Persico M, D'Ambrosio R, Sangiovanni A,

Cucchetti A, Trevisani E, Matteo Renzulli F, Miele L, Grieco A, Lodovico Rapaccini G, Pompili M, Gasbarrini A, Battista Levi Sandri G, Melandro F, Rossi M, Lenci I, Maria Manzia T, Tortora R, Di Costanzo GG, Rodolfo S, Ghinolfi D, Rreka E, Carrai P, Simonetti N, Sposito C, Bhoori S, di Sandro S, Foschi FG, Casadei Gardini A, Nicolini D, Mazzocato S, Alba K, Violi P, Bacarani U, Pravisani R, Vincenzi V. Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. *Dig Liver Dis.* 2018;50:1105-1114

73) A Loglio, **M Viganò**, G Grossi, S Labanca, M Goldaniga, A Pompa, L Farina, MG Rumi, P Corradini, F Facchetti, G Lunghi, L Baldini, P Lampertico. Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma. *DLD* 2019;51:419-424

74) **M Viganò**, Loglio A, Labanca S, Zaltron S, Castelli F, Andreone P, Messina V, Ganga R, Coppola N, Marrone A, Russello M, Marzano A, Tucci A, Taliani G, Fasano M, Fagioli S, Villa E, Bronte F, Santantonio T, Brancaccio G, Occhipinti V, Facchetti F, Grossi G, Rumi M, Lampertico P. Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir. *Liver Int.* 2019;39:484-493.

75) Occhipinti V, Farina L, **M Viganò**, Capecchi M, Labanca S, Fanetti I, Corradini P, Rumi M. Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma. *Dig Liver Dis.* 2018;51:719-723

76) **M Viganò**, Andreoni M, Perno CF, Craxì A, Aghemo A, Alberti A, Andreone P, Babudieri S, Bonora S, Brunetto MR, Bruno R, Bruno S, Calvaruso V, Caporaso N, Cartabellotta F, Ceccherini-Silberstein F, Cento V, Ciancio A, Colombatto P, Coppola N, Di Marco V, Di Perri G, Fagioli S, Gaeta GB, Gasbarrini A, Lampertico P, Pellicelli A, Prestileo T, Puoti M, Raimondo G, Rizzardini G, Taliani G, Zignego AL. Real life experiences in HCV management in 2018. *Expert Rev Anti Infect Ther* 2019;17:117-128.

77) Marzano A, Angelucci E, Astegiano M, Baratelli C, Biancone L, Bironzo P, Brancaccio G, Brunetto MR, Bruno R, Burra P, Cabras MG, Caraceni P, Chialà C, Clemente MG, Colli A, Daniele B, De Gasperi E, Di Marco V, Ditto MC, Fagioli S, Ferri C, Gaeta GB, Grossi PA, Imperatrice B, Lampertico P, Macaluso FS, Madonna S, Marignani M, Mazzarelli C, Mella A, Missale G, Parisi S, Pasulo L, Puoti M, Rendina M, Ribaldone D, Rossi G, Toniutto P, Tucci A, Vajro P, **M Viganò**, Volpes R, Zignego AL. AISF position paper on HCV in immunocompromised patients. *Dig Liver Dis.* 2019;51:10-23.

78) Tosetti G, Primignani M, La Mura V, D'Ambrosio R, Degaspero E, Mezzina N, **M Viganò** A, Lampertico P. Evaluation of three "beyond Baveno

VI" criteria to safely spare endoscopies in compensated advanced chronic liver disease. *Dig Liver Dis.* 2019;51:1135-1140.

79) Galati G, Muley M, **M Viganò**, Iavarone M, Vitale A, Dell'Unto C, Lai Q, Cabibbo G, Sacco R, Villa E, Trevisani F. Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis. *Expert Opin Drug Saf.* 2019;18:603-610.

80) Iavarone M, **M Viganò**, Piazza N, Occhipinti V, Sangiovanni A, Maggioni M, D'Ambrosio G, Forzenigo LV, Motta F, Lampertico P, Rumi MG, Colombo M. Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance. *Ann Hepatol.* 2019;18:318-324.

81) Loglio A, Iavarone M, **M Viganò**, Orenti A, Facchetti F, Cortinovis I, Lunghi G, Ceriotti F, Occhipinti V, Rumi M, Sangiovanni A, Colombo M, Lampertico P. Minimal increases of serum alpha-fetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy. *Liver Int.* 2019; 39:1964-1974

82) Giannini EG, Aglitti A, Borzio M, Gambato M, Guarino M, Iavarone M, Lai Q, Levi Sandri GB, Melandro F, Morisco F, Ponziani FR, Rendina M, Russo FP, Sacco R, **M Viganò**, Vitale A, Trevisani F; Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group. Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. *Cancers.* 2019;30;11:1689.

83) Lai Q, Vitale A, Manzia TM, Foschi FG, Levi Sandri GB, Gambato M, Melandro F, Russo FP, Miele L, Viganò L, Burra P, Giannini EG, Aglitti A, Aliberti C, Baccarani U, Bhoori S, Borzio M, Brancaccio G, Cabibbo G, Casadei Gardini A, Carrai P, Cillo U, Conti F, Cucchetti A, D'Ambrosio R13, Dell'Unto C, Dematthaeis N, Di Costanzo GG, Di Sandro S, Fucilli F, Galati G, Gasbarrini A, Giuliani F, Ghinolfi D, Grieco A, Gruttaduria S, Guarino M, Kostandini A, Iavarone M, Lenci I, Losito F, Lupo LG, Mazzocato S, Mescoli C, Miele L, Morisco F, Muley M, Nicolini D, Persico M, Pompili M, Ponziani FR, Pravisani R, Rapaccini GL, Rendina M, Renzulli M, Rossi M, Rreka E, Sacco R, Sangiovanni A, Sessa A, Simonetti N, Sposito C, Tortora R, Trevisani F, **M Viganò**, Villa E, Vincenzi V, Violi P. Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics. *Cancers.* 2019;11:1568.

84) Soria A, Fava M, Bernasconi DP, Lapadula G, Colella E, Valsecchi MG, Migliorino GM, D'Ambrosio R, Landonio S, Schiavini M, Spinetti A, Carriero C, Degaspero E, Cologni G, Gatti F, Viganò P, Hasson H, Uberti-Foppa C, Pasulo L, Baiguera C, Rossotti R, Vinci M, Puoti M, Giorgini A, Menzaghi B, Lombardi A, Pan A, Aghemo A, Grossi PA, Boldizzoni R, Colombo S, **M Viganò**, Rumi MG, Del Poggio P, Valenti L, Giglio O, De Bona A, d'Arminio

- Monforte A, Colombo A, Spinelli O, Pigozzi MG, Molteni C, Bonfanti P, Terreni N, Perini P, Capretti A, Bella D, Liani C, Polo S, Aimo G, Pagnucco L, Bhoori S, Centenaro R, Graffeo M, Ciaccio A, Dionigi E, Lazzaroni S, Carderi I, Di Marco M, Rizzardini G, Noventa F, Lampertico P, Faggioli S. Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicenter cohort. *Liver Int.* 2020;40:769-777.
- 85) **M Viganò**, Carbone M. Let's not forget our COVID-19-free cirrhotic patients! *Liver Int.* 2020;40:1508-1509
- 86) Loglio A, Iavarone M, Facchetti F, Di Paolo D, Perbellini R, Lunghi G, Ceriotti F, Galli C, Sandri MT, **M Viganò**, Sangiovanni A, Colombo M, Lampertico P. The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy. *Liver Int.* 2020;40(8):1987-1996.
- 87) **M Viganò**, Voza A, Harari S, Eusebio A, Ripoll Pons M, Bordonali M, Preti V, Rumi MG, Badalamenti S, Aghemo A. Clinical Management of Nonrespiratory Diseases in the COVID-19 Pandemic: What have we done and what needs to be done? *Telemed J E Health.* 2020;26:1206-1208.
- 88) M Iavarone, R D'Ambrosio, A Soria, M Triolo, N Pugliese, P Del Poggio, G Perricone, S Massironi, A Spinetti, E Buscarini, M Viganò, C Carriero, S Faggioli, A Aghemo, LS Belli, M Lucà, M Pedaci, A Rimondi, MG Rumi, P Invernizzi, P Bonfanti and P Lampertico High rates of 30-day mortality in patients with cirrhosis and COVID-19. *J Hepatol.* 2020;73:1063-1071.
- 89) **M Viganò**, Mantovani L, Cozzolino P, Harari S. Treat all COVID 19 positive patients, but do not forget those negative with chronic diseases. *Internal and Emergency Medicine* 2020;15:787-790.
- 90) Petta S, Sebastiani G, **M Viganò**, Ampuero J, Wong V W-S, Boursier J, Berzigotti A, Bugianesi E, Fracanzani AL, Cammà C, Enea M, des Grottes M, Di Marco V, Younes R, Keyrouz A, Mazzola S, Mendoza Y, Pennisi G, Romero-Gomez M, Craxì A, de Ledinghen V. Monitoring occurrence of liver-related events and survival by transient elastography in patients with NAFLD and cACLD. *Clin Gastroenterol Hepatol.* S1542-3565:30908-3
- 91) Lampertico P, Berg T, Buti M, Pathil A, Petersen J, Ryder S, Zoulim F, Botros I, Flaherty JF, Jump B, Op den Brouw ML, van Troostenburg A, Ramroth H, ReCoRd (Retrospective, Cohort, Renal, Viread) Investigators' GroupM: Bourlière, V. De Ledinghen, G. Riachi, V. Loustaud-Ratti, A. Tran, D. Larrey, J. Dumortier, V. Leroy, S. Metivier, P. Sellier; S. Mauss, I. Schiefke, C. Niederau, G. Teuber, T. Goeser, M. C. Jung, A. Grambihler, A. Pathil-Warth, K. Sprinzl, M. Von der Ohe, C. Antoni, K. Weigand; P. Andreone, V. Di Marco, S. Madonia, M. Puoti, T. Santantonio, M. Viganò, A. Ciancio, G. D'Offizi, M. Pirisi; E. Suarez Garcia, J. M. Pascasio Acevedo, R.

Andrade, F. Gea, M. A. Serra Desfilis, E. Molina Perez, M. Manzano Alonso, J. A. Carrion, S. Aoufi Rabih, M. M. Planas; K. Agarwal, A. Ustianowski, R. Aspinall, P. Kennedy, A. M. Geretti, R. McCorry, M. Foxton, B. Healy.

Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study. *Aliment Pharmacol Ther* 2020;52:500-512

92) Aghemo A, Valenti L, **M Viganò**, Masetti C, Rumi MG, Prati D. Should those who have been cured of hepatitis C and their partners be allowed to donate blood? *The Lancet Haematology* 2021;8:e8-e10.

93) D. D'Amato, A. De Vincentis, F. Malinverno, **M Viganò**, D. Alvaro, M. Pompili, A. Picciotto, V. Pace Palitti, M. Russello, S. Storato, M.G. Pigozzi, V. Calvaruso, E. De Gasperi, A. Lleo, A. Castellaneta, A. Pellicelli, N. Cazzagon, A. Floreani, L. Muratori, S. Fagiuoli, G.A. Niro, V. Feletti, R. Cozzolongo, N. Terreni, M. Marzioni, R. Pellicano, P. Pozzoni, L. Baiocchi, L. Chessa, F. Rosina, G. Bertino, M. Vinci, A. Morgando, E. Vanni, G. Scifo, R. Sacco, M. D'Antò, V. Bellia, R. Boldizzoni, S. Casella, B. Omazzi, G. Poggi, Cristoferi, A. Gerussi, V. Ronca, R. Venere, F. Ponziani, M. Cannavò, A. Mussetto, R. Fontana, F. Losito, E. Frazzetto, M. Distefano, F. Colapietro, S. Labanca, G. Marconi, G. Grassi, G. Galati, S.E. O'Donnell, C. Mancuso, G. Mulinacci, A. Palermo, E. Claar, A. Izzi, A. Picardi, P. Invernizzi, M. Carbone, U. Vespasiani Gentilucci, on behalf of the Italian PBC Registry and the Club Epatologi Ospedalieri (CLEO)/Associazione Italiana Gastroenterologi ed Endoscopisti Digestivi Ospedalieri (AIGO) PBC Study Group Real-world experience with obeticholic acid in patients with primary biliary cholangitis *JHEP Rep.* 2021;3:100248.

94) L Cristoferi, V Calvaruso, Overi D, **M Viganò**, C Rigamonti, E Degasperi, V Cardinale, S Labanca, N Zucchini, M A Fichera, V Di Marco, M Leutner, R Venere, A Picciotto, Lucà M, Mulinacci G, Palermo A, Gerussi A, D'amato D, O'Donnell S, Cerini F, De Benedittis C, Malinverno F, Ronca V, Mancuso C, N Cazzagon, A Ciaccio, Barisani D, M Marzioni, Floreani A, Alvaro D, Gaudio E, P Invernizzi, G Carpino, A Nardi, M Carbone. Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach *Hepatology* 2021;74:1496-1508

95) Loglio A, **M Viganò**, Lampertico P. Novel Therapies That May Cure Chronic Hepatitis B Virus. *Clin Liver Dis.* 2021;25:875-899.

96) Di Stefano M, Colombo C, De Leo S, Perrino M, **M Viganò**, Persani L, Fugazzola L. High Prevalence and Conservative Management of Acute Cholecystitis during Lenvatinib for Advanced Thyroid Cancer. *Eur Thyroid J.*

2021;10:314-322.

97) Valenti L, Pelusi S, Aghemo A, Gritti S, Pasulo L, Bianco C, Iegri C, Cologni G, Degasperi E, D'Ambrosio R, del Poggio P, Soria A, Puoti M, Carderi I, Pigozzi MG, Carriero C, Spinetti A, Zuccaro V, Memoli M, Giorgini A, **M Viganò**, Rumi MG, Re T, Spinelli O, Colombo C, Quirino T, Menzaghi B, Lorini L, Pan A, d'Arminio Monforte A, Buscarini E, Autolitano A, Bonfanti P, Terreni N, Aimò G, Mendeni M, Prati D, Colombo M, Lampertico P, Faggioli S for the NAVIGATORE-Lombardia Network. Dysmetabolism, diabetes and clinical outcomes in patients cured of chronic hepatitis C: a real-life cohort study. *Dysmetabolism, diabetes and clinical outcomes in patients cured of chronic hepatitis C: a real-life cohort study Hep Communications* 2022; 6:867-877

98) G Pennisi, M Enea, M Romero-Gomez, **M Viganò**, E Bugianesi, V W-S Wong, AL Fracanzani, G Sebastiani, J Boursier, A Berzigotti, M Eslam, J Ampuero, A Benmassaoud, C La Mantia, YP Mendoza, J George, A Craxi, C Camma, V de Ledinghen, S Petta. Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis *Aliment Pharmacol Ther.* 2022;55:604-615.

99) C Masetti, N Pugliese, A Aghemo, **M Viganò**. Safety of current antiviral drugs for chronic hepatitis B. *Expert Opinion on Drug Safety* 2022;21:939-945.

100) A Sonaglioni, C Lonati, E Rigamonti, **M Viganò**, GL Nicolosi, M Proietti, M Lombardo, S Harari. Chad2-Vasc score stratifies mortality risk in heart failure patients aged 75 years and older with and without atrial fibrillation *Aging Clinical and Experimental Research* 2022;34:1707-1720

101) A Sonaglioni, F Cerini, A Cerrone, L Argiento, G Nicolosi, E Rigamonti, M Lombardo, MG Rumi, **M Viganò**. Liver stiffness measurement identifies subclinical myocardial dysfunction in non-advanced non-alcoholic fatty liver disease patients without overt heart disease. *Internal and Emergency Medicine* 2022,17:1425-1438

102) Russo FP\*, **Viganò M\***, Stock P, Ferrarese A, Pugliese N, Burra P, Aghemo A. HBV-and HIV-positive organs in transplantation: a clinical guide for the hepatologist *J Hep* 2022;77:503-515

103) G Pennisi; R Pipitone; D Cabibi, M Enea M Romero-Gomez, **M Viganò**, E Bugianesi, V W-S Wong, AL Fracanzani, G Sebastiani, A Berzigotti, Di Salvo F, Giannone AG, La Mantia C, Lupo G, Porcasi R, Vernuccio F, Zito R, Di Marco V, Cammà C, Craxi A, de Ledinghen V, Grimaudo S, Petta S. A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease. *Liver Int* 2022;42:1037-1048

104) Sonaglioni A, Cerini F, Nicolosi GL, Lombardo M, Rumi MG, **Viganò M**. Left ventricular strain predicts subclinical atherosclerosis in non advanced

nonalcoholic fatty liver disease patients. Eur J Gastroenterol Hepatol. 2022;34:707-716

105) **M Viganò**, F Cerini, S Ridolfo, MG Rumi. HCV screening in the 1969-1989 birth-cohort: is not enough! Liv Int 2022;42:1915

106) A De Vincentis, D D'Amato, L Cristoferi, A Gerussi, F Malinverno, A Lleo, F Colapietro, F Marra, A Galli, C Fiorini, B Coco, M Brunetto, GA Niro, R Cotugno, C Saitta, R Cozzolongo, F Losito, EG Giannini, S Labanca, M Marzioni, G Marconi, A Morgando, R Pellicano, E Vanni, N Cazzagon, A Floreani, L Chessa, O Morelli, L Muratori, A Pellicelli, M Pompili, F Ponziani, A Tortora, F Rosina, M Russello, M Cannavò, L Simone, S Storato, **M Viganò**, L Abenavoli, M D'Antò, E De Gasperi, M Distefano, G Scifo, T Zolfino, V Calvaruso, G Cuccorese, VP Palitti, R Sacco, G Bertino, E Frazzetto, D Alvaro, G Mulinacci, A Palermo, M Scaravaglio, F Terracciani, G Galati, V Ronca, M Zuin, E Claar, A Izzi, A Picardi, P Invernizzi, U Vespasiani-Gentilucci, M Carbone, on behalf of the Club Epatologi Ospedalieri (CLEO)/Associazione Italiana Gastroenterologi ed Endoscopisti Digestivi Ospedalieri (AIGO) PBC Study Group and, the Italian PBC Registry. Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic Acid. Liv Int 2022;42:2453-2465

107) D Overi, G Carpino, L Cristoferi, P Onori Lindsey, KH Francis, N Zucchini, C Rigamonti, **M Viganò**, A Floreani, D D'Amato, A Gerussi, R Venere, G Alpini, S Glaser, D Alvaro, P Invernizzi, E Gaudio, M Carbone.

Role of ductular reaction and ductular-canalicular junctions in identifying severe primary biliary cholangitis. *JHEP Rep* 2022;19.100556

108) LA. Kondili, MG Quaranta, M Viganò, X Tata, F D'Angelo, C Lo Noce, L Palmieri, G Onder, F D'Amico, E Inglese, M Puoti, A Aghemo, ME Tosti. Obesity and dysmetabolic factors among deceased COVID-19 young adults in Italy: a retrospective case-control study. *Viruses* 2022;14:1981

109) Q Lai, N De Matthaeis, M Finotti, G Galati, G Marrone, F Melandro, F Morisco, D Nicolini, R Pravisani, E G Giannini, Aglitti A, Aliberti C, Baccarani U, Bhoori S, Borzio M, Brancaccio G, Burra P, Cabibbo G, Casadei Gardini A, Carrai P, Cillo U, Conti F, Cucchetti A, D'Ambrosio R, Dell'Unto C, Di Costanzo GG, Di Sandro S, Foschi FG, Fucilli F, Gambato M, Gasbarrini A, Giuliante F, Ghinolfi D, Grieco A, Gruttaduria S, Guarino M, Kostandini A, Iavarone M, Lenci I, Levi Sandri GB, Losito F, Lupo LG, Manzia TM, Mazzocato S, Mescoli C, Miele L, Muley M, Persico M, Plaz Torres MC, Pompili M, Ponziani FR, Rapaccini GL, Rendina M, Renzulli M, Rossi M, Rreka E, Russo FP, Sacco R, Sangiovanni A, Sessa A, Simonetti N, Sposito C, Tortora R, Trevisani F, Viganò L, **Viganò M**, Villa E, Vincenzi V, Violi P, Vitale A. The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma. *Eur J Clin Invest.* 2022;e13870.

110) **M Viganò**, N Pugliese, F Cerini, F Turati, V Cimino, S Ridolfo, S Rocchetto, Fa Foglio, M Terrin, C La Vecchia, M Rumi, A Aghemo. Accuracy of FIB-4 to detect elevated liver stiffness measurements in patients with non alcoholic fatty liver disease: a cross sectional study in referral centers. *International Journal of Molecular Sciences* 2022;23.12489

111) M Guarino, V Cossiga, M Capasso, C Mazzarelli, F Pelizzaro, R Sacco, FP Russo, A Vitale, F Trevisani, G Cabibbo, U Baccarani, S Bhoori, M Borzio, G Brancaccio, P Burra, A Casadei Gardini, P Carrai, L Centonze, M Cescon, U Cillo, R Cozzolongo, A Cucchetti, N De Matthaeis, GG Di Costanzo, S Di Sandro, S Famularo, F Farinati, M Finotti, FG Foschi, G Galati, M Gambato, EG Giannini, F Giuliante, D Ghinolfi, S Gruttaduria, M Iavarone, A Kostandini, Q Lai, I Lenci, LG Lupo, T Manzia, G Marasco, S Marengo, M Masarone, S Mazzocato, F Melandro, C Mescoli, L Miele, F Morisco, D Nicolini, D Pagano, M Persico, MC Platz Torres, FR Ponziani, R Pravisani, M Rendina, M Renzulli, L Ricci, F Romano, GB Levi Sandri, A Sangiovanni, C Sposito, R Tortora, L Viganò, **M Viganò**, V Vincenzi, P Violi. Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma. *J Clin Med* 2022;11:4475

112) Q Lai, N De Matthaeis, M Finotti, G Galati, G Marrone, F Melandro, F Morisco, D Nicolini, R Pravisani, EG Giannini, Aglitti A, Aliberti C, U

Baccarani, S Bhoori, M Borzio, G Brancaccio, P Burra, Cabibbo G, A Casadei Gardini, P Carrai, U Cillo, Conti F, A Cucchetti, D'Ambrosio R, Dell'Unto C, GG Di Costanzo, S Di Sandro, Foschi Fg, Fucilli F, Gambato M, Gasbarrini A, F Giuliani, D Ghinolfi, Grieco A, S Gruttaduria, M Guarino, A Kostandini, M Iavarone, I Lenci, GB Levi Sandri, F Losito, LG Lupo, T Manzia, S Mazzocato, C Mescoli, L Miele, M Muley, M Persico, MC Platz Torres, M Pompili, FR Ponziani, GL Rapaccini, M Rendina, M Renzulli, M Rossi, E Rreka, FP Russo, R Sacco, A Sangiovanni, A Sessa, N Simonetti, C Sposito, R Tortora, F Trevisani, L Viganò, **M Viganò**, E Villa, V Vincenzi, P Violi, A Vitale. The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma Eur J Clin Invest. 2023;53:e13870.

113) N Pugliese, G Franchellucci, **M Viganò**. Should we abandon FIB-4 to characterize non-invasively patients with NAFLD? Aliment Pharmacol Ther. 2023;57:920-921.

114) LA Kondili, MG Quarantaa, L Cavalletto, V Calvaruso, L Ferrigno, R D'Ambrosio, I Simonelli, G Brancaccio, G Raimondo, MR Brunetto, AL Zignego, C Coppola, A Iannone, E Biliotti, G Verucchi, M Massari, A Licata, F Barbaro, M Persico, FP Russo, F Morisco, M Pompili, **M Viganò**, M Puoti, T Santantonio, E Villa, A Craxi, Liliana Chemelloc on behalf of PITER Collaborating Investigators. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort. Digestive and Liver Disease 2023;55:907-917

115) G Brancaccio, B Coco, A Nardi, MG Quaranta, ME Tosti, L Ferrigno, I Cacciola, V Messina, L Chessa, F Morisco, M Milella, F Barbaro, A Ciancio, FP Russo, N Coppola, P Blanc, E Claar, G Verucchi, M Puoti, AL Zignego, L Chemello, S Madonia, S Fagiuoli, A Marzano, C Ferrari, P Lampertico, V Di Marco, A Craxi, TA Santantonio, G Raimondo, MR Brunetto, GB Gaeta, LA Kondili, L Pasulo, C Coppola, F Pisano, M Romano, C Porcu, IF Bottalico, V Cossiga, X Tata, C Sagnelli, P Pierotti, E Degaspero, V Rosato, L Badia, D Ieluzzi, M Monti, MG Bavetta, L Cavalletto, P Toniutto, E Fornasiere, A Colecchia, A Ferrarese, G Nardone, A Rocco, **M Viganò**, FG Foschi, F Conti, G Morsica, S Salpietro, C T, C Costa, A Federico, M Dallio, A Giorgini, M Anselmo, P De Leo, S Zaltron, A Cambianica, F Piscaglia, I Serio, S Schivazappa, A Mastroianni, L Chidichimo, M Massari, C Mazzaro, A Marrone, FM D'Amore, G D'Offizi, A Licata, GA Niro, T Pollicino, A Aghemo. Trends in chronic Hepatitis B virus infection in Italy over a 10-year period: clues from the nationwide PITER and MASTER cohorts towards elimination. Journal of Infectious Diseases 2023;129:266-273.

116) **M Viganò**, M La Milia, MV Grassini, N Pugliese, M De Giorgio, S Fagiuoli. Hepatotoxicity of small molecule protein kinase inhibitors for cancer.

Cancers (Basel). 2023;15:1766

117) Farina E, Loglio A, Tosetti G, Degaspero E, **Viganò M**, Gentile C, Monico S, Perbellini R, Borghi M, Facchetti F, Uceda Renteria S, Ceriotti F, Cerini F, Primignani M, Lampertico P. Long-term endoscopic surveillance in HBV compensated cirrhotic patients treated with Tenofovir or Entecavir for 11 years. *Aliment Pharmacol Ther.* 2023;57:1407-1416.

118) Pennisi G, Enea M, **Viganò M**, Schepis F, de Ledinghen V, Berzigotti A, Wong V W-S, Fracanzani AL, Sebastiani G, Lara-Romero C, Bugianesi E, Svegliati-Baroni G, Marra F, Aghemo A, Valenti L, Calvaruso V, Colecchia A, Di Maria G, La Mantia C, Lin H, Mendoza YP, Pugliese N, Ravaioli F, Romero-Gomez M, Saltini D, Craxi A, Di Marco V, Cammà C, Petta S. Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease *JHEP Rep.* 2023;5:100809.

119) FE Mózes, JA Lee, Y Vali, O Alzoubi, K Stauffer, R Stauber, AG Holleboom, AM van Dijk, AL Mak, J Boursier, M de Saint, M Trauner, R Paternostro, R Stauber, AG Holleboom, AM van Dijk, A L Mak, J Boursier, M de Saint Loup, T Shima, E Bugianesi, S Gaia, A Armandi, Shalimar, M Lupsor-Platon, VWS Wong, G Li, GLH Wong, J Cobbold, T Karlas, J Wiegand, G Sebastiani, E Tsochatzis, A Liguori, M Yoneda, A Nakajima, H Hagström, C Akbari, M Hirooka, WK Chan, S Mahadeva, RB Rajaram, MH Zhen, J George, M Eslam, S Petta, G Pennisi, **M Viganò**, S Ridolfo, GP Aithal, N Palaniyappan, DH Lee, M Ekstedt, P Nasr, C Cassinotto, V de Lédinghen, A Berzigotti, YP Mendoza, M Noureddin, E Truong, C Fournier-Poizat, A Geier, L, M Martic, T Tuthill, QM Anstee, SA Harrison, PM Bossuyt, M Pavlides. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. *Lancet Gastroenterol Hepatol.* 2023;8:704-713

120) A Vitale, G Cabibbo, M Iavarone, L Viganò, DJ Pinato, FR Ponziani Q Lai, A Casadei-Gardini, C Celsa, G Galati, M Gambato, L Crocetti, M Renzulli, EG Giannini, F Farinati, F Trevisani, U Cillo, Aglitti A, Aliberti C, Baccarani U, Bhoori S, Borzio M, Brancaccio G, Burra P, Carrai P, Conti F, Cucchetti A, D'Ambrosio R, Dell'Unto C, Di Costanzo GG, Di Sandro S, Foschi FG, Fucilli F, Gasbarrini A, Giuliante F, Ghinolfi D, Grieco A, Gruttaduria S, Guarino M, Kostandini A, Lenci I, Levi Sandri GB, Losito F, Manzia TM, Mazzocato S, Mescoli C, Miele L, Muley M, Persico M, Pieri G, Plaz Torres MC, Pompili M, Rapaccini G, Rendina M, Rossi M, Rreka E, Russo FP, Sacco R, Sangiovanni A, Sessa A, Simonetti N, Sposito C, Tortora R, **Viganò M**, Villa E, Vincenzi V, Violi P, Pelizzaro F, Famularo S, Romano F. Personalized management of patients with hepatocellular carcinoma: the concept of multi-parametric therapeutic hierarchy. *Lancet Oncol.* 2023 2:e312-

120) S Pelusi, C Bianco, M Colombo, G Cologni, P Del Poggio, N Pugliese, D Prati, MG Pigozzi, R D'Ambrosio, P Lampertico, S Fagioli, L Valenti, E De Gasperi, A Aghemo, S de Nicola, C Masetti, S Gritti, L Pasulo, C Iegri, **M Viganò**, A Soria, M Puoti, I Carderi, C Carriero, A, V Zuccaro, M Memoli, A Giorgini, A D'Arminio Monforte, MG Rumi, T Re, O Spinelli, MC Colombo, T Quirino, B Menzaghi, G Lorini, A Pan, E Buscarini, A Autolitano, P Bonfanti, N, G Aimo, M Mendeni. Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct-acting antivirals. *Liv Int* 2023;43:1593-1603.

121) A Loglio, **M Viganò**. Stopping Nucleos(t)ide Analogues treatment in non-cirrhotic HBeAg-negative patients: yes, we can!" *Dig Liver Dis*. 2023;55:1221-1222.

123) **M Viganò**, M Beretta, M Lepore, R Abete, SV Benatti, MV Grassini, S Camagni, G Chiodini, S Vargiu, C Vittori, M Iachini, A Terzi, F Neri, D Pinelli, V Casotti, F Di Marco, P Ruggenenti, M Rizzi, M Colledan, S Fagioli. Vaccination recommendations in solid organ transplant adult candidates and recipients. *Vaccines*. 2023;11:1611.

122) G Pennisi, M Enea, M Romero-Gomez, E Bugianesi, V W-S Wong, AL Fracanzani, V de Ledinghen, J George, A Berzigotti, **M Viganò**, G Sebastiani, R Cannella, A Delamarre, G Di Maria, N F. Lange, A Tulone, V Di Marco, C Cammà, S Petta. Risk of liver-related events in Nonalcoholic Steatohepatitis (NASH) patients with fibrosis: a comparative analysis of various risk stratification criteria. *Hepatology* 2024;79:912-925.

124) M. Castelli, M. Betelli, A. Valenti, B. Merelli, A. Loglio, **M. Viganò**, A. Benetti. A case of polyserositis, chylous ascites and hepatitis induced by immune checkpoint inhibitors. *European Journal of Case Reports in Internal Medicine* 2024 11:004237.

125) A De Vincentis, J Ampuero, F Terracciani, D D'Amato, A Gerussi, L Cristoferi, N Cazzagon, E Bonaiuto, A Floreani, V Calvaruso, L Cadamuro, E Degaspero, Anna M, E Vanni, A Lleo, F Colapietro, D Alvaro, A Castellaneta, S Labanca, **M Viganò**, M Distefano, V Pace Palitti, C Ricci, N De Mattheis, M Marzoni, E Gómez-Dominguez, J-L Montero, E Molina, L Garcia-Buey, M Casado, M Berenguer, I Conde, M-A Simon, J Fuentes, P Costa-Moreira, G Macedo, F Jorquera, R-M Morillas, J Presa, J-M Sousa, Gomes, L Santos, A Oliveira, M Hernandez-Guerra, L Aburruza, A Santos, A Carvalho, J Uriz, M-L Gutierrez, E Perez, L Chessa, A Pellicelli, M Marignani, L Muratori, G A Niro, M Brunetto, FR Ponziani, M Pompili, F Marra, A Galli, A Mussetto, G Alagna, L Simone, G Bertino, F Rosina, R Cozzolongo, M Russello, L

Baiocchi, C Saitta, N Terreni, T Zolfino, C Rigamonti, R Vigano, G Cuccorese, P Pozzoni, CI Pedone, S Grasso, A Picardi, P Invernizzi, R Sacco, A Izzi, C Fernandez-Rodriguez, U Vespasiani-Gentilucci and M Carbone. Development and validation of a scoring system to predict response to obeticholic acid in primary biliary cholangitis. *Clinical Gastroenterology and Hepatology* 2024;22:2062-2074.

126) LA Kondili, G Brancaccio, ME Tosti, B Coco, MG Quaranta, V Messina, A Ciancio, F Morisco, V Cossiga, E Claar, V Rosato, M Ciarallo, I Cacciola, FR Ponziani, L Cerrito, R Coppola, F Longobardi, E Biliotti, A Rianda, F Barbaro, N Coppola, M Stanzone, F Barchiesi, S Fagioli, **M Viganò**, M Massari, FP Russo, A Ferrarese, D Laccabue, V Di Marco, P Blanc, A Marrone, G Morsica, A Federico, D Ieluzzi, A Rocco, FG Foschi 29, A Soria, I Maida, L Chessa, M Milella, E Rosselli del Turco, S Madonia, L Chemello, I Gentile, P Toniutto, M Bassetti, L Surace, L Baiocchi, A Pellicelli, A De Santis, M Puoti, E Degasperis, GA Niro, ALinda Zignego, A Craxi, G Raimondo, TA Santantonio, MR Brunetto, GB Gaeta, on behalf of PITER Collaborating Investigators. A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and Delta cohort. *Int J Infect Dis.* 2024;146:107115.

127) Gerussi A, Saldanha OL, Cazzaniga G, Verda D, Carrero ZI, Engel B, Taubert R, Bolis F, Cristoferi L, Malinverno F, Colapietro F, Akpinar R, Di Tommaso L, Terracciano L, Lleo A, **Viganó M**, Rigamonti C, Cabibi D, Calvaruso V, Gibilisco F, Caldonazzi N, Valentino A, Ceola S, Canini V, Nofit E, Muselli M, Calderaro J, Tiniakos D, L'Imperio V, Pagni F, Zucchini N, Invernizzi P, Carbone M, Kather JN. Deep learning helps discriminate between autoimmune hepatitis and primary biliary cholangitis. *JHEP Rep.* 2024 Aug 31;7:101198.

128) A Savino, A Loglio, F Neri, S Camagni, L Pasulo, MG Lucà, R Trevisan, S Fagioli, **M Viganò**. Metabolic dysfunction associated steatotic liver disease (MASLD) after liver transplantation: a narrative review of an emerging issue *J Clin Med.* 2024;13:3871.

129) N Pugliese, FR Ponziani, F Cerini, L di Tommaso, F Turati, M Maggioni, MA Manini, F Santopaolo, C Bianco, C Masetti, MC Giustinian, C La Vecchia, L Valenti, L Terracciano, **M Viganò**, A Aghemo Link between persistent, unexplained gammaGT elevation and Porto-Sinusoidal Vascular Disorder *JHEP Rep.* 2024;6:101150.

130) V Casotti, P Stroppa, M Bravi, A Tebaldi, A Loglio, **M Viganò**, S Fagioli, L D'Antiga. Vaccinations in paediatric solid organ transplant candidates and recipients. *Vaccines.* 2024;12:952.

131) A Loglio, **M Viganò**, E Farina, P Marra MEG Arosio L Goisis S Fagioli,

Bulevirtide improves liver function in liver transplant candidates with advanced HDV cirrhosis and severe portal hypertension. *Liver Transpl.* 2025;31:254-258.

132) V Calvaruso, C Celsa, L Cristoferi, M Scaravaglio, R Smith, S Kaur, G Di Maria, L Capodicasa, G Pennisi, A Gerussi, E Nofit, F Malinverno, P Lampertico, N Cazzagon, M Marzioni, U Vespasiani-Gentilucci, F Colapietro, P Andreone, A Lleo De Nalda, C Rigamonti, **M Viganò**, EG Giannini, M Russello, E Vanni, F Cerini, A Orlandini, M Brunetto, GA Niro, G Vettori, A Castellaneta, V Cardinale, D Alvaro, A Mega, V Pace Palitti, V Cossiga, F Morisco, F Bellanti, L Baiocchi, L Fabris, M Persico, E Degasperi, S Labanca, E Bonaiuto, F Pezzato, A Federico, S Petta, V Di Marco, GF Mells, E Culver, P Invernizzi, C Cammà, M Carbone. Non-invasive assessment of portal hypertension in patients with primary biliary cholangitis is affected by severity of cholestasis. *Clinical Gastroenterology and Hepatology* 2024:S1542-3565(24)01070-X.

133) V Zuccaro, P Giordani, F Binda, E Asperges, E Farina, **M Viganò**, E Gervasi, E Pagani, S Fagioli, R Bruno. Antibiotic stewardship based on colonization with multi-drug resistant bacteria in liver transplantation: a narrative review. *Microorganisms* 2024;12:2493.

134) Dulcetta L, Marra P, Muglia R, Carbone FS, **Viganò M**, Di Giorgio A, D'Antiga L, Fagioli S, Sironi S. Percutaneous management of chronic total occlusion of the portal vein: a retrospective analysis of technical aspects and outcomes. *CVIR Endovasc.* 2024;7:81.

135) Degasperi E, Anolli MP, Jachs M, Reiberger T, De Ledinghen V, Metivier S, D'Offizi G, di Maria F, Schramm C, Schmidt H, Zöllner C, Tacke F, Dietz-Fricke C, Wedemeyer H, Papatheodoridi M, Papatheodoridis G, Carey I, Agarwal K, Van Bömmel F, Brunetto MR, Cardoso M, Verucchi G, Ciancio A, Zoulim F, Aleman S, Semmo N, Mangia A, Hilleret MN, Merle U, Santantonio TA, Coppola N, Pellicelli A, Roche B, Causse X, D'Alteroche L, Dumortier J, Ganne N, Heluwaert F, Ollivier I, Roulot D, **Viganò M**, Loglio A, Federico A, Pileri F, Maracci M, Tonnini M, Arpurt JP, Barange K, Billaud E, Pol S, Gervais A, Minello A, Rosa I, Puoti M, Lampertico P. Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis. *J Hepatol.* 2025;82:1012-1022.

136) Savino A, Rossi A, Fagioli S, Invernizzi P, Gerussi A, **Viganò M**. Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives. *Cancers* 2024;17:76.

137) L Rinaldi, **M Viganò**, A Ciancio, A Caturano, V Messina, GA Niro, N Capoluongo, A Loglio, L Marinaro, A Marrone, E Claar, M Russello, E Ciraci, U Vespasiani-Gentilucci, V Pace Palitti, C Acierno, C Cosentino, A Mormone, R Cotugno, F Terracciani, P Gallo, MR Cannavò, V Rosato, FC Sasso, C Petrucciello, G Petronio, G Villone, F Benanti, G Cariti, E Falbo, M Distefano, R Sacco, A Perrella, A Izzi. Assessment of Response and Impact of Safety Treatment with bulevirtide in patients with chronic delta virus infection: an Observational

Trial for Evaluating Long-term Efficacy. The ARISTOTELE pilot study  
*Viruses* 2025;17:251.

138) R Muglia, M De Giorgio, GL Poli, P Marra, FS Carbone, L Dulcetta, A Loglio, A Ghirardi, C Bianchi, L Grikke, A Gerali, PA Erba, S Sironi, S Faggioli, **M Viganò**. Long-term outcomes of Yttrium-90 transarterial radioembolization for Patients with hepatocellular carcinoma. *European Journal of Nuclear Medicine and Molecular Imaging* doi: 10.1007/s00259-025-07185-3.

139) Angelico R, Trapani S, Manzia TM, Lenci I, Grossi P, Ricci A, Burra P, Andorno E, Agnes S, Bhoori S, Baccarani U, Belli LS, Carrai P, Caccamo L, Carraro A, Cescon M, Colledan M, Cillo U, De Carlis L, De Maria N, De Simone P, di Benedetto F, Donato MF, Ettorre GM, Ferri F, Lanza AG, Ghinolfi D, Grieco A, Gruttadauria S, Marengo S, Martini S, Mazzaferro V, Pellicelli A, Pinelli D, Rendina M, Rizzetto M, Romagnoli R, Rossi M, Russo FP, Schiada L, Tandoi F, Toniutto P, Turco L, Vennarecci G, **Viganò M**, Vivarelli M, Tisone G, Feltrin G, Nardi A, Angelico M. Liver Transplantation For HDV/HBV Coinfection In Italy: An Intention-To-Treat Analysis Of Long-Term Outcomes. *Am J Transplant*. 2025;S1600-6135(25)00106-6.

140) Colapietro F, **Viganò M**, Cerini F, Plebani R, Savino A, Calabrese MP, Marra P, Martins de Mattos KD, Taboni S, Cosenza A, Loglio A, Selvaggio C, Lucà MG, Masellis C, Mori B, Pugliese N, Masetti C, Farina E, De Nicola S, Ceriani R, Lleo A, Muglia R, Sironi S, Faggioli S, Aghemo A. Incidence and Predictors of Complications Following Percutaneous Liver Biopsy: A Large Italian Multicentre Study. *Liver Int*. 2025;45:e70078.

141) N Pugliese, I Arcari, F Cerini, R Lombardi, F Turati, G Pennisi, M Soleri, S Rocchetto, D De Deo, M Sagasta, C Masetti, AL Fracanzani, S Petta, C La Vecchia, **M Viganò**, A Aghemo. Key Predictors of Relevant Weight Loss in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. *UEG Journal*.

142) A Loglio, E Farina, F Ideo, G Alfieri, T Negri, F Neri, V Zuccaro, S Faggioli, S Camagni, **M Viganò** COVID-19 vaccine perception in Liver Transplant recipients: patient-reported outcomes and real-life experience from the Bergamo Center. *Vaccines* 2025;13:455.

143) L Grikke, M De Giorgio, C Bianchi, E Balduzzi, FS Carbone, A Gerali, A Ghirardi, R Muglia, C Prussia, **M Viganò**, P Marra, PA Erba, S Sironi, S Faggioli, GL Poli. Dosimetric optimization and evaluation of hepatocellular carcinoma treatment effect prediction in Y-90 radioembolization. *Physica Medica* 2025;134:105000.

144) Pasta A, Pieri G, Plaz Torres MC, Missale G, Foschi FG, Piscaglia F, Boninsegna S, Mega A, Cazzagon N, Pelizzaro F, **Viganò M**, Trevisani F, Bucci L, Azzaroli F, Brunetto MR, Campani C, Celsa C, Ghittoni G, Magalotti D, Martini A, Morisco F, Nardone G, Ponziani FR, Sacco R, Sacerdoti D, Saitta C, Sangiovanni A, Lani L, Svegliati-Baroni G, Vidili G, Vitale A, Giannini EG;

Italian Liver Cancer (ITA.LI.CA) Group. Characteristics and Outcomes of Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis. *Dig Dis Sci*. 2025 May 3. doi: 10.1007/s10620-025-09064-1.

145) M Kalafateli, R Forlano, E Barnes, L Martinez-Gili, M Lacey, G Sigon, BH. Mullish, V Mallet, L Parlati, P Richardson, N Forde, G Serviddio, R Villani, S Lens, M Buti, E Vargas, **M Viganò**, A Loglio, P Lampertico, R D'ambrosio, S Monico, G Maffi, R Lombardi, AL Fracanzani, C De Luca, Patrick Ingiliz 15, A Mangia, F Leserre, AM Napolitano, V Piazzolla, FP Russo, G Raimondo, I Cacciola, C Saitta, M Lemoine, G Papatheodoridis, M Papatheodoridi, DN Samonakis, D O'Donnell, Jennifer O'Donoghue, RD Abeles, N Pugliese, A Aghemo, M Berenguer, A Brown, MR. Thursz P Manousou. Risk factors of metabolic dysfunction-associated steatotic liver disease in a cohort of patients with chronic hepatitis B. *Clinical Gastroenterology and Hepatology* in press


146) F Terracciani, A DeVincentis, D D'Amato, L Cristoferi, A Gerussi, P Invernizzi, M Scaravaglio, E Vanni, D Campion, A Morgando, V Valiani, V Boccaccio, F Morisco, L Surace, I Cavalli, G Delle Monache, F Salomone, D Ieluzzi, D Angrisani, R Tortora, B Cuffari, A Moretti, G Nardone, S Fagioli, **M Viganò**, G Vettori, F Cerini, G Gimignani, A Mattalia, F Pizzolante, N De Matthaes, C Rigamonti, GF Manfredi, V Boano, P Begini, A Lleo, F Colapietro, R Plebani, D Alvaro, R Venere, E Degasperis, M Borghi, P Lampertico, EG Giannini, S Labanca, R Viganò, F D'amico, Castellaneta, F Squeo, L Cadamuro, L Capodicasa, M Marzoni, V Buzzanca, G Poggi, A Mussetto, R Cozzolongo, F Losito, G Bertino, M Russello, M Cannavò, P Scivetti, M Pompili, A Tortora, AG Niro, R Cotugno, P Pozzoni, A Riva, L Chessa, M Miglianti, G Cuccorese, V Pace Palitti, L Abenavoli, N Terreni, T Zolfino, O Morelli, C Saitta, S Casella, A Pellicelli, M Brunetto, B Coco, A Galli, F Marra, A Curto, A Floreani, N Cazzagon, P Rollo, E Bonaiuto, L Simone, L Muratori, F Rosina, M Distefano, E Capello, V Bellia, R Sacco, G Alagna, L Baiocchi, LS Crocè, C Ricci, P Poisa, A Izzi, S Boninsegna, V Calvaruso, M Carbone, U Vespasiani-Gentilucci. Long-term effectiveness, safety, and liver stiffness dynamics of PBC treated with obeticholic acid in real-world. *J Hep Rep* 2025 in press

147) Pennisi G, Di Maria G, Wai-Sun Wong, V de Ledinghen V, Sebastiani G, **Viganò M**, Fracanzani AL, Miele L, Bugianesi E, Ekstedt M, D'Ambrosio R, Ravaioli F, Schepis F, Marra F, Aghemo A, Svegliati-Baroni G, Persico M, Valenti L, Berzigotti A, George J, Armandi A, Nasr P, Kechagias S, Liguori A, Saltini D, Mendoza YP, Calvaruso V, Enea M, Lin H, Infantino G, Masarone M, Pugliese N, Tulone A, Di Marco V, Cammà C, Petta S. Impact of first and further decompensation in patients with compensated ACLD due to MASLD. *J Hepatol*. 2025 Jun 21:S0168-8278(25)02282-2.

148) GP Caviglia, E Dileo, A Olivero, G Mengozzi, A Ciancio, A Loglio, **M Viganò**, S Fagioli, P Colombatto, B Coco, MR Brunetto, D Angrisani, A

Galeota Lanza, C Magni, G Rizzardini, V Messina, M Milella, A Saracino, L Marinaro, G Cariti, V Cossiga, F Morisco, S Cretella, G Verucchi, E Biliotti, G D'Offizi, M Feasi, E Pontali, C Coppola, R Rapetti, M Pirisi, A Izzi, T Santantonio, V Di Marco, A Marrone, N Coppola, M Rizzi, AM Cattelan, GA Niro, P Toniutto, FR Ponziani, LS Belli, A Federico, G Bertino, M Barone, M Puoti, A Civolani, M Distefano, LA Surace, R Cozzolongo, EMa Cela, E Teti, P Lampertico, T Stroffolini, M Rizzetto, on behalf of the HDV Describe Study Group. The Medical Impact of Hepatitis D Virus Infection in Natives and Immigrants: The Italian Paradigm. Liv Int 2025 First published: 29 July 2025  
149) Viganò R, Loglio A, Dibenedetto C, Carrai P, Martini S, Lenci I, Magro B, Conti S, Cortesi P, Mazzarelli C, Becchetti C, Perricone G, Cucco M, Carbone M, Cocchis D, Farina E, Pasulo L, **Viganò M**, Sagasta M, Degasperi E, Ghinolfi D, Lampertico P, Fagiuoli S, Belli L. Hepatitis B immunoglobulins withdrawal in Hepatitis B Virus mono-infected liver transplant recipients: an Italian multicenter prospective study. APT

Il sottoscritto è a conoscenza che, ai sensi dell'art. 76 del DPR 445/2000, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dal Regolamento UE n. 679/2016 – GDPR General Data Protection Regulation, D.Lgs 196/2003 modificato da D.Lgs 101/2018



Milano 30/07/2025

## Curriculum Vitae Europass

### Informazioni personali

Nome(i) / Cognome(i)

**Silvia Nozza**

Indirizzo(i)

Via Teodosio 36 20131 Milano.

Telefono(i)

0226437961

Cellulare: 3393950981

Fax

E-mail

nozza.silvia@hsr.it

Cittadinanza

Italiana

Data e luogo di nascita

Bergamo 13/07/1973

Codice fiscale

NZZSLV73L53A794A

Sesso

F

### Occupazione desiderata/Settore professionale

**Medico Specialista in Malattie Infettive presso Ospedale San Raffaele di Milano**

### Esperienza professionale

Date

Iniziare con le informazioni più recenti ed elencare separatamente ciascun impiego pertinente ricoperto. Facoltativo (v. istruzioni)

Lavoro o posizione ricoperti

Principali attività e responsabilità

Nome e indirizzo del datore di lavoro

Tipo di attività o settore

### Istruzione e formazione

Date

Specializzazione in Malattie Infettive conseguita il 8-11-2004 presso l'Università Vita Salute San Raffaele di Milano (voto 70/70 e lode).  
Laurea in Medicina e Chirurgia conseguita il 22-7-1998 presso L'Università degli Studi di Milano (voto 110/110).

### Capacità e competenze personali

Attività clinica presso il Dipartimento di Malattie Infettive dell'Ospedale San Raffaele di Milano.  
Organizzazione, scrittura ed esecuzione di protocolli clinici di ricerca

Madrelingua(e)

**Italiana**

- 1. Inglese**
- 2. Francese**

Altra(e) lingua(e)

Autovalutazione

Livello europeo (\*)

Lingua

Lingua

Comprensione				Parlato				Scritto	
Ascolto		Lettura		Interazione orale		Produzione orale			
1	BUON	1	BUONA	1	BUONA	1	BUONA	1	BUONA
2	BUONA	2	BUONA	2	BUONA	2	BUONA	2	BUONA

(\*) Quadro comune europeo di riferimento per le lingue

Capacità e competenze sociali

Capacità e competenze organizzative

Capacità e competenze tecniche

Capacità e competenze informatiche

Capacità e competenze artistiche

Altre capacità e competenze

Patente

Ulteriori informazioni

Allegati

Firma

Medico referente presso l'associazione LILA (Lega Italiana Lotta all'AIDS) di Milano

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali (facoltativo)".

Firma



11 / 06 / 10